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This dissertation aims to characterize genomic ageing using genetic and observational 
epidemiological approaches, with an emphasis on two markers of genomic ageing, leukocyte 
telomere length and mosaic loss of chromosome Y, providing insights into their biological 
mechanisms and clinical relevance. Besides the work I described here, I have contributed to 
other collaboration projects outside of the scope of this dissertation during the course of my 
PhD, including a genetic discovery of human plasma metabolome and iron metabolism, gene-
specific effects of low-density-lipoprotein cholesterol on type 2 diabetes and phenome-wide 
association studies across multiple traits in UK biobank. Much of this work has been written 
into scientific manuscripts, under review or published, which are listed in Appendix B. 
        I declare that the contents of this dissertation are original and have not been submitted 
in whole or in part for consideration for any other degree or qualification at the University of 
Cambridge or any other University or similar institution. This dissertation is my own work and 
contains nothing which is the outcome of work done in collaboration with others, except as 
specified in the Acknowledgements or main text. This dissertation contains fewer than 60,000 









Name Chen Li 
Title Genetic epidemiology of markers of genomic ageing 
Background Ageing is associated with changes in physical functioning, generally leading to a 
progressive decline in health and development of age-related diseases. Age-related changes 
also affect our genome and markers of genomic ageing, such as telomere length and 
chromosomal loss, have been linked to cancer. The genetic architecture of these markers is 
not well understood and studies investigating associations with common age-related 
cardiometabolic conditions have been limited in their design, analytical methods, power and 
genetic instruments used. Only a few studies have investigated prospective changes in these 
markers with age. 
Objectives To study the epidemiology of two heritable markers of genomic ageing, leukocyte 
telomere length (LTL) and mosaic loss of chromosomal Y (mLOY) and test their causal 
relevance for cardiometabolic and other age-related disorders. 
Methods Large-scale, genome-wide meta-analysis, two-sample Mendelian Randomization 
(MR), and prospective observational case-cohort analysis methods were used to (1) identify 
novel genetic determinants of LTL, (2) investigate causal associations of genetic differences 
in LTL with disease, (3) review the evidence on and assess the feasibility of studying 
longitudinal changes of LTL, and (4) assess observational associations between LTL and mLOY 
and future risk of type 2 diabetes (T2D) in a large, international case-cohort study. 
Results Genome-wide meta-analyses including 78,592 individuals identified 49 regions 
associated with LTL at FDR<0.05 including 17 (6 novel) at p-value<5X10-8. A total of 32 
candidate genes were prioritised with strong suggestive evidence for their roles in telomere 
homeostasis, DNA repair and nucleotide metabolism. Targeted and phenome-wide MR 
analyses suggested causal associations of shorter LTL with an increased risk of cardiovascular 
conditions, and decreased risks of multiple cancer types and diseases of excessive growth. 
LTL shortening was observed even in young and healthy individuals, and baseline LTL was 
strongly associated with the rate of shortening, questioning the usefulness of LTL shortening 
rate as an outcome in genetic association studies. No evidence was found for strong 
associations of mLOY or LTL either measured or genetically predicted with the risk of T2D.  
Conclusion Our findings substantially expand current knowledge on genes and mechanisms 
regulating LTL, as well as refine our understanding of the impact of genetic differences in LTL 
on human health and disease, while providing no strong evidence for prospective 
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and additionally for age in the smoking stratified analyses. 
 
Supplementary Table 21: Meta-regression analyses to identify sources of heterogeneity for 
associations between mLRRY and T2D risk. Smoking status and age band were analysed 
separately, i.e. individuals were stratified by country and smoking status (ever vs. never) or 
by country and age band (<50, 50-65 and >65), resulting in 14 and 18 strata, respectively. In 
each stratified analysis, beta coefficients were combined across strata using random-effects 
meta-regression models. variances between strata (tau2) were estimated by the residual 
(restricted) maximum likelihood (REML) algorithm with Knapp and Hartung modification to 
control type I error. In addition, permutation-based p-values were calculated, either with or 
without adjustment for multiple testing. 
 
Supplementary Table 22: Missingness of mLRRY in EPIC-InterAct study. A. Proportion of 
mLRRY missingness in each country. B. Proportions of mLRRY missingness in T2D incident 
cases and controls. C. Age distributions among individuals with or without mLOY 
measurements. D. Factors associated with the missingness of mLRRY. 
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Introduction and literature review 
 
Ageing is regulated by a dynamic interplay between genes and environment, which influences 
a number of cellular hallmarks, including genome integrity and telomere length (TL) 
homeostasis1,2. Genetic mutations of key genes governing these processes have been linked 
to age-related diseases and lifespan. However, understanding of genetic contribution to these 
hallmarks of ageing has so far largely been driven by experimental studies in short-lived non-
vertebrate model organisms, whereas in complex vertebrate systems, notably in humans, the 
genetic regulation of these ageing hallmarks is under-studied. Studying human genetic 
variation underlying dysregulation of these hallmarks of ageing may facilitate discovery of 
genes and signalling pathways that underpin natural ageing processes. Investigation of 
associations of these genetic variants with clinical outcomes can facilitate protection from 
disease development, thereby contributing to healthy longevity. In this chapter, I will first 
introduce background and methodology for studying human genome variation, with a 
literature review on genetics of ageing focused on two genomic markers of ageing: TL and 
chromosomal mosaicism (mosaic loss of chromosome Y (mLOY) in particular). 
 
1.1 Human genome variation 
 
Understanding of human genome variation lays the foundation for dissecting genetic 
pathophysiology of complex traits and diseases. High-throughput genotyping and sequencing 
technologies, with comprehensive curation of nearly all types of human DNA polymorphisms 
have driven the discovery of new disease-associated genes through genome-wide association 
studies (GWAS)3. Over the past decade, over 159,202 variant-trait associations have been 
reported, providing novel insights into genetic mechanisms underlying phenotypic variations 
in humans4. Despite these achievements, there are still significant challenges to overcome in 
order to better elucidate the relationship between genotypes and phenotypes. Rare and low 
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frequency variants (<1% and 1-5% minor allele frequency (MAF)5, respectively) are 
incompletely characterised in most of the previous genotyping chip-based association studies 
due to genotyping quality and power limitations, yet they extensively outnumber the 
common variants (>5% MAF)6,7. Moreover, once a disease-associated locus has been 
identified, further characterisation of functional involvement of the locus requires extensive 
uses of both bioinformatic and experimental tools. Therefore, larger sample sizes, more 
comprehensive and accurate haplotype reference panels, and various gene prioritisation 
methods are required for a deeper understanding of genetic architecture of human 
phenotypes. 
 
1.1.1 Structure of human genome 
 
Human genome consists of nuclear and mitochondrial components, with the former storing 
the vast majority of genetic materials, encoded into ~3.2 billion pairs of deoxynucleotides 
(monomer units of deoxyribonucleic acid (DNA)) that form two anti-parallel strands 
configured into a “double helix” structure8,9. They are wrapped around nuclear proteins, 
forming 22 pairs of autosomal chromosomes and two sex chromosomes, X and Y. DNA 
sequence is defined as the order of four nucleotide bases, adenine (A), cytosine (C), guanine 
(G) and thymine (T). These sequences are organised into different functional elements, 
including exons, introns, non-coding RNA transcribed fragments and intergenic sequences, 
with 5% evolutionarily conserved among mammals and other vertebrates10. There are around 
20-25 thousand protein coding genes based on current estimation11 comprising ~1.2% of the 
human genome. 
 
1.1.2 Genetic variation 
 
Around 0.1% of DNA sequences differ between humans worldwide12. These differences in the 
DNA sequences are defined as genetic variation, which can occur at different scales, ranging 
from alterations in chromosomal quantity and structure (~3Mb or more), to small indels (< 
1kb) and single nucleotide polymorphism (SNP, = 1bp)13. These can occur somatically in 
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various tissues, or germline cells which are capable of being transmitted to subsequent 
generations. 
        ‘Reference’ human genome sequences have provided the basis for building a 
comprehensive landscape of genetic variants across whole spectrums of allele frequencies 
and types of variations3. In a landmark study from 2005, the International HapMap Project 
Consortium published their first map of common variation in human genome that contains 
more than one million SNPs obtained from 269 DNA samples from 4 populations (the Yoruba 
in Ibadan, Nigeria; Europeans in Utah, USA; Han Chinese and Japanese)12. Since then 
significant progress has been made with the Haplotype Reference Consortium (HRC) currently 
reporting over 39 million SNPs covering a large proportion of rare and low frequency variants 
in 32,488 samples with predominantly European ancestry14. These sources, with new and 
better design of genotyping chips, have largely expanded the number of SNPs identified in 
populations across different ancestries. More recent development in genome sequencing has 
improved identification of genetic variants with an even broader coverage of rare and low 




1.2 Genome-wide association study (GWAS) 
 
GWAS represents a “hypothesis-free” approach to genetic discovery that systematically tests 
associations between genetic variants and continuous phenotypes, such as risk factors, or 
binary outcomes, such as disease endpoints, in cohort or case-control studies. This approach 
has proven extremely successful in robustly detecting associations between SNPs and 
diseases and quantifiable phenotypes, such as circulatory metabolite and protein levels, gene 
expression levels and cardio-metabolic risk factors15–18. Due to sample size expansion and 
new analytical method development, an increasing number of loci have been identified over 
the last decade4,19. However, as association does not necessarily indicate causation, for most 
of the identified genetic associations, causal variants within associated loci are unknown, and 
thus mechanisms of how these loci influence traits of interest are largely unveiled. 
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1.2.1 Rationale and basic principles 
 
Experimental design of GWAS relies heavily on the principle of linkage disequilibrium (LD), i.e. 
non-independent associations between genetic alleles within a population. This largely occurs 
when alleles in close proximity are less likely to be separated during recombination and tend 
to be co-inherited as haplotype blocks. Large number of recombination events occur over 
generations, which shrinks haplotype blocks such that distances between variants tagging 
haplotype blocks extend over short distances (<0.1Mb) on average20. By assessing LD 
structures in reference genomes, carefully selected sets of variants on conventional 
genotyping arrays, with total numbers ranging from several thousands to millions and allele 
frequencies from rare to common, can cover the majority of human genomes, thereby 
reducing complexity and cost of assessing all SNPs genome-wide21. 
        In addition, statistical imputation leveraging haplotypes estimated from fully sequenced 
reference panels can be used to predict untyped genotypes, help correct genotyping errors 
and facilitate cross-study association meta-analyses. The quality of genetic imputation heavily 
depends on the match of allele frequencies between genotyped tag variants and 
ungenotyped likely-causal variants21,22. Larger sample sizes of reference panels have 
improved imputation accuracy and coverage of rare and low-frequency variants, not only for 
European ancestry, such as panels curated by UK10K7 and HRC14, but also for diverse 
ancestries, including panels by 1000 Genomes3 and International Haplotype Map Project 
Consortium12,23.  
 
1.2.2 Key considerations in GWAS 
 
A primary consideration for GWAS is to determine whether significantly associated genetic 
variants are truly related to a phenotype of interest. Therefore a rigorous framework is 
required to distinguish causal from spurious signals across all stages of GWAS including 
extensive quality control (QC) checks, association testing methodology, and assessing 
robustness and validity of statistical inferences24. 
        QC checks are important in reducing spurious associations, which include QC for both 
genetic and phenotypic data. I will describe QC procedures in more detail in subsequent 
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chapters but in brief, genetic QC includes checks for batch or study-centre effects, deviation 
from Hardy-Weinberg equilibrium25, patterns of missingness, haplotype phasing and 
imputation of missing genotypes. Phenotype QC includes examination of outliers, checks for 
missingness, measurement errors and data distribution and normality, and subsequent 
transformation and standardisation of the data. 
        For association testing, various statistical methods have been developed26. For example, 
BOLT-LMM using a Bayesian mixed model association method is particularly designed to 
conducting biobank-scale GWAS. It was shown to deliver analyses in full UK biobank cohort 
in a few days on a single compute node, generating robust and powerful test statistics, while 
controlling for population structures27. For relatively smaller-scale GWAS, simple statistical 
models remain the most commonly used method of choice, such as logistic or linear 
regressions for binary or continuous outcomes, respectively. SNP genotypes or imputation 
probabilities are used as primary exposures, with one SNP tested each time with adjustments 
for potential confounding factors, such as age, sex, top principal components (PC) that 
represent an overall population structures, and other study-specific covariates. An additive 
mode of inheritance is most commonly assumed for each individual SNP, i.e. a heterozygote 
of disease-predisposing variants carries an intermediate risk between two homozygotes. 
Violation of this assumption, such as for SNPs with dominant and recessive effects, may lead 
to power loss. 
        Standard criteria to control false positive discovery while maintaining power is crucial for 
setting a balance between specificity and sensitivity of findings. Frequentist approaches are 
often used in GWAS, where statistical evidence of significance is measured by p-values – the 
probabilities of obtaining a value (in a population) that is the same or more extreme than the 
observed value (in a sample) when the null hypothesis (H0, often referring to an zero effect 
size of a genetic variant on a trait of interest) is true. In GWAS, as millions of SNPs being tested, 
keeping the significance at the conventional p-value threshold of 0.05 can lead to a large 
number of false positive association results (type 1 error: wrongly rejecting H0)28. Bonferroni 
correction, assuming each individual SNP as an independent test, overlooks correlations 
between SNPs in LD, and thus can be overly conservative. By taking into account of LD of 
variants across the genome, a standard p-value of 5 × 10−8 was proposed and is currently 
widely accepted as the genome-wide significance threshold for studies in European 
populations regardless of imputation density29–32. However, quantifying p-value alone is 
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insufficient to assess how likely a given SNP is truly associated with a phenotype. This is 
because in very low powered scenarios (e.g. due to either low SNP MAFs or small sample 
sizes), small p-values which may seem to offer strong evidence against the null hypothesis (H0) 
also indicate similar less likelihood under H1 (the alternative hypothesis)33. 
        Alternative ways for defining significance thresholds have also been proposed. One is 
based on permutation tests that use actual data to empirically evaluate probabilities of 
observing a more extreme result by chance34. Another is to use false discovery rate (FDR), by 
which the limitation of p-value is offset by first ranking p-values in an ascending order and 
then correcting them by their relative ranking positions28. The quantile–quantile (QQ) plot of 
log p-values can be used to visually interpret results with regards to their overall significance 
levels, wherein negatively ranked log p-values are plotted against corresponding null 
expectations (i/(n + 1) for the ith smallest p-value of n tests assuming H0 is true for all tests)28,35. 
        Moreover, Bayesian methods provide an alternative way of assessing significance of 
association results36. Using these methods, a posterior probability of association (PPA) is 
calculated for each SNP, jointly determined by evidence from observation (Bayes factor: the 
ratio of probabilities under H1 and H0) and prior knowledge (prior probability (!)), and thus is 
insensitive to statistical power and number of tests performed33,37. The value of ! can vary 
across SNPs, depending on MAFs or other bioinformatic annotations of SNPs; or be set to a 
constant value for all SNPs, indicating an overall proportion of SNPs being truly associated 
with traits of interest. However, Bayesian methods have not been used as commonly as the 
frequentist approaches, possibly due to a greater computational demand and an inconsistent, 
subjective pre-specification of !. Recent methodological developments, such as the BOLT-
LMM method, showing improved computational efficiency and more flexible specification of 
!,	 has	 become increasingly useful for GWAS practitioners, especially in biobank-scale 
studies27. 
 
1.2.3 General results 
 
The first GWAS was performed in 2005, which studied age-related macular degeneration in a 
case-control cohort of Southeast Asians. It examined 97,824 associations of autosomal SNPs 
in 226 participants38. The first large scale consortium effort by the Wellcome Trust Case 
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Control Consortium in 2007 examined associations with 7 common complex diseases, each 
consisting of ~2,000 cases and a shared set of ~3,000 controls39. This was widely regarded as 
a landmark GWAS in the field due to its substantial scale at the time and that it marked the 
beginning of an exponential rise in GWAS15,40. Since then, thousands of genetic loci have been 
identified to be associated with hundreds of complex traits, ranging from common diseases, 
biomarkers, brain imaging and anthropometric phenotypes, gene expression and protein 
levels, and sociobehavioural traits. As of September 2019, the GWAS Catalog has recorded 
4,220 research papers (PubMed ID) that contained 7,661 study-specific traits (Study 
Accessions) across 4,669 unique human phenotypes that can be mapped to 2,608 
Experimental Factor Ontology traits. The average number of significant associations identified 
with each study-specific trait is 20. However, the thresholds of significance varied, which on 
average were set as the p-value of 1X10-6, even though ~66% of reported associations have 
reached the canonical level of genome-wide significance threshold (p-value=5X10-8). The 
sample sizes also varied from several hundreds to over a million individuals with single or 
mixed ancestry backgrounds. Although only ~47% of the SNP-trait associations reported have 
been tested in independent data sets and proven to be replicable, evidence has proven that 
GWAS results in general are highly reproducible, even across ethnicities, on condition that LD 
patterns underlying causal variants are similar between populations41. 
 
1.2.4 Heritability and genetic architecture 
 
Heritability measures proportions of total phenotypic variations attributable to genetics. This 
is classically estimated from empirical data with informed relationships of individuals (such as 
offspring-parents, siblings and twin pairs). These classic estimates of heritability can be 
categorised into two groups: narrow- and broad-sense heritability. The latter expands on the 
former by also including interactions between alleles at the same or different loci42. However, 
estimates from these classical approaches are susceptible to biases originating from 
assortative mating and natural selection, and their accuracy depends on sampling variation, 
which is jointly determined by sample size and pedigree structure42. GWAS provided a novel 
way of estimating the narrow-sense heritability based on co-segregation of alleles tagged by 
genotyped and imputed SNPs across human genomes, referred to as the “SNP heritability”21. 
In contrast to the classical methods, the SNP heritability is estimated based on genetic 
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relationship matrices, which are calculated in large-scale population cohorts that are often 
unrelated and do not necessarily contain pedigree information21,27. Therefore, it can avoid 
the conventional biases and improve accuracy with increasingly larger sample sizes.  
        Common complex diseases, unlike Mendelian disorders, are often driven by multiple 
genetic variants, with each explaining a small proportion of the total heritability. Current 
technologies using SNP-array based genotyping platforms restrict findings to mostly common 
variants, whereas how rare variants contribute to heritability estimation is largely unexplored. 
With the emergence of large-scale next-generation sequencing, we can investigate whether 
and how much rare variants increase the total variability explained, thereby facilitating 
discovery of overall genetic architecture of diseases.  
        Genetic architecture characterises the impact of individual variants on a broad sense of 
phenotypic variability43. It describes heritability at a finer resolution than the overall SNP 
heritability, which includes total numbers of variants associated, correlations between effect 
sizes and allele frequencies of the variants, and potential interactions between variants and 
between variants and non-genetic environment44,45. Genetic architecture varies between 
different phenotypes and diseases in terms of total numbers of variants associated and 
variants’ allele frequencies and effect sizes. For example, the two types of diabetes mellitus 
are both highly heritable and polygenically-driven, yet with distinct genetic architecture. Type 
1 diabetes is mainly driven by a few large-effect variants with relatively low-frequencies on 
average46,47, whereas type 2 diabetes (T2D) is cumulatively driven by a large number of 
common variants with small effect sizes44. In addition to complex diseases, intermediate traits, 
such as anthropometric traits and biomarkers, also demonstrate different genetic 
architecture43,48. For example, there are 47 independent variants associated with plasma 
glycine levels, exhibiting a broad range of effect sizes and allele frequencies, whereas only 6 
with 25-hydroxyvitamin D, most of which are common variants with small effect sizes49,50, 
even though the sample sizes and SNP imputation densities are comparable between the two 
GWAS. 
 
1.2.5 Main challenge and new approaches 
 
A main challenge for GWAS is to pinpoint possible causal variants and genes among 
association signals. GWAS results typically cannot provide direct evidence to pinpoint causal 
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variants and genes because (a) many of the significantly associated variants are in non-coding 
or intergenic regions with no known functional implications, and (b) the presence of LD leads 
to multiple variants statistically showing similar association strengths to causal variants. 
        Rare variants with functionally detrimental consequences on gene products, such as 
missense and nonsense mutations, if showing robust association signals, are often causal due 
to natural selection against functional mutations in surviving essential genes. However, 
associations with rare variants are difficult to identify due to limitations in genotyping and 
imputation methods and reduced power of association tests for rare variants. Recently, rapid 
advances in sequencing technologies have enabled a more complete and accurate 
identification of low-frequency and rare variants, and with rare variants-oriented GWAS 
methods, these can potentially enhance the capability of GWAS to detect rare variant 
associations. For example, the gene-based burden tests21 and variance component tests51,52, 
in which effects of rare variants are combined through aggregation algorithms, can boost 
power of association tests for rare variants. Scalable approaches, such as SAIGE-GENE, can 
handle large sample sizes at biobank-scale, further improving statistical power in detecting 
rare variant associations53. 
        Post-GWAS annotation can also facilitate selection of likely causal variants and genes. 
Using multiple bioinformatic sources, such as VEP (Variant Effect Predictor)54, UCSC human 
genome55, ENCODE (ENCyclopedia Of DNA Elements)56, and Exome Aggregation Consortium57 
databases, a variety of information can be obtained for variants in their potential roles in gene 
transcriptional regulation and disease pathogenicity and their evolutionary conservation 
levels. For example, variants that play roles in gene transcription, such as those located within 
histone modification markers or transcription factor binding sites, are more likely to be causal, 
as well as variants that are more conserved across species, and with aetiological relevance to 
diseases. Such functional annotations of variants can be integrated into fine-mapping 
approaches, for example, through weighting and adjusting prior probabilities in Bayesian 
models58. Moreover, linking variants with gene expression quantitative trait loci (eQTL) can 
also help infer causality. Besides simple search of individual SNPs across relevant databases, 
such as Genotype-Tissue Expression (GTEx) database59, integrative methods have recently 
been developed, such as transcriptome-wide association (TWA) and statistical colocalization 
methods. The former imputes gene expression levels via incorporating eQTLs with individuals’ 
genetic profiles and correlates the imputed gene expressions to traits of interest60–62; the 
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latter tests probabilities of gene expressions sharing the same causal variants with the traits 
of interest63,64. These methods have demonstrated extreme power in prioritising likely causal 
variants and genes, underpinning methodological development in the future post-GWAS era. 
 
1.2.6 Statistical application of GWAS results 
 
Sharing of GWAS summary statistics (effect sizes of millions of SNPs and their standard errors 
or estimates of equivalent parameters for associations with different traits) have benefited 
the entire field of population genetics, because it enables comparison and integration of 
results across studies as well as stimulating method development. This has facilitated 
discovery of novel disease-predisposing loci in larger meta-analyses, improvement of 
accuracy in estimating SNP heritability, more comprehensive characterisation of genetic 
architecture and ‘in silico’ investigation of specificity and pleiotropy for individual SNP 
effects21. Moreover, owing to this tremendous data resource, various statistical approaches 
have been developed which uses summary statistics to infer causalities and predict disease 
risks, thereby deepening our understanding in disease aetiologies and facilitating clinical 
utilities. 
 
1.2.6.1 Mendelian randomisation (MR) 
Evidence from double-blinded, randomised controlled trails (RCTs) are considered the gold 
standard for causal inference, because study participants are selected with balanced 
distribution of known and unknown confounders, yet randomly assigned to intervention and 
control groups to minimise selection bias65. RCTs are often infeasible, as they are extremely 
expensive, difficult and time consuming, and may not be ethically appropriate, depending on 
exposures of question. In contrast, observational studies in epidemiology are prone to 
confounding and reverse causation, as participants in such study cohorts are randomly 
recruited with minimal controls for confounding factors and undetermined time sequence of 
exposures and outcomes. Hence, statistically significant associations found and reported in 
such studies do not allow inference about causality66. 
        MR studies have been proposed as a natural analogue of RCTs, in which randomly 
allocated genetic alleles are used as instrumental variables that mimic randomised groups of 
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RCTs, i.e. absence or presence of genetic alleles mimic control and intervention groups in RCTs, 
respectively. Similar to RCTs, MR aims to investigate putative causal effects of risk factors on 
outcomes while minimising influence of confounders67. Because genetic variants are fixed at 
conception and randomly assigned during meiosis, therefore using them as proxies for 
exposures of interest can overcome the two major limits of observational association studies: 
unmeasured confounding and reserve causation. Three key assumptions must be satisfied for 
MR analyses. The genetic instruments must (1) be strongly associated with risk factors of 
interest (relevance assumption), (2) not associated with any confounding factors 
(independence assumption) and (3) influence outcomes exclusively through pathways that 
are mediated via the risk factors (exclusion restriction assumption)67–69. 
        To ensure the relevance assumption, genetic instruments are often selected based on 
evidence obtained from published GWAS. Ideally data sets from which genetic instruments 
are selected should be different from but within the same underlying populations as those 
for causal association inferences, the so-called “two-sample MR framework”70,71. One-sample 
MR, where estimates of associations with risk factors and outcomes are derived in the same 
data sets, may suffer from the ‘Winner’s curse’72. Instrumental variables are often 
constructed from multiple genetic variants known to be associated at the level of genome-
wide significance. Advantages of using multiple variants are that (1) they collectively explain 
more variability of risk factors than using single variants, and thus are statistically more 
powerful, and (2) potential pleotropic effects are diluted, although unlikely to be eliminated 
entirely73. Variants at independent loci are most commonly used, whilst correlated variants 
can also be used with adaptive methods that incorporate variance-covariance matrices69. 
Including additional variants, even if correlated to a certain degree, can improve accuracy of 
MR analyses, however, at the cost of exacerbating ‘weak instrument bias’ due to the 
overfitting problem. Similarly, applying a lower association threshold to variants can result in 
a greater number of variants selected, and thus increase power but also at an increased risk 
of overfitting. 
        Unbalanced pleiotropy of genetic variants is a major concern of violation of 
independence and exclusion restriction assumptions. Although these assumptions are not 
fully testable, a systematic investigation of associations of each genetic instrument with a 
broad spectrum of phenotypes can help verify these assumptions. These tests are analogous 
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to checking equal distributions of potential measured confounders between treatment and 
control groups in RCTs67. 
        Owing to an increasing number of summary association estimates generated via GWAS, 
the MR methods have been expanded with enhanced statistical power and allowing for 
relaxation of some of the MR assumptions, including MR-Egger regression and (weighted) 
median MR. The MR-Egger regression, developed on the basis of the Egger’s test - a test that 
assesses small study bias in meta-analysis, provides a valid method of detecting directional 
(unbalanced) pleiotropy via testing the hypothesis of the Egger’s intercept being equal to 0. 
In scenarios where the assumption of exclusion restriction is violated due to unbalanced 
pleiotropy, MR-Egger can be applied to generate consistent causal estimates under the InSIDE 
(Instrument Strength Independent of Direct Effect) assumption - association strengths of 
genetic variants with exposures are independent of direct effects of genetic variants on 
outcomes68. Similarly, the (weighted) median MR method can tolerate up to 50% invalid 
instruments, because the method takes median instead of mean of causal ratio estimates74. 
 
1.2.6.2 Polygenic risk score (PRS) 
Genetic risk profiling, considered as an early measurable predictor of disease risk, has 
demonstrated crucial values in disease risk prediction and prevention. Previous clinical 
utilities of genetic risk profiling have largely focused on rare functional mutations embedded 
within causal genes for rare monogenic diseases. For complex polygenic diseases, the genetic 
risk profiling can be summarised and assessed using PRS75–79. 
        Construction of PRS is similar to that of an instrumental variable (i.e. allele score) in MR, 
both of which are calculated as a weighted sum of genetic risk alleles of all associated regions 
across individual human genomes, where the weights, defined as association effect sizes, are 
obtained from GWAS80. However, considerations of what and how many genetic variants are 
included into PRS may be different from those into an instrumental variable in MR, as the 
former focuses on prediction of disease risks, whereas the latter on causation between risk 
factors and disease outcomes. A threshold of genome-wide significance is most commonly 
used when determining the set of genetic variants to be incorporated into PRS construction, 
but a lower threshold may also be used, thereby increasing total variability of diseases 
explained and predictability of PRS, often at the cost of reduced generalizability in clinical 
applications (for example, to individuals of different ethnicity backgrounds)81–83. An optimal 
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threshold depends on sample sizes and genetic architecture underlying traits of interest. 
Inclusion of additional variants that are below genome-wide significance may harm the 
performance of prediction models (often assessed by areas under the receiver-operator curve 
(AUC)), especially when the variants are obtained from insufficiently powered GWAS84. In 
contrast, for certain late-onset diseases, for which large-scale, well-powered GWAS have 
been undertaken, such as T2D44, coronary artery disease (CAD)85 and Alzheimer’s disease 
(AD)86, inclusion of more modestly associated variants can improve prediction accuracy 
because their genetic determinants have been demonstrated to mainly consist of common 
variants of small effect sizes, with little or no evidence showing rare variants of large effect 
sizes are involved in their disease aetiologies80.  
        Clinical utilities of PRS are still under debate, especially considering common 
conventional non-genetic risk factors, such as age, gender and behavioural and 
environmental risk factors explain the majority of phenotypic variance89. Moreover, for many 
diseases, heritability estimates attributable to PRS are still limited, even with increasingly 
larger numbers of disease-susceptibility genetic loci identified, (e.g. ~20% by over 400 loci for 
T2D)44,88. Applying the most recent PRS of T2D to participants in UK biobank produced an AUC 
of ~65%87, which, although substantially increased previous prediction performance89–91, was 
still worse than simply using conventional T2D risk factors, such as age, gender, family history 
and biomarker and adiposity levels. However, the relatively small proportion of heritability 
explained may not necessarily restrict possible utilities of PRS in disease prediction. For 
example, mutations within Breast Cancer Susceptibility Protein Type (BRCA)1 and BRCA2 
genes are rare in general populations (<<1%), and the number of incident cases of breast 
cancer that carry these mutations is small (~5% of all cases), so that heritability explained by 
these mutations is also limited. However, the relative risk of developing breast cancer due to 
these mutations is large (4-5 folds)80. Therefore, using such highly penetrant pathogenic 
mutations in certain diseases can help clinical practitioners take earlier interventions to 
prevent disease occurrence. 
        PRS can be helpful in identifying a subset of population who are at extreme tiers of risks 
for common complex diseases, and the subset may vastly outnumber extreme phenotypes 
due to single pathological gene mutations. For example, using PRS alone identified 8% of a 
general population who were at a 3-fold higher risk of CAD, whereas only 0.4% of the same 
population carried familial hypercholesterolemia mutations that exert similar risk effects on 
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CAD92. Overall PRS-informed population stratification and individual risk assessment for 
certain diseases can facilitate personalised medicine, and better inform clinical communities 
in making decisions in disease prediction and prevention80,84. 
 
 
1.3 Genetics of ageing 
 
The proportion of elderly populations is growing rapidly worldwide and it is expected that 
proportion of those aged over 60 years will be doubled over the next three decades93. Ageing 
is often associated with a progressive functional decline that involves a variety of 
physiological and psychological changes that impair organ functionality and rejuvenescence, 
memory and cognition, and overall physical performance and intellectual ability2. Risks of 
many common complex diseases, including different cardio-metabolic diseases, cancers and 
neurodegenerative disorders, increase with age, resulting in a profound reduction in life 
quality of older populations and a huge burden on social and health care systems76,93–95. 
        There is a substantial heterogeneity in life expectancy between individuals, which is 
largely driven by both environmental and genetic factors2. Based on twin studies, the 
heritability of human lifespan has been estimated to range between 20-30%, although 
estimates differ between studies96,97. A recent study has shown that heritability estimates of 
human longevity may be inflated due to assortative mating and the true heritability may be 
less than 10%98. Understanding genetic mechanisms that regulate ageing may provide 
insights into aetiologies of age-related diseases, and ultimately lead to novel approaches to 
reduce age-related morbidity and mortality rates and improve quality of life1. 
        From experimental studies in animal models, genes that play fundamental roles in 
conserved pathways have shown lifespan-altering capacities99. These so-called gerontogenes 
(gene expressions negatively associated with longevity) or longevity-assurance-genes (gene 
expressions positively related to longevity) are often pleiotropic, as they are involved in 
different pathways that regulate hallmarks of ageing100. These hallmarks have been 
categorised into nine main interconnected domains: genome instability, TL attrition, 
epigenetic alterations, loss of protein homeostasis, dysregulated nutrient sensing, 
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mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered 
intercellular communication (Figure 1.1)1,2. 
 
Figure 1.1 Hallmarks of ageing.  
The nine hallmarks of ageing are interconnected with each other through shared molecular 
components and pathways. They interact with environmental signals to jointly determine trajectories 




1.3.1 Genetic studies in animal models - evolutionarily conserved pathways 
 
Fundamental mechanisms that regulate ageing and related phenotypes converge onto 
several classic signalling pathways and gene sets, including the well-characterised 
mechanistic target of rapamycin (mTOR), insulin/insulin-like growth factor (IGF), and 
adenosine monophosphate-activated protein kinase (AMPK) pathways, and sirtuin 
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deacetylases1,101. Under normal circumstances, genes implicated within these pathways 
regulate growth and metabolism, while in extreme conditions (e.g. dietary restriction, 
oxidative stress and extremely high or low ambient temperatures), their functions adapt 
accordingly to protect organisms from those environmental stresses, resulting in a shift of 
physiological states towards a standstill that facilitates global maintenance and stability, and 
thus slowing down growth and ageing processes101. Each condition involves specific proteins, 
but the multifaceted functionalities of these proteins imply their involvements in multiple 
pathways, through which interconnections between regulatory pathways of ageing are 
established. Because of this network of ageing regulatory pathways, pharmacological or 
genetic interventions that target individual gene products are sufficient to slow down ageing, 
even though ageing itself is a complex phenotype that is subjected to numerous regulatory 
mechanisms. Such experimental hypothesis underscores the latent potential of extending 
lifespan via drugs that target single molecular candidates. For example, inhibitors of the 
mTOR pathway (such as rapamycin and several derivative compounds) have been clinically 
approved or under development for a variety of clinical uses, including therapies for post-
transplantation and several types of cancers102,103. Metformin, an anti-diabetic drug that 
activates AMPK, can manipulate ageing phenotypes and healthspan in lower organisms 
through multiple mechanisms, including downregulation of the insulin/IGF signalling and the 
mTOR signalling pathways101. 
        Insulin/IGF signalling is the first pathway that has been shown to influence longevity in C. 
elegans, wherein loss-of-function mutations in an orthologue (abnormal dauer formation-2, 
daf-2) of the IGF receptor (IGFR) gene left worms arrested in juvenile forms with more than 
doubled healthy lifespan104,105. In humans, lower levels of IGF-1 hormone106, or loss-of-
function mutations in the IGF1/2R genes107 or in the related transcriptional factor gene, 
Forkhead box O 3 (FOXO3)108–112, have been associated with longer survival in centenarians. 
Further, growth hormone (GH) has been negatively correlated to longevity in both mice and 
humans through mechanisms that were independent of IGF11,113. A homozygote deletion 
variant in the exon 3 of the GH receptor gene has been positively associated with older age in 
long-lived human cohorts114. 
        Most genes identified in animal studies lack replication in human genetic studies, which 
will be further discussed in section 1.3.2. Nevertheless, these candidate genes and signalling 
pathways primarily found in animal models provide a potential catalogue of drug targets for 
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ageing and age-related diseases, yet validation of their roles in humans is still the key to 
facilitate further investigation for any pharmaceutical potentials.  
 
1.3.2 Human genetics of aging 
 
The complexity of human ageing lies in joint effects of a variety of risk factors, including 
genetic, behavioural and environmental risk factors, such that the extent to which genetic 
variation affects human lifespan is under debate. Thus far, most of the candidate genes that 
manipulate lifespan have been identified through gene screening in non-vertebrate model 
organisms, with only a handful of them supported by evidence from human population 
studies115. Many of these genes overlap with genes associated with age-related complex 
disorders, revealing shared pathophysiological pathways between ageing and diseases97. 
 
1.3.2.1 Candidate gene studies 
Few genes have been consistently reported to be associated with human longevity and 
lifespan across different studies, including Apolipoprotein E (APOE), Cholinergic Receptor 
Nicotinic (CHRN) Alpha 3/5 Subunit, Human Leukocyte Antigen (HLA)-DQA1/DRB1, lipoprotein 
A (LPA), FOXO3, IGF1/2R, SIRTURIN 3 and Interleukin 6 (IL6)1,108,109,111,112,116–120. Although 
hundreds of genes have been suggested from animal model experiments, they failed to 
replicate in human studies, possibly due to the complexity of human ageing, which restricts 
genetic discoveries to be highly context-dependent. Environmental factors, such as 
geographical and anthropological segregation, socioeconomic status and education, can bias 
genetic association analyses and affect interpretation of novel findings116. Therefore, 
generalisability of results is often limited and possibly under specific study populations and 
times. Moreover, the general lack of reproducibility can also be due to different study designs, 
measurements of longevity outcomes, age stratifications and power121, which will be further 
discussed in section 1.3.2.2. 
 
1.3.2.1.1 Informed by model organisms 
Candidate genes selected for human association studies have mainly been based on 
experimental evidence from animal models. They are involved in regulation of different 
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ageing hallmarks or conventional risk factors of age-related diseases. For example, IGF1/2R 
and FOXO3 genes are involved in the nutrient sensing pathway, and their orthologues have 
been shown to play important roles in model animals (section 1.3.1). HLA-DQA1/DRB1 and 
IL6 genes are involved in the immune function and inflammation; CHRNA3/5 locus, encoding 
various subunits of nicotinic acetylcholine receptors, is associated with smoking-related 
behaviours and diseases, and smoking is a well-established strong cause of premature death; 
APOE, encoding a receptor-binding ligand on the surface of multiple lipoprotein particles, and 
LPA, encoding a constitutive protein component of lipoprotein(a), have been linked to an 
array of age-related diseases and relevant risk factors, including AD, CVD and total and low-
density lipoprotein cholesterol and triglycerides119,120. Together, these findings have 
demonstrated that candidate genes emerging from animal studies can inform relevant 
epidemiological studies in human populations, but replication may need larger cohorts with 
diverse ethnic backgrounds and careful consideration of gene-gene and gene-environment 
interactions. 
 
1.3.2.1.2 Informed by rare diseases 
A group of rare premature ageing diseases (e.g. Hutchinson-Gilford progeria syndrome (HGPS) 
or Werner syndrome (WS)), known as progeria, with clinical presentation of dramatic and 
premature ageing, i.e. early appearance of phenotypes generally associated with ageing, such 
as atherosclerosis, osteoporosis, greying and loss of hair, skin ulcers and occurrence of 
multiple rare cancers1. Studies of genetic aetiology of progeria can help to understand 
regulatory mechanisms of normal aging. For example, nuclear aberrations, including altered 
histone modification patterns and increased DNA damage, were found in cells from HGPS 
patients, as well as in skin fibroblasts from older individuals in general populations122. Donor 
cells from older individuals showed a remarkable change in the nuclear location of Lamin A/C 
(LMNA): changing from nuclear lamina at nucleoplasmic side of inner nuclear membrane to 
nuclear periphery, thereby disrupting integrity of nuclear membranes, leading to 
dysregulated cell cycle and gene transcription; similar dislocation of LMNA was also found in 
cells from progeria patients that possess truncated LMNA isoforms122,123. Moreover, the WRN 
(Werner Syndrome RecQ Like Helicase) gene that causes WS, encodes an ATP-dependent 
helicase that functions in DNA replication, transcription, repair and recombination, and 
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telomere maintenance. This supports genome instability as a hallmark of both, premature 
ageing disorders and normal ageing processes124,125. 
 
1.3.2.2 GWAS 
GWAS provides a hypothesis-free method of characterising genetic architecture of human 
ageing. It has the potential of identifying novel genes and perhaps human-specific 
mechanisms of regulating age-related physiological changes. Case-control studies, in which 
people who live exceptionally longer are included as cases and compared to those with 
normal lifespan have been conducted111,126,127. This simple design is often restricted due to 
inaccessibility of control samples who are born in the same period of time (early 90’s) as the 
long-lived cases but die at younger ages. Using alternative controls from later generations 
may introduce bias towards the null due to environmental variation and secular trends in 
factors affecting longevity across generations126–128. To minimise selection bias, a prospective 
birth cohort design is employed with participants followed up from birth and outcomes 
defined as continuous measures of lifespan (e.g. time to death or to the first incidence of fatal 
diseases)129. More recently, a cross-generational design has been developed, in which 
parental age at death was regressed on genetic variants obtained from offspring. The 
rationale behind this method is that a) half of genetic materials are shared between parents 
and offspring, b) there is a positive correlation between general health states of middle-aged 
individuals and their parents’ ages, i.e. people who have longer-lived parents are generally 
healthier130. This study design can increase effective sample sizes, given that the number of 
death events among parents is more than doubled than that in participants (offspring), 
especially in large population cohorts where the majority of participants are recruited in their 
middle ages and hence may have aged or deceased parents120. For example, UK biobank is a 
such resource, in which half a million participants were recruited at ages 40-69 years and over 
60% of their parents were recorded as dead at baseline120. 
        New analytical approaches can also facilitate novel gene identification. For example, a 
concept of the “informed GWAS” that integrates prior knowledge of age-related disease loci 
has been realised by different approaches, one based on a multivariate MR model with 
Bayesian priors97 and another using a centenarian enrichment approach131 (Figure 1.2). Both 
of these approaches are successful in identifying novel genes associated with human lifespan, 
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indicating ageing and age-related diseases are interconnected through shared genetic 
determinants.  
        However, despite a large increase in statistical power in recent GWAS on human 
longevity and lifespan (sample sizes increased from several thousands to one million, Figure 
1.2), only a few loci have consistently shown genome-wide significant association signals 
across studies. These include not only APOE and FOXO3 genes that have consistently been 
reported in both animal and candidate gene studies, but also previously unidentified loci with 
potential roles in various hallmarks of ageing. For example, the CDKN (Cyclin Dependent 
Kinase Inhibitor) 2A/B genes, consistently reported by several large-scale, parental longevity 
studies118–120,132, is involved in regulation of cell cycle and cellular senescence. Dysfunction of 
this protein can lead to stem cell exhaustion and increased risks of many age-related diseases, 
including cardiometabolic disorders and cancers97,118,121. Similarly, the MAGI3 (Membrane-
Associated Guanylate Kinase Inverted 3) gene, encoding a membrane-associated guanylate 
kinase that acts as a scaffolding protein at cell-cell junctions, thereby facilitating intercellular 
communications, has been associated with autoimmune diseases and lifespan118,133. LPA and 
LDLR, together with APOE, the first well-documented human longevity locus, are all involved 
in transport and metabolism of lipoprotein particles, thereby influencing levels of lipid risk 
factors for cardiometabolic diseases118. These show that genes with functional involvements 
in hallmarks of ageing may be associated human lifespan and can be identified in general 
population studies. 
        Although recent GWAS have expanded longevity loci from one (APOE) to more than a 
dozen with sample sizes increased from several thousands to more than 1 million individuals, 
power is still a limiting factor due, at least partly, to relatively small numbers of death events 
in large-scale general population cohorts, as which are often in short of follow-up time. 
Moreover, not all deaths are attributed to heritable age-related diseases, other factors may 
also influence individual lifespans and such confounding factors may be overlooked in GWAS, 
causing lifespan-associated loci rather context-dependent, and thus reducing power in meta-
analyses132. In order to detect more novel and robustly associated loci, larger sample sizes, 
increased coverage of rare variants and more advanced mathematical approaches may help.
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1.4 Genomic markers of ageing 
 
While a large body of research has focused on identification of biomarkers of age-related 
diseases, assessing their values for prediction of disease risk and response to clinical 
interventions, no consensus exists for biomarkers of ‘biological age’ – indicators that can 
capture and measure ageing process as opposed to actual chronological age134. Several 
criteria have been proposed as prerequisites for such markers, including they should (1) 
demonstrate a continuous change along with age and allow for longitudinal monitoring, (2) 
reflect physical and cognitive decline associated with ageing, (3) and predict age-related 
multi-morbidities and mortality better than chronological age121. Recent studies have 
highlighted the importance of genomic changes that occur while we age, including TL 
shortening and chromosomal loss, which have been associated with cancers and possibly also 
other age-related diseases1,2,135. In this section, I will give a comprehensive literature review 
on two markers of genomic ageing, TL and mosaic chromosomal loss, mLOY in particular, 
corresponding to telomere shortening and genome instability hallmarks of ageing (Figure 1.1). 
Other markers of biological age (e.g. circulatory small molecule metabolites, blood pressure 
and frailty phenotypes), capturing other aspects of pathophysiological changes during ageing, 
are involved in the other hallmarks of ageing, which will not be covered in this section. For 
example, insulin and blood lipid levels indicate nutrient sensing, IL-6 and high-sensitivity C-
reactive protein are inflammation markers involved in cell senescence, accumulation of 
reactive oxygen species and peroxidised lipids reflect mitochondrial dysfunction, and 
alterations in DNA methylation and histone modifications consist of epigenetic changes along 
with ageing121,136–140. The markers of genomic ageing, in combination with other well-
established markers of biological age can facilitate more comprehensive characterisation of 
ageing-related physical and mental decline at a molecular level and improve early prediction 





1.4.1.1 Definition, structure and function of telomeres 
Telomeres are DNA-protein complexes found at the end of eukaryotic chromosomes, which 
serve to maintain genomic stability and determine cellular lifespan141,142. Telomeric DNA 
consists of a long tract (10-15 kb) of double stranded TTAGGG repeats with a guanidine-rich 
single stranded overhang at the 3’ end143. Protein complexes, including the SHELTERIN 
complex [Telomeric Repeat Binding Factor (TERF)1, TERF2, Protection of Telomeres Protein 1 
(POT1), Ras-Related Protein Rap-1 (RAP1), TERF1-Interacting Nuclear Factor 2 (TIN2) and 
Tripeptidyl Peptidase 1 (TPP1)] and the CST complex [Oligonucleotide/Oligosaccharide-
Binding Fold-Containing Protein 1 (OBFC1), CST Telomere Replication Complex Component 1 
(CTC1) and TEN1 Subunit Of CST Complex (TEN1)] along with DNA helicases, such as Regulator 
Of Telomere Elongation Helicase 1 (RTEL1), bind telomeres and regulate TL and telomere 
structure144–146. Together telomeres form a highly compact chromosomal configuration, 
protecting telomeric DNA from uncontrolled elongation or being recognized as double-
stranded breaks that trigger DNA damage responses (DDR)147. Telomeres shorten with 
cellular divisions due to the end replication problem and once critical lengths are reached 
cells enter replicative senescence142. In some cell types, such as stem and germ line progenitor 
cells, TL is maintained by the enzyme telomerase, a ribonucleoprotein containing the RNA 
template [Telomerase RNA Component (TERC)], the enzymatic protein [Telomeric Reverse 
Transcriptase (TERT)] and accessory proteins, including Dyskerin Pseudouridine Synthase 1 
(DKC1) and several nucleolar proteins148. 
 
1.4.1.2 Germline genetic variants associated with TL  
TL has previously been estimated to be highly heritable (h2=0.70 (95%CI=0.64-0.76)) 
according to a meta-analysis of family/twin-based cohort studies, although heritability 
estimates varied between studies, ranging from 0.34149 to 0.82150, likely due to differences in 
methods used to measure TL and study designs and cohorts (twin-, non-twin sibling pairs- or 
multi-generational relatives-based cohorts). Overall, these have suggested a strong genetic 
component underlying TL regulation. 
        GWAS performed to date have identified 10 genes to be associated with TL measures in 
leukocytes, including 6 known biologically relevant ones. Among these candidate genes, three 
of them, TERC, TERT and Nuclear Assembly Factor 1 (NAF1) in 3q26, 5p15.33 and 4q32.2, 
respectively, encode RNA/protein products that are involved in telomerase ribonucleoprotein 
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complex assembly; two genes, OBFC1 (also known as STN1, 10q24.33) and CTC1 (17p13.1) 
encode protein members of the heterotrimeric CST (CTC1, STN1 and TEN1) complex, which 
regulate telomerase activity by controlling accessibility of telomerase to telomeric DNA 
substrates96,151–154. Mutations in the CTC1 gene, disrupting configuration of the CST complex, 
were causally linked to Dyskeratosis congenita and Coats Plus syndrome96. RTEL1 (20q13.3), 
encoding a DNA helicase that facilitates structural unwinding of telomeric DNA sequences, 
also plays an essential role in telomeric DNA replication. Besides RTEL1, genes encoding other 
members of the helicase protein family, such as RecQ, have been reported to be involved in 
maintaining telomere homeostasis155. Disrupted functions of these helicases have been 
associated with telomere syndromes, such as the Werner and Bloom syndrome. Additionally, 
three loci, including Acylphosphatase 2 (ACYP2)151, PX Domain Containing Serine/Threonine 
Kinase Like (PXK)156 and DEAH-Box Helicase 35 (DHX35)157,158, have been reported once, but 
not replicated in other independent studies, and thus their biological relevance to TL 
regulation remain uncertain. Finally, the Zinc Finger Protein (ZNF)208/ZNF257/ZNF676 (19p12) 
region has been reported to be associated with LTL by several studies, but biological 
mechanisms remain to be established96,151. 
 
1.4.1.3 Non-genetic risk factors associated with TL 
It has been widely acknowledged that shorter TL is associated with older age159. Other factors 
have also been associated with shorter TL, such as male sex, increased adiposity160–162, 
smoking163,164, alcohol consumption165, reduced physical activity166. Much of the evidence 
comes from observational studies and which factors are causally associated with TL or subject 
to bias, reverse causation and/or confounding is unknown. Moreover, results reported by 
prospective cohort studies have been inconsistent or contradictory, possibly due to 
differences in methods of DNA extraction and TL measurement, power, study design and 
sampling, and statistical approaches used162. 
        A large meta-analysis that collected 63 observational studies has reported that 38 of 
them found significant inverse correlations between LTL and adiposity levels, however, with 
extremely large between-study heterogeneity (I2=99%)167. The large heterogeneity has been 
suggested to be possibly due to differences in statistical methods used and diverse study 
populations included, but not due to differences in methods used for TL quantification, 
stratifications on age or obesity, tissue types or countries of origin167. 
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        Other modifiable factors have been reported to be associated with LTL, yet only by one 
or two studies, which may also suffer from similar study limitations as described above. These 
included serum leptin levels160, self-reported physical activity levels in leisure time166, 
sedentary lifestyle164, educational attainment168, violent exposures169,170, paternal age at 
children’s births and paternal lifespan171. 
        Therefore, the degree to which TL is causally influenced by modifiable factors such as 
obesity is uncertain. MR with genetic instrumental variables may help to elucidate such 
causality questions. GWAS on various modifiable factors have identified genetic variants that 
are robustly and specifically associated with those factors, and these genetic variants can 
serve as good instruments, with which causalities can be investigated under the MR 
framework (section 1.2.6.1). 
 
1.4.1.4 Clinical consequences of dysregulated TL 
In healthy somatic cells, shortened TL functions as a mitotic clock that prohibits indefinite 
proliferation of cells, thereby avoiding accumulation of carcinogenic DNA mutations172. 
However, extremely shortened TL leads to accelerated aging, and premature ageing 
syndromes, commonly characterised with impaired capacity for tissue renewal and stem cell 
exhaustion173. Dysregulated TL has been causally linked to both rare monogenic and common 
polygenic diseases, the former based on identification of rare pathogenic mutations in rare 
diseases, whereas the latter by using genetic approaches to assess causality or observational 
inferences from large prospective cohort studies. Therefore, maintaining telomere 
homeostasis is essential for healthy lifespan. 
 
1.4.1.4.1 Rare diseases (telomeropathies) 
Telomeropathies are a cluster of rare monogenic diseases due to disrupted telomere 
homeostasis. These can be categorized into two groups depending on their onset times: 
congenital and adult-onset disorders; onset of the former is during infancy, whereas the latter 
manifest at older ages in adulthood. These diseases are attributed to point mutations in genes 
directly involved in either telomere regulation or DNA repair174. 
        Dyskeratosis congenita is clinically typified by dermatological dystrophy and bone 
marrow deficiency, and commonly associated with aplastic anaemia and liver cirrhosis. 
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Missense variants that lead to partial loss-of-function of the dyskerin protein, resulting in 
impaired binding to telomerase RNA subunit, were found to be causal for X-inherited 
dyskeratosis congenita. Moreover, mutations that impair TERC gene transcription, leading to 
impaired enzymatic activity of telomerase, were found to cause 10% of autosomal dominant 
dyskeratosis congenita173,174. Hoyeraal–Hreidarsson syndrome is a severe form of the 
dyskeratosis congenita, showing the earliest disease onset time among all telomeropathies; 
TIN2, one of the structural component of SHELTERIN complex, was identified as the causal 
gene for this syndrome174. 
        Ataxia telangiectasia, clinically presenting with hyper-radiosensitivity and 
immunodeficiency, is an autosomal recessive disorder. Ataxia Telangiectasia Mutated (ATM), 
which encodes a serine/threonine protein kinase that phosphorylates and activates several 
key enzymes in DDR and cell cycle arrest, has been identified as the causal gene173. 
        Fanconi anaemia, another autosomal recessive disorder, is caused by mutations in genes 
(including BRCA2) that encode proteins involved in protecting genome integrity from 
carcinogenic and oxidative stress. Pancytopenia and cancer susceptibility (acute myeloid 
leukaemia in particular) are two clinical phenotypes that manifest the disease, with 
significantly increased rates of cellular turnover and thus shorter TL173,175. 
        WS and HGPS are the two best-characterised premature ageing syndromes, 
pathologically linked to drastic telomere attrition. Although their causal genes are neither 
direct regulators nor structural components of the telomeres, their genetic causes can 
indirectly affect telomere homeostasis. For example, the WRN gene, encoding the RecQ DNA 
helicase, is a major causal candidate for WS and likely to be involved in telomeric DNA 
replication; the LMNA gene, encoding a protein that contributes to formation of nuclear 
lamina matrix, has been identified as a major cause of HGPS, with functions in DNA repair and 
chromosomal stability, and thus is also essential for TL mainteinance125. 
        Idiopathic pulmonary fibrosis, an autosomal dominant disease, with relatively higher 
prevalence in populations and a broader spectrum of ages of onset, can be ascribed to 




1.4.1.4.2 Common complex diseases  
TL has been consistently shown to be associated with various common complex diseases in 
epidemiological studies, including MR and observational studies176. 
        MR studies have used summary statistics of genetic associations with LTL and various 
common complex diseases to estimate causal associations of LTL with different 
diseases158,177–181. This has suggested genetically predicted longer LTL is associated with 
increased risks of different types and sites of cancers (glioma, ovarian cancer, lung 
adenocarcinoma, neuroblastoma, bladder cancer, melanoma, testicular cancer, kidney 
cancer, and endometrial cancer)158, and altered risks of several non-cancerous diseases, 
including increased risks of abdominal aortic aneurysm, celiac disease and interstitial lung 
disease158 and decreased risks of coronary heart disease (CHD)158,177–179 and AD and early-
onset dementia180,181. 
        In line with MR suggested protective effects of longer LTL on CHD and AD, recent meta-
analyses of published observational studies have reported reverse associations of LTL with 
CHD182 and AD183. However, contradictory results have been found on associations between 
LTL and cancers. For example, a large prospective cohort study has found longer LTL was 
associated with decreased risks of overall cancers and all-cause mortality during a 15-year 
follow-up184,185. Another study has shown that over 70% of cancer patients (n=9,127 patients, 
31 cancers) exhibited shorter telomeres in their tumour samples in comparison to their 
matched normal tissue control samples, with the greatest differences found in melanoma, 
lymphoma and kidney tumours186. Moreover, patients with prostate cancers exhibited a U-
shape of TL over the prostatic cancer development, with shorter telomeres during primitive 
or progressive stages, and longer telomeres during metastatic stages187. 
        Based on previous studies, it is still unclear whether and how TL alteration is causally 
linked to different common complex diseases, including cancers and non-cancerous diseases. 
Observational studies can be subject to confounding and reverse causation, which are 
avoided in MR studies under the assumptions that genetic instruments are robustly and 
specifically associated with the exposure of interest. However, previous MR studies were 
performed based on summary results obtained from recent GWAS on LTL, which have only 
identified less than 10 genome-wide independent variants, explaining ~1% of total variation 
in LTL151. Larger GWAS meta-analyses can increase power of MR studies. Moreover, potential 
pleiotropic effects can be minimised through cross-referencing GWAS summary statistics for 
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thousands of traits for each variant. Overall, more robust and specific instrumental variables 




1.4.2.1 Definition of mosaic chromosomal alterations and mLOY  
Mosaic chromosomal alterations are post-zygotically acquired structural changes that can 
occur on any chromosomes, with a minimum size of 50bp188,189. It can arise early during 
development and thus influence both somatic and germline cells, or later in adulthood and 
influence only certain cell types190. It often originates during cell proliferation, where errors 
in chromosomal replication and subsequent transmission into daughter cells may lead to 
chromosomal anomalies that include copy number variation (CNV, segments or entire copies 
of chromosomes amplified or deleted) and uniparental disomy (two copies of an entire 
chromosome or sections of a chromosome coming from one parent)189,190. In principle, 
mosaic chromosomal alterations can lead to aberrant clonal expansions of progenitor and 
stem cells carrying structural alterations that provide cellular growth advantages191. The 
aberrant clonal expansions can occur in all tissues regardless of the clonal or developmental 
origin of cell lineages189. In particular, clonal expansions among hematopoietic stem cells are 
referred to as the “clonal hematopoiesis”, which is the most extensively studied type of 
mosaicism, possibly due to an easier accessibility to blood DNA samples192, although no 
significant differences were found between DNA extracted from different samples, such as 
blood and buccal cells189. mLOY is a particular type of mosaic chromosomal alterations that 
occurs on the chromosome Y. mLOY is by far the most common mosaic chromosomal 
alteration present in men193. 
 
1.4.2.2 Germline genetic variants associated with mosaic chromosomal alterations and mLOY 
Mosaic chromosomal alterations by definition were non-heritable due to somatic nature of 
the mutations that drive disproportionate expansions of clonal lineages; however, several 
large-scale GWAS have demonstrated that inherited germline variants can influence risk and 
chromosomal positions of such mosaic loss194–196. 
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        While most of the previous genetic studies on mosaic chromosomal alterations were 
restricted to only a limited number of mosaic events that have been demonstrated to be 
potentially pathogenic, several studies have used a systematic approach and analysed mosaic 
chromosomal alterations at a genome-wide scale194,197–199. The clonal mosaic events analysed 
in these studies were either aneuploidy or copy-neutral loss of heterogeneity, with scales 
ranging from 50kb to a whole chromosome. For cis-associations, six germline variants have 
been linked to nearby mosaic chromosomal alterations, including those near FRA10B, MPL, 
ATM, TM2D3/TARSL2, DXZ1 and DXZ4 genes194. For trans-associations, a variant at the SP140L 
gene and a variant within the HLA region have been associated with mosaic loss of 
chromosome X (mLOX)194. Moreover, a more specific search within a subset of carcinogenic 
variants identified TERT, TP53 and CHEK2 genes to be associated with multiple types of clonal 
mosaic events194.  
        Several recent studies have performed GWAS on mLOY in leukocytes at increasingly 
larger scales. The first GWAS on this trait found an common variant located at the 5’ end of 
TCL1A gene, an oncogene that causes T cell leukemia196. More recently, a GWAS meta-
analysis combining samples from UK Biobank, EPIC (European Prospective Investigation of 
Cancer)-Norfolk and deCODE (Diabetes Epidemiology: Collaborative analysis of Diagnostic 
criteria in Europe) cohorts has largely expanded the number of genomic regions associated 
with mLOY to a total of 19, explaining 2.7% of total variance in mLOY195. Functional analyses 
of candidate genes within these regions highlighted pathways involved in DNA repair and cell 
cycle regulation195. Applying a newly developed algorithm of mLOY detection within UK 
Biobank, a study has identified 156 autosomal genetic determinants of mLOY, highlighting 
novel candidate genes functioning in cell-cycle regulation and cancer susceptibility135. 
 
1.4.2.3 Non-genetic risk factors associated with mosaic chromosomal alterations and mLOY 
Mosaic chromosomal alterations occur in an age-dependent manner in normal healthy 
populations200. Structural de novo variants (>50kb) occur more frequently in elderly 
populations, and the frequencies increase proportionately to age between 50 and 80 years201. 
Other studies have reported consistent findings showing that the frequencies of post-zygotic 
structural variants increase along with age in healthy individuals189,190,194,202–206. Moreover, 
distributions of clonal mosaic events were non-random, which exhibited region-specific 
stratifications by age and sex, and higher frequencies around carcinogenic genes194. 
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        Other haematological, behavioural phenotypes and clinical treatments have also been 
associated with clonal mosaicism, including multiple blood cell components, smoking and 
therapeutic treatments for addiction and psychiatric disorders206. 
        mLOY exhibited similar distributions and phenotypic associations to the overall mosaic 
chromosomal alterations206. Several studies have demonstrated that older age and current 
smoking status were strong risk factors for mLOY, and suggested a causal effect of current 
smoking on mLOY193,195,196. 
 
1.4.2.5 Clinical consequences of mosaic chromosomal alterations and mLOY 
A variety of clinical consequences can be attributed to mosaic chromosomal alterations and 
mLOY in particular, including cancers, and age-related diseases, such as AD and cardio-
metabolic disorders189,190,207. 
        Mosaic chromosomal alterations often affect specific genes that are involved in cancer 
development200. For instance, somatic mutations in DNMT3A, ASXL1, and TET2 genes have 
frequently been observed in detectable clonal expansions, which have previously been 
implicated in haematological malignancies192. Aberrant clonal expansions of hematopoietic 
cells were strongly linked to carcinogenesis, and often acknowledged as pre-cancerous states, 
with evidence supported by a clinical study that showed ~42% of haematological cancer 
patients (12,380 individuals from the Swedish national patient registers without prior 
selection for haematological phenotypes) exhibited clonality more than 6-months before 
their first cancer diagnoses192. Clonal hematopoiesis has been shown to be associated with 
more than 10-fold higher risks of cancers in haematological tissues194, as well as cancers in 
several non-haematological tissues, yet with smaller effect sizes189,190,193,205. Similar to the 
overall mosaic alterations, mLOY has been associated with cancer-related and all-cause 
mortality193, and risks of cancers at specific sites, such as bladder and prostate but not lung 
tissues196. 
        Non-cancer related diseases have also been reportedly associated with mosaic 
chromosomal alterations and mLOY, such as CVD and AD. Clonal haematopoiesis has been 
suggested to increase risks of CHD and ischemic stroke by approximately 2-fold, as well as 
early-onset myocardial infarction by 4-fold on average17,19. mLOY has been associated with 
increased risk of late onset, sporadic AD207, implying a role of mLOY in age-related 
neurodegenerative disorders. Compared to the implication of mosaic events in cancers, their 
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relevance to non-cancerous age-related diseases, such as CVD, AD and T2D has been less 
studied. How mosaic chromosomal alterations, and mLOY in particular, influence risks of 





GWAS of LTL 
Abstract 
Background LTL is a highly heritable trait, yet previous GWAS have identified only a small 
number of genetic loci, with a large proportion of the heritability unexplained. 
Objectives To expand our current knowledge of genetic regulation of LTL, and propose likely 
causal mechanisms underlying such regulation. 
Methods Genome-wide association analyses were performed in EPIC-InterAct, EPIC-CVD and 
ENGAGE studies followed by meta-analyses, accumulating to 78,592 individuals with densely 
imputed genotypes. Causal gene candidates were prioritised via multi-omic data integration 
using methods, such as S-PrediXcan and statistical co-localisation. Pathway enrichment 
analyses were performed to identify potential biological mechanisms that underpin genetic 
regulation of LTL.  
Results There were 17 genomic regions associated with LTL at genome-wide significance level, 
among which 6 were novel, located in or near SENP7, MOB1B, CARMIL1, PRRC2A, TERF2, 
RFWD3 genes. Moreover, there were 32 additional regions identified at FDR<0.05. In total, 
we prioritised 32 causal gene candidates, which were functionally enriched in pathways 
involving telomere structure and maintenance, DNA damage response, and nucleotide 
metabolism. 
Conclusions Our findings increase the total number of genomic regions associated with LTL, 
with a more comprehensive elucidation of the genetic architecture, and provide better 






Telomeres are ribonucleoprotein complex located at the end of chromosomes, regulating cell 
division and genome integrity, as outlined in more detail above (section 1.4.1.1). TL, most 
commonly measured in human leukocytes (LTL), displays large variation between individuals, 
from birth and throughout the life course, yet is highly heritable, with heritability estimates 
between 44-86%128,171. GWAS so far have Identified 10 genetic regions associated with LTL, 
with a large proportion of the heritability unexplained. Identification of genetic determinants 
of LTL through GWAS has enabled further studies to suggest a causal role of LTL in several 
diseases, including CAD, abdominal aortic aneurysm, various cancers, interstitial lung disease 
and celiac disease151,179,180,208,209. These studies are however limited due to the small number 
of genetic variants that have been identified that replicate between studies96,151–154,157,210,211. 
To further our understanding of LTL regulation and its relationship with diseases we 
conducted a GWAS meta-analysis of 78,592 individuals from ENGAGE (European Network for 
Genetic and Genomic Epidemiology), EPIC-CVD and EPIC-InterAct studies. This chapter 
focuses on the genetic discovery part of the GWAS, including identification of genetic variants, 
and their functional implications with telomere biology via causal gene characterisation and 






2.2.1 Study design 
 
We used data from EPIC-InterAct, EPIC-CVD and ENGAGE studies to perform GWAS on 
standardised mean LTL in up to 79,000 individuals (Supplementary Figure 1). Detailed 
description and demographic characteristics of all study cohorts, for both discovery and 
replication phases are shown in Supplementary Notes and Supplementary Table 1. In brief, 
both EPIC-InterAct and EPIC-CVD are case-cohort studies, with focuses on incident T2D and 
CVD respectively. EPIC-InterAct consists of 12,403 ascertained cases of T2D and a quasi-
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random sub-cohort of 16,154 participants212,213. EPIC-CVD uses the same sub-cohort as 
InterAct, and thus participants included in this analysis are incident cases only (7722 CHD 
cases and 3451 cerebrovascular disease cases)214. ENGAGE study consists of 21 independent 
cohort studies across European countries, which has been previously described151, and 3 
additional studies included in this meta-analysis are GENMETS215, a Finnish population-based 
cohort study of T2D cases and controls; NESDA (the Netherlands Study of Depression and 
Anxiety)216 and Rotterdam Study that investigates occurrence and determinants of diseases 
in the elderly217. All individuals included in the analyses are of European descent and provided 
written informed consent.  
        GWAS were performed separately for each study or subset/stratum contributing to 
either EPIC-InterAct, EPIC-CVD or ENGAGE, followed by inverse variance weighted meta-
analyses, as outlined in more detail below (section 2.2.3). Compared to the previous 
publication by the ENGAGE consortium, this GWAS meta-analysis more than doubled the 
previous sample size, and largely expanded SNP coverage by ~5-fold via upgrading the 
imputation reference panel from HapMap II to HRC and 1000G, increasing the total number 
of genetic variants to over 10 million (section 2.2.2)151. A systematic conditional analysis was 
performed for each locus at FDR<0.05 (section 2.2.5), followed by cross-platform 
bioinformatic annotations of independent variants at each locus as well as their closely 
correlated variants (LD r2>0.8). Causal gene candidates were prioritised using a variety of 
computational prediction methods that integrate transcriptional and epigenetic data and 
validated by knowledge-driven manual curation. Pathway enrichment analyses were 
performed to characterise functional commonalities shared between prioritised genes. 
Clinical consequences of genetic variations in LTL were tested in a hypothesis-free, phenome-
wide scan in UK Biobank (chapter 3).  
 
2.2.2 LTL Measurements and QC analysis 
 
LTL measurements were conducted using an established quantitative polymerase chain 
reaction (PCR) technique which expressed TL as a ratio of the telomere repeat numbers (T) to 
the single copy of a housekeeping gene (S)42,43. LTL measurements were standardised using 
either a calibrator sample or by quantifying against a standard curve, depending on 
laboratories (Supplementary Table 1 and Supplementary Notes). Full details of methods 
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employed by different laboratories, along with QC parameters, are given in the 
Supplementary Notes. As the use of different calibrator samples and standard curves can lead 
to different ranges in T/S ratios observed between laboratories, we standardised LTL using a 
z-transformation approach (z = (µ - µ0)/σ, µ, T/S ratio, µ0, mean of T/S ratio, σ, standard 
deviation (SD)). 
 
2.2.3 Genotyping, GWAS analysis and study level QC 
 
Genotyping platforms and imputation methods and panels varied across participating study 
centres. Detailed information about these is provided in Supplementary Figure 1 and 
Supplementary Table 2. GWAS was performed within each contributing study or 
subset/stratum: for EPIC-InterAct and EPIC-CVD studies, analyses were stratified by disease 
status (incident T2D cases, incident CVD cases, control cohort participants) and genotyping 
platforms (Human CoreExome, Illumina-660W-Quad and HumanOmniExpress), resulting in 9 
individual GWAS for the EPIC meta-analysis; for ENGAGE consortium cohorts, a total of 24 
contributing studies were analysed separately and then meta-analysed. We used linear 
regression under an additive mode of inheritance with adjustment for age, sex and study 
specific covariates including batch of LTL measurement, study centre and genetic PCs. Within 
each study or subset/stratum, related samples (k>0.088) were removed. Population 
stratification was estimated using the genomic control inflation factor, λ (QQ plots were 
shown in Supplementary Figure 2), and used to adjust standard errors of results from each 
GWAS. Genetic variants were kept based on standard criteria including call rates > 95%, 
Hardy–Weinberg equilibrium p-value > 1 X 10−6, imputation quality scores > 0.4 or R2>0.3, 
minor allele counts ≧ 10 and standard errors of association estimates ranging from 0 to 




GWAS summary statistics were combined via two steps of meta-analyses using inverse 
variance weighting in GWAMA (Genome-Wide Association Meta-Analysis)218. In the first step, 
we performed the EPIC meta-analysis across 9 subsets/strata that contribute to the EPIC-
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InterAct and EPIC-CVD studies, and a separate meta-analysis across all 24 cohort studies 
within the ENGAGE consortium. Fixed effects were used except for variants with significant 
heterogeneity (Cochrane’s Q: p-value<1x10-6) where random effects were used. Genomic 
control was applied at this step of meta-analysis. Genetic variants that had more than 40% of 
the total sample size in each of these two meta-analyses were retained. In the second step, 
we meta-analysed results from EPIC meta-analysis with those from ENGAGE using fixed 
effects inverse variance weighted method. No genomic control was applied at this step. We 
calculated FDR by estimating q-values219.  
 
2.2.5 Conditional association analysis 
 
Conditionally independent signals were identified by an approximate genome-wide stepwise 
method using GCTA (Genome-wide Complex Trait Analysis, Version 1.25.2)220,221. Summary 
statistics for SNPs included in the final step of meta-analysis were used as the input, with a p-
value cut-off of 1.03X10-5 (FDR=0.05) used to indicate regional significance level. The model 
starts with the most significant SNP, with more SNPs added iteratively in a forward stepwise 
manner, and conditional p-values calculated for all SNPs considered within the model. This 
forward selection process was repeated until no more SNPs can be added into the model, i.e. 
no more added SNPs that can reach the conditional p-value threshold. During the selection 
process, if SNPs show evidence of collinearity (LD r2>0.9, estimated based on a random 
subcohort of UK biobank, n=50k) with any of the existing SNPs in the model, those SNPs will 
be automatically dropped and excluded from the model220. Joint effect of each selected SNP 
in the model was calculated and reported as conditionally independent effect of that SNP. 
Regional plots of genome-wide significant loci were generated using LocusZoom222 with LD 
structure estimated using the random subcohort of UK biobank (Supplementary Figure 3). 
 
2.2.6 Gene prioritization 
 
2.2.6.1 Variant annotation 
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Variants (conditional p-value < 1.03 X 10-5) and their closely related variants (LD r2>0.8) were 
annotated on the human reference genome sequence hg19 using Annovar (v2017July16)223 
and Variant Effect Predictor (VEP)54. Their functional consequences on protein sequences 
encoded by the nearest genes were cross-referenced by definitions from RefGene224, 
Ensembl gene annotation225, GENCODE226 and UCSC human genome database55. These 
variants were also evaluated for features (UCSC genome database) including evolutionary 
conservation: whether they reside in or specifically encode a conserved element by multiple 
alignments across 46 vertebrate species, chromatin states predicted using Hidden Markov 
Models trained by CHIP-seq (CHromatin ImmunoPrecipitation assays with sequencing) data 
from ENCODE (ENCyclopedia Of DNA Elements, 15 classified states across 9 cell types), 
histone modification markers (active promoter: H3K4Me3, H3K9Ac; active enhancer: 
H3K4me1, H3K27Ac; active elongation: H3K36me3; and repressed promoters and broad 
regions: H3K27me3) and CCCTC-binding Factor (CTCF) transcription factor binding sites across 
9 cell lines, conserved putative transcription factor binding sites (TFBS) and DNaseI 
hypersensitive areas curated from ENCODE database. For variants within exons, they were 
further annotated with allele frequencies from 7 ethnic groups from the Exome Aggregation 
Consortium database, and functional predictions using a number of different algorithms 
(Supplementary Table 6). For non-coding variants we performed integrated analysis with SNP 
Nexus IW scoring227 (Supplementary Table 8). 
 
2.2.6.2 Transcriptomic data integration 
 
(1) With summary statistics, we performed a gene-level analysis using S-PrediXcan that links 
LTL to predicted gene expressions across 44 tissues (GTex v6p). It uses multivariable sparse 
regression models that integrate cis-SNPs within 2Mb windows around boundaries of gene 
transcripts to predict corresponding gene expression levels. Detailed description of the 
method can be found elsewhere60,228. In brief, individual SNP-LTL associations were weighted 
by SNP-gene (wlg) and SNP-SNP (
"#
"$ ) association matrices estimated from the PredictDB 
training set (zg = ∑ wlg "#"$ 	zl#∈$ , for a gene (g); the set of SNPs (l) were selected from an elastic 
net model with a mixing parameter of 0.5). Protein-coding genes with qualified prediction 
model performance (average Pearson’s correlation coefficients r2 between predicted and 
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observed gene expression levels >0.01, FDR<0.05) were included in our analysis. We 
considered a predicted gene expression to be significantly associated with LTL at a Bonferroni 
corrected p-value threshold (p-value<2.61 X 10-7), conservatively assuming association test 
for each gene-tissue pair as an independent test. 
 
(2) Because the S-PrediXcan analysis may contain false positive findings especially when LD 
structures do not match closely between populations where the SNP-LTL and the SNP-gene 
association matrices were estimated, and/or tissue sample sizes are small228, we used another 
eQTL integration method to calibrate S-PrediXcan results, the statistical colocalisation 
method63. This method, using a COLOC Bayesian approach, tested whether there was 
evidence for potential causal variants being shared between LTL and gene expression levels. 
We analysed all loci significantly associated with LTL at FDR<0.05, and defined a region for 
testing as a 2Mb window flanking the lead variant of that region. Regional summary statistics 
were extracted from this GWAS meta-analysis for associations with LTL and GTex v759 for cis-
eGenes (genes with at least one significant eQTL at FDR < 0.05) located within or on 
boundaries of LTL loci identified at FDR < 0.05. Default priors were applied (prior probabilities 
of SNPs to be associated with either LTL or gene expressions to be 1X10-4 and with both to be 
1X10-5). Evidence for colocalisation was assessed by comparing PPAs for two hypotheses: 
associations with both traits were driven by the same causal variant (hypothesis 4) and by 
distinct variants (hypothesis 3). We defined an eGene as having evidence of genetic 
colocalisation with LTL when the ratio of PPA for the hypothesis 4 to the sum of PPAs for both 
hypotheses 3 and 4 was larger than 0.9. 
 
2.2.6.3 Epigenomic (DNA methylation) data integration 
 
For genes whose expressions are modulated by epigenetic modifications, such as methylation 
of transcriptional regulators in cis, integrating genetic associations with cis-methylation 
probes (cis-meQTLs at FDR<0.05) can help prioritise causal gene candidates with evidence 
from epigenetic transcription modulation. For this, I conducted 1) a systematic search of lead 
variants of LTL-associated loci and their proxies (r2>0.8) in multiple publicly available meQTL 
databases229–231. 2) an epigenome-wide association scan that integrates multiple variant 
associations with cis methylation probes with those with LTL, using a regularised linear 
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regression model, which algorithmically is similar to a transcriptome-wide association 
analysis, previously described in detail elsewhere61. A reference panel for the cis-meQTLs was 
constructed based on individuals in the EPIC-Norfolk cohort, with detailed descriptions 
published elsewhere195. Bonferroni correction was applied, accounting for the total number 
of CpG markers tested (p-value=1.00 × 10−7). 
 
2.2.8 Pathway enrichment analysis 
 
2.2.8.1 Protein ANalysis THrough Evolutionary Relationships (PANTHER) 
 
A list of prioritised genes at each locus (or the nearest gene where no prioritization was 
possible) was submitted for statistical overrepresentation testing (Fishers exact test) in 
PANTHER232. Pathways were considered over-represented where FDR<0.05.  
 
2.2.8.2 Data-driven Expression-Prioritized Integration for Complex Traits (DEPICT) 
 
I also used a hypothesis-free, data-driven approach to highlight reconstituted gene sets and 
tissue/cell types where LTL-associated loci were enriched using DEPICT. Detailed description 
of gene set construction has been published elsewhere233. Briefly, DEPICT leveraged a broad 
range of pre-defined pathway-oriented databases to construct gene sets (14,461), including 
GO (Gene Ontology) terms234, KEGG (Kyoto Encyclopaedia of Genes and Genomes) 
database235, Reactome pathways236, experimentally-derived protein-protein interaction sub-
network237 and a gene-phenotype matrix curated by Mouse Genetics Initiative238. Summary 
statistics of uncorrelated SNPs (LD r2≦0.5) significantly associated with LTL at a genome-wide 
level (p-value<5X10-8) were used as input, with the HLA region (chr6:29691116–33054976) 
excluded. DEPICT first characterised gene functions based on pairwise co-regulation of gene 
expressions, which were quantified as membership probabilities across all reconstituted gene 
sets. Then for each gene set, it assessed enrichment by testing if the sum of membership 
probabilities of all genes within each LTL-associated locus was higher than that for a gene 
density-matched random locus. Correlations (Pearson’s r2≧0.3) between significant gene sets 






2.3.1 Discovery of novel genetic determinants of LTL 
 
In total, 20 sentinel variants at 17 genomic loci were independently associated with LTL at a 
level of genome-wide statistical significance (p-value<5x10-8, Table 2.1, Supplementary Figure 
2), including 6 novel loci [Sentrin/SUMO Specific Peptidase 7 (SENP7), MOB Kinase Activator 
1B (MOB1B), Capping Protein Regulator And Myosin 1 Linker 1 (CARMIL1), Proline Rich Coiled-
Coil 2A (PRRC2A), TERF2, Ring Finger And WD Repeat Domain 3 (RFWD3)]. We also identified 
genome-wide significant variants in 4 recently reported loci from a Singaporean Chinese 
population [POT1, Poly(ADP-Ribose) Polymerase 1 (PARP1), ATM and M-Phase 
Phosphoprotein 6 (MPHOSPH6)]240 (Supplementary Table 5) and confirmed associations at 7 
previously reported loci in European ancestry studies (TERC, NAF1, TERT, OBFC1, ZNF208, 
RTEL1, and DDB1 And CUL4 Associated Factor 4 (DCAF4))151,153. Two and three conditionally 
independent signals were detected within the TERT and RTEL1 loci respectively (section 2.2.5, 
Table 2.1). Within the known loci, three variants within the DCAF4 (r2=0.05) and TERT (r2<0.5) 
loci were distinct from previously reported sentinel variants, while five (r2>0.8, TERC, NAF1, 
OBFC1, ZNF208 and RTEL1, Supplementary Table 3) were in high LD with the previously 
reported ones from European studies. For loci identified in the Singaporean Chinese 
population, we observed the same sentinel variant for PARP1, high LD variants for ATM and 
MPHOSPH6 (r2>0.8) but a distinct sentinel for POT1 (r2<0.5, Supplementary Table 5). For the 
RTEL1 locus, there were significant differences in LD structures between ancestral 
populations. All variants within the RTEL1 locus we reported at genome-wide statistical 
significance were in low LD with those reported in the Singaporean Chinese study211,240. Our 
novel variants were of lower frequency (MAF<0.1) and were either reported as being 
monoallelic (monomorphic) or fell below the MAF threshold for analysis in the Singaporean 
Chinese population (MAF<0.01). This suggested that genetic variation in this region may be, 
in part, population specific or that the MAF was so low that we currently were unable to 
detect any associations. 
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        A total of 32 additional variants met the FDR threshold of 0.05 (Supplementary Table 4). 
These variants were located within separate loci to those reported above, with the exception 
of a fourth, independent signal in the RTEL1 locus. Although we did not replicate the 
previously reported ACYP2 locus at genome-wide significance, this remained within variants 
identified at the FDR<0.05 threshold. Thymidylate Synthetase (TYMS), identified as genome-
wide significant in a trans-ethnic meta-analysis of the Singaporean Chinese240 and the 
previously reported ENGAGE analysis151, was also within the FDR<0.05 identified loci. This was 
to be expected considering a substantial sample overlap with the ENGAGE data, however our 
sentinel variant was distinct and not reported in the Singaporean Chinese study. Aligning our 
data to available summary statistics from that study (Singaporean Chinese samples only) we 
saw at least nominal support for the vast majority of our genome-wide significant loci, with 
the exception of OBFC1 and SENP7 (Supplementary Table 5). Whilst SENP7 is a novel locus, 
variants in high LD (r2>0.6) with our OBFC1 sentinel variant have been reported in other 
European populations154,210. There is also support for many variants in our extended FDR list. 
However, it should be noted that data was not available for around half of our FDR<0.05 loci, 
with most of these being either monoallelic or of too low frequency to have been included 
within the analysis in the Southern Chinese Han population, again suggesting several of the 
FDR<0.05 loci may be specific to the European population. 
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Table 2.1 Independent variants associated with LTL at genome-wide significance (p-value=5X10-8). 
Additional, independent signals detected using conditional analysis are included*. Gene denotes the closest or candidate genes within the region. EA is effect 
allele, EAF is effect allele frequency within the study, Beta is per-allele effect on z-scored LTL and SE is standard error. Previously reported loci were defined 
as loci reported before 1st September 2019. 
  SNP Gene Chr Position EA EAF Beta SE p-value 
Previously  rs3219104 PARP1 1 226562621 C 0.83 0.042 0.006 9.60E-11 
reported loci rs10936600 TERC 3 169514585 T 0.24 -0.086 0.006 7.18E-51 
 rs4691895 NAF1 4 164048199 C 0.78 0.058 0.006 1.58E-21 
 rs7705526 TERT 5 1285974 A 0.33 0.082 0.006 5.34E-45 
 rs2853677* TERT 5 1287194 A 0.59 -0.064 0.006 3.35E-31 
 rs59294613 POT1 7 124554267 A 0.29 -0.041 0.006 1.17E-13 
 rs9419958 STN1 (OBFC1) 10 105675946 C 0.86 -0.064 0.007 5.05E-19 
 rs228595 ATM 11 108105593 A 0.42 -0.029 0.005 1.43E-08 
 rs2302588 DCAF4 14 73404752 C 0.10 0.048 0.008 1.68E-08 
 rs7194734 MPHOSPH6 16 82199980 T 0.78 -0.037 0.006 6.94E-10 
 rs8105767 ZNF208 19 22215441 G 0.30 0.039 0.005 5.42E-13 
 rs75691080 RTEL1/STMN3 20 62269750 T 0.09 -0.067 0.009 5.99e-14 
 rs34978822* RTEL1 20 62291599 G 0.02 -0.140 0.023 7.26E-10 
 rs73624724* RTEL1/ZBTB46 20 62436398 C 0.13 0.051 0.007 6.33E-12 
Novel loci rs55749605 SENP7 3 101232093 A 0.58 -0.037 0.007 2.45E-08 
 rs13137667 MOB1B 4 71774347 C 0.96 0.077 0.014 2.43E-08 
 rs34991172 CARMIL1 6 25480328 G 0.07 -0.061 0.011 6.19E-09 
 rs2736176 PRRC2A 6 31587561 C 0.31 0.035 0.006 3.53E-10 
 rs3785074 TERF2 16 69406986 G 0.26 0.035 0.006 4.64E-10 
 rs62053580 RFWD3 16 74680074 G 0.17 -0.039 0.007 4.08E-08 
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2.3.2 Prioritization of likely causal genes 
 
We applied in silico prediction tools, leveraging large-scale human genomic data integrated 
with multi-tissue gene expression, transcriptional regulation and DNA methylation data, and 
knowledge-driven manual selection to prioritise likely-causal genes (section 2.2.6, 
Supplementary Tables 7, 9 and 10, and Supplementary Notes). Where prioritisation methods 
suggested multiple causal genes for a given locus, we pinpointed the most probable one, 
where feasible, as that showing the greatest number of lines of evidence with supports from 
manual annotation (Supplementary Notes). We were able to predict likely causal genes at 15 
of the 17 loci at genome-wide significance and 17 of the 32 loci at FDR<0.05, many of which 
were for the first time linked to telomere biology, providing novel insights into gene functions 
that are potentially implicated in TL regulation (Table 2.1, Supplementary Table 10). 
        Within the novel loci, four genes have known roles in TL regulation (PARP1, POT1, ATM, 
TERF2, Figure 2.1). For PARP1, a variant in complete LD with our identified sentinel variant 
causes the V762A substitution (Supplementary Table 6) known to reduce PARP1 activity34. 
This variant was associated with shorter LTL, in agreement with studies showing that knock 
down of PARP1 led to telomere shortening35,36. 
        Three genes, DCAF430-31, SENP731 and RFWD3, prioritised based on deleterious protein 
coding changes (DCAF4, SENP7) or strong evidence linking to gene expression levels (RFWD3) 
were all involved in DNA repair. SENP7 has been demonstrated to have binding affinity to 
damaged telomeres33, giving further credibility to this gene. Components of DDR and repair 
pathways (such as ATM) have previously been shown to play roles in telomere regulation32. 
        The PRRC2A locus contains 11 genetically-linked SNPs located across the major 
histocompatibility complex (MHC) class III region, which is a highly polymorphic and gene-
dense region with complex LD structure. BAG6 and CSNK2B were suggested as causal gene 
candidates for this region, which were supported by evidence showing associations of their 
genetically predicted gene expressions with LTL (Supplementary Notes, Table 2.1, 
Supplementary Table 7). BAG6 is linked to DNA damage signalling and apoptosis241, whilst 
CSNK2B, a subunit of casein kinase 2, binds to TERF1 and regulates telomere homeostasis242. 
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Figure 2.1. Loci with established roles in telomere biology. 
Candidate genes found in this study are in red, genes not identified in this GWAS meta-
analysis are in yellow. Candidate genes include genes that encode components of the 
SHELTERIN complex (Aa), regulate the formation and activity of telomerase (Ab), and 






































2.3.3 Pathway enrichment 
 
To investigate context-specific functional connections between prioritised genes of the 17 
genome-wide significant loci and suggest plausible biological roles of these genes in TL 
regulation, we performed enrichment analyses for pathways using DEPICT and PANTHER 
(Section 2.2.8). Over 300 reconstituted gene sets (DEPICT) were significantly (FDR<0.05) 
enriched for the LTL loci, which can be further clustered into 34 meta-gene sets, highlighting 
pathways that are involved in several major cellular activities, including DNA replication, 
transcription and repair, cell cycle regulation, immune response and intracellular trafficking 
(Figure 2.2A). 
        The PANTHER analysis identified several telomere related pathways, including regulation 
of telomeric loop disassembly, t-circle formation, protein binding at telomeres and single 
strand break repair as being the most highly overrepresented. Amongst other expected 
pathways, cellular ageing and senescence were also highlighted. Of note, nucleotide 
metabolism pathways were overrepresented (2'-deoxyribonucleotide metabolic process, 
deoxyribose phosphate metabolic process, deoxyribonucleotide metabolic process, Figure 
2.2B, Supplementary Table 11). Three genes were matched to this pathway, SAM and HD 
domain containing deoxynucleoside triphosphate triphosphohydrolase 1 (SAMHD1), single-
strand selective monofunctional uracil DNA glycosylase 1 (SMUG1) and TYMS. In addition, two 
further genes within other identified loci, deoxycytidine kinase (DCK), thymidine kinase 1 
(TK1), were key regulators of dNMP biosynthesis, even though not highlighted in the pathway 
analysis, adding further support to nucleotide metabolism as a key pathway in regulating 
LTL243. dNTPs constitute the fundamental building blocks required for DNA replication and 
repair244,245. Genetic perturbations that disrupt dNTP homeostasis have been shown to result 
in increased replication error, cell cycle arrest and DNA damage induced apoptosis246–248. 
        TK1 and DCK are the rate-limiting enzymes that catalyse the first step of the salvage 
pathway of nucleotide biosynthesis, either phosphorylating deoxythymidine (dT) to produce 
dTMP, or deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA) to dCMP, dGMP 
and dAMP respectively (Figure 2.2B). The salvage pathway relies on extracellular nucleosides 
originated from diet or dephosphorylation of recycled nucleotides, whereas the de novo 
pathway utilises basic constituents, including glucose and amino acid derivatives249. TYMS is 
considered as a component of the de novo pathway, converting dUMP to dTMP, where the 
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dUMP substrates can be derived either from de novo synthesis or deamination of dCMP 
(Figure 2.2B). 
        Besides controlling biosynthetic pathways, equilibrium of cellular dNTP levels is also 
achieved by regulating degradation that prevents overproduction of dNTPs, where an enzyme 
encoded by another prioritised gene, SAMHD1 plays a role. It catalyses hydrolysis of dNTPs 
to deoxynucleosides and triphosphates, thereby preventing accumulation of excess dNTPs250 
(Figure 2.2B). The finely-tuned dNTP supply system inhibits incorrect insertion of bases into 
DNA synthesis, which is also monitored by a base excision repair enzyme, SMUG1 that 
removes uracil and oxidised derivatives from DNA molecules248,251 (Figure 2.2B).  
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Figure 2.2 Pathways Enriched for Telomere-associated Genes. 
A. Gene sets significantly (FDR<0.05) enriched for prioritised LTL-associated genes. Colour 
intensity of nodes (gene sets) was classified into three levels, reflecting enrichment strengths 
(FDR). Edge width indicates Pearson correlation coefficient (r2) between each pair of the gene 
sets. B. Role of telomere-associated genes in nucleotide metabolism. Five enzymatic reactions 





















































In this chapter, I present genome-wide genetic association findings for LTL, biological 
relevance of prioritised genes and their functional interconnections. The clinical 
consequences of TL dysregulation will be elucidated in detail in the subsequent chapter. 
 
2.4.1 Discovery of novel variants within loci containing known telomere-related genes 
 
Using this larger, and more densely imputed dataset we identified 20 lead variants at level of 
genome-wide significance and a further 32 at FDR<0.05. Within established loci we reported 
a second, independent, association signal within the TERT locus and redefined the RTEL1 locus 
into three independent signals. By applying a range of in silico tools that integrate multiple 
lines of evidence, we were able to pinpoint likely causal genes for the majority of independent 
lead variants (32 of 52), several of which represent key telomere regulating pathways 
(including components of the telomerase complex, the telomere binding SHELTERIN and CST 
complexes and the DDR pathway). 
        Telomeres function to prevent 3’ single-stranded overhangs at the end of chromosomes 
from being detected as double-stranded DNA breaks. This is achieved through binding of the 
SHELTERIN complex (TERF1, TERF2, RAP1, TIN2, TPP1 and POT1) which acts to block activation 
of DDR pathways by several mechanisms252. SHELTERIN also binds a number of accessory 
factors that facilitate processing and replication of the telomere, including the DNA helicase 
RTEL1253. SHELTERIN also interacts with the CST complex that regulates telomerase access to 
telomeric DNA254. The identified loci contain two of the SHELTERIN components (TERF2, 
POT1), a regulator of TERF1, CSNK2B at the PRRC2A locus255, the helicase RTEL1 and the CST 
component STN1.  
        Whilst telomere binding proteins and structure aims to inhibit activation of DDR 
pathways, there is also evidence of a paradoxical involvement of a number of DDR factors in 
TL maintenance, including both of the prioritised genes ATM and PARP1256–259. TERF2 inhibits 
ATM activation and classical non-homologous end joining (c-NHEJ) at telomeres, and thus 
preventing synapsis of chromosome ends260–262. However, ATM activation is required for 
telomere elongation, potentially by regulating access of telomerase to telomeres end through 
ATM-mediated phosphorylation of TERF1256,257. It is possible that other DDR regulators can 
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impact TL maintenance through regulating telomeric chromatin states, t-loop dynamics and 
single-stranded telomere overhang processing263. Other prioritised genes (SENP7, RFWD3) 
also function within the DDR pathways, suggesting a plausible mechanism through which they 
may influence LTL. 
        The telomerase enzyme is capable of extending telomeres and/or compensating 
sequence loss due to the end replication problem in stem and reproductive cells264,265. 
Associated loci include genes encoding the core telomerase components TERT and TERC along 
with the chaperone protein NAF1. NAF1 is required for TERC accumulation and its 
incorporation into the telomerase complex266. After transcription, TERC undergoes complex 
3’ processing to produce the mature 451bp template267,268. This post-transcriptional process 
involves components of the RNA exosome complex, PARN (Poly(A)-Specific Ribonuclease) and 
PAPD5 (PAP-Associated Domain-Containing Protein 5, also known as the Non-Canonical 
Poly(A) RNA Polymerase PAPD5) amongst others; this process is not fully understood269–271. 
In addition to variants within regions containing TERT, TERC and NAF1, a prioritised gene from 
another locus (MPHOSPH6) is a component of the RNA exosome272. 
 
2.4.2 Nucleotide metabolism as a key pathway for TL regulation 
 
Utilising the prioritised gene list as well as closest genes to the sentinel variants, we showed 
several pathways were enriched for telomere-associated loci. Of note, we observed 
significant overrepresentation of genes in several nucleotide metabolism pathways 
(Supplementary Table 11 and Figure 2.2). Key genes highlighted within these pathways 
involve in both the biosynthesis (TYMS, TK1 and DCK) and catabolism (SAMHD1) of dNTPs. 
Biosynthesis of dNTPs occurs via two routes, de-novo synthesis and nucleotide salvage 
pathway. TK1 and DCK are the rate-limiting enzymes that catalyse the first step of the salvage 
pathway of nucleotide biosynthesis, converting deoxynucleosides to their monophosphate 
forms (dNMPs) before other enzymes facilitate further phosphorylation to dNDPs and dNTPs 
(Figure 2.2B)273–276.  TYMS is considered as a component of the de novo pathway, and is the 
key regulator of dTMP biosynthesis, converting dUMP to dTMP277,278. However, as dUMP 
substrates can be derived from either de novo synthesis or deamination of dCMP produced 
from the salvage pathway, it could be considered to function within both pathways (Figure 
2.2B)276. Besides controlling biosynthetic pathways, equilibrium of cellular dNTP levels is also 
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achieved by regulating degradation of dNTPs, a key regulator of which is the SAMHD1. It 
catalyses hydrolysis of dNTPs to deoxynucleosides and triphosphates, thereby preventing 
accumulation of excess dNTPs. Besides fine-tuning the dNTP supply system, potential errors 
in base insertion into DNA synthesis are monitored by another prioritised enzyme, the base 
excision repair enzyme, SMUG1248,251.  
        A balanced cellular pool of dNTPs is required for DNA replication and repair as well as 
maintaining proliferative capacity and genome stability. Low levels of dNTPs can induce 
replication stress, subsequently leading to increased mutation rates249,279. A surplus of dNTPs, 
on the other hand, reduces replication fidelity, which also causes higher levels of spontaneous 
mutagenesis280,281. A dynamic balance between biosynthesis and catabolism is required to 
maintain the equilibrium. Since maintaining the balance of intracellular dNTP pool is also 
fundamental to other pathways that are implicated in telomere homeostasis, including 
cellular proliferation and DNA repair, disruption of dNTP homeostasis may trigger a sequence 
of cellular events that interplay synergistically leading to abnormalities of TL and genome 
instability.  
        By clustering the prioritised genes via their functional connections, we highlighted a 
number of pathways that were enriched for TL regulation, which included DNA replication, 
transcription and repair, cell cycle regulation, immune response and intracellular trafficking 
(Figure 2.2A). However, we noted that because the gene prioritisation was based on 
integration of bioinformatic evidence from several publicly available databases, which also 
laid the foundation for establishing pathways used in the enrichment analyses, this approach 
may suffer from self-fulfilling circular arguments. For example, genes involved in telomere 
homeostasis have been prioritised as likely-causal genes, such as TERT, TERC, TERF2, RTEL1 
and POT1, because they have well-established roles in telomere maintenance; however, in 
pathway enrichment analysis, they are also the key contributors that drive the telomere-
related pathways that were significantly enriched, such as regulation of telomere 
maintenance via telomere lengthening, regulation of telomeric loop disassembly, telomere 
capping etc. (Supplementary Table 11). Nevertheless, through analysing functional 
interconnections between our prioritised gene candidates, we can highlight some of the 
known as well as novel mechanisms underlying TL regulation, and provide more relevant gene 
targets for future experimental follow-up studies. 
Chapter 3 
 
Clinical relevance of LTL to cardiometabolic and other common, 
chronic conditions  
 
Abstract 
Background LTL, as a marker of biological age, has been associated with various age-related 
diseases, including CVD and cancers. However, the degree to which LTL is causally linked to 
these diseases is uncertain, and no systematic studies for causal roles of LTL in a broad 
spectrum of common chronic diseases have been conducted. 
Objectives To refine previously reported and discover novel associations of LTL with 
cardiometabolic traits and diseases, as well as other common chronic conditions, including 
cancers. 
Methods Observational association between LTL and incident T2D risk was analysed in EPIC-
InterAct case-cohort study using Prentice-weighted Cox proportional hazards regression 
models with different covariate adjustments. Causal associations with cardiometabolic 
diseases and risk factors were analysed using summary-level results under the MR framework 
with genetic instruments at genome-wide significance or FDR<0.05. Sensitivity analyses were 
performed by excluding the HLA region or implementing other MR models. Phenome-wide 
association study was performed in >350,000 UK Biobank participants testing causal 
associations of LTL with a broad range of common diseases using allele score MR method. 
Results LTL was not associated with T2D risk, either observationally or genetically determined. 
Genetically-longer leukocyte telomeres were associated with lower risk for CHD, as previously 
suggested, but only when using genome-wide significant (OR[95%CI] = 0.87[0.80-0.94], p-
value=4.42X10-4), not FDR variants (OR[95%CI] = 1.05[0.99-1.10], p-value=0.08). They were 
also associated with higher levels of established cardiovascular risk factors, including blood 
pressure, adiposity and circulatory lipid levels; and a range of proliferative conditions, 
including both malignant as well as non-malignant neoplasms, in the phenome-wide analyses. 
Conclusions Our analyses refine previously reported clinical relevance of LTL, including 
relevance to cardiometabolic traits and diseases as well as cancers, and systematically 
characterise potential roles of telomere dysregulation in a broad spectrum of human diseases, 




Severe telomere loss, through loss of function mutations of core telomere and telomerase 
components leads to several diseases, which share features such as bone marrow failure and 
organ damage. These “telomere syndromes” include rare, childhood-onset diseases such as 
dyskeratosis congenita, and adult-onset diseases including aplastic anaemia and idiopathic 
pulmonary fibrosis172–174,282–284. One of the common features of the telomere syndromes is 
premature ageing, as outlined in the introduction (section 1.4.1.4.1). Together with shorter 
TL observed at older ages, this has led to TL (most commonly measured in human leukocytes 
(LTL)) to be proposed as a marker of biological age. Observational studies have linked LTL to 
risks of a range of common age-related diseases, including CAD and some cancers285–290. 
However, the degree to which LTL is causally linked to these diseases is unknown as the 
observed associations may have been due to reverse causation or confounding. Previous MR 
analyses using independent variants in up to 10 genome-wide significant loci as genetic 
instruments for LTL have found some causal evidence to support such associations158,177,179,291, 
but power of the earlier MR studies has been limited by the number and strength of loci 
identified and sample sizes of outcome GWAS. Comparison to observational estimates for 
selected disease outcomes, such as various cancers and CVD, has suggested discrepant 
findings where certain cancers exhibited strong evidence of associations in MR but 
completely no evidence in observational analyses, such as lung cancer, melanoma and glioma 
cancers158, or the patterns and directions of associations were different in MR and 
observational analyses (section 1.4.1.4.2). Whether the MR results were driven by specific 
loci or biased by horizontal pleiotropy or the observational results influenced by confounding 
and reverse causality are unclear. In addition, associations of genetically determined LTL with 
disease outcomes have not been performed systematically to elucidate potential causal 
implications of LTL in a broad spectrum of common chronic diseases. 
        In this chapter, I will characterise roles of LTL in various types of human diseases, 
including cardiometabolic and other common chronic diseases. Using the expanded pool of 
genetic instruments that increased total LTL variability explained, with over 30% or 50% of 
total chip-based heritability of LTL (h2=5.0%) explained by independent variants at genome-
wide significance or FDR<0.05, respectively, I substantially increased power of MR studies. 
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Moreover, with largely increased spectrum of clinical outcomes from biobank cohort studies, 
I discovered causal relevance of LTL to more clinical phenotypes that have not been previously 
studied, such as benign tumours and non-neoplastic, common chronic diseases. With 
increased sample sizes from consortia-led GWAS meta-analyses, I refined uncertain 
associations, such as those with cardiometabolic diseases and related risk factors. Overall this 
chapter identifies more clinical outcomes linked to and refines uncertain associations with 
genetically determined LTL, shedding light upon aetiological mechanisms that underlie 





3.2.1 Observational association of LTL with T2D 
 
Observational association between LTL and incident T2D was analysed in EPIC-InterAct, a 
large-scale prospective case-cohort study, described in more detail previously and in other 
sections (sections 2.2.1 and 5.2.1.1, Supplementary Notes)212,213. The association was 
analysed separately in each country, using Prentice-weighted Cox proportional hazards 
regression models with age as the underlying timescale212,292 and different adjustments for 
confounding. The basic model included adjustments for age, sex, centre and batch; other 
covariates were added successively, including Mediterranean diet score, lifetime pattern for 
alcohol consumption frequency, smoking intensity, questionnaire-based physical activity 
index, the highest level of education attained, BMI and waist circumference. Moreover, a 
multivariable model that included all covariates except for two measures of adiposity, BMI 
and waist circumference; and two models each with BMI or waist circumference were tested. 
These multivariable models were designed to take account of more potential confounders 
and examine effects of obesity on the association of LTL with T2D. Continuous variables, 
except age, were normalised via inverse normal transformation in each country separately; 
categorical variables were coded ordinally. The resultant hazard ratios (HRs) were meta-
analysed across countries using random-effects meta-analysis models. 
 
3.2.2 Assessment of causal effects of LTL on cardio-metabolic traits and diseases 
 
3.2.2.1 Cardio-metabolic diseases 
Causal effects of LTL on the risks of T2D and CHD were studied using summary-level results 
under the MR framework. Two sets of genetic instruments were defined, one with 
conditionally independent lead SNPs of loci at genome-wide significance (p-value=5X10-8), 
and the other more inclusive with all variants that reached the FDR threshold of 0.05. 
Association estimates with the exposure (LTL) were taken from the final GWAS meta-analysis 
(chapter 2), and applied to recent large-scale GWAS meta-analyses for T2D and CVD: for T2D, 
this consisted of three non-overlapping studies/consortia (EPIC-InterAct, UK Biobank, and 
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DIAGRAM (DIAbetes Genetics Replication And Meta-analysis) v3293 with exclusion of the 
InterAct samples), for a total number of 44,417 cases and 489,910 controls; for CHD, this 
consisted of a meta-analysis of results from CARDIoGRAMplusC4D (Coronary ARtery DIsease 
Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery 
Disease (C4D) Genetics) and UK Biobank, for a sample size of 85,358 cases and 551,249 
controls. 
        In the primary analysis, I first calculated the Wald ratio (causal estimate) for each 






; βY, βX, beta 
coefficients for associations with disease outcomes (T2D or CHD) and LTL, respectively; k = 
1,2…the total number of genetic instruments), and then pooled the ratio estimates using 
inverse-variance weighted fixed-effects meta-analysis models, mathematically equivalent to 
weighted linear regression models forced through the origin. In the secondary sensitivity 
analyses, I applied alternative MR methods to correct for horizontal pleiotropic outliers, 
including the MR Egger regression method68,294 and the (penalised) weighted median MR 
method74. I also removed the HLA region due to its high pleiotropy, from both sets of the 
genetic instruments and re-applied the same MR methods with HLA-excluded genetic 
instruments.  
 
3.2.2.2 Cardio-metabolic traits 
I examined associations between genetically predicted longer LTL and a series of continuous 
traits associated with CVD risk, including glycaemic, lipid, blood pressure and adiposity-
related measures. Summary statistics for associations of genetic instruments with glycaemic 
traits were retrieved from the MAGIC (Meta-Analyses of Glucose and Insulin-related traits 
Consortium)295,296, with lipid traits from the GLGC (Global Lipids Genetics Consortium)297, with 
blood pressure traits from the UK biobank and with adiposity-related traits from a meta-
analysis of the GIANT (Genetic Investigation of ANthropometric Traits) and UK Biobank 
studies298,299. 
        I then utilised the same MR approaches as described above in the 3.2.2.1, including 
approaches used in both the primary and secondary analyses. For genetic instruments that 
were missing in the outcome meta-analysis results, I selected proxy SNPs that were 
genetically correlated (LD r2>0.8) and physically closest to them if available. 
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3.2.3 Genetic correlations of LTL to human phenotypes and ageing-related traits 
 
Cross-trait LD score regression (LDSC) analysis was used to measure genetic correlations 
between LTL and selected traits within the LD Hub database300,301 (version 1.4.1). From 832 
available traits curated in the LD Hub, I filtered them for the purpose of QC and avoiding 
redundancy. To be more specific, I removed traits and diseases without prior evidence of 
genetic bases (heritability z-score < 2), traits of medication uses, lipid sub-fractions and for 
which studies with sample sizes<1000. Where multiple datasets of a same trait existed, I firstly 
prioritised results from the largest or most recent consortia-led studies over UK Biobank 
samples only studies. Following this, I prioritised the trait selection based on sample size, 
(publication) date and quality of outcome definition (diagnosed conditions versus self-
reported only). In total, there were 320 phenotypes included in the analysis, covering diverse 
conditions ranging from behavioural risk factors to common complex diseases. 
        Genome-wide summary statistics were used as inputs. In addition to standardised QC 
implemented within the software, variants with MAF (<1% for HapMap3 or <5% for 1000 
Genomes EUR imputed SNPs), sample size (<0.67 times 90th percentile of variants’ sample 
sizes), alleles not aligned to 1000 Genomes, or insertions or deletions or structural variants 
were removed. 
 
3.2.4 Phenome-wide association study (PheWAS) 
 
3.2.4.1 UK Biobank 
The UK Biobank study is a population-based cohort of 500,000 people aged between 40 and 
69 years and recruited from multiple centres in UK from 2006 to 2010302. A range of 
modifiable factors were taken via questionnaires and nurse interviews (such as demographic 
features, family histories of diseases, health status and lifestyles); anthropometric 
measurements, blood pressures and circulatory biomarkers were measured; and blood, urine 
and saliva samples were taken for future analyses. Genome-wide genetic data has been 
collected for every participant with purpose-designed genotyping arrays (the UK Biobank 
BiLEVE and Axiom Arrays) and processed with extensive QC procedures. Clinical follow-up 
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data has been provided through linkage to health and medical records, including primary care 
data and data from national hospital data electronic record systems and national death and 
cancer registries. Detailed description of these datasets can be found elsewhere303. In this 
study, participants that are in close familial relationships (equal to or closer than the third 
degree), or of non-European descent were excluded, resulting in 352,071 individuals for the 
PheWAS. 
 
3.2.4.1 PheWAS on manually curated clinical outcomes 
Using two-sample MR methods304,305 we investigated potential causal effects of LTL on 122 
diseases manually curated in UK Biobank306 (Supplementary Table 13). Disease definitions 
were generated using self-reported histories of diseases or disease-relevant medical 
treatments, combined with records of hospitalisation for the 9th/10th revision of the WHO 
International Classification of Diseases (ICD9/10)-coded clinical outcomes. Diseases were 
selected where there were sufficient case numbers to have 80% power to detect an odds ratio 
(OR) of 1.1 or 0.9 at the 5% alpha level (Supplementary Table 14). LTL was genetically proxied 
by 52 independently associated variants (FDR<0.05). In addition, individual SNP effects on 
diseases were tested using logistic regression in SNPTEST307 adjusted for sex, age, genotyping 
array and the top 5 genetic PCs. Causal association estimates were calculated using the 
inverse variance weighted MR approach. Sensitivity analyses were performed using median-
based MR308, MR-RAPS (Mendelian Randomization using Robust Adjusted Profile Score)309 
and MR-Egger regression310 to cross-validate results and evaluate unbalanced pleiotropic 
effects. 
 
3.2.4.2 PheWAS on the full set of ICD10-codes defined clinical outcomes 
To analyse associations between genetically predicted longer LTL and a broad spectrum of 
clinical outcomes, we performed PheWAS on all individual ICD10-coded diseases at level 2. 
The analyses were restricted to diseases with case numbers greater than 500. In addition, I 
also analysed 35 self-reported cancers, among which 27 were combined with corresponding 
ICD10-coded cancer diagnoses (Supplementary Table 16). Logistic regression was used with 
ICD10-defined outcome cases coded as 1, and the rest as controls coded as 0. Adjustments 
included age, sex, genotyping array and the top 10 PCs. For each participant, we constructed 
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PRS of LTL (alleles aligned to the direction of increasing LTL) by summing up weighted dosages 
of conditionally independent genome-wide significant SNPs. SNP weights were defined as 
absolute values of association beta coefficient estimates. 
        I used the glm() function implemented in R with binomial distribution to test associations 
of weighted PRS of LTL with each of the disease outcomes. Moreover, I adapted the PheWAS 
R package311, converting ICD9 to ICD10 codes, and examined associations between disease 
outcomes and the weighted PRS of LTL, as well as individual locus sentinel SNPs at genome-
wide significance. The same database of disease outcomes was used for the glm() function 
and the PheWAS R package based methods. The two methods produced exactly the same 
results for overlapping associations tested. Associations with p-values smaller than 1.3x10-4 
(Bonferroni corrected for a total number of 370 diseases tested) were reported as being 
statistically significant. 
 
3.2.5 Variants-based cross-database query 
 
Independent variants (FDR<0.05) and their strong proxies (r2≥0.8) were queried against 
publicly available GWAS results using PhenoScanner312 for computational efficiency. A list of 
GWAS results implemented in the software was previously published312. Results were filtered 
to include associations with p-values<1X10-6 and in high LD (r2≥0.6) with locus sentinel SNPs. 
To avoid redundancy, for each trait, only results from the most recent and/or largest studies 





3.3.1 Observational association between LTL and incident T2D 
 
Using the largest incident T2D case-cohort study (EPIC-InterAct study, n = 29,238; 45.1% 
cases), I investigated whether measured differences in LTL were associated with development 
of future T2D. No evidence has been found to support an association between LTL and 
incident T2D in any of the models (Figure 3.1) and no substantial between-country 
heterogeneity was found (I2<30% in any models). Of note, France showed a distinct pattern 
of associations compared to the other countries across all models tested, especially after 
adjusting for adiposity-related traits (BMI or waist circumference), such that French 
participants (n=485, all women) showed larger, but opposite associations. However, due to 
the small sample size of the French subset, confidence intervals were large (HR[95%CI] = 
1.12[0.91-1.38] from the basic model and 1.51[1.10-2.08] from a multivariable model 
adjusted for waist circumference) and the overall contribution of the French subset to the 
meta-analysis was small (weight=1.48-2.13% across models). 
 
Figure 3.1. Observational association between LTL and incident T2D risk. 
X-axis indicates HRs of T2D per 1-SD increase of LTL. Alcohol_re: alcohol consumption 
frequency; Mdiet: Mediterranean diet score; pa: physical activity; ed: the highest educational 
level; bmi: body mass index; waist: waist circumference 
 
to be continued on the next page 
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3.3.2 Associations of genetic differences in LTL with cardio-metabolic diseases and traits 
 
3.3.2.1 T2D 
Although observational analyses provided no evidence of a significant or strong association 
between LTL and incident T2D, a negative confounding effect cannot be ruled out. When such 
confounding effects are not properly adjusted, the observed association can be biased 
towards null. To minimise effects from unadjusted confounders and reverse causation, 
summary-level, two-sample MR approaches were used. I observed no significant associations 
between genetically determined LTL and T2D (OR[95%CI] = 1.00[0.92-1.10] for 1-SD increase 
of genetically predicted LTL, p-value=0.92, Table 3.1 and 3.2A) using conditionally 
independent genome-wide significant variants as genetic instruments. The intercept of the 
MR-Egger regression model was not significantly different from 0 (p-value=0.15, Table 3.2A), 
indicating there was no statistically significant directional pleiotropy detected, although there 
was a moderate heterogeneity observed (I2=55.7%). The effect size in the MR Egger 
regression model was smaller (OR[95%CI] = 0.82[0.66-1.01], p-value=0.07, Table 3.2A), yet 
below nominal significance. 
        Using the inverse-variance weighted MR approach but FDR variants as genetic 
instruments, a nominally significant association was observed (OR[95%CI] = 0.94[0.93-0.99], 
p-value=0.01, Table 3.2B), yet below the Bonferroni corrected threshold (p-value=2.08X10-3, 
assuming 24 traits/diseases as independent tests). The between-variant heterogeneity was 
slightly larger among the FDR variants (I2=62.6%).  
        HLA was shown to be strongly associated with the risk of T2D (OR[95%CI] = 2.51[1.60-
3.93]), and because this region has been known to be highly pleiotropic, which might violate 
the MR assumption that genetic instruments cannot be associated with any confounders, and 
not with the outcome conditioning on the exposure, we performed sensitivity analyses 
excluding the HLA region. These showed that the HLA did not influence the MR results, as 
effect sizes were not significant in either stringent or more inclusive (genome-wide versus 
FDR variants) models (OR[95%CI] = 0.97[0.88-1.06], p-value=0.51 and OR[95%CI] = 0.95[0.90-




Shorter LTL has been widely acknowledged to be associated with a higher risk of CHD158,177. 
Using our new genetic instruments that explained a larger proportion of the variability of LTL, 
I replicated earlier studies that showed genetic predisposition to longer LTL was associated 
with a lower risk of CHD (Table 3.1 and 3.2). One SD increase of genetically predicted LTL was 
associated with about 23% reduced CHD risk using the inverse variance weighted MR method 
with conditionally independent genome-wide significant variants as instrumental variables 
(OR[95%CI] = 0.87[0.80-0.94], p-value=4.42X10-4, Table 3.1 and 3.2A). The protective effect 
of longer LTL was in line with previous findings where 7 previously identified genome-wide 
significant variants151 were used as instrumental variables to assess causalities of LTL on 
CAD151 and CVD177, in CARDIoGRAM and UK biobank interim release datasets, respectively. 
The effect sizes were comparable, yet the association strength in our analysis was larger 
possibly due to the better genetic instruments used and the larger sample size of the outcome 
GWAS dataset. 
        The result was further validated in sensitivity analyses using the MR Egger regression 
method (OR[95%CI] = 0.70[0.58-0.85], p-value=2.42X10-4, Table 3.2A). The Egger intercept 
term was not significantly different from 0 (p-value=0.24, Table 3.2A), suggesting no 
statistically detectable horizontal pleiotropy among the genome-wide significant variants, 
even though the overall heterogeneity of causal estimates among these genome-wide 
significant variants was substantial (I2=76.9%). In addition, HLA region showed a strong causal 
effect on CHD (Figure 3.2), but in the opposite direction compared to the overall effect. 
Exclusion of HLA improved the significance of the MR association (OR[95%CI] = 0.83[0.76-
0.90], p-value=1.56X10-5), and slightly reduced the overall heterogeneity (I2=60.9%). 
        Moreover, using the extended list of variants at FDR loci, the protective effect of 
genetically determined longer LTL on CHD became much weaker and below nominal 
significance (OR[95%CI] = 1.05[0.99-1.10], p-value=0.08, Table 3.2B). Exclusion of the HLA 
region did not improve the association strength, as a small weight (1.76%) was given to the 
HLA region. The association was even weaker and remained to be non-significant using the 
MR-Egger approach (OR[95%CI] = 1.01[0.91-1.15], p-value=0.90). The Egger intercept term 
was statistically no different from 0 (p-value=0.52), indicating there was no evidence for 
unbalanced pleiotropy among the FDR variants. Given that FDR variants almost doubled the 
variation explained by genome-wide significant variants, and with these two different sets of 
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genetic instruments, the same dataset for CHD summary statistics was used, such discrepant 
results might suggest that there were specific loci that drove the causal association observed 
between LTL and CHD. This notion was supported by further analyses on causalities of 
individual variants. 
        Further analyses of individual genome-wide significant variants showed that lead variants 
at specific loci (PARP1, TERT and OBFC1 loci) were strong drivers of the protective effect of 
genetically longer LTL on CHD, due to their relatively larger and more precise estimates of the 
causal effects (Figure 3.2), with all being directionally consistent with the overall effect.   
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Table 3.1 Associations between genetically predicted LTL and cardio-metabolic diseases. 
The associations with T2D and CHD are presented in each study that contributed to the 
outcome GWAS meta-analysis separately and overall. LTL was predicted using sentinel 




Disease Study OR [95% CI] weight (%) case N control N p -value
UK Biobank 0.83 [0.74-0.93] 52.17 24,557 427,745 9.29X10
-4
CHD CARDioGRAMplusC4D 0.91 [0.81-1.02] 47.83 60,801 123,504 0.10
Overall 0.87 [0.80-0.94] 100 85,358 551,249 4.42X10
-4
UK Biobank 1.08 [0.97-1.21] 68.28 25,529 424,577 0.15
EPIC-InterAct CoreExome chip 0.86 [0.62-1.21] 7.28 5,121 7,269 0.39
T2D EPIC-InterAct 660W chip 0.83 [0.56-1.23] 5.2 4,187 4,254 0.36
DIAGRAM 0.86 [0.70-1.05] 19.24 34,840 114,981 0.14
Overall 1.00 [0.92-1.10] 100 69,677 551,081 0.92
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Figure 3.2 Pleiotropic effects of LTL-associated variants (p-value<5X10-8) on CHD risk.  
Association beta coefficients are plotted with bars indicating standard errors (SE). Colours 
indicate association strength (p-values) for each variant with the CHD risk, as shown in the 
legend. None of the variants reached genome-wide significance level for their associations 
with the CHD risk.  
 




B. Forest plot showing causal effect estimate for each individual locus sentinel variant. 






3.3.2.3 Cardio-metabolic traits 
We systematically analysed associations of genetically predicted increase of LTL with various 
cardio-metabolic traits. These traits were categorised into several groups, including lipid, 
glycaemic, blood pressure and adiposity-related traits. Genetically predicted longer LTL was 
found to be significantly associated with higher levels of diastolic and systolic blood pressures, 
body fat percentage, BMI-adjusted waist hip ratio, total triglyceride and cholesterol and LDL 
cholesterol levels (Table 3.2A). The BMI-adjusted waist and hip circumferences were 
associated with genetically predicted LTL only in the MR-Egger regression, but not the inverse 
variance weighted MR analyses, possibly due to biases from unbalanced pleiotropy in the 
latter (Egger intercept term p-values = 0.09 and 0.06, respectively, Table 3.2A). 
        Results were similar when using the FDR variants (Table 3.2B). However, because these 
FDR variants-based MR analyses were restricted to traits for which summary results of their 
recent GWAS were available and conducted within Europeans and imputation panels were 
up to date, fewer traits were analysed. 
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Table 3.2 Associations between genetically predicted LTL and cardio-metabolic diseases and traits. 




Extra columns are shown on the next page 
  
Beta (SE) for continous variable
Category Phenotype OR [95% CI] for binary variable Cochran's Q p -value
Disease CHD 0.87 [0.80-0.94] 4.42E-04 15.48 0.56
T2D 1.00 [0.92-1.10] 0.92 9.40 0.93
Adiposity BMI -0.02 (0.01) 0.03 4.33 1.00
BMI-adjusted Wasit/Hip Ratio 0.06 (0.01) 3.51E-08 7.06 0.98
BMI-adjusted Wasit Circumference -0.01 (0.01) 0.56 7.79 0.97
BMI-adjusted Hip Circumference -0.02 (0.01) 0.17 9.71 0.92
Body Fat Percentage -0.04 (0.01) 2.85E-03 11.32 0.84
Lipid Total triacylglycerol 0.08 (0.03) 2.77E-03 3.58 1.00
Total cholesterol 0.11 (0.03) 3.93E-04 5.13 1.00
LDL 0.09 (0.03) 2.85E-03 5.65 1.00
HDL -0.03 (0.03) 0.34 5.48 1.00
Blood Pressure Diastolic BP 0.06 (0.01) 7.33E-07 9.69 0.92
Systolic BP 0.12 (0.01) 3.70E-22 6.67 0.99
Glycaemia Insulin Sensitivity Index Adjusted for BMI 0.01 (0.06) 0.90 6.07 0.99
Insulin Secretion at 30min during OGTT -0.02 (0.14) 0.89 12.20 0.79
HbA1C 0.02 (0.02) 0.26 1.14 1.00
Fasting Plasma Glucose 0.02 (0.01) 0.22 1.23 1.00
BMI-adjusted Fasting Plasma Glucose 0.01 (0.01) 0.31 1.21 1.00
Fasting Plasma Insulin -0.01 (0.01) 0.60 2.48 1.00
BMI-adjusted Fasting Plasma Insulin -0.01 (0.01) 0.22 1.84 1.00
Corrected Insulin Response Adjusted for Insulin Sensitivity 0.03 (0.14) 0.84 9.01 0.91
Plasma Glucose at 120min during OGTT -0.24 (0.21) 0.27 6.79 0.98
Fasting ProInsulin 0.03 (0.05) 0.47 5.07 1.00












Beta (SE) for continous variable Beta (SE) for continous variable Beta (SE) for continous variable
OR [95% CI] for binary variable OR [95% CI] for binary variable OR [95% CI] for binary variable
0.70 [0.58-0.85] 2.42E-04 0.24 0.88 [0.77-1.00] 0.05 0.92 [0.80-1.05] 0.22
0.82 [0.66-1.01] 0.07 0.15 0.97 [0.86-1.10] 0.61 0.96 [0.85-1.09] 0.56
0 (0.03) 0.86 0.55 0.01 (0.02) 0.73 0.01 (0.02) 0.63
0 (0.03) 0.89 0.27 0.04 (0.02) 0.01 0.04 (0.02) 0.01
0.10 (0.02) 5.19E-05 0.09 -0.01 (0.02) 0.78 -0.03 (0.02) 0.08
0.12 (0.03) 6.84E-06 0.06 -0.02 (0.02) 0.21 -0.03 (0.02) 0.11
-0.01 (0.03) 0.83 0.68 -0.01 (0.02) 0.46 -0.02 (0.02) 0.44
0.13 (0.07) 0.04 0.47 0.1 (0.04) 0.01 0.1 (0.04) 0.01
0.01 (0.07) 0.94 0.23 0.04 (0.04) 0.35 0.04 (0.05) 0.38
-0.03 (0.07) 0.68 0.14 0.07 (0.04) 0.09 0.07 (0.04) 0.11
-0.09 (0.07) 0.19 0.51 -0.07 (0.04) 0.12 -0.08 (0.04) 0.07
0.14 (0.03) 8.50E-07 0.23 0.06 (0.02) 7.42E-04 0.06 (0.02) 9.72E-04
0.16 (0.03) 2.73E-08 0.51 0.11 (0.02) 1.75E-08 0.11 (0.02) 2.16E-08
0.2 (0.16) 0.20 0.16 0.06 (0.09) 0.53 0.06 (0.09) 0.53
-0.53 (0.34) 0.12 0.06 -0.01 (0.19) 0.94 -0.01 (0.18) 0.94
-0.02 (0.05) 0.66 0.24 0 (0.03) 1.00 0 (0.03) 0.97
-0.03 (0.03) 0.43 0.17 0.02 (0.02) 0.40 0.02 (0.02) 0.32
-0.05 (0.03) 0.16 0.06 0.01 (0.02) 0.72 0.01 (0.02) 0.66
-0.04 (0.03) 0.24 0.47 -0.01 (0.02) 0.48 -0.02 (0.02) 0.24
-0.05 (0.03) 0.07 0.29 -0.02 (0.01) 0.12 -0.03 (0.01) 0.06
-0.46 (0.35) 0.18 0.05 -0.18 (0.2) 0.37 -0.18 (0.19) 0.34
-0.25 (0.53) 0.64 0.98 -0.1 (0.28) 0.72 -0.1 (0.29) 0.73
0.12 (0.12) 0.31 0.45 0.06 (0.07) 0.40 0.06 (0.07) 0.38
-0.72 (0.35) 0.04 0.03 -0.13 (0.2) 0.51 -0.13 (0.2) 0.50
p -value
MR Egger regression method Median weighted MR method Penalised median weighted MR method






Extra columns are shown below. 
 
 
Beta (SE) for continous variable
Category Phenotype OR [95% CI] for binary variable Cochran's Q p -value
Disease CHD 1.05 [0.99-1.10] 0.08 24.34 1.00
T2D 1.06 [1.01-1.08] 0.01 27.21 1.00
Adiposity BMI 0.01(0.01) 0.09 14.76 1.00
BMI-adjusted Wasit/Hip Ratio 0(0.01) 0.83 18.51 1.00
BMI-adjusted Wasit Circumference 0(0.01) 0.70 19.11 1.00
BMI-adjusted Hip Circumference 0(0.01) 0.70 19.11 1.00
Body Fat Percentage 0.03(0.01) 4.51E-03 21.11 1.00
Blood Pressure Diastolic BP -0.01(0.01) 0.25 18.17 1.00
Systolic BP -0.01(0.01) 0.33 19.08 1.00
Heterogeneity test
Cochran's Q test





Dependent variable Inverse variance weighted MR method
p -value
Beta (SE) for continous variable Beta (SE) for continous variable Beta (SE) for continous variable
OR [95% CI] for binary variable OR [95% CI] for binary variable OR [95% CI] for binary variable
0.99 [0.87-1.1] 0.90 0.52 1.05 [0.94-1.14] 0.37 1.05 [0.94-1.14] 0.36
1.08 [0.97-1.12] 0.17 0.86 1.01 [0.94-1.04] 0.74 1.01 [0.93-1.04] 0.85
-0.03(0.02) 0.20 0.23 -0.02(0.02) 0.28 -0.02(0.02) 0.30
0(0.02) 0.86 0.97 -0.01(0.02) 0.42 -0.02(0.02) 0.16
-0.04(0.02) 0.05 0.40 0.01(0.02) 0.69 0.01(0.02) 0.49
-0.04(0.02) 0.05 0.40 0.01(0.02) 0.69 0.01(0.02) 0.49
-0.05(0.02) 0.02 0.07 0.01(0.02) 0.58 0.02(0.02) 0.27
-0.09(0.02) 2.88E-05 0.06 -0.03(0.02) 0.09 -0.03(0.02) 0.07
-0.08(0.02) 2.36E-04 0.13 -0.02(0.02) 0.20 -0.02(0.02) 0.34
p -value
MR Egger regression method Median weighted MR method Penalised median weighted MR method




3.3.3 Genetic correlations to a variety of human phenotypes and diseases 
 
We explored human diseases and traits that shared common genetic aetiologies with LTL by 
performing LDSC analyses that tested genome-wide genetic correlations between LTL and 320 
selected traits and diseases curated within the LD hub300,301 (section 3.2.3). In comparison to 
the MR approach, these analyses utilise overall GWAS results rather than selected SNPs with 
the most significance. In agreement with our MR analyses, LTL was negatively genetically 
correlated with CAD (r=-0.17, p-value=0.01, Supplementary Table 12). In contrast to the MR 
results in the section 3.3.2.3, genetic correlations of LTL with dyslipidaemic risk factors were 
all in the negative direction, i.e. longer LTL genetically correlated with lower levels of these 
risk factors, therefore directionally concordant with the correlation with CAD. These risk 
factors included LDL and total cholesterol, total triglycerides and HDL cholesterol levels 
(Supplementary Table 12). These suggested shared genetic architecture underlying LTL, CAD 
and CAD risk factors. However, it should be noted that despite some correlations observed, 
the levels of significance were nominal and did not reach the Bonferroni corrected threshold. 
 
3.3.4 PheWAS in UK Biobank 
 
Telomere homeostasis is important for suppressing tumorigenesis and metastatic malignant 
transformation313,314. LTL has previously been associated with risks of overall and site-specific 
cancers158,177,208,315, but causations remain controversial, and significant findings so far have 
been restricted to certain types of diseases that had large-scale GWAS results available. Large 
homogenous cohorts with a more comprehensive coverage of a variety of diseases can help 
to identify associations with additional diseases that have not been studied before, and 
provide additional reference for uncertain causations, yet only when sufficient cases are 
present in such cohorts, which may include cardiometabolic disorders and some common 
cancers. To refine causal associations of LTL with diseases previously reported and discover 
novel associations of LTL with a broader range of diseases, I used a dual approach: PheWAS 
in a smaller but manually refined subset of clinical outcomes, and a larger yet crude full set 
of ICD10-codes defined clinical outcomes in UK Biobank. 
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3.3.4.1 Manually refined subset of clinical outcomes 
Investigating 122 curated outcomes in UKBB, a total of 30 nominally significant associations 
were identified, nine of which passed the Bonferroni corrected threshold (p-value<4.1x10-4, 
Figure 3.3, Supplementary Table 15). These included novel findings of decreased risk of 
hypothyroidism, and increased risks of thyroid cancer, lymphoma and diseases of excessive 
growth (uterine fibroid, uterine polyps and benign prostatic hyperplasia) for individuals with 
longer LTL. Moreover, in line with previous findings genetically predicted longer LTL was 
associated with decreased risk of CAD (p-value=0.01) and significantly increased risks of lung 
and skin cancers and leukaemia after multiple testing correction158,177,185,186,285,291,313,314,316–321. 
Our results also supported a causal role of longer LTL in reducing risks of rheumatoid arthritis, 
aortic valve stenosis, chronic obstructive pulmonary disease (COPD) and heart failure, all of 
which have previously been associated with LTL in prospective, retrospective and MR 
studies158,178,179.  
 
3.3.4.2 Full set of ICD10-codes defined clinical outcomes  
In contrast to previously published findings that highlighted carcinogenic sites with lower 
rates of stem cell division to be more susceptible to genetic differences in LTL158, we found 
various tissues with higher proliferative capacity to have strong associations with LTL, 
including haematological malignancies, male genital and prostate cancer, melanoma and 
malignant neoplasms in epidermal tissue. Similarly, benign neoplasms and non-neoplastic 
disorders were also found more likely to be associated in such tissues (Figure 3.4, 
Supplementary Table 17). It seemed that significant diseases (p-value<0.05) were 
concentrated in two clusters, neoplasms and diseases in genito-urinary system (Figure 3.5). 
        Over one third of the strongly associated diseases exhibited high levels of between-
variants heterogeneities (Cochran's Q test p-value <0.05, Figure 3.4, Supplementary Table 17). 
Some showed locus-specific effects, for example, intestinal malabsorption was heavily driven 
by the HLA locus, excluding which decreased the estimated causal effect by more than 70% 
(OR[95%CI]=0.95[0.92-0.97], Figure 3.4, Supplementary Table 17). Other results did not 
change much after excluding the HLA locus. Moreover, malignant neoplasm of the brain, of 
which 80% cases were attributed to glioma322, one of the most significantly associated cancers 
found by previous studies158,323, was specifically associated with the TERT locus (OR[95% CI] 
per risk allele=1.50[1.27-1.78], p-value =2.05X10-6), but not genetically determined LTL using 
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all genome-wide independent variants combined. Some specific diseases showing evidence 
of associations with individual LTL loci were phenotypically reminiscent of monogenic 
telomere syndromes, for instance, seborrheic keratosis was associated with TERC and TERT 
loci and reminiscent of dyskeratosis congenita, as both of which are commonly featured with 
dermatological dystrophy.  
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Figure 3.3. MR results for effects of shorter LTL on risks of 122 diseases in UK Biobank. 
Data shown are ORs and 95% CIs per 1-SD shorter genetically predicted LTL. LTL is genetically 
predicted using independent variants with FDR<0.05. Diseases are classified into groups as 
indicated by boxes and sorted alphabetically within each disease group. Nominally significant 
(p-value<0.05) causal associations estimated via inverse-variance weighted MR method are 
shown in green for a reduction in risk and red for an increase in risk due to shorter LTL. Where 
O indicates nominal (p-value<0.05) evidence of pleiotropy estimated by MR-Egger intercept. 






Figure 3.4 Significantly associated diseases with longer LTL estimated using genome-wide significant independent lead variants. 
The forest plot shows significant associations with genetically determined LTL, and the heatmap shows z-scores of individual variant associations 

























Figure 3.5 Circular plot of PheWAS of LTL. 
LTL is estimated using independent lead variants at genome-wide significant loci. All ICD10-coded disease outcomes are clustered into 22 
categories colour labelled. Z-scores were plotted as bar heights. Diseases with absolute z-scores larger than 1.96, corresponding to a nominal 

















































































Certain conditions originating in the perinatal period
Certain infectious and parasitic diseases
Codes for special purposes
Congenital malformations, deformations and chromosomal abnormalities
Diseases of the blood and blood−forming organs and certain disorders involving the immune mechanism
Diseases of the circulatory system
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Diseases of the ear and mastoid process
Diseases of the eye and adnexa
Diseases of the genitourinary system
Diseases of the musculoskeletal system and connective tissue
Diseases of the nervous system
Diseases of the respiratory system
Diseases of the skin and subcutaneous tissue
Endocrine, nutritional and metabolic diseases
External causes of morbidity and mortality
Factors influencing health status and contact with health services
Injury, poisoning and certain other consequences of external causes
Mental and behavioural disorders
Neoplasms
Pregnancy, childbirth and the puerperium











































































Certain conditions originating in the perinatal period
Certain infectious and parasitic diseases
Codes for special purposes
Congenital malformations, deformations and chromosomal abnormalities
Diseases of the blood and blood−forming organs and certain disorders involving the immune mechanism
Diseases of the circulatory system
Diseases of the digestive system
Diseases of the ear and mastoid process
Diseases of the eye and adnexa
Diseases of the genitourinary system
Diseases of the musculoskeletal system and connective tissue
Diseases of the nervous system
Diseases of the respiratory system
Diseases of the skin and subcutaneous tissue
Endocrine, nutritional and metabolic diseases
External causes of morbidity and mortality
Factors influencing health status and contact with health services
Injury, poisoning and certain other consequences of external causes
Mental and behavioural disorders
Neoplasms
Pregnancy, childbirth and the puerperium











































































Certain conditions originating in the perinatal period
Certain infectious and parasitic diseases
Codes for special purposes
Congenital malformations, deformations and chromosomal abnormalities
Diseases of the blood and blood−forming organs and certain disorders involving the immune mechanism
Diseases of the circulatory system
Diseases of the digestive system
Diseases of the ear and mastoid process
Diseases of the eye and adnexa
Diseases of the genitourinary system
Diseases of the musculoskeletal system and connective tissue
Diseases of the nervous system
Diseases of the respiratory system
Diseases of the skin and subcutaneous tissue
Endocrine, nutritional and metabolic diseases
External causes of morbidity and mortality
Factors influencing health status and contact with health services
Injury, poisoning and certain other consequences of external causes
Mental and behavioural disorders
Neoplasms
Pregnancy, childbirth and the puerperium
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
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3.3.5 Single-locus based cross-phenotype associations 
 
We also examined individual locus-driven genetic correlations between LTL and a variety of 
human phenotypes and diseases by querying 52 conditionally independent variants at FDR 
loci and their closely-related SNPs in LD (r2≧0.8) across publicly available GWAS databases 
using PhenoScanner312. While some morbidities showed specific correlations to individual loci, 
others were correlated to a broader spectrum of loci. For example, self-reported 
hypothyroidism or myxoedema exhibited strong associations particularly with the TERT locus, 
which was also exclusively responsible for several subtypes of ovarian cancers. Moreover, 
Leucine-Rich Repeat-Containing Protein 16A (LRRC16A) gene located near the HLA region was 
responsible for several types of gastrointestinal disorders, including intestinal malabsorption, 
coeliac disease and primary sclerosing cholangitis. In contrast, some diseases or traits were 
associated with multiple LTL loci, including blood cell traits and haematological diseases that 
involved TERC, TERT, LRRC16A, SENP7, ATM, SAMHD1, and ENTPD5 (Ectonucleoside 
Triphosphate Diphosphohydrolase 5); similarly, respiratory function and lung cancers involved 
TERC, TERT, LRRC16A, OBFC1 and MPHOSPH6, suggesting multiple common genetic 





This chapter substantially expands our current knowledge on potential impacts of telomere 
dysregulation on cardio-metabolic traits, cancers and a broad spectrum of human diseases, 
providing insights onto roles of LTL in disease susceptibilities, and how variation of individual 
LTL-associated genes affects disease risks. 
 
3.4.1 Clinical relevance of genetically predicted LTL 
 
We have not only confirmed previous findings linking genetically predicted shorter LTL to a 
higher risk of CAD and lower risks of several cancers, but also demonstrated novel causalities 
of LTL on thyroid diseases and cancers, lymphoma and several non-malignant neoplasms. 
Notably, shorter genetically predicted LTL was found to be protective for all of these 
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proliferative disorders, potentially through limiting cell proliferative capacity, which in turn 
reduced occurrence of potential oncogenic mutations that can occur during DNA replication. 
Furthermore, we also provided evidence showing genetic predisposition to shorter LTL 
increased risks of several cardiovascular, inflammatory and respiratory disorders that have 
previously been linked to LTL in observational epidemiological studies158,173. 
 
3.4.2 Association of LTL with cardio-metabolic disorders 
 
No observational evidence has been found to support an association between LTL and 
incident T2D. Primary MR analysis using independent genome-wide significant variants as 
genetic instruments have also suggested no evidence for an association between LTL and T2D 
risk, which was further supported in sensitivity analyses by excluding the HLA region, or using 
variants at FDR<0.05 as instruments or different MR approaches.  
        The association between genetically predicted longer LTL and decreased risk of CHD was 
only observed when using genome-wide significant but not FDR variants, with substantial 
levels of between-variants heterogeneity in both analyses, suggesting several specific loci 
with larger effect sizes and more precise estimates drive the overall protective effects of 
longer LTL on CHD.  
        Conventional risk factors for CHD all showed significant but positive associations with 
genetically predicted longer LTL, implying that these factors do not mediate the protective 
effect of longer LTL on CHD, or the MR analyses are not powerful enough to capture true 
causal associations. These included higher triglyceride, total and LDL cholesterol levels, higher 
BMI, waist circumference and body fat percentage and blood pressure. The associations with 
these risk factors could be driven by specific loci that were distinct from those for CHD. On 
the contrary, genome-wide genetic correlation analyses demonstrated directionally 
concordant correlations of LTL to CAD and CAD-related risk factors that included lipid profiles 
of dyslipidaemia, adiposity-related traits and smoking. The discrepant results between MR 
and genome-wide genetic correlation analyses on the CVD-related risk factors might be due 
to different genetic factors employed in the two approaches, with the former completely 
driven by a limited number of significant loci from GWAS, whereas the latter by millions of 
variants covering the whole-genome. Hence the MR results might be heavily driven by specific 
loci that showed relatively large causal effects on the CVD-related risk factors, whereas the 
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genetic correlation results reflected an overall consistency of associations with LTL and CVD-
related risk factors at genome-wide scale. Further investigation might be needed to study 
specific driving forces that led to the directional discrimination of causalities of LTL on CHD 





Feasibility of studying longitudinal change of LTL 
Abstract 
Background Causes and consequences of prospective longitudinal changes of LTL may differ 
from those of LTL measured once at study baseline. Few studies have attempted to analyse 
the differences, and little consensus has been reached. 
Objectives To conduct a systematic literature review on the longitudinal change of LTL and 
evaluate feasibility of studying it in a relatively young and healthy prospective cohort in the 
Fenland study. 
Methods A systematic review was conducted for repeated measures of LTL over time. 
Searches were performed in PubMed of studies published from January 2009 to January 2018 
using the following search strategy: telomeres AND (shortening OR lengthening) AND (cohort 
studies OR genetics). Quality of studies was assessed, and results were extracted. A pilot 
analysis was performed within the Fenland study cohort, where two distinct groups of 
individuals were selected on the basis of different durations of follow-up time: one (n=14) 
with 3-5-year, and the other (n=40) with 8-10-year intervals.  
Results Sixty-five papers were included in the final set of eligible studies, and these showed 
differences in terms of study designs, demographics of participants, methods of LTL 
measurement and statistical approaches. Reported results were inconsistent, except for 
baseline LTL as a strong determinant of longitudinal changing rate of LTL, which was also 
observed in the Fenland pilot study. Annual changing rates were comparable between the 
shorter (3-5-year) and longer (8-10-year) time intervals studied. 
Conclusions Changes in LTL are detectable in relatively young and healthy individuals, but are 
technically challenging and unlikely to be scientifically useful as an outcome or cost-efficient 





Most previous epidemiological studies of LTL measured LTL at one time point, and thus were 
unable to investigate longitudinal changes of LTL, for which repetitive measures at more than 
one time point are required. The few studies that analysed changes over time showed 
inconsistent results in associations with risk factors and disease outcomes yet no systematic 
literature review has been conducted. Moreover, studies that compared the results for 
studying LTL at one versus multiple time points (i.e. longitudinal changes of LTL over time), 
have demonstrated discrepant findings in associations with risk factors and diseases324,325, 
emphasising the importance of studying the longitudinal change as a separate trait from one-
time measure of LTL. Longitudinal changes of LTL provide additional temporal information in 
LTL dynamics compared to a snapshot one-time measurement, and may differ from the one-
time measurement of LTL in terms of their associated genetic and non-genetic risk factors, 
pathological links to diseases and potential suitability as a biomarker of LTL-associated 
diseases. 
        Despite the clear rationale and scientific importance of studying longitudinal changes of 
LTL, there are many technical challenges, such as sensitivity and accuracy of the LTL 
measurements and statistical issues arising when repeated measures are made on the same 
individuals, such as the regression to the mean problem that makes true longitudinal changes 
difficult to distinguish from random fluctuation of LTL measures. Therefore, I conducted a 
feasibility test by first systematically reviewing epidemiological studies of the longitudinal 
changes of LTL, and then initiated a preliminary test in a population-based prospective cohort 
study in Fenland, where LTL was measured at two time points in 40 and 14 individuals with 8-
10-year and 3-5-year time intervals, respectively, to assess influences of different duration 
time on longitudinal measures. In addition, seventy-four individuals were measured at 
baseline and evenly clustered into 10-year age bins to confirm a correlation of baseline LTL 





4.2.1 Systematic Literature Review 
 
A systematic literature review was conducted following the MOOSE guideline326, in order to 
critically evaluate and summarise previously published research on longitudinal changes of 
LTL. The search strategy, applied to the PubMed database, used a combination of terms or 
their synonyms: “telomeres” AND (“shortening” OR “lengthening”) AND (“cohort studies” OR 
“genetics”), with details provided in the Supplementary Notes. Records without full text 
available online, published prior to 2009 when the real time qPCR method for LTL 
measurement was published327, studies in species other than humans and those not written 
in English were excluded from the search prior to screening titles and abstracts. When 
reviewing titles and abstracts, exclusion criteria included studies without repetitive measures 
of LTL or reviews not related to telomere dynamics. The articles that passed the filtering 
criteria were reviewed for their full text and excluded if the study design was not longitudinal 
or the longitudinal component only involved a small subset of the study, resulting in a total 
of 65 papers included into the final set of eligible studies (Figure 4.1). 
 
Figure 4.1: Flow-chart of the systematic literature search for epidemiological studies of 




4.2.2 LTL changes over time in the Fenland study 
4.2.2.1 Study participants and design 
The Fenland study is a prospective cohort study of 12,435 participants born between 1950 
and 1975328,329. Between 2005 and 2015 (phase 1), participants were recruited from general 
practices in Cambridge, Ely and Wisbech (UK), and predominantly healthy. Individuals who 
were pregnant, previously diagnosed with diabetes, unable to walk unaidedly, or had 
psychosis or terminal illness were excluded. Metabolic phenotypes and genome-wide 
genotypes were measured in detail, and the second follow-up of the cohort (phase 2) is 
ongoing, collecting longitudinal data of the same cohort of participants on key risk factors and 
continuous metabolic traits. All study procedures were approved by the Health Research 
Authority National Research Ethics Service Committee East of England-Cambridge Central, 
and all participants provided written informed consent. 
        To evaluate feasibility of studying differences in LTL changing rates between different 
follow-up time intervals, two distinct groups of participants were selected on the basis of 
different durations between Fenland phase 1 and 2 visits: one group (n=14) with a time 
interval of 3-5 years, and the other (n=40) with 8-10 years. In addition, there were 74 samples 
measured at phase 1 only and clustered into several age groups (25-35, 35-45, 45-55 and 55-
60 years), which were used to confirm correlations of baseline LTL and age. 
 
4.2.2.2 Sample preparation and DNA extraction 
All blood samples were collected in tubes of ethylenediaminetetraacetic acid using standard 
venepuncture protocols, with plasma, serum and buffy coat aliquots extracted by differential 
velocity centrifugation and stored in -80 °C prior to use330. Following a standard protocol, DNA 
was extracted via the Autopure method (Qiagen) for phase 1 plasma samples, and for phase 
2 samples, the Promega ReliaPrepTM Large volumeHT gDNA isolation system (Promega, 
A2751) was used, coupled with a Tecan EVO automated liquid handling platform with 
integrated HSM 2.0 Heater shaker Magnet (Promega). DNA samples were diluted 25-folds to 
2 ng/µL, and 5 µL of the diluted DNA samples were used in all experiments. 
        Control DNA samples were used for each plate, which consisted of negative and positive 
controls and standard curves. Negative control: nuclease-free water; positive control: pooled 
phase 1 samples that contained 12 participants, two for each gender at age 20, 40 and 60 
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years, and genomic DNA (G304A, Promega) at low (1.56ng), medium (6.25ng) and high (25ng) 
absolute concentrations; standard curves: genomic DNA (G304A, Promega) at concentrations 
of 50ng, 25ng, 12.5ng, 6.25ng, 3.13ng and 1.56ng, and genomic DNA (K562, Promega) at 
concentrations of 50ng, 25ng, 12.5ng, 6.25ng, 3.13ng and 1.56ng. 
 
4.2.2.3 LTL measurements 
LTLs were measured in DNA samples extracted from blood in both Fenland phase 1 and 2 
samples, using the ViiA™ Real-Time PCR System with monochrome multiplex qPCR method331. 
The telomeric DNA was amplified simultaneously with a single copy housekeeping gene, the 
albumin gene. The primer sequences were designed using the validated method described in 
detail by Cawthon et al.331. LTL was calculated as the T/S ratio, in which T represents the 
amount of standard DNA (ng) that matches the experimental sample for copy number of the 
telomere template, divided by S, the amount of standard DNA (ng) that matches the 
experimental sample for copy number of the albumin gene. Each experimental sample was 
assayed in triplicate, and the mean of three replicative measures was reported as the final 
LTL estimate for each sample, following the standard protocol331. 
 
4.2.2.3.1 Initial experimental set-up 
We used two real time qPCR reagents: the GoTaqTM qPCR Master Mix (Promega) and the SYBR 
Select qPCR Mastermix (Thermo), in combination with two standard curves: K562 and gDNA 
standard curves. In order to compare experimental performance of different combination of 
these settings, we used 5 individuals in the initial test, that were randomly selected among 
Fenland participants with DNA samples available at two phase visits. Experimental reaction 
and program settings were shown below (Table 4.1). LTL of each individual was measured 
using DNA samples collected at each phase visit, together with control samples, all analysed 
in triplicate. DNA samples were dispensed before adding reaction mix. We compared 
experimental efficiencies of standard curve samples against the optimum efficiency 
parameters recommended from manufacture guidelines (R2>0.99, slope coefficients = [-3.6, -
3.1], Efficiency(%) = [90,110]). 
        The qPCR protocols were optimised based on experimental efficiencies using different 
reagents. The protocol that used the combination of genomic DNA standard curve and GoTaq 
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reagent exhibited the best performance, and it was the only one that satisfied the optimum 
efficiency threshold recommended by the manufacture guideline (Table 4.2). The correlations 
between age and LTL measures were stronger when using the best-performance 
experimental data, which also exhibited larger intraindividual differences of LTL measures 
between two time points (Figure 4.2). 
 
Table 4.1 Initial qPCR experimental reaction and program settings: 
 
Reaction setting per well  
Total reaction volume 15ul 
DNA samples (2ng/ul) 5ul 
SYBR Select or GoTaq Mastermix 7.5ul 
Forward Primer (10mM) 0.3ul + 0.3ul 
Reverse Primer (10mM) 0.3ul + 0.3ul 
Nuclease free water 1.3ul 
Programme setting per 96-well plate  
Primer concentration (nM) 300 
Mastermix (lot number) SYBR Select (1705053) and GoTaq (0000280334) 
Pipetting method Repeater 1.0mL 
Singleplex or duplex Duplex 
Hold stage 50°C 2min Yes 
Duration of hot start (minutes) 2 
Annealing temperature (Tel) 62 
Annealing temperature 1 (Alb) 84 
Number of cycles 32 
Signal acquisition temperature (Tel) 73 
Signal acquisition temperature (Alb) 87 
 
Table 4.2 Efficiency parameters of qPCR experiments for the two standard curves with 
different reagents (N=5). 
The two standard curves were generated using standard gDNA or DNA extracted from K562 
cell lines. Reaction reagents were SYBR Select or GoTaq.  
 
K562 standard curve 
 
SYBR Select GoTaq 
Telomere Albumin Telomere Albumin 
R2 0.999 0.998 0.998 0.997 
Slope -3.798 -3.788 -4.183 -3.892 
Efficiency (%) 83.354 83.650 73.412 80.683 
gDNA standard curve 
R2 0.989 0.997 0.997 0.996 
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Slope -4.172 -3.625 -3.588 -3.604 
Efficiency (%) 73.655 88.729 89.993 89.439 
 
Figure 4.2 Correlations between age and LTL measures for protocols using two different 
reagents (SYBR Select and GoTaq, coded with different colours). Phase 1 and phase 2 





4.2.2.3.2 Scaling-up of the experimental set-up 
To examine whether the qPCR protocol can maintain a satisfactory performance when 
undertaken with larger sample sizes, we expanded sample sizes in three settings as described 
in the study design: (A) 40 individuals with 8-10-year time intervals, (B) 14 individuals with 3-
5-year time intervals, (C) 74 samples at phase 1 (baseline) only. Half of the samples in setting 
A (20 samples) were measured twice on different plates in order to assess plate effects. 
Correlation of inter-plate measurement was high (Pearson’s correlation coefficient r2=0.95), 
suggesting no between-plate heterogeneity. The same best-performance reaction system 
was applied as in the smaller-scale set-up for all settings (Table 4.4). For reaction program 
settings, all steps stayed the same, except that the 2-minute hold stage was removed. Each 
experimental unit (one sample at each time point or a control sample) was tested in triplicate.  
        The setting A failed to produce a satisfactory performance, i.e. efficiency parameters 
from this experimental setting were below recommended standards (Table 4.3). Technical 
issues that might contribute to the lack of efficiency were investigated with multicomponent 
plots (fluorescence vs. cycle). These plots were spontaneously generated for every single 
reaction unit, serving as a technical surveillance for the real-time qPCR instrument. We noted 
that in certain regions of the plate, specifically the upper half (row A-G), and not the lower 
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half (row I-P) of the plate, amplification curves exhibited abnormal shapes (Figure 4.2), 
implying an underperformance of the machine. In the settings B and C, we switched each half 
of the plates, and with extra care for sample loading and dispersion, efficiencies of both 
targets (Telomere and Albumin) improved and satisfied the optimum threshold, as shown in 
Table 4.3. 
 
Table 4.3 qPCR efficiency parameters in different experimental settings. 
 
 gDNA (40 samples, 8-
10-year intervals) 
gDNA (14 samples, 3-
5-year intervals) 
gDNA (74 samples only 
at baseline) 
Tel Alb Tel Alb Tel Alb 
R2 0.997 0.997 0.998 0.998 0.995 0.999 
Slope -4.025 -3.717 -3.55 -3.582 -3.282 -3.469 
Efficiency (%) 77.188 85.792 91.275 90.201 100.000 94.193 
 
Figure 4.2 Multicomponent plots for the qPCR reactions. 
The left panel shows the upper half of an exemplar plate, indicating normal qPCR 
performance; whereas the right panel shows the lower half the same plate, which contains 
abnormal reactions marked with irregular curve shapes shown as distortions towards the 
ends and dips in the middle. 
 
 
Table 4.4 The final optimised qPCR protocol, including the reaction system and the program 
setting. 
 
Reaction setting per well  
Total reaction volume 15ul 
DNA samples (2ng/ul) 5ul 
GoTaq (Promega) 7.5ul 
Forward Primer (10mM) 0.3ul + 0.3ul 
Reverse Primer (10mM) 0.3ul + 0.3ul 
Nuclease free water 1.3ul 
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Program setting per 96-well plate  
Primer concentration (nM) 300 
Standard curve DNA G304A (Promega) 
Mastermix GoTaq (Promega) 
Pipetting method Repeater 1.0mL 
Singleplex or duplex Duplex 
Hold stage 50°C 2min No 
Duration of hot start (minutes) 2 
Annealing temperature (Tel) 62 
Annealing temperature 1 (Alb) 84 
Number of cycles 32 
Signal acquisition temperature (Tel) 74 
Signal acquisition temperature (Alb) 88 
 
4.2.3 Statistical analyses 
 
Correlations between age and LTL at each phase were calculated using the Pearson’s 
correlation test. Linearity and homoscedasticity assumptions were visually examined by 
drawing scatter plots (Figure 4.4). Longitudinal changing rates of LTL were estimated by 
subtracting LTL measures at phase 1 from those at phase 2, and dividing the resultant 
differences by the time interval. Statistical associations of the longitudinal changing rates with 
age and baseline LTL measures were tested in linear regression models. Mann-Whitney U test 
was performed to compare whether the longitudinal changing rates differ between shorter 




4.3.1 Systematic literature review 
 
4.3.1.1 Main characteristics of the studies 
Studies identified in this systematic literature review examined associations between LTL 
attrition rates and a variety of risk factors and clinical outcomes. Main characteristics of these 
studies varied, including time intervals between measuring points, measuring techniques, 
health profiles and ethnicities of study participants, sample types and sizes, and risk factors 
and clinical outcomes tested (Supplementary Notes). Follow-up times ranged from 4 months 
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in a randomized pilot bio-behavioural clinical study to 41 years in a multi-ethnic cohort study, 
with most studies (47/65 = 72.3%) exceeding five years of follow-up time. While most of the 
studies were at small scale, two of them had relatively large sample sizes, the Prevention of 
REnal and Vascular ENd stage Disease (PREVEND) study (n=8,074) and the Copenhagen City 
Heart (CCH) study (n=4,576). Most of the studies (42/65 = 64.6%) used qPCR to measure LTL, 
while there were 17 studies that also employed the terminal restriction fragment analysis, 
the gold-standard approach to quantify TL, which is not feasible to do at large scale. 
Peripheral blood leukocytes were the most frequently used cell/tissue types, a few also used 
cord blood from new-borns, bone marrow compartments and blood cell subtypes retrieved 
from sophisticated isolation experiments, which included granulocytes, monocytes and 
lymphocytes and subtypes of circulating immune cells.  
 
4.3.1.2 Factors associated with accelerated telomere attrition in observational studies 
Telomeres have been shown to shorten at different rates in men and women and at different 
ages in population-based studies. The gender difference occurred in an age-dependent 
manner after adulthood. Annual attrition rates increased with age and were faster on average 
in men than in women164,332. Studies have shown telomere attrition decelerated in women 
during menopausal transition, while in men the attrition rate tended to increase with age333. 
Moreover, several studies have consistently suggested the baseline LTL as a powerful 
predictor of telomere attrition rate334–336. They found longer telomeres at baseline were 
associated with accelerated telomere attrition. This could possibly imply a negative feedback 
regulation of LTL336, or it may also be simply due to a statistical problem of the regression to 
the mean because of unsystematic measurement errors that result in random fluctuation 
within the measurements. 
        Several lifestyle factors have been identified to accelerate LTL attrition, including 
smoking332, alcohol consumption337, higher energy intake338, dietary composition (lower 
levels of serum phenylalanine and omega-3 fatty acids and higher scores of dietary 
inflammatory index)339–341, and lower physical activity and fitness levels342. Cardio-metabolic 
traits, such as increased overall or abdominal adiposity, higher triglyceride and glucose levels, 
lower HDL cholesterol levels332; neuropsychological and mental health features, such as 
psychological stress, neuroticism, somnolence, loneliness and lack of early institutional 
care343,344, also increased LTL attrition rates. Moreover, some diseases clinically manifested 
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with shorter LTL have been reported to increase LTL shortening rates, such as Herpesvirus 
infection and acute myeloid leukaemia; and on the contrary, the corresponding clinical 
interventions, such as Danazol treatment, reduce attrition rates345–347 (Figure 4.2).  
        However, associations between LTL shortening and factors other than age and baseline 
TL were inconsistent across studies. For example, in the two largest studies of LTL attrition 
rates, the PREVEND study332 and the CCH Study164, annual attrition rates of LTL were higher 
in smokers and in participants with greater abdominal obesity in the PREVEND cohort study 
with 6.6-year of follow-up332. In contrast, no associations were found between telomere 
attrition rate and smoking and body weight in the CCH Study with 10-year of follow-up164.  
 
Figure 4.3 Overview of determinants and consequences associated with accelerated telomere 
attrition. 
The left block contains changes of the factors that lead to acceleration of telomere shortening, and 




4.3.1.3 Consequences of accelerated telomere attrition 
Accelerated telomere attrition, potentially reflecting more rapid impairment of overall 
genomic integrity along with age, has been associated with higher risks of age-related 
complex diseases and mortality. In a prospective cohort study of T2D patients, telomeres 
were found at comparable lengths at baseline and significantly shorter in patients who 
developed non-alcoholic fatty liver disease than patients who did not during a 6-year follow-
up time348, suggesting that it might be the telomere shortening rather than the baseline TL 
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that affected susceptibilities of metabolic disorders. Lending support to this notion, another 
cohort study on cardiovascular phenotypes also found that individuals with increased rates 
of telomere shortening, but similar telomere measures at baseline were at higher risks of 
cardiac and vascular damage349, as well as cardiovascular mortality350. Other diseases have 
also been associated with telomere attrition rates. For example, patients with haematologic 
malignancies who carried mutations in genes encoding telomere-associated proteins (e.g. 
TERT, TERF1, TERF2, ATM and POT1) or showed altered expressions of these proteins have 
shown accelerated telomere attrition compared to normal volunteers. Accelerated attrition 
was also seen in patients who received therapeutic treatment of hematopoietic stem cell 
transplantation351. Evidence suggests that genetic variation and clinical intervention can 
modulate telomere attrition rates, which can in turn influence disease occurrence and 
progression. 
 
4.3.2 Age correlation to LTL measures at phase 1 and phase 2 
 
For the 40 samples with repeated measurements at 8-10-year intervals, both measures of LTL 
at phase 1 (mean[SD]=1.22[0.22]) and phase 2 (mean[SD]=0.91[0.13]) were significantly 
associated with age (p-value=0.007 and 0.01, respectively); effect sizes were comparable 
between the two phases (beta coefficient[SD] = -0.01[0.004] and -0.007[0.003], respectively, 
Figure 4.4A). The correlation between age and LTL measures was further confirmed within 
the independent set of 74 samples measured at baseline (beta coefficient[SD]=-0.02[0.004], 
P-value=5.73X10-7, Figure 4.4C). For the 14 samples measured at both phases of 3-5-year 
intervals (mean[SD]=0.99[0.16] and 0.87[0.14] for the phase 1 and 2 measurements, 
respectively), the correlation with age was not significant in either phase (beta coefficient[SD] 
= 0.004[0.008], 0.005[0.007], p-value=0.63 and 0.47, respectively), possibly due to insufficient 
power. 
 
Figure 4.4 Changes of LTL measures at two time points and their associations with age. 
On the left panel, LTL measures are plotted against age. Measures at phase 1 are labelled in 
red, and at phase 2 in green. Two measures of the same individuals are connected. On the 
right panel, blue and orange dots indicate measures at phase 1 and 2, respectively. 
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A. Forty samples measured at two phases with 8-10-year intervals. 
 































C. Seventy-four samples measured at phase 1. 
 
 
4.3.3 Longitudinal changing rates of LTL within long (8-10-year) and short (3-5-year) time 
intervals 
 
The 40 samples with 8-10-year intervals showed a wide range of differences between two 
time-point measures (mean[SD]=-0.31[0.18]), ranging from -0.66 to 0.24, which 
corresponded to a LTL change of 39.7% decrease to 44.4% increase compared to the baseline 
LTL measures. All except one sample had shorter LTLs in phase 2 than in phase 1. Excluding 
the outlier that showed LTL lengthening, the range upper bound changed to -0.03, 
corresponding to a decrease of 3.8% of the baseline measure. Within this set of 40 samples, 
the shortening rates varied between individuals (mean[SD]=-0.04[0.02] per year, Figure 4.3), 
and were associated with baseline LTL measures (beta coefficient[SD] = -0.07[0.01], p-
value=6.47X10
-8
, Figure 4.5A), but not age (beta coefficient[SD] = 0.0002[0.0005], p-
value=0.70, Figure 4.5B). The association between shortening rate and baseline LTL was 
robust after adjusting for age (beta coefficient[SD] = -0.08[0.01], p-value=4.55X10-9). 
Excluding the one outlier that showed LTL lengthening, mean and SD of LTL shortening rates 
remained the same, as well as associations with baseline LTL with or without adjustment for 
age. 
        Similarly, twelve out of fourteen samples with 3-5-year intervals exhibited LTL shortening 
overtime. Differences between two time-point measures (mean[SD]=-0.12[0.12]) ranged 

















These corresponded to a LTL change from -25.0% to 14.0% of the baseline measures, and to 
-2.2% after excluding the two outliers. The shortening rate (mean[SD]=-0.03[0.03] per year) 
was not associated with age (Figure 4.5B), while the association with baseline LTL was 
marginally significant (beta coefficient[SD]=-0.09[0.04], p-value=0.06, Figure 4.5A), and 
remained at the same level of significance after adjusting for age. After excluding the two 
outliers of LTL lengthening, the association strength between shortening rate and age slightly 
increased (beta coefficient[SD]=-0.08[0.03], p-value=0.02), and stayed robust after 
adjustment for age. 
        We compared LTL shortening rates estimated using the 40 samples with longer (8-10-
year) time intervals against those using 14 samples with shorter (3-5 years) time intervals. 
The average shortening rates within the two sets of time intervals were statistically 
comparable (Mann-Whitney U test p-value = 0.60, Figure 4.6), although longitudinal changes 
of LTL were smaller within shorter than longer time intervals (Mann-Whitney U test p-value 
= 7.12X10
-5
, Figure 4.6) as expected. These results were similar after excluding outliers that 
showed LTL lengthening. 
 
Figure 4.5 Longitudinal changing rates of LTL within 3-5- and 8-10-year intervals. 
Changing rates are stratified by quartiles of baseline LTL in the panel A, and by baseline age 
groups (30-40 years, 40-50 years and 50 years and above) in the panel B. The pale blue and 
red bars indicate 3-5-year (N=14) and 8-10-year (N=40) intervals, respectively. Within each 
boxplot, the horizontal line reflects the median, the top and the bottom of each box reflect 
the interquartile range, the whisker indicates an additional 1.5 times interquartile range 
within each grouping, and the red dots show outliers. 
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A.              B. 
 
Figure 4.6 Comparing longitudinal changes and annual changing rates of LTL within 3-5- and 
8-10-year intervals. 
Boxplots are drawn in the same format as described above. The left and right panels show 
longitudinal changes and annual changing rates of LTL, respectively. The T/S ratio (LTL 
measure) change within each time interval is shown as the y-axis in the left panel and the T/S 





4.4 Summary and discussion 
 
The work presented in this chapter aims to examine feasibility of conducting large-scale 
observational and GWAS on longitudinal changes of LTL. To examine such feasibility, I 
 98 
conducted a systematic literature review, and performed pilot study analyses with two time-
point measures of LTL in the Fenland prospective cohort. 
 
4.4.1 Systematic literature review 
 
LTL attrition rates have been suggested to increase with age and their association patterns 
with age vary between men and women. The baseline LTL measure has been consistently 
reported to be strongly associated with LTL attrition rates. Other environmental and 
behavioural factors may also influence the LTL attrition rates, but previous reports are not 
consistent. These factors include smoking, alcohol intake, dietary patterns, physical activity, 
body weight and other metabolic traits. To address such discrepancies, further studies are 
needed with larger sample sizes and statistical models that can properly address technical 
issues of repeated measures in longitudinal studies, such as the issue of regression to the 
mean. Furthermore, accelerated LTL attrition has been suggested to be associated with higher 
risks of age-related common complex diseases, such as cardiometabolic morbidities and 
mortality and haematologic malignancies. These associations with clinical outcomes show the 
promise of using LTL attrition rate as a biomarker to predict disease risk and progression, and 
patients’ responses to therapeutic treatments. However, current studies, including both 
population cohort studies and clinical trials are far from being sufficient to draw any solid 
conclusions about clinical values of the LTL attrition rates. Further studies are needed to 
validate these associations and explore aetiological roles of LTL attrition in disease occurrence 
and development. 
 
4.4.2 Pilot analyses within the Fenland study 
In the pilot study, I found the longitudinal changing rate of LTL was associated with baseline 
LTL measurement as previously reported, but not age. The changing rates estimated within 
longer and shorter time intervals showed comparable results, indicating that duration of time 
intervals does not affect such estimation. 
        There are few cohort studies that have analysed longitudinal changes of LTL, with 
extensive heterogeneities in their association findings. In fact, most of the reported 
associations are inconsistent, except with baseline LTL. Therefore, a prospective cohort study 
with a larger sample size and optimised measuring approach can potentially help to 
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distinguish true association findings from false positive ones. However, there are plenty of 
technical and statistical issues in analysing longitudinal measures of LTL. First of all, regression 
to the mean, a statistical phenomenon that is commonly observed in repeated data, where 
relatively high (or low) measured values are likely to be followed by less extreme ones near 
the true means of these values in the same individuals
352
. This issue is caused by non-
systematic variation (i.e. random errors) in the measurements of LTL, and practically can 
cause a problem in distinguishing a true change from an expected change due to natural 
fluctuation of the data. Because of this issue, participants with much longer LTL 
measurements in the phase 1 will have greater decreases (i.e. faster shortening) of LTL 
measurements in the phase 2, whereas those with shorter LTL measured in the phase 1 tend 
to have less decreases or even elongation (i.e. slower shortening or lengthening) of LTL in the 
phase 2. In support of this possibility, we and others have consistently found LTL at baseline 
is strongly positively associated with LTL shortening rate. Therefore, the regression to the 
mean problem must be taken special care of in the future longitudinal studies of LTL. Secondly, 
it can be technically challenging to discriminate between LTL measures at baseline and 
longitudinal changes of LTL, as these two are highly correlated. Adjusting for baseline LTL in 
regression models that test associations with LTL shortening rates may induce an issue of 
collinearity, and thus challenges model stability. Thirdly, a selection bias of samples may be 
present when measuring LTL in the phase 2. Because as previously reported, various clinical 
disorders are associated with shorter LTL (section 1.4.1.4), these disorders may reduce 
chances of participants being re-examined in the second visit, causing individuals with 
relatively shorter LTL to become largely underrepresented in the repeated measures.  
        GWAS can help to identify genetic variants that are strongly associated with LTL attrition 
rates, which can be useful in delineating causality in the MR framework. Given that 
epidemiological studies of LTL shortening so far have all been observational, therefore, 
associations identified in these studies can be confounded by known and unknown risk factors 
and biased by reverse causality. Causal associations between previously identified risk factors 
and diseases and LTL shortening rate are still unexplored. MR analyses leveraging genetic 
instruments as proxies for the LTL shortening rate may assist in dissecting causal pathways. 
Therefore, a primary stimulus of performing the GWAS and thus this feasibility study is to 
identify genetic factors that are strongly and specifically associated with LTL shortening, 
which could then be used as instruments for MR-based causal association analyses. However, 
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identifying robust genetic instruments for LTL shortening can have several challenges: 1) 
There may be insufficient power to discover any variants due to relatively small sample sizes. 
Additionally, external studies with both longitudinal LTL changes and genotypes measured, 
such as the PREVEND study, have the capability of performing GWAS in parallel to our study, 
and can potentially be meta-analysed with our study to increase overall discovery power. (2) 
Even if there are variants found to be strongly associated with LTL shortening rates, it is 
technically challenging to determine whether these variants are specifically associated with 
LTL shortening or simply baseline LTL, as these two are highly correlated, both observationally 
and biologically. Therefore, even larger sample sizes with more advanced mathematical 
modelling are required to conduct such GWAS. 
        Even if the GWAS on LTL shortening rate lacks power to identify any genome-wide 
significant loci, the summary statistics produced from these studies can still be useful for 
reverse MR analyses, in which causal effects of diseases or intermediate traits on LTL 
shortening can be tested. For example, genetic instruments for cardiometabolic traits and 
diseases have been well established and the their summary statistics are publicly available, 
by linking their association estimates with those with LTL shortening rates in the two-sample 
MR framework, we can shed light upon whether and how cardiometabolic diseases or the 
related risk factors influence LTL shortening.  
        In conclusion, studies on longitudinal changes of LTL can be scientifically interesting, but 
technically challenging. To tackle the challenges, larger sample sizes with more advanced 





Characterisation of mLOY and its association with T2D risk 
Abstract 
Background mLOY, the most common post-zygotic chromosomal alteration in men, has been 
strongly correlated to age and age-related common complex diseases. While mLOY has been 
suggested to play an essential role in cancer development, few studies have analysed 
prospective associations of mLOY with T2D risk. 
Objective To characterise observational associations between mLOY and T2D. 
Methods mLOY was estimated based on SNP-array intensity data and expressed as the 
median value of logarithmic ratios of observed to expected intensity values (R, 
log2(Robserved/Rexpected), mLRR) across all SNPs on chromosome Y specific regions. mLRRY was 
analysed as a continuous variable with mLRRY<0 indicating mLOY. Association between mLOY 
and incident T2D risk was analysed in the EPIC-InterAct case-cohort study (n=11,892 men, 
51.84% cases), using Prentice-weighted Cox regression models with age as the underlying 
timescale and adjusted for age, sex, smoking and other lifestyle factors. The association was 
analysed in each country separately, with results meta-analysed using random-effects models. 
UK biobank (221,597, 3.38%) was used as a replication cohort. 
Results Men with increased mLRRY (less mLOY) were at a modestly lower risk of T2D after 
adjusting for age, centre and genotyping array, but the association was not statistically 
significant (HR[95%CI] = 0.91[0.83-1.01] per 1-SD increased mLRRY, p-value=0.07), and 
showed large heterogeneity across countries (I
2
=81.7%). Adjusting for smoking further 
attenuated the association (HR[95%CI] = 0.94[0.86-1.04], p-value=0.23). Younger men (<50 
years) exhibited larger risk effects (HR[95% CI] = 0.95[0.91-0.99], p-value=0.02) compared to 
older men (50-65 years: HR[95%CI] = 0.98[0.94-1.02], p-value=0.33; and >65 years: HR[95%CI] 
=0.91[0.79-1.04], p-value=0.18; pinteraction=0.002). Other than smoking, no modifiable risk 
factors showed significant associations with mLRRY after Bonferroni correction (p-
value=1.52X10
-3
, for 33 traits tested). In UK biobank, the association between mLRRY and T2D 
risk was significant but in the opposite direction (HR[95%CI] = 1.05[1.03-1.07], p-
value=4.27X10
-5
). The association significance was reduced in men younger than 50 years 
(HR[95%CI] = 1.08[0.99-1.16], p-value=8.84X10-2), and there was no evidence for interaction 
between mLRRY and age for their effects on the T2D risk (pinteraction=0.43). 
Conclusion Observational evidence shows no strong support for an association between 






mLOY in peripheral blood is the most common mutation acquired during adulthood for 
men
353
. The occurrence of mLOY is strongly correlated to age, with ~20% of men aged 80 
years or older having >10% of blood cells with mLOY
193,207
. 
        mLOY in leukocytes has been suggested as a signal of impaired immunosurveillance, 
leading to disrupted immune response, thereby increasing risks of tumorigenesis in various 
tissues, neurodegenerative development, CVD, T2D and autoimmune disorders
354–356
. Strong 
relationships have been established between mLOY and cancer diagnosis and 
mortality
193,196,357–359




        T2D has been identified as a major risk factor for mortality and a wide range of clinical 
disorders that influence human longevity, including CVD and cancers
361
. It has grown rapidly 
to epidemic proportions worldwide and deemed as an essential cause for accelerated ageing. 
It has been suggested that glucose homeostasis plays an important role in regulating life span 
in animal models; in humans, genetic variations in genes involved in GH and IGF1 signalling 
pathways are associated with longevity (section 1.3.2)
114,362,363
. Besides conventional 
biomarkers for T2D risk prediction, including family history, obesity, blood pressure, and 
HbA1c
364,365
, recent developments in omic biomarkers have demonstrated some potential 
values in predicting T2D risk, including PRS
366,367
 and branched chain amino acids
368–372
. 
However, the role of mLOY in T2D susceptibility has not been fully understood. Here, using 
the largest incident T2D case-cohort study, the EPIC-InterAct, we were able to examine 
associations of mLOY with T2D incidence and shed light upon potential utilities of mLOY in 









InterAct is a case-cohort study nested within the EPIC cohort, designed to investigate how 
inherited and modifiable risk factors interact to influence T2D susceptibility. Participants and 
study design have previously been described
212
. In brief, the project involves 23 research 
centres across Europe in 8 countries (Denmark, France, Germany, Italy, Netherlands, Spain, 
Sweden and UK). All incident T2D occurring in the EPIC cohort between 1991 and 2007 were 
ascertained using multiple sources of evidence (self-report, linkage to primary care registers, 
secondary care registers, medication use, hospital admission data, and mortality data). In 
total, 340,234 EPIC participants were included in the InterAct, and followed up for a mean 
[range] of 11.7 [0–17.5] years, during which 12,403 incident T2D cases were verified
213
. A 
centre-stratified, random sub-cohort of 16,835 individuals was selected, among which 778 
individuals developed incident T2D. Only men were included (n=12,238, from 7 countries), 
and after excluding those who had missing mLOY measurements, there were 6,099 men left. 
Missingness of mLOY was further examined with regards to missing patterns and random 
distributions (Supplementary Table 22). We further removed men who showed any evidence 
of diabetes at baseline, had no blood samples stored, or diabetes status missing, which 
resulted in a total of 5,841 men included for analyses. All participants gave written informed 
consent, and the study was approved by local ethics committees in the participating countries 
and the Internal Review Board of the International Agency for Research on Cancer.  
 
5.2.1.2 UK Biobank 
We used data collected as part of UK biobank, a prospective cohort study of over 5 million 
individuals aged 40-69 years and recruited from 22 assessment centres across England, 
Scotland and Wales
302
. Participants provided baseline information on demographic, lifestyle 
and other health-related factors through online questionnaires and completed a range of 
physical and imaging-based measurements. They also provided biological samples which 
allowed various biochemical, genomic and other omics-based assays to be conducted, and 
objective measures of physical activity and multi-modal imaging assessment within different 
subsets of the cohort. The UK Biobank study was approved by the North West Multi-Centre 
Research Ethics Committee and all participants provided written informed consent. To define 
T2D cases, we implemented a previously calibrated algorithm to call prevalent T2D cases, 
which comprised self-reported and nurse interview validated diagnoses, ages at diagnoses 
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and diabetes medications and complications (n=487,915, 4.08% cases)
373
; and incident T2D 
cases (2.42%) using heath-care data linked from hospital episode statistics and cause of death 
data from the National Death Registries. Disease categories were defined using the ICD10 
codes (E11: T2D). Participants whose dates of their first hospital admissions for T2D preceded 
the baseline assessment dates or with HbA1c ≧ 48mmol/mol at baseline were excluded. 
Samples from the full release of UK biobank (May 2018) were analysed for estimating mLOY. 
In addition to the centrally performed QC procedures by UK biobank
303
, we further excluded 
individuals who shared relatedness closer than third degree and of ancestry other than white 
European. We restricted our analyses to men (n=221,597). 
 
5.2.2 Genotyping and mLOY measurements 
 
Blood samples of 10,004 men in EPIC-InterAct were genotyped on two slightly different arrays: 
About 61% (6,102) were analysed on the Infinium CoreExome-24 v1.3 BeadChip array and the 
remainder (39%, 3,902) on the HumanCoreExome-12 v1.1 BeadChip array. Imputation was 
performed according to the HRC panel
14
. Genotyping, imputation and mLOY measurements 




5.2.2.1 Continuous and binary measurements of mLOY 
mLOY of each individual was measured using SNP microarrays-based method coupled with 
the PennCNV calling algorithm
375
. Observed signal intensity values (R) were estimated using 
SNP array-intensity data and shown as average read depths (normalized signal intensities) 
over chromosome Y, exclusively the X-degenerate regions
193,195,196,207
. Expected R values were 
extracted from a standard reference (*.egt) file. The ratios of observed to expected R values 
on a base 2 logarithmic scale (log2(Robserved/Rexpected), LRR) were calculated for all SNPs that 




        For each participant, the median value of LRRs of all SNPs within the male-specific region 
of chromosome Y (mLRRY), was used as the quantitative measurement of mLOY, with 
negative values indicating LOY. In analyses using binary measurements of mLOY, the variable 
was defined as “mLOY” based on mLRRY<0. 
 105 
 
5.2.2.2 Distributions of mLRRY and data transformation 
mLRRY values ranged from -4.6 to 0.3 in the EPIC-InterAct sub-cohort and -0.3 to 0.3 in the 
UK biobank. Distributions of the mLRRY values were examined overall, and in each country of 
the EPIC-InterAct study, separately. They exhibited normal distributions with means centred 
at 0 and SDs ranging from 0.04 to 0.14 (Supplementary Table 18, Supplementary Figure 4 and 
5). However, normality tests of mLOY measures showed large absolute values of skewness (-
23.1) and kurtosis (935.3) in the EPIC-InterAct, indicating a heavy-tailed, asymmetric 
distribution, i.e. left-skewed deviation from normality. Therefore, to reduce effects of 
potential outliers that constituted the heavy tails, and maintain consistency between analyses 
within the two cohorts, the following data processing procedures were performed in both 
cohorts, (1) winsorisation of mLRRY values at 5SD to exclude extreme outliers; (2) inverse 
normal transformation separately for each genotyping array; and (3) standardisation to a 




Besides age (age at recruitment), study centre and genotyping array, other covariates were 
considered for inclusion based on previous evidence for their associations with T2D, which 
were illustrated as below. Smoking: smoking status was classified into four categories: never, 
former and current smokers and unknowns; or two categories: never and ever smokers. 
Alcohol: categorised into six groups (never: 0 g/day, light: 0.1-4.9 g/day, moderate: 5-14.9, 
regular: 15–29.9, heavy: 30–59.9, and extreme ≥60 g/day drinkers)
376
. Education: educational 
levels were self-reported the highest and categorized into five categories (with the 
unspecified excluded): none, primary school, technical school, secondary school, university 
degree
377
. BMI: BMI was measured (kg/m2) with correction for clothing and assessed as a 
continuous variable. Waist circumference: Waist circumference was measured either at the 
narrowest circumference of the torso or at the midpoint between the lower ribs and the iliac 
crest, assessed as a continuous variable
378
. In the EPIC-InterAct, two additional covariates 
were included in the fourth model, which were described as follows. Mediterranean diet score: 
dietary intake of nine nutritional components characteristic of the Mediterranean dietary 
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pattern was estimated (gram per 1,000 kcal, except alcohol consumption) and each divided 
into 3-quantiles, according to the distributions observed in the EPIC-InterAct subcohort
379
. A 
score was derived by adding up these 3-quantiles, therefore ranging from 0 to 18, which were 
further classified into three categories (low: 0-6 points, medium: 7-10 points, high: 11-18 
points). Physical Activity: physical activity levels were assessed at baseline by a validated self-
report questionnaire combining occupational and leisure time physical activity levels, and 
categorized into four groups (inactive, moderately inactive, moderately active and active) 




5.2.4 Statistical analyses 
To estimate associations between mLRRY (mLOY measurements) and T2D risk in the EPIC-
InterAct cohort, I applied Prentice-weighted Cox regression models modified for case-cohort 
analyses with age as the underlying timescale within each country
212,292
, and HRs were 
combined using random-effects meta-analyses. The percentage of overall variation in the HRs 
attributed to heterogeneity between countries was estimated and expressed as I
2
. In the UK 
Biobank cohort, we used multivariable logistic regression models to examine risk effects of 
mLRRY on prevalent T2D, and Cox regression models for incident T2D. In either cohort, four 
models with different adjustments were considered. The first model included adjustments for 
genotyping array and centre, the second for one additional adjustment for age, the third for 
two additional adjustments for age and smoking status, and the fourth for multiple factors 
including age, smoking status, lifetime alcohol consumption, educational level, BMI and waist 
circumference within both cohorts, and Mediterranean diet score and physical activity level 
in the EPIC-InterAct, as only a small subset of individuals in the UK Biobank had equivalent 
measures for these two covariates. The main exposure, mLRRY, was normalised and 
standardised as described in the 5.2.2.2, and treated as a continuous variable in the primary 
analyses, and in the secondary analyses, dichotomised by 0 (men with mLRRY<0 as mLOY 
cases, coded as 0; whereas men with mLRRY≧0 as mLOY controls, coded as 1). 
        To assess linearity of associations between mLRRY and incident T2D risk in the EPIC-
InterAct, I further analysed the primary exposure of mLRRY in quantiles. These analyses were 
conducted in each country separately using Prentice-weighted Cox regression models as 
described above; the resultant HRs were combined using the inverse-variance weighted 
random-effects meta-analysis models within each quantile. 
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        To assess interactions of mLRRY with age or smoking on their risk effects on T2D, I 
conducted stratification analyses. Age was stratified into three groups (<50, 50-65 and ≧65 
years old) in the EPIC-InterAct and five groups (<50, 50-59, 60-69, ≧70) in the UK biobank, 
and the associations of mLRRY with T2D risk were analysed within each age group, and in the 
EPIC-InterAct, additionally in each country as well. Similarly, smoking status was stratified into 
two (never or ever smokers) groups, with subjects with missing smoking status excluded, and 
associations of mLRRY with T2D risk were analysed within each smoking status group in each 
country of EPIC-InterAct or in UK biobank. In the EPIC-InterAct, HRs estimated across 
countries were meta-analysed using random-effects models, and the resultant country-
combined HRs were further meta-analysed using fixed-effects models across age or smoking 
strata. Heterogeneities across age or smoking strata were evaluated using I
2 
estimates. In 
addition, significance levels of interactions between mLRRY and age or smoking groups were 
assessed using likelihood ratio tests. 
        To identify additional risk factors for mLOY, I performed an exploratory analysis, 
examining associations between mLRRY and a variety of traits, including lifestyle and 
anthropometry traits and circulatory biomarkers in the quasi-random subcohort of the EPIC-
InterAct study. Linear regression models were applied with adjustments for age, centre and 
genotyping array, in each country separately, and the resulting beta estimates were meta-
analysed across countries using random-effects models. Continuous factors were normalised 
by inverse normal transformation and standardised to distributions with means of 0 and SD 
of 1. Categorical factors were analysed at an ordinal scale and treated as continuous variables 






5.3.1 Baseline characteristics of mLOY measurements 
 
Characteristics of the two study population cohorts, EPIC-InterAct case-cohort and UK 
biobank were presented overall and stratified by mLOY indicator (mLRRY<0, ≧0, or missing, 
Table 5.1). In EPIC-InterAct, a total number of 6,099 men with non-missing mLRRY estimates 
were included in the analyses, among which 1,413 men had detectable mLOY (mLRRY<0) and 
of these men 73 had relatively higher degrees of mLOY (mLRRY<-0.15). In UK biobank, all men 
(n=221,597) of white European ancestry had mLRRY measured, among which 44.7% had 
detectable mLOY (mLRRY<0) and 8.24% showed higher degrees of mLOY (mLRRY<-0.15). The 
proportions of men with college/university education were comparable between the three 
groups of mLOY measurements (positive, negative and missing mLRRY values) in either the 
EPIC-InterAct T2D case or the quasi-random sub-cohort, or in the UK biobank. Adiposity levels 
were also similar between the three groups of mLOY measurements in the three study parts 
(Table 5.1). 
        Previous studies have identified age and smoking as strong risk factors for 
mLOY
193,196,207,353
, and these two factors have also been reported to affect T2D risk
212,213,381
, 
therefore we considered them as potential confounders, and investigated their associations 
with mLOY (mLRRY<0). In line with previous studies, I found the prevalence of mLOY 
(mLRRY<0) was relatively higher in men at older ages (≧65 years) or among ever (current and 
previous) smokers (Table 5.2). Higher degrees of mLOY (mLRRY<-0.15) were only present 
among elderly men above certain ages (50-60 years in EPIC-InterAct and 40-50 years in UK 
biobank), with the prevalence increasing along with age, reaching 7.87% and 5.48% among 
men over 70-year old in EPIC-InterAct and UK biobank cohorts, respectively (Table 5.2). In 
contrast to age, the higher degrees of mLOY (mLRRY<-0.15) were present in all smoking status, 
but more frequently observed in current or previous smokers than never smokers (Table 5.2). 
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Table 5.1. Baseline characteristics of the study population cohorts, overall and stratified by the mLOY indicator. 




total mLRRY0 mLRRY<0 mLRRY=. total mLRRY0 mLRRY<0 mLRRY=.
No.participants 11,892 5,781 1,965 683 3,133 6,111 2,488 704 2,919 221,597 122,597 98,984
Incident T2D, % 51.84 100.00 100.00 100.00 100.00 6.28 5.39 3.27 7.78 3.38 3.08 3.77
College/university education, % 20.27 16.52 17.46 16.54 15.93 23.81 25.32 25.28 22.17 33.78 34.61 32.77
Age, years 54.1 (8.4) 55.4 (7.5) 55.1 (6.8) 58.0 (7.3) 55.0 (7.9) 52.9 (8.9) 52.4 (8.6) 56.1 (8.6) 52.4 (9.1) 56.8 (8.2) 55.6 (8.2) 58.1 (7.9)
Body mass index, kg/m2 27.9 (4.1) 29.3 (4.1) 29.4 (4.2) 28.7 (3.9) 29.4 (4.0) 26.6 (3.6) 26.5 (3.6) 26.2 (3.4) 26.8 (3.6) 27.8 (4.2) 27.9 (4.3) 27.7 (4.2)
Waist circumference, cm 98.8 (11.0) 102.6 (10.6) 103.0 (10.7) 102.0 (10.6) 102.5 (10.4) 95.1 (10.1) 95.0 (10.2) 94.6 (9.7) 95.3 (10.1) 96.3 (11.3) 96.9 (11.4) 96.9 (11.2)
Age group
<50 years, % 28.81 22.44 17.91 12.59 27.42 34.84 31.99 19.74 40.90 21.75 27.59 14.52
50-65 years, % 64.31 70.11 77.96 75.11 64.09 58.83 64.47 68.75 51.63 51.34 55.88 45.73
65 years, % 6.88 7.46 4.12 12.30 8.49 6.33 3.54 11.51 7.47 18.30 16.54 20.49
Smoking status
Current smoker, % 32.43 33.71 33.94 42.90 31.57 31.22 29.90 36.36 31.11 12.33 11.46 13.42
Previous smoker, % 38.40 40.72 41.17 38.80 40.86 36.21 36.94 37.36 35.32 38.26 37.12 39.68
Never smoker, % 27.85 24.23 24.07 16.98 25.92 31.27 31.83 24.86 32.34 48.87 50.89 46.38








Table 5.2. mLOY distribution, overall and stratified by 10-year age bin and smoking status. 
Counts and frequencies of mLOY (mLRRY<−0.15 or <0) were calculated in each stratum. 
 
 
Count Frequency Count Frequency Count Frequency Count Frequency
Age band
20-30 53 7 13.21% 0 0% 0 0 0% 0 0%
30-40 195 28 14.36% 0 0% 6 2 33.33% 0 0%
40-50 1,184 190 16.05% 0 0% 51,623 17,802 34.48% 8 0.02%
50-60 3,035 603 19.87% 18 0.59% 70,960 29,506 41.58% 299 0.42%
60-70 1,501 505 33.64% 45 3.00% 97,841 51,003 52.13% 2271 2.32%
70-80 127 78 61.42% 10 7.87% 1,167 671 57.5% 64 5.48%
Smoking status
Never smoker 1,624 296 18.23% 9 0.55% 108,295 45,908 42.39% 743 0.69%
Previous smoker 2,361 534 22.62% 29 1.23% 84,792 39,281 46.33% 1264 1.49%
Current smoker 2,039 561 27.51% 34 1.67% 27,326 13,279 48.59% 616 2.25%
Unknown 71 20 28.17% 1 1.41% 1,184 516 43.58% 15 1.27%
Total count
mLRRY < 0  mLRRY < -0.15
UK BiobankEPIC-InterAct
 mLRRY < -0.15Total count
mLRRY < 0
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5.3.2 Observational associations of mLOY measures with T2D risk 
 
5.3.2.1 EPIC-InterAct 
Men with decreased mLRRY values were at a suggestively higher risk of T2D (HR[95%CI] = 
0.91[0.83-1.00], p-value=0.05, Figure 5.1, Supplementary Figure 6) in the basic model 
adjusted for centre and array. While additionally adjusting for age (main model) had little 
impact on the association estimate (HR[95%CI] = 0.91[0.83-1.01], p-value=0.07, Figure 5.1, 
Supplementary Figure 6), adjusting for both age and smoking (model 3) markedly attenuated 
the association strength (HR[95%CI] = 0.94[0.86-1.04], p-value=0.23, Figure 5.1, 
Supplementary Figure 6). Further adjustment for multiple additional covariates (model 4) did 
not change the association estimate as much as for age and smoking in the model 3 (Figure 
5.1, Supplementary Figure 6). All these models exhibited large values of I2, indicating 
substantial levels of heterogeneity between countries. Moreover, given that the basic model 
produced a relatively stronger result than the other models, to eliminate the possibility that 
it is merely because of the slightly larger sample size in this model than in the other models, 
I restricted the analysis to the complete set of 5,191 men within whom the model 4 was 
performed. As a result, the association was comparable (HR[95%CI] = 0.91[0.83-1.00], p-
value=0.05, 51.6% cases), suggesting that the attenuated association results in the other 
models compared to the basic model were mainly because of the adjustment for confounding 
factors rather than the sample size. Applying the same models but using a binary variable of 
the mLOY indicator (mLRRY<0) as the main exposure showed similar results, but they were all 
non-significant (Supplementary Figure 7).  
 
5.3.2.2 UK Biobank 
In line with the previous study, we found a negative association of mLRRY with the risk of 
prevalent T2D373 (OR[95%CI] = 0.79[0.78-0.81], p-value=0.013) in a model consistent with the 
previous paper357, which only adjusted for two covariates (centre and genotyping array in UK 
biobank). Interestingly, additional adjustment for age substantially increased the strength of 
the association, but led to an reversal of the direction of the association (OR[95%CI] = 
1.08[1.06-1.10], p-value=2.33X10-16). Given that age is a confounding factor, showing strong 
associations with both the main exposure (mLRRY) and the outcome (T2D), such models 
should include age in their adjustments. 
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        Next I investigated why adding age as a covariate completely changed the direction of 
the association. I suspected that this might be biased by a multicollinearity problem. In the 
model that adjusted for age, centre and genotyping array, age demonstrated a large variance 
inflation factor (48.86), indicating a major concern of collinearity, even though the pair-wise 
correlation between age and mLRRY was small (Spearman’s Rho = -0.2). Further, the condition 
number was extremely large (978.2), indicating a global instability of beta coefficients 
estimated from these models in UK biobank. 
        Association with incident T2D was more significant than that found in the EPIC-InterAct, 
but in an opposite direction, either with or without adjustment for age (Table 5.3, 
Supplementary Table 19). Additional adjustment for smoking alone or in combination with 
other confounding factors, including alcohol consumption, education level, BMI and waist 
circumference did not substantially change the result (Table 5.3, Supplementary Table 19). 




Figure 5.1. Observational associations between mLRRY and T2D risk across countries in EPIC-InterAct. 
Associations were analysed using Cox regression models with different adjustments. The main exposure, mLRRY, was analysed as a continuous 
variable, with higher values indicating less ‘loss’ of Y. Association estimates across countries were combined using inverse variance weighted 
random-effects models, with between-country heterogeneity in each model quantified as I2. Association estimates in the model adjusting for 







Table 5.3. Observational associations between mLRRY and T2D risk in UK Biobank. 
Associations were analysed using Cox or logistic regression models for incident and prevalent T2D, respectively, and with different adjustments, 





Adjustment HR Beta SE P-value total N case N OR Beta SE P-value total N case N
centre, array 1.06 0.06 0.01 5.22E-06 196,171 6,831 0.98 -0.02 0.01 1.28E-02 218,665 12,490
age, centre, array 1.05 0.05 0.01 4.27E-05 196,171 6,831 1.08 0.07 0.01 4.72E-16 218,665 12,490
age, smoking, centre, array 1.06 0.06 0.01 1.26E-06 195,992 6,822 1.08 0.08 0.01 1.76E-17 218,428 12,462
age, smoking, alchol consumption, education, 
BMI and wasit circumference, centre, array 1.04 0.04 0.01 5.88E-04 195,172 6,757 1.07 0.06 0.01 2.84E-11 217,239 12,357
Incident T2D (Cox regression models) Prevalent T2D (logistic regression models)
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5.3.3 Linear trend of associations between mLRRY and T2D risk 
 
There was no evidence observed for a non-linear association between mLRRY and T2D risk. 
The linearity was examined by comparing effects of quartiles of mLRRY on T2D risk. The risk 
effects of mLRRY on T2D gradually increased in proportion to the increasing order of the 
quartiles of mLRRY, yet below nominal significance, which was possibly due to limited 
statistical power (Figure 5.2). The linear trend of associations between mLRRY quartiles and 
T2D risk was supported by the likelihood ratio test that showed low probabilities of being 
non-linear (Pnon-linearity>0.5). 
 
Figure 5.2. Association of quartiles of mLRRY with T2D risk. 
The lowest quartile is set as the baseline. Quartiles were defined based on cut-offs derived in 
the InterAct subcohort (1st=[-3.42,-0.69], 2nd=[-0.69,-0.01],3rd=[-0.01-0.66], 4th=[0.66-3.42]). 
 
  














HR(95% CI) per one quantile increase of mLRRY
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5.3.4 Stratified analyses by age group or smoking status 
 
The risk effects of mLRRY on T2D differed between age groups, and the heterogeneity was 
consistently observed across all four models (I2>80%, Pheterogeneity<0.005, Figure 5.4A). 
Individuals at younger ages (<50 years) exhibited higher risks of T2D per 1-SD decrease of 
mLRRY, which were attenuated to below nominal significance in men at older ages (≧50 years, 
Figure 5.3A). The variation in the risk effects of mLRRY on T2D across age bands was supported 
by a significant interaction observed between age-band and mLRRY (Pinteraction<0.002). This 
suggested that mLOY might exert a relatively higher risk on T2D within the younger age group 
(< 50 years), even though the overall risk effect was weak. 
        Stratification by smoking status dampened the overall risk effect, with minor 
heterogeneity between different smoking strata (I2<10%, Pheterogeneity>0.20, Figure 5.3B). 
Likelihood ratio tests also suggested a non-significant interaction between smoking status and 
mLRRY for their effects on the T2D risk (Pinteraction>0.70). 
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Figure 5.3. Stratified analyses by age group or smoking status. 
A. Age and B. smoking status were divided into three groups with cut-offs at 50 and 65 years and two groups of never and ever smokers, 
respectively. Associations were analysed in each age group or smoking status in each country, and combined across countries using random-
effects meta-analysis models. The country-combined association estimates in each age group or smoking status were further meta-analysed 










5.3.5 Associations of mLOY measures (mLRRY) with lifestyle and anthropometry traits and 
circulatory biomarkers 
 
Besides smoking, we investigated whether there were other modifiable risk factors associated 
with mLOY. However, except smoking, all the other traits failed to reach the significance level 
after Bonferroni correction. There were several traits that reached the nominal significance 
level (p-value<0.05). Serum creatine and uric acid levels showed evidence of association with 
mLRRY, with 0.04 (95%CI, 0.01-0.07) and 0.03 (95%CI, 0-0.07) SD increase of the mLRRY values 
per 1-SD increase of the two risk factors, respectively, suggesting that reduced renal function 
and hypouricemia may affect mLOY (Figure 5.4). Increased mLRRY were also associated with 
lower levels of transferrin, with 1-SD lowering of transferrin levels reducing mLRRY by 0.04 
SD (95%CI, 0-0.07SD, Figure 5.4). Lower levels of transferrin, pathologically ascribed to 
impaired production of transferrin in the liver or excessive loss through the kidney, suggested 
impaired capacity of iron transportation into circulation, leading to iron deficiency anaemia. 
Moreover, reduced mLRRY was associated with higher levels of glycated haemoglobin 
(HbA1c), a biomarker routinely measured for diagnosis and monitoring of T2D, with 1-SD 
increase of HbA1c levels reducing mLRRY by 0.04 SD (95%CI, 0-0.07SD, Figure 5.4). 
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Figure 5.4. Associations of mLRRY with lifestyle and anthropometry traits and circulatory biomarkers in the random subcohort of EPIC-InterAct 
study. 






5.4.1 Summary and conclusion 
 
The main finding of this study is that there was some suggestive evidence showing mLRRY, 
the measure of mLOY, was associated with increased risk of T2D in the model adjusted for 
centre, array and age, but the effect was weak, and substantially reduced after adjusting for 
smoking. In addition, in UK biobank, the association was observed in an opposite direction, 
causing the findings to become even more inconclusive. 
        Moreover, in EPIC-InterAct, the risk effects of mLRRY on incident T2D, although non-
significant, were proportionally increased to the increasing order of quartiles of mLRRY, 
suggesting a linear trend in associations between mLRRY and T2D risk, even though the 
overall effect of mLRRY on T2D risk was weak. Men younger than 50 years were more 
susceptible to T2D with decreased mLRRY than men older than that age. Finally, some 
modifiable risk factors showed nominally significant associations with mLRRY, yet all below 
Bonferroni corrected threshold, except smoking status. 
 
5.4.2 Age-stratified risk effects of mLOY on T2D 
 
The risk effect of mLOY on T2D was stronger in the young (< 50 years of age) than the middle-
aged (50-65 years of age) or old (> 65 years of ages) populations. A statistically significant 
interaction between mLOY and age group was observed for their risk effects on T2D. Post-
zygotic mutations occur stochastically across human genomes, among which those that 
confer proliferative advantages can lead to aberrant clonal expansions200. Such mosaic 
mutations are often rarely observed in young individuals, although they have also been 
described in new-born babies with significantly higher risk of leukaemia200,382, suggesting that 
they can occur throughout the entire human lifespan, but are enriched in the elderly. In our 
study, we found that higher degrees of mLOY (mLRRY<-0.15) began to emerge after the age 
of 50 years, hence in the younger population, whether the mLRRY values indicate true mLOY 
events or merely reflect some background noises is unclear. Therefore, although we observed 
a larger risk effect of mLOY on T2D in the younger population, we cannot rule out the 
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possibility that this was induced by technical errors. 
 
5.4.3 mLOY mediating the risk effect of smoking on T2D 
 
Previous studies have suggested a causal effect of smoking on mLOY under the MR framework, 
where genetic variants at the CHRNA5–CHRNA3–CHRNB4 nicotinic receptor locus were used 
as instrumental variables195,196. Given that smoking has also been reported as a modifiable 
risk factor for T2D independent of educational level, physical activity, alcohol consumption, 
and diet381, and adjusting for smoking substantially attenuated the risk effect of mLRRY on 
T2D, we speculated that mLOY may be one of the pathological consequences of smoking, 
thereby partially mediating the risk effect of smoking on T2D. In other words, mLOY may act 
as a mediator that contributes to the detrimental effect of smoking on T2D. 
 
5.4.4 Discordant findings between EPIC-InterAct and UK Biobank 
 
We showed that in UK biobank, the association between mLRRY and incident T2D became 
much stronger, but completely reversed. There are several potential factors that might 
partially explain the discrepant findings between EPIC-InterAct and UK biobank. Firstly, the 
study design and participant demographics can differ; EPIC-InterAct is a case-cohort study 
with enriched T2D cases that account for over half of the overall sample size, whereas UK 
biobank is a population-based cohort study, prospective in design, but so far with limited 
longitudinal data. The proportion of incident T2D cases is relatively small in UK biobank, 
accounting for approximately 4% of the study population, and therefore leading to an 
unbalanced case-control ratio that can result in type I error rate inflation due to violation of 
asymptotic assumptions of logistic regression383. Secondly, definition of incident T2D 
between two studies can differ. Because the aim of the EPIC-InterAct study is T2D-focused, 
the T2D cases have been ascertained through comprehensive reviewing of various sources of 
evidence, including questionnaire and nurse interview, linkage to primary and secondary care 
registers, medication use, and mortality data212; whereas in UK biobank, the incident T2D 
cases were defined primarily based on electronic health records data through linkage to 
ICD10 codes. The less stringent ascertainment of incident T2D in UK biobank may cause 
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inaccurate or even biased estimation of associations. Thirdly, the model diagnostic statistics 
suggested a potential multi-collinearity problem in UK biobank, and thus a risk of global 
instability of model estimates. Moreover, the intercept terms from logistic and Cox regression 
models were highly correlated to age and centre, which also indicated instability of the 
models applied in UK biobank. Because of the massive and complex data structure in UK 
biobank, there might be unknown confounding factors that are essential but underexplored, 
such that omission of them can lead to biased results. Investigations into the model reliability 
and better refined algorithms for defining T2D incidence in UK biobank may help to address 
such discrepancies and improve research reproducibility. 
 
5.4.5 Impact and strength 
 
Post-zygotic variations sporadically emerged in somatic cell lineages from the zygote stage 
onwards throughout the entire lifespan are largely under-investigated200, and they have been 
demonstrated to underlie pathophysiology of various clinical disorders, including early 
developmental defects and age-related diseases, such as cancer predisposition (both within 
and outside the haematological system), cardio-metabolic phenotypes and AD189,190,207. A 
recent study collecting data from several case-control cohorts (n=7,437, 29.7%) has shown 
T2D increased the average risk of clonal mosaic events in autosomes by more than 5-fold360, 
but whether clonal mosaicism, and particularly on chromosome Y, affects T2D risk is unknown. 
This study, with an aim to answer this question, is the first study that has examined 
observational association of mLOY with T2D in a large prospective cohort. It benefited from a 
large-scale case-cohort study design, comprising a large sample size of incident T2D cases 
with diagnoses verified during a long-term follow-up, as well as a quasi-random subcohort. A 
variety of phenotypes were measured, which allowed comprehensive adjustments for 
potential confounding factors. 
 
5.4.6 Limitation and future perspectives 
 
The analyses showed a lack of statistical power, especially when dichotomising mLRRY or 
categorising it into quartiles. Substantial between-country heterogeneities were observed, 
which also compromised the statistical power. Moreover, the observational associations 
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analysed in this study can be biased by confounding factors and reverse causation, while 
causal evidence is lacking. MR analyses with strong and specific genetic instruments for mLOY 
can help to further dissect potential causal roles of mLOY on T2D. Given that little evidence 
has been found to suggest an observational association, to demonstrate a convincing causal 
association, MR studies need to be well-sufficiently powered, and with genetic instruments 
specifically capturing phenotypic variations of mLOY. Finally, this study analysed clonal mosaic 
events on chromosome Y only, given that previous studies have suggested a strong 
correlation between mLOY and clonal mosaic events across autosomal chromosomes206, and 
between mLOY and mLOX in women195, a further investigation of associations of overall and 




Summary and discussion 
 
6.1 Key findings 
 
Several key findings have arisen from the work presented in my thesis. (1) I identify 49 
genomic regions associated with LTL, and prioritise likely-causal gene candidates at 32, many 
of which are related to telomere structure, DNA replication and repair. Nucleotide 
metabolism is highlighted as an important regulatory pathway of TL for the first time, using a 
data-driven method in combination with knowledge-based manual curation. (2) Using genetic 
approaches to understand causal associations between LTL and disease, I report several 
associations not previously identified, including a higher risk of hypothyroidism and lower 
risks of thyroid cancer, lymphoma and several malignant as well as benign tumours, 
particularly of proliferative tissues. I replicate the previously reported association of shorter 
LTL with increased risk of CHD but show that this association appears to be mainly driven by 
specific genes that exert relatively large and directionally concordant effects on CHD. (3) I 
suggest that investigating longitudinal changes of LTL in a large prospective cohort can be 
theoretically valuable, but practically challenging. My systematic literature review 
summarises epidemiological studies of risk factors that are associated with the longitudinal 
changes of LTL, i.e. attrition rate, and how such changes are consequently associated with 
disease outcomes. Results show that evidence is inconsistent, except for baseline LTL being a 
strong determinant of the LTL attrition rate, the association that I also observe in the small 
pilot study within the Fenland cohort. Fenland results in combination with evidence from the 
literature review question the feasibility and scientific efficiency of studies of longitudinal 
change of LTL, given the strong correlation of baseline LTL with the prospective ‘rate of 
change’. (4) I find little evidence to suggest an observational association between mLOY and 
T2D risk. Although there is some suggestive evidence for a modest effect of mLOY on the risk 
of T2D in EPIC-InterAct case-cohort study, the effect is largely attenuated to be non-significant 
after adjusting for smoking. In addition, such association appears to be in an opposite 
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direction in UK biobank. Therefore, considering confounding effects and inconsistency across 
study cohorts, I conclude that there is insufficient evidence to suggest mLOY is observationally 
associated with T2D risk. 
        This chapter summarises findings and conclusions from the work undertaken across all 
chapters in this thesis, with a focus on the overall impact, strengths and limitations of my 
work. Future directions for studying genomic markers of aging and their potential utilities in 
clinical healthcare and drug development are highlighted in the last part of this chapter. 
 
6.2 Summary and discussion 
 
This thesis focuses on genomic ageing in the population and includes detailed studies of key 
markers of genomic ageing: LTL and mLOY. Original research has been performed to 
characterise novel genetic determinants and biological mechanisms of LTL regulation and 
dissect causal roles of LTL in various clinical outcomes. Moreover, literature evidence on risk 
factors that are associated with longitudinal changes of LTL and clinical consequences due to 
such changes has been systematically reviewed. Feasibility of studying LTL shortening in a 
young and healthy cohort has been examined within a small-scale pilot study in Fenland. 
Finally, the observational association between mLOY and incident T2D risk has been 
characterised in two of the largest international prospective studies of incident T2D, EPIC-
InterAct and UK biobank. 
        Strengths and limitations specific to each study have been discussed in each relevant 
chapter and this section focuses on some of the more general aspects of the work undertaken 
in my thesis. The GWAS meta-analysis of LTL substantially increases sample sizes of previous 
studies by adding two large-scale population cohorts, EPIC-InterAct and EPIC-CVD, and SNP 
coverage has been increased via upgraded, more densely imputed panels. Overall, this study 
has more power to discover rare and low frequency variants that were difficult to study in the 
past due to a lack of statistical power and/or accurate genotyping/imputation of the variants. 
Moreover, with rich sources of publicly available data for variant and gene level functional 
annotations, and cutting-edge analytical methods of integrating such data with genomic 
results, I generate more evidence to help with pinpointing likely-causal genes for associated 
LTL loci identified. Through analysing functional inter-connections between likely-causal 
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genes, I prioritise signalling pathways, some of which have not been previously implicated 
with telomere biology. Furthermore, owing to increasingly expanding international consortia 
that provide GWAS summary statistics, I dissect causal roles of LTL in cardiometabolic traits 
and diseases with substantially increased power. I also systematically elucidate clinical 
relevance of LTL in a broad spectrum of disease outcomes via a phenome-wide association 
scan in UK biobank; many of the diseases have not been investigated before. 
 
6.2.1 Genetic architecture of LTL 
Despite doubling sample size of the recent genome-wide meta-analysis of LTL151, I identify 
only a relatively small number of loci not previously identified, and this can be attributed to 
several reasons. (a) A couple of GWAS of LTL, similar to this work, have been published very 
recently, and some of their novel loci overlap with ours, which are not counted as novel in 
our study. However, our work is independent from theirs, and has been written up and was 
under internal review by the time these publications emerged. These include a multi-ethnic 
analysis in TOPMed (Trans-Omics for Precision Medicine) (n=75,000) with LTL estimated using 
whole genome sequencing data384, and a meta-analysis of results from a Singaporean Chinese 
study and the previously published ENGAGE study (n=60,601)240. (b) Rare variant discovery: 
Firstly, given that extremely shortened LTL is often observed in patients with premature 
ageing syndromes, who die at fairly young ages, mutations of these disease-causing genes, if 
at a relatively high level of penetrance, are unlikely to be transmitted to subsequent 
generations. Therefore, even though their effect sizes are large, their observed frequencies 
in a general population are too low to be genotyped or imputed accurately. Secondly, even if 
they can be accurately genotyped, for example, through direct genotyping or whole 
genome/exome sequencing, identification of them suffers from a lack of statistical power, 
and finding such associations needs much larger sample sizes. (c) identification of common 
variants with small effects: Despite conducting the largest existing GWAS on LTL, genome-
wide independent variants identified explain only 1.5% of the total heritability. The missing 
heritability is likely to be explained by both unidentified rare variants with large effects as well 
as many more common variants with small effects that this study was still not powered to 
detect. In comparison to other complex traits, such as lipids385,386 and blood pressure387, 
where hundreds of independent variants that span a wide range of allele frequencies have 
been identified in recent multi-ethnic GWAS meta-analyses in large-scale biobanks, genetic 
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discovery on LTL is restricted by limited samples available possibly due to measurement 
efficiency and accuracy. Future meta-analyses of studies from biobanks and consortia can 
help to expand the catalogue of genetic determinants of LTL to include ultra-rare variants 
with extremely large effect sizes, as well as common variants with very small effects388. 
 
6.2.2 Causal gene annotation 
Identifying causal variants and genes underlying association signals has been a general 
challenge in genetic association studies. To address this, I gathered and integrated extensive 
genomic and regulatory annotations and gene expression data, in addition to manual curation 
with help and guidance from senior study authors of the related publication. Although these 
efforts have successfully resulted in over two thirds of the FDR loci being assigned to likely-
causal gene candidates, annotation was difficult for the remainder due to inconsistent 
prediction results of likely-causal genes by different methods and/or limited knowledge of 
candidate genes within those loci. Large-scale GWAS on other traits typically rely on one or 
two methods of causal gene prioritisation, and therefore do not have such problem of 
showing inconsistent results across methods used. Different algorithms implemented and 
training data used may lead to discrepancies observed within the prediction results of causal 
gene candidates, however, no studies have systematically compared and evaluated strengths 
and limitations of these methods. Therefore, I employed a conservative approach, where only 
genes supported by multiple bioinformatic evidence showing consistent results are deemed 
as likely-causal genes. Given that rare variants with extreme effects on protein functions can 
facilitate causal gene prioritisation, exome and whole-genome sequencing at scale, as 
planned and ongoing for UKBB and other studies, can help to pinpoint likely-causal genes for 
these loci and those identified in the future. 
 
6.2.3 Trans-ethnic analyses 
This and other recent LTL GWAS are predominantly Europeans-focused, with the exception 
of the Singaporean Chinese study (n=23,096 with Southern Han Chinese ancestry)240 and the 
TOPMed study (n=75,176 with 28% African, 13% Hispanic/Latino, 6% Asian and 2% Samoan 
ancestries)384. Under-representation of non-European populations is a recognised and 
important limitation of most genetic population studies. Inclusion and study of diverse 
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ethnicities are valuable for several reasons: First, novel loci can be identified through meta-
analysing studies across populations. Because variants may show distinct allele frequencies 
in different populations, loci that are monomorphic or rare in the European populations can 
be polymorphic and common in other populations, therefore meta-analyses can increase the 
power of identifying rare variants-driven loci that may be missed in studies with European 
ancestry samples only. Second, multiple conditionally independent variants can be identified 
with improved fine-mapping resolution by leveraging ethnic differences in LD structure. For 
example, studies have shown that inclusion of African ancestry samples leads to marked 
improvement in localisation of causal variants because of low LD and high genetic 
heterogeneity within the African genomes389. Third, generalisability of scientific and clinical 
utilities of summary statistics from GWAS can be improved. For example, the optimal choice 
of SNPs and weights for PRS construction may differ between populations due to different LD 
and allele frequency patterns, increasing diversity of sample ethnicities in GWAS can help 
improve prediction accuracy of PRS in individuals of non-European ancestries81. Although 
some efforts have shown promise in levelling the imbalance of sample ethnicities, in general, 
cross-ethnic analyses are still dominated by Europeans. Future research that includes larger 
proportions of individuals with more diverse ancestries may further increase the power of 
identifying novel loci and variants involved in LTL regulation, and facilitate biomedical 
applications of GWAS results in wider populations.  
 
6.2.4 Measurement of LTL and longitudinal assessment 
Imprecise measurement of LTL is another potential limitation of this study. We used the qPCR 
method for LTL measurement, which may be less reliable than other procedures like Southern 
Blot, but more suitable for large-scale studies due to less amounts of DNA samples required 
and time and cost efficiency. However, there are several issues of the qPCR measurement, 
which can result in power loss and false positive discoveries. First, a relatively large random 
variation within cross-sectional measures reduces statistical power in regression analyses. To 
control such random errors, we measured all samples in triplicate and excluded samples with 
coefficient of variation larger than 10%. Second, batch- and centre-effects, i.e. 
heterogeneities of measurement between different batches and centres due to different 
experiment times, handlers, reagent lots etc., decrease power of meta-analyses while 
increase false positive findings. To control these, we adjusted for batch and centre in linear 
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regression models and applied post-hoc corrections in meta-analyses to filter out variants 
with substantial between-study heterogeneities. 
        In terms of repeated LTL measures, i.e. longitudinal change of LTL, random errors within 
repeated measures of same individuals over time can mask real longitudinal changes due to 
the regression to the mean problem (section 4.4.2). Such problem can lead to an artificial 
correlation between the change (follow-up minus baseline measurements) and the baseline 
of measurements, because individuals whose baseline measures are lower than average tend 
to increase (so that change values are larger) and vice versa. This is specifically true for genetic 
discovery studies, where small effect sizes are expected and for which very large-scale (cross-
sectional) GWAS now exist on LTL and hence new longitudinal studies are likely to only 
identify established loci already known to affect baseline LTL. This technical challenge 
questions the feasibility of conducting large-scale epidemiological and GWAS on the 
longitudinal change of LTL. 
        While protocol prioritisation of the existing method and extensive QC procedures have 
been undertaken, alternative methods may be worth trying in future researches, such as 
estimation of LTL from whole genome sequencing data390. The recent TOPMed study has 
leveraged computational methods using the whole genome sequencing data, which made a 
marked progress in realising high-throughput and fully unsupervised measurement of LTL, 
however, showed only a moderate level of correlation (Pearson correlation r<0.60) to 
Southern blot estimation396, highlighting the challenge and technical enhancement required 
for further improvement of accuracy and efficiency of the LTL measurement. 
 
6.2.5 Measurement of mLOY 
Population studies on clonal mosaicism, including mLOY, have largely been limited by 
technical challenges of accurately detecting such events, due to expected low cell fractions of 
mosaic events in leukocytes. In this study, a mLRRY approach that quantifies mLOY based on 
median genotyping intensity over the Y chromosome specific (non-pseudoautosomal) region 
was used. This method has been previously used in a GWAS meta-analysis of mLOY and 
showed potentials of being implemented to large-scale cohort studies with genotyping array 
data available. However, as this method needs to be applied to different array data separately, 
heterogeneity between arrays can be an issue that decreases power when meta-analysing 
across arrays. Moreover, such estimation was found to be missing in up to 50% of men in the 
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EPIC-InterAct study, and the missingness was shown to be correlated to genotyping array, 
casting further doubts on the accuracy and stability of this method of measurement. 
        Recently, a more refined approach has been developed, which uses signal intensity 
imbalance between two statistically phased haplotypes over the pseudo-autosomal region of 
the X and Y chromosomes135. It showed improved precision of estimation compared to the 
mLRRY approach, which, if applied to the EPIC-InterAct study, can potentially increase the 
power of observational analyses. This is especially important considering the observed 
association between mLRRY and incident T2D, if present, is weak, and suffers from a lack of 
statistical power.  
 
6.3 Future work and applications 
 
Telomeres 
Restricting telomere elongation has been proposed as a tumour suppression mechanism but 
shortened telomeres can in turn influence stem cell differentiation and tissue renewal, 
highlighting an important role of telomere homeostasis in various diseases, including cardio-
metabolic and neurodegenerative diseases, cancers, as well as rare diseases of premature 
ageing (section 1.4.1.4). 
 
6.3.1 TL and premature ageing syndromes 
My work and previous studies have highlighted overlaps between genetic determinants of 
premature ageing syndromes and normal ageing-related phenotypes and diseases. Therefore 
a deeper understanding of mechanistic pathways underlying the pathogenesis of rare and 
extreme ageing syndromes, such as HGPS and WS, can help to also shed light upon 
pathophysiological changes that occur during ageing age-related diseases in general 
populations and may provide novel therapeutic approaches for treating both rare premature 
ageing syndromes and common age-related complex diseases. 
        One example for an overlapping genetic mechanism between premature ageing 
syndromes and telomere regulation is via the WRN gene, the causal gene for WS, which has 
a well-established role in homology-dependent recombinational DNA repair and telomere 
maintenance. Loss of WRN leads to critically shortened telomeres and genomic instability124, 
the hallmarks of ageing (Figure 1.1). Another example is an alternative splicing mutation of a 
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LMNA gene transcript, the most frequent cause of the HGPS, resulting in protein truncation 
from the C terminus of lamin A123. The truncated protein mutant is called progerin and several 
studies have indicated that progerin modifies nuclear environment in which DNA repair 
pathways are activated125. Cell samples from HGPS patients show reduced recruitment of 
protein components of DDR pathway at DNA double-stranded breaks, leading to impaired 
genome integrity and cell proliferative capacity122,123. In chapter 2, I identify multiple genes 
(ATM, PARP1, TERF2, SENP7 and RFWD3) that are associated with LTL and involved in the DDR 
pathway (section 2.3.3). Mutations in these genes have been shown to disrupt telomere 
homeostasis and lead to premature ageing phenotypes172–174, suggesting DDR as a potential 
mechanistic pathway that conveys genetic effects of telomere dysregulation onto organismal 
phenotypes that resemble ageing. It remains uncertain whether TL shortening lies on the 
causal path that leads to clinical phenotypes manifested in the premature ageing syndromes 
or merely a consequence of shared genetic factors that drive both TL shortening and 
accelerated ageing phenotypes. Genetic and molecular characterisation of TL can deepen our 
understanding of mechanisms of rare disorders of premature ageing, thereby providing an 
aetiological link between premature ageing syndromes and common complex diseases 
occurring during normal ageing, and eventually facilitating novel therapeutic target discovery 
and prevention and treatment of age-associated diseases. 
 
6.3.2 TL and age-related complex diseases 
Besides rare disorders of premature ageing, TL has been causally linked to various complex 
morbidities that occur more frequently in general populations, including CVD158,177,291, AD180, 
dementia and mortality181. The causalities are mainly inferred from genomic research where 
genetic determinants of TL are used as instruments within the MR framework (section 1.2.6.1). 
However, mechanistic pathways of how telomeres are involved in age-related complex 
diseases, for example, which genes regulating TL influence disease risks are poorly 
understood. These are important questions for translating TL into clinical applications and for 
developing cancer immunotherapies that target TL-associated genes391. 
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6.3.2.1 TL and CVD 
Endothelial cell senescence triggered by critically shortened TL at atherosclerotic lesions has 
been shown to contribute to atherogenesis, providing a mechanistic link between shortened 
TL and increased CVD risk392. Although TL exhibits a certain level of heterogeneity across 
tissues, for example, LTL was reported to be shorter than TL in vascular tissues393, the high 
correlation between tissues and the feasibility of measuring LTL at large-scale make LTL an 
excellent proxy for TL across tissues392. However, several prospective population-based 
studies casted doubts on the concept that longer TL can always protect against CVD, 
depending on disease onset and progression394–396. Moreover, additional studies that showed 
supporting evidence for the protective effects of longer TL on CVD are often debatable due 
to relatively small effect sizes reported. Alternative hypotheses have been postulated that 
suggest other aetiological causes of CVD, including oxidative stress and inflammation, 
influence LTL attrition rate397, which in turn result in the observed association between cross-
sectional measurement of LTL and CVD. Such caveat of reverse causation has been discussed 
in relevant sections (sections 1.4.1.4.2 and 3.4.2). 
 
6.3.2.2 TL shortening and CVD 
Studies have suggested that genetic determinants of LTL shortening rate may be more directly 
relevant to CVD aetiologies compared to those of LTL measures at birth391. Identification of 
genetic determinants of LTL shortening rate have presumably been included in GWAS of 
cross-sectional measurement of LTL, because such GWAS should identify genetic factors that 
regulate LTL at two levels: LTL at birth and LTL shortening rate. For instance, genes that 
encode protein components of the core telomere structure and the telomerase 
ribonucleoprotein, can constitutively regulate TL from birth and throughout the entire life 
course. Therefore, these genes can determine TL at birth as well as TL attrition later in life. In 
contrast, genes that function in inflammatory pathways, such as HLA-mediated immune 
responses and stress-triggered DDR, may regulate TL attrition rate via interactions with 
physiological stress conditions, such as oxidative stress and nutrient deficiency. 
        Age-related LTL attrition rate seems to reach the highest level early in life, and then 
sustain at a relatively low level throughout the adulthood, suggesting that interindividual 
variation of LTL is mainly dependent on LTL at birth and attrition rate during childhood rather 
than middle or late adulthood when CVD risk assessment is warranted398. A study cohort of 
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adult participants should capture the main sources of pre-disease variation of LTL with only 
baseline measurement. Moreover, this and earlier work has shown that LTL shortening rate 
is highly correlated with baseline LTL (Chapter 4). Because of these, given the fact that a 
simple, single point measure a) reflects genetic influences as well as accumulative burdens of 
non-genetic environmental risk effects on LTL, and b) is a strong determinant of LTL 
shortening rate, it is unlikely that assessing LTL shortening rate can provide any additional 
values in either identifying genetic determinants associated with LTL or predicting risk of CVD.  
 
6.3.2.3 Gene-specific effects of LTL on CVD  
Because candidate genes identified in GWAS of LTL can have very different biological 
functions, and thus may be directly or indirectly associated with telomere biology. Their 
individual involvements in telomere regulation are likely to vary and their impact on CVD risk 
may be mediated through distinct mechanisms rather than LTL alone. For example, 
telomerase was found to be involved in the Wnt/β-catenin pathway and the E2F1-based 
transcription, both of which have been implicated in atherosclerosis independently of TL399,400. 
Therefore, although genetically determined shorter LTL increases the risk of CVD, potential 
pleotropic effects of variants used to proxy LTL may undermine this conclusion, and further 
considerations about individual gene-specific effects may be necessary. 
 
6.3.2.4 Conclusion 
The telomere hypothesis is attractive in that rather than a single gene test, it provides a global 
property of the genome that is both heritable itself and modifiable by other conventional risk 
factors of CVD, thereby serving as an integrative marker of biological age that could at least 
partially explain interindividual variation in risk of occurrence and age of onset94. However, 
given the methodological challenges of assessing LTL attrition rate simply and accurately, and 
the relatively small changes that are observed during middle age, distinguishing individuals’ 
CVD risks based on repeated measures of LTL (i.e. longitudinal change) seems unfeasible at 




mLOY in peripheral blood is reportedly the most common form of clonal mosaicism (post-
zygotic mutations) in men during a physiological process of ageing, with a prevalence of up to 
20% (among three prospective cohorts that include 8,679 cancer cases and 5,110 cancer-free 
controls) in men over 80-years196. Besides age, smoking is a well-documented risk factor for 
mLOY, with more than 3-fold increase of mLOY risk in current versus never smokers401, 
although this effect was reported to be transient, as cessation of smoking for several years 
reduced the risk towards baseline196. Several recent studies have linked mLOY in blood 
leukocytes to higher risks of all-cause mortality and common age-related diseases, including 
AD,207 severe atherosclerosis356, and cancers, not only in blood but many other 
tissues193,200,359, but the extent to which these observations represent causations is unclear. 
Understanding fundamental mechanisms of how mLOY in leukocytes affect occurrence and 
progression of age-related diseases is important for assessing clinical significance of mLOY as 
a biomarker for these diseases135,402. 
 
6.3.5 mLOY and T2D 
6.3.5.1 Observational association between mLOY and T2D 
In Chapter 5, I have demonstrated that mLOY exerts little effect on incident T2D in a large 
European prospective case-cohort study (EPIC-InterAct). There is no association after 
adjusting for important confounding factors, including age and smoking. However, the 
association between mLOY and T2D risk appeared somewhat more pronounced in younger 
compared to older men. Whether mLOY in younger men is truly involved in T2D pathology or 
acts as a molecular mediator of conventional risk factors of T2D not accounted for in the 
present study is unknown. Also, mLOY may simply serve as a marker of genome instability 
that underpins various age-related disorders, but not directly contribute to disease 
aetiologies. To further elucidate the role of mLOY in T2D aetiology, further investigation into 
common genetic mechanisms that drive mLOY and susceptibility to T2D would be crucial. 
 
6.3.5.2 Genetic determinants of mLOY and T2D 
A recently published GWAS identified 19 genetic loci that are associated with mLOY, many of 
which are functionally implicated in cell cycle regulation and DNA repair195. These help to 
highlight relevance of mLOY in carcinogenesis due to substantial overlap of mLOY-associated 
loci with known oncogenic genes and gene targets for cancer therapies. A larger GWAS with 
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improved methods of detection of mLOY is underway, providing more novel loci and deeper 
insights into their clinical relevance135.  
        Several mLOY-associated loci identified in the ongoing GWAS of mLOY are correlated with 
loci previously reported for T2D risk, highlighting several genes that encode for cyclins and 
cyclin-dependent kinases expressed in pancreatic β cells, essential for β-cell growth and 
maturation135. These may reflect plausible involvement of cell cycle regulation and genome 
integrity in β-cell proliferation and differentiation, and thus linking mLOY to insulin-
dependent diabetic phenotypes. However, because such relevance is driven by specific genes, 
and thus does not reflect a causation of mLOY on T2D, but merely suggests a common genetic 
susceptibility to genome instability that leads to both mLOY and β-cell loss. Moreover, 
reduced β-cell mass is a pathological feature of T1D rather than T2D, the latter is caused by 
insulin resistance in peripheral tissues, but not reduced insulin secretion from β cells360. 
Therefore, although there are some genetic evidence linking mLOY to metabolic disorders, 
these do not counterpose our conclusion in the prospective cohort study mentioned above. 
 
6.3.5.3 Conclusion 
Our epidemiological analyses suggest no association between mLOY and incident T2D, and 
with genetic discovery from previously published work, these can help to facilitate our 




The work conducted in this thesis brings together evidence from large-scale studies of two 
genomic markers of ageing, LTL and mLOY, including assessments of genetic and non-genetic 
determinants and clinical consequences, with a focus on T2D. The GWAS meta-analysis of LTL 
with downstream in silico annotations provides an expanded pool of likely causal genes 
implicated in telomere homeostasis and highlights novel biological mechanisms regulating 
LTL for experimental follow-up. LTL attrition is observed in a relatively young and healthy 
contemporaneous population but studying it at scale is questioned with technical and 
statistical challenges. I demonstrate a fundamental implication of LTL in cancer development, 
whereas no association is observed with T2D for either of the two markers of genomic ageing. 
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Overall, this work helps to build the foundations for future studies in exploring causal roles of 
genomic ageing markers in various age-related diseases, as well as investigating their 
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Supplementary Notes  
 
Information on study cohorts 
 
The demographic characteristics of all study cohorts, for both discovery and replication 




The majority of the studies included have previously been described151. In addition to these 
the following studies were included in this analysis. 
 
GENMETS 
GENMETS is a subcohort of the Finnish population-based Health 2000 study, comprising of 
metabolic syndrome cases and controls. This cohort is described in more detail elsewhere215. 
 
NESDA 
The Netherlands Study of Depression and Anxiety (NESDA) is an ongoing cohort study into the 
long- term course and consequences of depressive and anxiety disorders. A description of the 
study rationale, design, and methods is given elsewhere216. Briefly, in 2004 to 2007, 
participants aged 18 to 65 years were recruited from the community (19%), general practice 
(54%), and secondary mental health care (27%), therefore reflecting various settings and 
developmental stages of psychopathology to obtain a full and generalizable picture of the 
course of psychiatric disorders. A total of 2981 participants were included, consisting of 
persons with a current or past depressive and/or anxiety disorder and healthy control 
subjects. Exclusion criteria were a clinically overt primary diagnosis of psychotic, obsessive 
compulsive, bipolar, or severe addiction disorder and not being fluent in Dutch. The research 
protocol was approved by the ethical committee of participating universities, and all 
respondents provided written informed consent. 
 
ROTTERDAM  
The Rotterdam Study is a population-based cohort study that investigates the occurrence 
and determinants of diseases in the elderly, which has been ongoing since 1990217. As of 
2008, detailed phenotypic and genetic data has been collected on ~15,000 subjects aged 45 
years or over. For this study the RS-I and RS-III cohorts were used. The Medical Ethics 
Committee at Erasmus Medical Centre approved the study protocol. 
 
EPIC-InterAct case-cohort study 
The EPIC-InterAct study aimed to investigate the independent and interactive effects of 
genetic and behavioural risk factors on type 2 diabetes risk212,213. EPIC-InterAct is a case-
cohort study nested within 8 of the 10 countries participating in the EPIC-Europe cohort study. 
EPIC-InterAct ascertained 12,403 cases of type 2 diabetes from a total cohort of 340,234 
participants who provided blood samples at baseline and were followed-up for an average of 
 175 
7 years (~4 million years of follow-up). Cases were ascertained from multiple data sources 
including self-report of a physician diagnosis of diabetes, linkage to primary/secondary care 
records, medication use, hospital admission data and death registration data. We also 
established a random sub-cohort of 16,154 participants who were representative of 
participants within each country. By design there is an overlap with the set of incident 
diabetes cases (n=778). Participant characteristics have been previously reported in 
detail212,213. Observational statistics of LTL, genotyping and imputation are summarised in the 
Supplementary Table 1 and 2. 
 
EPIC-CVD case-cohort study 
EPIC-CVD was designed as a case-cohort study that uses the same random sub-cohort as 
InterAct, with a focus on incident coronary heart disease and stroke events214. The 
participants included in this analysis are thus incident cases only (7722 coronary heart disease 
cases and 3451 cerebrovascular disease cases). We also included an additional 752 
participants as a random sub-cohort from the two countries not included in EPIC-InterAct 




Telomere length measurements 
 
Telomere length measurements were performed using an established quantitative PCR 
technique327 across 6 laboratories.  Laboratory specific information is given below and in 
Table S1. Details of the techniques used within Helsinki, Leicester and London have been given 
elsewhere151.  
 
NESDA: Fasting blood was drawn from participants in the morning between 8:30 and 9:30 am 
and blood samples were stored in a -80°C freezer afterwards. Leukocyte TL was determined 
at the laboratory of Telomere Diagnostics, Inc. (Menlo Park, CA, USA), using quantitative 
polymerase chain reaction (qPCR), adapted from the published original method327. Telomere 
sequence copy number in each patient’s sample (T) was compared to a single-copy gene copy 
number (S), relative to a reference sample. The detailed method is described elsewhere404. 
 
Rotterdam: Telomere length was measured using a qPCR assay based on the method 
described elsewhere327. with minor modifications. For each sample the telomere and 36B4 
assay were run in separate wells but in the same 384 wells PCR plate. Each reaction 
contained 5ng DNA, 1uM of each of the telomere primers (tel1b-forward: 
GGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT, tel2b-reverse: 
GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT) or 250nM of the 34B4 primers (36B4u-
forward: CAGCAAGTGGGAAGGTGTAATCC, 36B4d-reverse: CCCATTCTATCATCAACGGGTACAA) 
and 1x Quantifast SYBR green PCR Mastermix (Qiagen). The reactions for both assays were 
performed in duplicate for each sample in a 7900HT machine (Applied Biosystems). Ct values 
and PCR efficiencies were calculated per plate using the MINER algorithm405. Duplicate Ct 
values that had a Coefficient of Variance (CV) of more than 1% were excluded from further 
analysis. Using the average Ct value per sample and the average PCR efficiency per plate the 
samples were quantified using the formula Q=1/(1+PCR eff)^Ct. The relative telomere length 
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was calculated by dividing the Q of the telomere assay by the Q of the 34B4 assay. To validate 
the assay 96 random samples were run twice and the CV of that experiment was 4.5%. 
 
Cambridge: Relative mean LTL was measured using a ViiATM Real-Time quantitative PCR 
system (ThermoFisher Sicentific, Inc), and expressed as a ratio (T/S) of the relative quantities 
of the telomeric TTAGGG repeat (T) and the single copy of a housekeeping gene, Albumin (S). 
The denominator determines total genome copies per sample, controlling the technical errors 
during quantification. The measurement was validated by the Terminal Restriction Fragment 
(TRF) analysis (the “gold standard” measurement of TL) using separate DNA samples 
extracted from peripheral blood mononuclear cells in 30 individuals (Pearson’s r =0.69). Batch 
effect was corrected by normalising all the other batches to the fourth batch. Each sample 
was measured repetitively for three times within one batch, when the same sample was 
measured in more than one batch, measurement from the last batch was kept for the sample. 




Description of Individual loci associated with LTL 
 
Chr1p13.2. The lead SNP (rs12065882) and three high LD variants are all located within 
introns of MAGI3 (membrane associated guanylate kinase, WW and PDZ domain containing 
3). MAGI3 has been proposed to act as a tumour suppressor; it regulates cell proliferation in 
glioma via wnt/β-catenin signalling and interacts with PTEN406,407. Both S-PrediXcan and 
COLOC analyses give evidence to support expression of AP4B1 (adaptor related protein 
complex 4 subunit beta 1) being influenced by the associated variants. This gene encodes a 
subunit of a heterotetrametric adapter-like complex 4 that involves in Golgi-associated and 
lysosomal vesicle biogenesis and membrane trafficking, transporting proteins from the trans-
Golgi network to the endosomal-lysosomal system408,409. Mutations in this gene are 
associated with an autosomal recessively inherited disease, spastic paraplegia type 47410. 
There is also evidence of a colocalised eQTL signal for PTPN22 (protein tyrosine phosphatase, 
non-receptor type 22) in three tissues. PTPN22 interacts with the proto-oncogene CBL, a 
member of the E3 ubiquitin ligase family that has been implicated in several cancers. 
 
Chr1q24.2. rs35675808 is located downstream of the 3’ UTR of CD247 (CD247 molecule), 
which encodes T-cell receptor zeta that constitutes the T-cell receptor-CD3 complex, coupling 
antigen recognition to several signalling transduction pathways, essential in adaptive immune 
response411,412. Pathways that have been shown to be implicated with this gene include HIV 
life cycle and translocation of ZAP-70 to immunological synapse (Reactome). Mutations in this 
gene are associated with autosomal recessive immunodeficiency 25, characterised by T-cells 
impaired response to alloantigens, tetanus toxoid and mitogens (OMIM #610163). Another 
gene, the POU2F1 (POU class 2 homeobox 1), located 3kb upstream of this variant, might be 
biologically relevant. This gene, also known as the OCT1, belongs to the first identified 
members of the POU transcription factor family413,414. Members of this family contain the 
POU domain, a 160-amino acid region necessary for DNA binding to the octameric motif (5’-
ATGCAAAT-3’) (OMIM  #164175). POU2F1, as a transcriptional factor, is involved in cell cycle 
regulation and transcription of histone H2B and other cellular housekeeping genes414,415. It 
has also been suggested that the expression of histone H2B was downregulated in response 
to double-stranded DNA breaks via a mechanism that modulates transcriptional regulatory 
potential of POU2F1 by site-specific phosphorylation416. POU2F1 is implicated with various 
pathways, including the RNA Polymerase III transcription initiation, cytokine signalling in 
immune system, BRCA1 pathway and glucocorticoid receptor signalling (Reactome). This gene 
also facilitates human herpes simplex virus (HSV) infection by forming a multiprotein-DNA 
complex with the virion proteins, activating transcription of the viral immediate early genes417. 
 
Chr1q42.12. Variants at this locus are focused across the PARP1 gene, which encodes the first 
protein member of the poly(ADP-ribosyl)transferases family, also termed as the ADP-
ribosyltransferases with diphtheria toxin homology (ARTDs).  It plays an essential role in 
various pathways of DNA repair and chromatin remodelling, including single- and double-
strand break repair, nucleotide excision repair, stabilization of replication forks, and 
modulation of chromatin structure, thereby maintaining genomic integrity and stability418. 
Because the DNA double-strand breaks structurally resemble telomeres, regulators and 
components of DNA repair machinery have been shown to be implicated in telomere 
homeostasis263. Of note, rs1136410 (r2=1.0 to the lead) causes a known V762A substitution in 
PARP1 (poly(ADP-ribose) polymerase 1), which has been shown to reduce PARP1 activity. The 
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allele that reduces activity is associated with shorter LTL, consistent with previous studies 
where knockdown of PARP1 leads to telomere shortening. PARP1 was identified as a 
telomeric double-stranded repeats binding factor in a proteomic study of telomeres using 
DNA in situ hybridization in conjugation with mass spectrometry419. PARP1 poly(ADP-
ribosyl)ates TRF2, which affects TRF2 binding to the telomere (Gomez et al., 2006). In addition 
to the coding change there is also eQTL evidence for PARP1 (S-PrediXcan and COLOC, online 
methods, Supplementary table 7) in pancreas, with the shorter LTL allele associating with 
reduced PARP1 expression. Another SNP, rs907187, is highlighted in the integrated analysis 
of non-coding variants and is located within the 5’ UTR of PARP1, which could mediate the 
effect on gene expression.  
 
Chr2p16.2.  rs754017156 is located within intron 3 of ACYP2 (acylphosphatase 2) and also 
causes an in-frame insertion of two amino acids into TSPYL6 (TSPY like 6). This gene encodes 
a nuclear protein, the Testis-Specific Y-Encoded-Like Protein 6, that involves in the 
nucleosome assembly. Biological function of this protein is largely unexplored. Studies have 
associated genetic polymorphisms of this gene region with increased risk of ischemic stroke420, 
and breast cancer in the Han Chinese population421. There are no high LD SNPs, but an 
evidence of an eQTL in testis for TSPYL6.  
 
Chr2q34. rs56810761 is located within intron 7 of UNC80 (unc-80 homolog, NALCN channel 
complex subunit, A) gene. There are no high LD SNPs, but an evidence of an eQTL for SNAI1P1 
(snail family zinc finger 1 pseudogene 1) in testis in the co-localisation analysis. SNAIP1 is a 
processed pseudogene of SNAI1, which encodes the human ortholog of a zinc finger protein 
of the snail family, first cloned in Drosophila, which was demonstrated to be essential in the 
formation of mesoderm during gastrulation and embryonic development422.  
 
Chr3q12.3. This locus consists of a 77 SNPs located predominantly across SENP7 
(SUMO1/sentrin specific peptidase 7) gene. The lead SNP is located 53bp upstream of SENP7 
within a proximal promoter. It is associated with a DNaseI sensitivity QTL and with SENP7 
expression in one tissue (co-localisation). Lower expression of SENP7 associates with shorter 
LTL. Although it has no known role in telomere regulation, the small ubiquitin-like modifier 
(SUMO) functions as a post-translational modification, regulating various biological events, 
especially in DNA repair, chromatin organization, transcription, and RNA metabolism423, 
which are essential biological events pertinent to telomere homeostasis. 
 
Chr3q13.2. The variants in this region are all located within intron 2 of a predicted mRNA, 
RP11-572M11.4 and downstream of a non-coding RNA RP11-572M11.3 (also named 
LINC02044). There is no supporting evidence to suggest which gene is potentially influenced 
at this locus. 
 
Chr3q26.2. This locus contains 47 SNPs in high LD (r2 < 0.8) with the lead SNP (rs1093660). 
The telomerase RNA component (TERC) is the functional candidate in this locus. One SNP 
(rs2293607, r2=0.81 to rs1093660) is located 63bp downstream of the TERC sequence, which 
potentially leads to altered TERC expression424. However, the lead variant, rs10936600, 
encodes a L241I substitution within LRRC34 (Leucine rich repeat containing 34), which is 
predicted to be deleterious (Supplementary Table 6). The CADD score (19.81) places this SNP 
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just outside of the 1% most deleterious mutations. LRRC34 is a member of the leucine rich 
repeat containing protein family. Although little is known about its biological function, it has 
been suggested to be implicated in the maintenance and regulation of pluripotency425. Knock 
down of LRRC34 results in reduced expression of some, but not all, pluripotency genes425. As 
genes encoding the telomerase enzyme share the same expression patterns as those of the 
pluripotency genes, thereby they are potentially subjected to the LRRC34-mediated 
transcriptional regulation. Another highly linked variant, rs10936599 (r2=1.0) is predicted to 
have a functional effect in the integrated analysis of non-coding variants (Supplementary 
Table 7). It is located on the edge of the active promoter region of MYNN, just inside the 
coding sequence. An eQTL is observed for MYNN in testis (shorter TL associated with higher 
expression), suggesting that this SNP may alter MYNN expression. MYNN protein is a member 
of the BTB/POZ and zinc finger containing family that is involved in transcriptional regulation. 
It has also been shown to interact with CUL3, a core component of the E3 Ubiquitin ligase 
complex, which functions in many cellular processes including DNA repair. LTL variants at this 
locus have been associated with idiopathic pulmonary fibrosis, of which telomere 
dysregulation is attributed to the disease aetiology426. Despite the obvious involvement of 
TERC in telomere length regulation, little bioinformatic evidence is available to support it to 
be the only likely-causal gene in this region, i.e. other candidate genes might also explain the 
locus association, such as LRRC34 and MYNN. However, it is also possible that with TERC being 
a processed non-coding RNA, the relevant information is limited in standard datasets. There 
are no eQTLs for TERC in the GTex dataset, but a study has shown that variants in the 
regulatory region can affect its expression level, possibly by facilitating the maturation of 
TERC via 3’ processing424. 
 
Chr4q13.3. The lead variant rs13137667 is located within the first intron of MOB1B (MOB 
kinase activator 1B). There are 49 variants in high LD, the majority of which are located 
intronically within MOB1B or DCK (deoxycytidine kinase). No high LD non-synonymous 
variants or co-localised eQTLs were found at this locus. MOB (Mps one binder) was originally 
identified as an Mps1 binding protein in yeast, regulating mitotic checkpoint and cytokinesis, 
and is evolutionarily conserved across all major kingdoms427. Human MOB1B homolog 
activates LATS1/2 (Large tumour suppressor 1/2) through protein-protein interaction in the 
Hippo signalling pathway, resulting in the inhibition of cell proliferation, apoptosis, and thus 
tumour suppression428. DCK is a key component of the deoxyribonucleoside salvage pathway 
and phosphorylates deoxycytidine, deoxyguanosine and deoxyadenosine to dCMP, dGMP 
and dAMP respectively.  
 
Chr4q31.23. There are 65 associated variants clustered towards the 5’ end of DCLK2 
(doublecortin like kinase 2). There is an eQTL co-localised with DCLK2 in one tissue 
(Supplementary table 7). DCLK2 encodes a protein that contains four independent functional 
domains: two doublecortin domains at the N-terminus, essential for microtubule binding and 
regulating microtubule polymerisation, a serine/threonine protein kinase domain at the C-
terminus, sharing substantial homology to Ca2+/calmodulin-dependent protein kinase, and a 
serine/proline-rich domain in between the two termini, which mediates multiple protein-
protein interactions. Mouse models with single or double copies of Dclk2 gene ablated are 
viable and fertile, however, a simultaneous deletion of Dcx gene, encoding another protein 
member of the doublecortin family, results in spontaneous seizures, hippocampal 
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disorganisation and poor survival429, phenotypically mimicking human X-linked lissencephaly 
(OMIM #613166). 
 
Chr4q32.2. This locus contains 70 closely related (r2>0.8) SNPs spanning NAF1 (nuclear 
assembly factor 1 ribonucleoprotein), a gene encoding an RNA-binding protein, required for 
the synthesis of box H/ACA RNAs and sequential assembly with proteins to form 
ribonucleoprotein (RNP) complex. The box H/ACA RNPs regulates three fundamental cellular 
processes: protein synthesis, mRNA splicing via site-specific pseudouridylation of ribosomal 
RNAs and small nuclear RNAs and telomere maintenance by facilitating the maturation of 
TERC in telomerase430. Expression evidence was found for NAF1 (S-PrediXcan and COLOC) and 
an antisense transcript RP11-563E2.2 (COLOC, online methods, Supplementary Table 7). The 
lead SNP, rs4691895, is a non-synonymous variant in NAF1 (L368V) along with another high 
LD variant (rs4691896, r2=1, I162V). Individually both are predicted to be benign; however, it 
is unclear what effects they may have in combination. 
 
Chr5p15.33. There are two independently associated SNPs at this locus, neither of which have 
any high LD variants. Both SNPs are located within intron 2 of TERT, but little functional 
evidence was found to support their involvements in regulating TERT levels, which might be 
due to the transcriptional repression of TERT in most somatic tissues. 
 
Chr5q14.1. The lead variant, rs62365174, is located in intron 4 of TENT2 (terminal 
nucleotidyltransferase 2, previously named PAPD4 and GLD2). There are 137 SNPs in high LD 
(r2<0.8), which fall across the region of TENT2 and include upstream, intronic and 3’ UTR 
variants. There is strong evidence that these variants can affect the expression of TENT2, with 
eQTLs co-localised in 9 tissues, exhibiting consistent positive correlations, i.e. reduced 
expression associates with decreased LTL. TENT2 functions as the cytoplasmic poly(A) RNA 
polymerase that adds successive AMP monomers to the 3'-end of specific RNAs, forming a 
poly(A) tail, exhibiting strict substrate specificity, that, different from the canonical nuclear 
poly(A) RNA polymerase, only functions on cytoplasmic RNAs431. Previous studies have 
suggested its role in the polyadenylation and stability of p53 mRNA432 and several miRNAs433. 
 
Chr5q31.2. The associated variant, rs112347796, has no further variants in high LD (r2>0.8). 
It is located within intron 1 of UBE2D2 (ubiquitin conjugating enzyme E2 D2), which is involved 
in the DNA damage repair434. There is no evidence to suggest the potential function of this 
variant. 
 
Chr6p22.2. This locus contains 10 SNPs in high LD (r2>0.8) with the lead SNP, all located 
around CARMIL1 (capping protein regulator and myosin 1 linker 1, previously named LRR16A). 
One SNP, rs913455, causes a synonymous change within exon 3 and has scored to have 
possible regulatory function (Supplementary Table 8), which may be driven in part by its high 
conservation and location within the coding region. There is no supporting literature evidence 
to identify which gene(s) may be influenced at this locus. 
 
Chr6p21.33. There are 11 SNPs in high LD (r2>0.8) with the lead SNP, which are located across 
the major histocompatibility complex (MHC) class III region. MHC is a highly polymorphic and 
gene-dense region with complex linkage disequilibrium structure, and thus characterisation 
of potential causal genes within this region is difficult. A number of genes can potentially 
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serve as causal gene candidates, including PRRC2A, CSNK2B and BAG6. There is evidence that 
the expression of both BAG6 and CSNK2B (S-PrediXcan and COLOC, Supplementary Table 7) 
is affected. The lead variant is located upstream of PRRC2A, which was previously known as 
the BAT2 (HLA-B associated transcript 2) gene, encoding a large protein (2157 amino acids). 
PRRC2A has been shown to be involved in the pre-mRNA editing, as spliceosome and splicing 
regulators were found to be able to bind to the PRRC2A in protein-protein interaction assays, 
including the heterogeneous nuclear RNPs and the cleavage and polyadenylation specific 
factor 1435. As maturation of the telomerase RNA subunit involves a spliceosome-mediated 
single cleavage reaction436, PRRC2A may regulate telomere length via involvement in the 
biogenesis of TERC. Of note, another variant, rs805299 (r2=1), located within intron 1 of BAG6 
(BCL2 associated athanogene 6), shows a high probability for promoter activity and is 
predicted to have regulatory function in the integrated analysis of non-coding variants 
(Supplementary Table 8). BAG6 was part of a cluster of genes that encode a multifunctional 
protein, involved in various pathways, including intracellular protein quality controls by 
promoting proteasomal degradation of misfolded and mislocalised proteins, and DNA 
damage-induced apoptosis. Another variant, rs5872 (r2=1), is located within the 3’UTR of 
CSNK2B (casein kinase 2 beta). CSNK2B is a subunit of CSNK2 that is involved in multiple 
pathways but of note has been shown to interact with TRF1. CSNK2-mediated 
phosphorylation of TRF1 is required for the binding of TRF1 to telomeres, which has been 
proposed to be essential for telomere length homeostasis255. 
 
Chr7q31.33. The associated variants cover the POT1 (protection of telomeres 1) gene, which 
encodes the most conserved protein component of the shelterin complex among all 
eukaryotes437. It is tethered to the TERF1 and TERF2 homodimers via a TIN2-mediated linkage, 
and specifically bound to the single-stranded telomeric repeats, protecting it from nucleolytic 
degradation438. Moreover, POT1 controls the sequence precision at the 5’ ends, which are 
identical among nearly all human chromosomes, and regulates telomere length by restricting 
telomerase binding439. Rare nonsense mutations within this gene, which blocked physical 
interactions of POT1 with telomeric single-stranded repeats and other components of the 
shelterin protein complex, were identified by whole-exome sequencing in families with strong 
histories of chronic lymphocytic leukaemia317. The integrated analysis of non-coding variants 
highlights rs2239532 (r2=0.85), located within the 5’UTR of GPR37 (G protein-coupled receptor 
37), as having regulatory function (Supplementary Table 8). Although no direct eQTL evidence 
is available to support POT1, there is evidence to link the expression of an uncharacterised 
POT1-AS transcript (RP11-3B12.1) to LTL via co-localisation in two tissues (Supplementary 
Table 8). 
 
Chr8p23.2. This region contains 52 SNPs in high LD (r2<0.8) and is located within 3 introns 
towards the 3’ end of CSMD1 (CUB and Sushi multiple domains 1) gene. CSMD1 was 
potentially associated with a rare neurological disease, the benign adult familial myoclonic 
epilepsy440. It may also act as a suppressor of squamous cell carcinomas, yet unequivocal 
evidence is lacking441,442. The gene-knockout mouse was used as a schizophrenia human 
disease model, exhibiting increased levels of exploratory activity, behavioural despair anxiety-
related response, and decreased startle reflex (MGI: 3528558). However, no direct supporting 




Chr8q22.2. Four SNPs are located upstream of COX6C (cytochrome c oxidase subunit 6C). 
COX6C is a subunit of complex IV that catalyses the final step of the mitochondrial respiratory 
chain443. No functional data is available to pinpoint causal genes for this locus.  
 
Chr10p15.1. The 6 associated variants (in LD, r2>0.8) at this locus are clustered within the first 
intron of ASB13 (ankyrin repeat and SOCS box containing 13), a member of the suppressor of 
cytokine signalling box protein superfamily. Members of this protein family can also be 
components of E3 ubiquitin ligase complexes444. No causal gene candidates can be prioritised 
for this locus. 
 
Chr10q24.33. This region contains STN1 (STN1, CST complex subunit, also termed OBFC1 in 
humans), a component of the telomere binding CST complex. There is strong evidence that 
the variants affect STN1(OBFC1) expressions across multiple tissues (S-PrediXcan and COLOC, 
Supplementary Table 7). The CST complex regulates telomere maintenance by mediating the 
access to telomeres for telomerase and DNA polymerase α445. 
 
Chr11q21. The lead variant, rs117037102, is located within intron 5 of CEP295 (centrosomal 
protein 295, also termed KIAA1731). There is a potentially damaging protein coding variant 
(rs117405490, r2=1), which results in a P to A substitution at position 783 of CEP295. CEP295 
is a centriole-enriched microtubule-binding protein, highly conserved across species and 
involved in centriole biogenesis, essential for cell cycle regulation and mitotic progression446. 
 
Chr11q22.3. The associated variants fall across a ~321kb region which includes several genes, 
including ATM (ATM serine/threonine kinase), encoding a protein kinase that phosphorylates 
many checkpoint-determining and regulatory proteins, such as p53, Chk2 and BRCA1, and 
thus playing an essential role in cell cycle control and DNA-damage-activated signalling 
pathways447. ATM is responsible for the human genetic disorder ataxia telangiectasia (A-T), 
manifested with genome instability, cerebellar and thymic degeneration, immunodeficiency, 
premature ageing, sensitivity to ionizing radiation and predisposition to cancer (OMIM 
#208900)448. There are eQTLs supporting ATM and another gene, ACAT1 (acetyl-CoA 
acetyltransferase 1), within the region. ACAT1 is a mitochondrial protein, expression levels of 
which have been linked to some cancers449. Defects in this gene are associated with 3-
ketothiolase deficiency, an inborn error of isoleucine catabolism450. 
 
Chr12p13.1. The lead variant and 2 in high LD (r2<0.8) are located upstream of ATF7IP 
(activating transcription factor 7 interacting protein), also named MCAF1, actively involved in 
histone modification, chromatin organisation, and Sp1-dependent maintenance of 
telomerase activity in cancer cells451. It was previously shown to regulate expression of both 
TERT and TERC and consequently telomerase activity452.  
 
Chr12q13.13. There are 7 variants in high LD (r2 <0.8), located within a 3kb region upstream 
of SMUG1 (single-strand-selective monofunctional uracil-DNA glycosylase 1), a gene involved 
in base-excision repair. Although there is no bioinformatic evidence to show that these 
variants affect SMUG1 expression levels, previous functional studies have suggested that 
SMUG1 might influence telomere length by interacting with the telomerase component 
Dyskerin (DKC1) with which it controls rRNA processing251. 
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Chr14q24.2. The lead variant is a non-synonymous (W22C) variant in DCAF4 (DDB1 and CUL4 
associated factor 4). Another variant in high LD (rs3815460, r2=1) also causes a protein coding 
change (S345C). Both variants are predicted to be damaging individually. DCAF4 interacts with 
the Cul4-Ddb1 E3 ubiquitin ligase macromolecular complex, which regulates processes 
including DNA repair and cellular proliferation453. DDB (DNA damage binding protein) is highly 
expressed in multipotent hematopoietic progenitors, conditional ablation of which in 
hematopoietic stem and progenitor cells led to a complete loss of pluripotency and self-
renewal of progenitors and stem cells, suggesting its role in cell differentiation, apoptosis and 
death454. An intronic G-to-A variant (rs2535913) has been associated with shorter LTL153. A 
further SNP, rs2286838 (r2=0.9) causes a coding change in ZFYVE1 (zinc finger FYVE-type 
containing 1, S408R), which also has a predicted damaging effect. This protein, also known as 
the double FYVE-containing protein 1 (DFCP1), contains two zinc-binding FYVE domains in 
tandem, which has been shown to be localised on endoplasmic reticulum and Golgi apparatus 
via binding to phosphatidylinositol 3-phosphate containing membranes, essential for the 
regulation of autophagy455. 
 
Chr14q24.3. The lead variant, rs59192843, is located within intron 6 of BBOF1 (basal body 
orientation factor 1, also termed as CCDC176). There are no coding variants or eQTLs 
associated with the lead variant. Two variants in high LD (r2<0.8), rs73301475 and rs17094157 
scored highly in the integrated analysis of non-coding variants (Supplementary Table 8). These 
are located within an enhancer of ENTPD5 (ectonucleoside triphosphate diphosphohydrolase 
5) and the 3’ UTR of COQ6 (coenzyme Q6, monooxygenase), respectively. ENTPD5 hydrolyses 
UDP to UMP to promote protein N-glycosylation and folding. It has been shown that ENTPD5 
was upregulated in cell lines and primary human tumour samples with active AKT, promoting 
cell growth and survival456. AKT activation also contributes to the elevation of aerobic 
glycolysis seen in tumour cells, known as the Warburg effect. Of note, ENTPD5 was also 
involved in stimulating glycolysis by providing substrates for cytidine monophosphate kinase-
1 that converts UMP to UDP using a phosphate molecule generated during the ATP hydrolysis 
cycle457. COQ6 is an evolutionarily conserved monooxygenase, belonging to the ubiH/COQ6 
family, which is required for the biosynthesis of coenzyme Q10 (or ubiquinone), an essential 
component of the mitochondrial electron transport chain and one of the most potent 
lipophilic antioxidants implicated in the protection of cell damage by reactive oxygen species. 
Gene-ablated mouse model showed abnormal embryo size and growth retardation (MGI: 
5548683). Mutations in this gene are associated with autosomal recessive coenzyme Q10 
deficiency-6, which manifests as nephrotic syndrome with sensorineural deafness458. 
 
Chr14q32.11. In this locus the variants are focused across CALM1 (calmodulin 1). There is an 
eQTL co-localised with CALM1 expression in testis. Two SNPs (rs12885713 and rs2300496) are 
within the CALM1 promoter/enhancer region and predicted to have regulatory function. 
CALM1 encodes a member of the EF-hand calcium-binding protein family, regulating a 
number of protein kinases and phosphatases, among which CP110, by interacting with CALM1 
and centrin, regulates centrosome function and cytokinesis459. 
 
Chr14q32.33. The lead SNP, rs117536281, is located upstream of CDCA4 (cell division cycle 
associated 4). CDCA4 encodes a member of the E2F family of transcription factors, regulating 
spindle organization, cytokinesis and cell proliferation, which may be also involved in 
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differentiation of hematopoietic stem cells and progenitor cell lineage460. There are no coding 
variants or eQTL data for this locus.  
 
Chr15q14. This locus consists of two associated SNPs, rs9972513 and rs12324579, which are 
located in an intergenic region upstream of both c15orf53 and RASGRP1 (RAS guanyl releasing 
protein 1). There are no coding variants or eQTL data for this locus. C15orf53 is a protein 
coding gene with uncharacterised functions, with disputable evidence suggesting its 
implication with schizophrenia and bipolar disorder461. RASGRP1 encodes a protein that 
functions as a calcium- and diacylglycerol (DAG)-regulated nucleotide exchange factor 
specifically activating Ras through the exchange of bound GDP for GTP. RASGRP1 contains a 
pair of calcium-binding EF hands and a DAG-binding domain462. The RASGRP1-mediated Ras 
activation regulates T cell proliferation, development and homeostasis463. 
 
Chr15q21.2. There are 17 SNPs clustered around the 5’ end of ATP8B4 (ATPase phospholipid 
transporting 8B4 (putative)). There are no coding variants or eQTL data for this locus. ATP8B4 
encodes a member of the cation transport ATPase (P-type) family and type IV subfamily, 
which consists of a P4-ATPase flippase complex that catalyses the hydrolysis of ATP coupled 
to phospholipid translocation across various membranes, playing a role in vesicle biosynthesis 
and lipid signalling transduction464,465. Deleterious rare variants within this gene have been 
associated with systemic sclerosis, for which the principal cause of death was pulmonary 
diseases, including interstitial lung disease and pulmonary arterial hypertension466. An 
intronic common variant at the distal promoter region of this gene has been reported to be 
associated with Alzheimer’s Disease467. 
 
Chr15q21.3. This single variant, rs117610974 is located in an intergenic region, ~220kb 
downstream of the closest gene, UNC13C (unc-13 homolog C), which might be implicated with 
vesicle formation during exocytosis, with potential capabilities of diacylglycerol and calcium 
binding468. However, there is no evidence to suggest what role this lead variant may have. 
 
Chr15q22.31. The lead variant, rs55710439, is located within intron 6 of ANKDD1A (ankyrin 
repeat and death domain containing 1A). There is an eQTL for this gene co-localised in one 
tissue. Little is known about the ANKDD1A protein, except that it contains an ankyrin repeat 
domain and a death domain, both of which function in the protein-protein interaction. A 
closely-related SNP (in LD, r2<0.8), rs57438358, predicted to have potential functional effects, 
is located within the 3’UTR of SPG21 (SPG21, maspardin), a gene which is mutated in mast 
syndrome.  
 
Chr16p13.3. This is a single variant, rs11640926, located within intron 5 on CACNA1H. There 
is no supporting evidence to suggest the effects of this variant. CACNA1H encodes a protein 
component of the voltage-dependent calcium channel complex, a T-type calcium channel that 
belongs to the "low-voltage activated” group, which plays an essential role in both central 
neurons and cardiac nodal cells and supports calcium signalling in secretory cells and vascular 
smooth muscle469,470. It is associated with a form of familial hyperaldosteronism, clinically 
characterised by hypertension, elevated aldosterone levels and abnormal adrenal steroid 
production471; and another genetic rare disease, the Childhood Absence Epilepsy 6472. 
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Chr16q22.1. The most significantly associated variants in this region are located within and 
around TERF2 (telomeric repeat binding factor 2), a component of the shelterin complex. 
TERF2 protein directly and specifically binds to the telomeric double-stranded repeats, and 
by interacting with other telomeric factors forming a T-loop configuration that protects 
chromosome ends from disruptive end-to-end joining and ligation to exogenous DNA. Mutant 
forms of this gene induced DNA fusion, such as formation of anaphase bridges and lagging or 
ring-like chromosomes473,474. 
There is evidence that the variants affect expression of several genes in this region, with the 
strongest evidence for TERF2 (S-PrediXcan and COLOC, Supplementary Table 7). Longer LTL is 
associated with reduced expression of TERF2, consistent with TERF2 being a negative 
regulator of telomere length475. One variant predicted to have a functional effect, rs9939705, 
is located within an enhancer region upstream of TERF2. There is also evidence to suggest 
that expression of two other genes (COG8, and PDF) are also affected by the associated 
variants. 
 
Chr16q23.1. Variants at this locus show co-localisation with eQTLs for RFWD3 (ring finger and 
WD repeat domain 3) in multiple tissues. RFWD3 is a ubiquitin ligase that interacts with and 
ubiquitinates replication protein A (RPA), which has been shown to be essential for DNA 
replication and repair. Upon replication stress, RPA was recruited to stalled replication folks 
and ubiquitinated by the RFWD3, an essential process for recovery and homologous 
recombination-mediated DNA repair476. RFWD3 also ubiquitinates and stabilises p53/TP53 in 
response to DNA damage, thereby regulating the cell cycle checkpoint477. This gene was also 
clinically attributable to the Fanconi anaemia, an autosomal recessive inheritance disease 
manifested with chromosomal instability, bone marrow failure, dermal pigmentary changes 
and predisposition to malignancies (OMIM #614151).  
 
Chr16q23.3. The association signal at this locus is across MPHOSPH6 (M-phase 
phosphoprotein 6). There is strong eQTL evidence (S-PrediXcan and COLOC) in multiple tissues 
to support the associated variants influencing MPHOSPH6 expression. MPHOSPH6 is a 
component of the RNA exosome, a protein complex required for the degradation of RNA 
molecules and is required for the 3’ processing of the 5.8S rRNA272. There is also evidence that 
MPHOSPH6 interacts with PARN (poly(A)-specific ribonuclease)478, an important regulator of 
mRNA catabolism which is also required for the formation of mature TERC RNA269. 
 
Chr17q25.3. The lead variant (rs144204502) is situated within the 5’ UTR of TK (thymidine 
kinase 1), with evidence of regulatory functions (Supplementary Table 8). There are co-
localised eQTLs for TK1 in three tissues. TK1 encodes a cytosolic enzyme that catalyses the 
conversion of thymidine to dTMP, which is the first step of the salvage pathway of dTTP 
biosynthesis, essential for DNA replication. There are two forms of the TK enzyme, besides 
the TK1, TK2 catalyses the same reaction but in the mitochondria. The activity of TK1 is 
delicately regulated by a configurational transition, changing from dimer to tetramer upon 
increases in ATP and enzyme concentrations, with a consequently accompanied upregulation 
of catalytic efficiency274. This regulatory fine-tuning of TK1 activity ensured a balanced pool 
of nucleic acid precursors. High TK1 expression was detected in numerous types of cancers, 




Chr18p11.32. All variants within the locus are located within the TYMS (thymidylate 
synthetase) gene, either within the intronic or the 3’UTR regions. There is an eQTL for TYMS 
co-localised in one tissue. TYMS is involved in the de novo biosynthesis of dTMP, catalysing 
the methylation of dUMP to dTMP using a serine-derived one-carbon donor, the 5,10-
methyleneTHF278. TYMS has been targeted for cancer chemotherapeutics, as high expression 
of which has been detected in various types of cancers, including gastrointestinal 
adenocarcinomas and squamous cell uterine carcinomas479. 
 
Chr19p13.3. The lead variant is located within intron 5 of NMRK2 (Nicotinamide Riboside 
kinase 2), with 6 SNPs in high LD (r2<0.8) located around this gene. NMRK2 enzyme catalyses 
the phosphorylation of nicotinamide riboside (NR) and nicotinic acid riboside (NaR) to form 
nicotinamide mononucleotide (NMN) and nicotinic acid mononucleotide (NaMN), the vitamin 
precursors of NAD+, which is required for the function of Sirtuins, a key player in lifespan 
extension and energy metabolism480. It has been demonstrated that increased NAD+ 
biosynthesis elevated the Sirtuin 2 function, which improved the subtelomeric gene silencing 
effects and elongated replicative lifespan in eukaryotic cell models480. One further variant in 
high LD, located upstream of DAPK3 (death associated protein kinase 3), is a regulator of 
apoptosis. There is no functional data supporting any gene candidates at this locus. 
 
Chr19p12. The lead variant is intergenic, located between ZNF257 and ZNF208, with closer 
proximity to the former. There is eQTL evidence for both ZNF257 and ZNF265, yet stronger 
for the ZNF257 (Supplementary Table 7). ZNF257 encodes a member of a zinc finger protein 
family, the Krüppel-like zinc finger subfamily, signified by a consensus sequence of TGEKPYX 
(X denotes any amino acids) between concatenated zinc finger motifs481. The proteins have 
the KRAB domain at their amino terminus, which determines the specificity of binding to DNA 
and other transcriptional co-regulators. 
 
Chr19q13.2.  The single associated variant, rs11665818, is located within an intergenic region, 
downstream of INFL2 (interferon lambda 2, also termed IL28a) and within a cytokine gene 
cluster that consists of three closely related INFL genes. INFL2 encodes a protein with antiviral 
activities, predominantly in the epithelial tissues482. There is no supporting functional 
evidence at this locus. 
 
Chr20p12.3a. The lead and one variant in high LD (r2<0.8) are located upstream of PROKR2 
(Prokineticin receptor 2), a G protein-coupled receptor for the prokineticin 2, which is a 
secreted protein expressed in gut and brain, and has been shown to oscillate on a circadian 
basis483. Homozygous gene-knockout mice showed impaired circadian behaviour and 
thermoregulation (MGI:2181363). Mutations in this gene led to gonadotropin-releasing 
hormone deficiency and hypogonadism484. There are no coding variants or eQTLs associated 
with this locus. 
 
Chr20p12.3b All variants of this locus are located within an intergenic region, with the closest 
gene being LINC01706 (long intergenic non-coding RNA 1706), an uncharacterised non-coding 
transcript. 
 
Chr20q11.23. The association signal spans two genes MROH8 (maestro heat like repeat family 
member 8) and RBL1 (RB transcriptional corepressor like 1). There is eQTL evidence to support 
 187 
changes in both RBL1 and SAMHD1 (SAM and HD domain containing deoxynucleoside 
triphosphate triphosphohydrolase 1) expression. RBL1 functions as a transcriptional repressor 
for E2F binding sites-containing genes485, which shares similarity in amino acid sequence and 
biochemical features to the retinoblastoma 1 (RB1) gene product that functions as a tumour 
suppressor implicated in cell cycle regulation. SAMHD1 encodes a dNTP triphosphohydrolase 
(dNTPase) that converts deoxynucleoside triphosphates (dNTPs) to deoxynucleosides. The 
gene expression was regulated during cell cycle to maintain a homeostatic pool of dNTP, 
required for DNA replication 250. Studies have suggested an antiretroviral role of SAMHD1 in 
dendritic and myeloid cells by depleting the intracellular pool of dNTPs486,487. 
 
Chr20q13.33. There are four independent signals within this locus, which harbours several 
genes, including the DNA helicase RTEL1 (regulator of telomere elongation helicase 1). There 
are non-synonymous coding variants in RTEL1 and ZBTB46 (zinc finger and BTB domain 
containing 46) although neither are predicted to be deleterious. There are eQTLs for RTEL1, 
STMN3(stathmin 3) and TNFRSF6B (TNF receptor superfamily member 6b, also termed decoy 
receptor 3). RTEL1 encodes an ATP-dependent DNA helicase that functions in the regulation 
of telomeres, DNA repair and genomic integrity. RTEL1 facilitates access of telomerase to the 
3’ ends of telomeres by transiently dismantling the T-loop configuration, a lariat-like structure 
that protects telomeres from degradation and deleterious DNA damage response488. 
Mutations of this gene led to Hoyeraal Hreidarsson syndrome, a clinically severe form of 
dyskeratosis congenita, of which half of the inherited families carry germline mutations of 
telomere-related genes489. Loss-of-function missense variants of this gene was found to be 
associated with idiopathic pulmonary fibrosis and shortened telomere lengths490. STMN3 
gene encodes a member of the stathmin protein family, which shows microtubule-
destabilizing activity and is known to be involved in the development of central nervous 
system and glioma pathology491. TNFRSF6B is a regulator of apoptosis and has been linked to 
angiogenesis492–494. ZBTB46 gene encodes a member of a large BTB zinc-finger protein family, 
characterised by a DNA binding motif that consists of a tandem array of C2H2 krüppel-like 
zinc fingers at the carboxyl terminus, with each finger containing a consensus sequence of 
~30 amino acids and an embedded zinc ion495. In contrast, the BTB domains at the amino 
termini are more divergent across the family, mainly contributing to the hetero- or homo-
dimerization. The BTB domain determines DNA binding specificity and recruitment of co-
regulators to form higher chromosomal structures495. ZBTB46 has been shown to function as 
a transcriptional repressor involved in prostate cancer malignancy and cell cycle regulation496. 
Recently, studies have identified another member of the BTB zinc-finger protein family, 
ZBTB48, also termed as the telomeric zinc finger–associated protein, to be specifically 
associated with telomeres via the zinc finger domain. Further investigation demonstrated 
that it was preferentially bound to longer telomeres where protein components of the 
shelterin complex are rather sparse497. Experimental studies suggested that the ZBTB48 might 
compete with the TERF2 for binding to the telomeric DNA repeats, thereby setting an upper 
limit of the telomere length, which can further influence lifespan and cancer 
susceptibility497,498. Because the zinc finger domain is conserved among all members of the 
family, we speculated that the ZBTB46 was also capable of binding to the telomeric DNA, 
regulating telomere homeostasis via similar mechanisms. However, further experiments are 
required to validate this hypothesis. 
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Chr21q22.3. The lead variant is a loss-of-stop mutation in KRTAP10-4 (keratin associated 
protein 10-4), which was located within a cluster of related genes, encoding proteins that 
form disulfide bonds between cysteine residues in hair keratins. A genome-wide siRNA-based 
screen implicated this gene with the homologous recombination DNA double-strand break 
repair499. Although transcripts lacking stop codons would be targeted for degradation, there 
is no eQTL evidence to suggest loss of expression with this allele, possibly due to poor 
detection of this transcript in GTex (Median transcripts per million=0). There is one variant in 
high LD, located within intron 2 of TSPEAR (thrombospondin type laminin G domain and EAR 
repeats), a regulator of the NOTCH signalling. 
 
Chr22q13.31. This is a single variant located within intron 1 of KIA1644 (Also termed SHISAL1). 
There is no supporting functional data for gene prioritisation at this locus. 
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Systematic literature review on longitudinal changes of TL 




Summary of the study results: 
Abbreviations: SCDS: Seychelles Child Development Study, HBCS: Helsinki Birth Cohort Study, HSS: 
Heart and Soul Study, BEIP: Bucharest Early Intervention Project, SATSA: Swedish Adoption/Twin Study 
of Aging, GEMINAKAR: Genes, Familiar and Common Environment for the Development of Insulin 
Resistance, Abdominal Adiposity, and Cardiovascular Risk Factors, CBMC: Cord blood mononuclear cell, 
PBMC: peripheral blood mononuclear cell, NESDA: Netherlands Study of Depression and Anxiety, LBC: 
Lothian Birth Cohort, DMHDS: Dunedin Multidisciplinary Health and Development Study, ESTHER: 
Epidemiological investigations on chances of preventing, recognizing early and optimally treating 
chronic diseases in an elderly population, PREDIMED-NAVARRA: PREvención con DIeta MEDiterránea-
NAVARRA, PREVEND: Prevention of REnal and Vascular ENd stage Disease, CHS: Cardiovascular Health 
Study, JLRC: Jerusalem Lipid Research Clinic, MRC-NSHD: MRC-National Survey of Health and 
Development, HAS: Hertfordshire Ageing Study, CCHS: Copenhagen City Heart Study, HBLS: Harvard 
Boilermakers Longitudinal Study, ERA: Evolution de la Rigidite Arterielle, BHS: Bogalusa Heart Study, 
CaPS: Caerphilly Prospective Study, LSADT: Longitudinal Study of Aging Danish Twins, MHAS: 
MacArthur Health Aging Study, NSHDS: North Sweden Health and Disease Study. 
 
 Query Number 
of items 
Telomeres #1 telomere[Mesh] OR telomeres[ti] OR telomere[ti] 15,044 
Changing rates #2 rate[tiab] OR rates[tiab] OR shortening[tiab] OR 
abrasion[tiab] OR attrition[tiab] OR erosion[tiab] OR 
extension[tiab] OR acceleration[tiab] OR accelerating[tiab] 
OR lengthening[tiab] OR elongation[tiab] NOT “telomere 
elongation helicase1”[tiab] NOT “alternative lengthening of 
telomeres”[tiab] 
2,619,963 
Cohort studies #3 “cohort studies”[Mesh] OR cohort[tiab] OR cohorts[tiab] OR 
“longitudinal studies”[Mesh] OR longitudinal[tiab] OR “long 
term”[tiab] OR “short term”[tiab] OR prospective[tiab] OR 
retrospective[tiab] 
2,810,034 
Genetics #4 genetics[Mesh] OR genetic[tiab] OR gene[tiab] OR 
genes[tiab] OR genome[tiab] OR genomes[tiab] OR 
genomics[tiab] OR “genome-wide”[tiab] 
2,438,596 
Combined strategy #1 AND #2 AND (#3 OR #4) 2,043 
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Index Publication Study cohort Time Interval Study Participants 
(at maximum) (baseline age in years)
1 Yeates AJ. J Nutr. 2017 SCDS 5 years newborn babies (0)
2 Dowd JB. J. Infect. Dis. 2017 Whitehall II 3 years healthy individuals (53-76)
3 Ventura Ferreira MS. Ann Hematol. 2017 1 year patients
4 Vasu V. Plos One. 2017 5 years preterm infants (0)
5 Toupance S. Hypertension. 2017 10 years French (31-76)
6 Steptoe A. J Clin Endocrinol Metab. 2017 3 years healthy individuals (53-76)
7 Eriksson JG. Am J Clin Nutr. 2017 HBCS 10 years healthy individuals (71)
8 de Melo AS. Gene. 2017 5 years healthy women (30)
9 Goglin SE. PLoS One. 2016 HSS 5 years patients with stable CAD
10 Humphreys KL. Psychiatry Res. 2016 BEIP 6 years children (8)
11 See VH. Prostaglandins Leukot Essent Fatty Acids. 2016 12 years offspring (0)
12 Ping F. J Diabetes Investig. 2017 6 years T2D patients
13 Berglund K. Aging (Albany NY). 2016 SATSA 20 years twins (69)
14 Townsley DM. N Engl J Med. 2016 2 years patients with telomere diseases
15 Verhulst S. Diabetologia. 2016 GEMINAKAR 12 years twins (37)
16 Lin J. J Immunol Res. 2016 18 months healthy premenopausal women (41.9)
17 Wojcicki JM. Mol Genet Genomics. 2016 1 year mother-child pairs
18 Kato S. Blood Purif. 2016 1 year Japanese incident dialysis patients
19 Verhoeven JE. Am J Psychiatry. 2016 NESDA 6 years patients with depressive/anxiety disorders
20 Révész D. Psychoneuroendocrinology. 2016 NESDA 6 years patients with depressive/anxiety disorders and healthy controls (18-65)
21 Harris SE. Mech Ageing Dev. 2016 LBC1936/1921 6/13 years healthy individuals (70/79)
22 Thomson WM. J Clin Periodontol. 2016 DMHDS 12 years healthy individuals (26)
23 Müezzinler A. Exp Gerontol. 2016 ESTHER 8 years healthy individuals (50-75)
24 Jenkins EC. Am J Med Genet B Neuropsychiatr Genet. 2016 3 years DS patients with syndromes of cognitive impairment
25 Dalgård C. Int J Epidemiol. 2015 GEMINAKAR 12 years twins (18-59)
26 García-Calzón S. Am J Clin Nutr. 2015 PREDIMED-NAVARRA 5 years individuals at high cardiovascular disease risk (67)
27 Guzzardi MA. Ann Med. 2015 HBCS 10 years healthy individuals (71)
28 Hou L. EBioMedicine. 2015 NAS 3 years prevalent and incident cancer cases and others
29 Müezzinler A. Exp Gerontol. 2015 ESTHER 8 years healthy individuals (50-75)
30 van Ockenburg SL. Psychol Med. 2015 PREVEND 6 years healthy individuals (53)
31 Révész D. J Clin Endocrinol Metab. 2015 NESDA 6 years patients with depressive/anxiety disorders and healthy controls (18-65)
32 Soares-Miranda L. Med Sci Sports Exerc. 2015 CHS 5 years healthy individuals (73)
33 Cohen-Manheim I. Eur J Epidemiol. 2016 JRC 13 years healthy individuals (28-32)
34 Ashbridge B. Biol Blood Marrow Transplant. 2015 1 year patients with high-risk hematologic malignancies
35 Hjelmborg JB. J Med Genet. 2015 GEMINAKAR 12 years twins (19-64)
36 García-Calzón S. Circ Cardiovasc Genet. 2015 PREDIMED-NAVARRA 5 years individuals at high cardiovascular disease risk (55-80)
37 Puterman E. Mol Psychiatry. 2015 1 year postmenopausal, non-smoking, disease-free women (50-65)
38 Masi S. Eur Heart J. 2014 MRC-NSHD 10 years study participants (53)
39 Baylis D. Calcif Tissue Int. 2014 Normative Aging 10 years study participants (67)
40 Tamayo M. Mutat Res. 2014 3 years patients with ankylosing spondylitis/psoriatic arthritis
41 Rewak M. Biol Psychol. 2014 EdHealth 41 years study participants (0)
42 Duggan C. J Natl Cancer Inst. 2014 30 months patients with breast cancers
43 Weischer M. PLoS Genet. 2014 CCHS 10 years study participants (20-100)
44 Wong JY. Genet Epidemiol. 2014 HBLS 29 months boilermakers (43)
45 Bendix L. J Gerontol A Biol Sci Med Sci. 2014 Danish MONICA 10 years study participants (30-70)
46 Huzen J. J Intern Med. 2014 PREVEND 6.6 years study participants (39-60)
47 Verhulst S. Eur J Epidemiol. 2013 JLRC/BHS/ERA 13/12/9 years study participants (30/31/58)
48 Gardner MP. PLoS One. 2013 CaPS/HAS/LBC1921/MRC-NHSD 8/9/7/9 years study participants (65/67/79/53)
49 van Ockenburg SL. Psychol Med. 2014 PREVEND 6 years study participants (53)
50 Benetos A. Ageing Cell 2013 JLRC/BHS/ERA/LSADT 13/12.4/9.5/10.8 years study participants (30/31/58/75)
51 Steenstrup T. Eur J. Epidemiol. 2013 LSADT 10 years study participants (73-81)
52 Bansal N. Am J Nephrol. 2012 HSS 5 years patients with stable CAD
53 Biegler KA. Cancer Prev Res (Phila). 2012 4 months patients with cervical cancers
54 Lobetti-Bodoni C. Mech Ageing Dev. 2012 22 months patients with chronic myeloid leukemia (23-88)
55 Kark JD. Am J Clin Nutr. 2012 JLRC 13 years study participants (30)
56 Selleri S. J Allergy Clin Immunol. 2011 9 years patients with immune deficiency (1-5)
57 McCracken J. Environ Health Perspect. 2010 NAS 7 years never-smoking men (56-94)
58 Shlush LI. Mech Ageing Dev. 2011 1 year CCORDA diver group (19)
59 Chen W. J Gerontol A Biol Sci Med Sci. 2011 BHS 12.4 years study participants (31)
60 Farzaneh-Far R. JAMA. 2010 HSS 5 years patients with stable CAD
61 Farzaneh-Far R. PLoS One. 2010 HSS 5 years patients with stable CAD
62 Aviv A. Am J Epidemiol. 2009 BHS 12.4 years study participants (white 31.4/black 37.4)
63 Epel ES. Aging (Albany NY). 2008 MHAS 2.5 years Caucasian participants (70-79)
64 Nordfjäll K. PLoS Genet. 2009 NSHDS 10 years participants from a multigenerational cohort




Index Publication Study cohort Time Interval Study Participants 
(at maximum) (baseline age in years)
1 Yeates AJ. J Nutr. 2017 SCDS 5 years newborn babies (0)
2 Dowd JB. J. Infect. Dis. 2017 Whitehall II 3 years healthy individuals (53-76)
3 Ventura Ferreira MS. Ann Hematol. 2017 1 year patients
4 Vasu V. Plos One. 2017 5 years preterm infants (0)
5 Toupance S. Hypertension. 2017 10 years French (31-76)
6 Steptoe A. J Clin Endocrinol Metab. 2017 3 years healthy individuals (53-76)
7 Eriksson JG. Am J Clin Nutr. 2017 HBCS 10 years healthy individuals (71)
8 de Melo AS. Gene. 2017 5 years healthy women (30)
9 Goglin SE. PLoS One. 2016 HSS 5 years patients with stable CAD
10 Humphreys KL. Psychiatry Res. 2016 BEIP 6 years children (8)
11 See VH. Prostaglandins Leukot Essent Fatty Acids. 2016 12 years offspring (0)
12 Ping F. J Diabetes Investig. 2017 6 years T2D patients
13 Berglund K. Aging (Albany NY). 2016 SATSA 20 years twins (69)
14 Townsley DM. N Engl J Med. 2016 2 years patients with telomere diseases
15 Verhulst S. Diabetologia. 2016 GEMINAKAR 12 years twins (37)
16 Lin J. J Immunol Res. 2016 18 months healthy premenopausal women (41.9)
17 Wojcicki JM. Mol Genet Genomics. 2016 1 year mother-child pairs
18 Kato S. Blood Purif. 2016 1 year Japanese incident dialysis patients
19 Verhoeven JE. Am J Psychiatry. 2016 NESDA 6 years patients with depressive/anxiety disorders
20 Révész D. Psychoneuroendocrinology. 2016 NESDA 6 years patients with depressive/anxiety disorders and healthy controls (18-65)
21 Harris SE. Mech Ageing Dev. 2016 LBC1936/1921 6/13 years healthy individuals (70/79)
22 Thomson WM. J Clin Periodontol. 2016 DMHDS 12 years healthy individuals (26)
23 Müezzinler A. Exp Gerontol. 2016 ESTHER 8 years healthy individuals (50-75)
24 Jenkins EC. Am J Med Genet B Neuropsychiatr Genet. 2016 3 years DS patients with syndromes of cognitive impairment
25 Dalgård C. Int J Epidemiol. 2015 GEMINAKAR 12 years twins (18-59)
26 García-Calzón S. Am J Clin Nutr. 2015 PREDIMED-NAVARRA 5 years individuals at high cardiovascular disease risk (67)
27 Guzzardi MA. Ann Med. 2015 HBCS 10 years healthy individuals (71)
28 Hou L. EBioMedicine. 2015 NAS 3 years prevalent and incident cancer cases and others
29 Müezzinler A. Exp Gerontol. 2015 ESTHER 8 years healthy individuals (50-75)
30 van Ockenburg SL. Psychol Med. 2015 PREVEND 6 years healthy individuals (53)
31 Révész D. J Clin Endocrinol Metab. 2015 NESDA 6 years patients with depressive/anxiety disorders and healthy controls (18-65)
32 Soares-Miranda L. Med Sci Sports Exerc. 2015 CHS 5 years healthy individuals (73)
33 Cohen-Manheim I. Eur J Epidemiol. 2016 JRC 13 years healthy individuals (28-32)
34 Ashbridge B. Biol Blood Marrow Transplant. 2015 1 year patients with high-risk hematologic malignancies
35 Hjelmborg JB. J Med Genet. 2015 GEMINAKAR 12 years twins (19-64)
36 García-Calzón S. Circ Cardiovasc Genet. 2015 PREDIMED-NAVARRA 5 years individuals at high cardiovascular disease risk (55-80)
37 Puterman E. Mol Psychiatry. 2015 1 year postmenopausal, non-smoking, disease-free women (50-65)
38 Masi S. Eur Heart J. 2014 MRC-NSHD 10 years study participants (53)
39 Baylis D. Calcif Tissue Int. 2014 Normative Aging 10 years study participants (67)
40 Tamayo M. Mutat Res. 2014 3 years patients with ankylosing spondylitis/psoriatic arthritis
41 Rewak M. Biol Psychol. 2014 EdHealth 41 years study participants (0)
42 Duggan C. J Natl Cancer Inst. 2014 30 months patients with breast cancers
43 Weischer M. PLoS Genet. 2014 CCHS 10 years study participants (20-100)
44 Wong JY. Genet Epidemiol. 2014 HBLS 29 months boilermakers (43)
45 Bendix L. J Gerontol A Biol Sci Med Sci. 2014 Danish MONICA 10 years study participants (30-70)
46 Huzen J. J Intern Med. 2014 PREVEND 6.6 years study participants (39-60)
47 Verhulst S. Eur J Epidemiol. 2013 JLRC/BHS/ERA 13/12/9 years study participants (30/31/58)
48 Gardner MP. PLoS One. 2013 CaPS/HAS/LBC1921/MRC-NHSD 8/9/7/9 years study participants (65/67/79/53)
49 van Ockenburg SL. Psychol Med. 2014 PREVEND 6 years study participants (53)
50 Benetos A. Ageing Cell 2013 JLRC/BHS/ERA/LSADT 13/12.4/9.5/10.8 years study participants (30/31/58/75)
51 Steenstrup T. Eur J. Epidemiol. 2013 LSADT 10 years study participants (73-81)
52 Bansal N. Am J Nephrol. 2012 HSS 5 years patients with stable CAD
53 Biegler KA. Cancer Prev Res (Phila). 2012 4 months patients with cervical cancers
54 Lobetti-Bodoni C. Mech Ageing Dev. 2012 22 months patients with chronic myeloid leukemia (23-88)
55 Kark JD. Am J Clin Nutr. 2012 JLRC 13 years study participants (30)
56 Selleri S. J Allergy Clin Immunol. 2011 9 years patients with immune deficiency (1-5)
57 McCracken J. Environ Health Perspect. 2010 NAS 7 years never-smoking men (56-94)
58 Shlush LI. Mech Ageing Dev. 2011 1 year CCORDA diver group (19)
59 Chen W. J Gerontol A Biol Sci Med Sci. 2011 BHS 12.4 years study participants (31)
60 Farzaneh-Far R. JAMA. 2010 HSS 5 years patients with stable CAD
61 Farzaneh-Far R. PLoS One. 2010 HSS 5 years patients with stable CAD
62 Aviv A. Am J Epidemiol. 2009 BHS 12.4 years study participants (white 31.4/black 37.4)
63 Epel ES. Aging (Albany NY). 2008 MHAS 2.5 years Caucasian participants (70-79)
64 Nordfjäll K. PLoS Genet. 2009 NSHDS 10 years participants from a multigenerational cohort






Index Sample Size Measurement Tissue or Cell Line  Risk Factors or Consequences Tested
1 229 qPCR leucocytes PUFA status and methylmercury levels
2 400 qPCR leucocytes human herpesviruses
3 49 qPCR leucocytes acute myeloid leukemia 
4 5 qPCR leucocytes gestational age
5 154 TRF-Southern blots leucocytes carotid atherosclerotic plaques
6 411 qPCR leucocytes cortisol responses
7 812 qPCR leucocytes serum phenylalanine concentration
8 165 qPCR leucocytes birth weight
9 608 qPCR leucocytes mortality
10 79 MMP-qPCR saliva institutional care
11 98 qPCR CBMCs and PBMCs LCPUFA supplementation during pregnancy
12 70 qPCR leucocytes NAFLD
13 636 qPCR leucocytes age
14 27 qPCR leucocytes Danazol Treatment
15 338 TRF-Southern blots leucocytes insulin resistance
16 39 qPCR PBMCs and lymphocytes circulating immune cell types
17 70 qPCR leucocytes baseline telomeres and cross-generational change
18 59 qPCR leucocytes baseline telomeres and leukocyte counts
19 2,292 qPCR leucocytes depressive and anxiety disorders
20 2,981 qPCR leucocytes baseline telomeres, lifestyle factors and diseases
21 1091/550 qPCR leucocytes cognitive and physical abilities
22 661 qPCR leucocytes periodontitis
23 961 qPCR/TRF (n=20) leucocytes BMI-related variables
24 5 FITC-labeled PNA probes T-lymphocytes clinical progression of AD for patients with DS
25 734 TRF-Southern blots leucocytes menopausal status and age
26 520 qPCR leucocytes diet-associated inflammation
27 1,082 qPCR leucocytes cardiometabolic risk factors
28 792 qPCR leucocytes cancer development
29 961 qPCR/TRF (n=20) leucocytes smoking
30 1,094 MMP-qPCR leucocytes psychosocial stress
31 1,808 qPCR leucocytes cardiometabolic risk factors
32 582 TRF-Southern blots leucocytes physical activity and fitness
33 497 TRF-Southern blots leucocytes cognitive function
34 13 TRF-Southern blots CBMCs and PBMCs cord blood transplantation
35 652 TRF-Southern blots leucocytes heritability
36 521 qPCR leucocytes PPARγ2 polymorphysm and diet intervention
37 239 qPCR leucocytes life stressors and health behaviours
38 1,033 qPCR leucocytes cardiovascular risk factors
39 253 qPCR leucocytes low-grade systemic inflammation and grip strength
40 44/42 qPCR leucocytes spondyloarthritis
41 143 qPCR leucocytes race
42 478 qPCR leucocytes all-cause or breast cancer-specific mortality
43 4,576 qPCR leucocytes lifestyle factors morbidity and mortality
44 87 qPCR leucocytes LINE-1 and Alu methylation
45 1,356 qPCR leucocytes lifestyle factors, age and mortality
46 8,074 qPCR leucocytes metabolic traits and smoking
47 620/271/185 TRF-Southern blots leucocytes RTM effect and baseline telomere
48 966/656/493/2558 qPCR leucocytes physical performance
49 3,432 MMP-qPCR leucocytes neuroticism
50 620/271/185/80 TRF-Southern blots leucocytes telomere length at censor
51 80 TRF-Southern blots leucocytes age
52 608 qPCR leucocytes kidney function
53 22 flow-FISH PMBCs chronic stress response
54 59 TRF-Southern blots granulocytes, and PMBCs hematopoiesis upon treatment of chronic myeloid leukemia
55 609 TRF-Southern blots leucocytes energy intake and macronutrients
56 12 qPCR BM/PB compartments and T cells hematopoietic stem cell gene therapy
57 165 qPCR leucocytes ambient air pollution
58 14 flow-FISH/TRF granulocytes and lymphocytes hyperbaric oxidative stress
59 271 TRF-Southern blots leucocytes age
60 608 qPCR leucocytes blood levels of marine omega-3 fatty acids
61 608 qPCR leucocytes baseline telomeres and cardiometabolic risk factors
62 635 TRF-Southern blots leucocytes baseline telomeres and lifestyle factors
63 236 qPCR leucocytes mortality
64 959 qPCR leucocytes baseline telomeres and tumor development
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Supplementary Figure 1. Study design. Schematic graph to illustrate study design of the LTL 
GWAS meta-analysis. GWAS was conducted in each individual study cohort, stratified by 
genotyping platform and disease status. SNP genotyping, GWAS and meta-analyses as well as 









Random-effects meta-analysis for SNPs with Cochrane’s Q P value < 1x10
-6
Double Genomic control
Sample size ≧ 40%
MAF ≧ 1% for study-specific SNPs
GWAS
Stratified by study, disease status and genotyping platform












Supplementary Figure 2. Manhattan Plot. Manhattan plot with quantile-quantile plot inlay. 
Known loci were labelled in blue, novel loci associated with LTL at genome-wide significance 








Supplementary Figure 3: Regional plots of genome-wide significant loci (regions around 
conditionally independent lead variants). Regional plots of genome-wide significant loci 
(400kb windows encompassing conditionally independent variants, except the TERT locus 
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Supplementary Figure 4: Distributions of mLRRY values in A. EPIC-InterAct and B. UK biobank, 
before (left) and after (right) data transformation. Z_invn_mL_n means the standardised 
values of mLRRY after a series of data transformation (winsorisation at 5SD, followed by  









Supplementary Figure 5: Distribution of mLRRY values in each EPIC-InterAct participating 
country separately, before (upper) and after (bottom) data transformation. 
 























Supplementary Figure 6: Observational associations between mLRRY and T2D risk. Same 
models were applied as described in the Figure 5.1, with association estimates shown in each 
country. Mdiet: Mediterranean diet score, alc: lifetime alcohol consumption, pa: physical 






Supplementary Figure 7: Observational associations between mLRRY and T2D risk. Same models were applied as described in the Figure 5.1, but 






Supplementary Table 1: Cohort demographics and LTL measurement data. T/S distributions are given from the primary data prior to z-
transformation. Level of statistical significance is denoted by *p<0.01, **p<0.0001. All cohorts showed expected age-associated decline in LTL 
and higher LTL in women compared to men, except In FINNRISK and NTR_GO2 cohorts, the gender effect was not significant, most likely due to 
small sample sizes. For the measurement laboratory: 1, Leicester; 2, Helsinki; 3, London; 4, Genetic Laboratory Erasmus MC, Rotterdam; 5, 
laboratory of Telomere Diagnostics Inc., CA, USA; 6, Cambridge. The inter-run coefficient of variation (CV) is given for LTL measurements 
performed on triplicates of the same samples. 
 
 
Cohort Nationality Cohort Type N
Age distribution 













EPIC-InterAct T2D cases Europe T2D case-cohort 8,499 55.6±7.7 (29-77) 49.16 0.88±0.05(0.67-1.33) -0.01** 0.15** 6 4.8
EPIC-InterAct subcohort Europe T2D case-cohort 12,242 52.5±9.2 (21-79) 37.50 0.88±0.06(0.61-1.36) -0.016** 0.10** 6 4.8
EPIC-CVD CHD cases Europe CVD case-cohort 7,713 59.1±8.4 (21-81) 60.98 0.90±0.09 (0.63-2.11) -0.001** 0.01** 6 9.8
EPIC-CVD CRBV cases Europe CVD case-cohort 3,450 59.2±8.4 (22-84) 50.96 0.88±0.06 (0.65-1.54) -0.001** 0.01** 6 6.9
EPIC-CVD controls Europe CVD case-cohort 752 51.7±12.2 (25-78) 38.70 0.98±0.16 (0.71-2.05) -0.002** 0.02 6 16.3
BHF-FHS UK CAD 1,487 60.8±7.9 (36-82) 80.10 1.35±0.22 (0.69 - 2.13) -0.006** 0.033* 1 3.5
EGCUT_370 Estonia Population 2,354 39.87±16.3 (18-
91)
47.40 1.85±0.33 (0.89-3.52) -0.026** 0.246** 1 3.7
EGCUT_OMNI Estonia Population 2,234 51.93±20.36 45.80 1.73±0.31 (0.87-3.85) -0.019** 0.172** 1 3.7
ERF Netherlands Population Family based 2,836 49.76±14.87 44.50 1.78 ±0.36 -0.008** 0.068** 1 3.5
FINRISK Finland Population 502 51.9±13.8 (25-74) 46.20 1.18± 0.22 (0.69 - 1.93) -0.0058** 0.035 2 7.7
FTC/NAG-FIN Finland Twin, Smokers 831 54.9±4.5 (42-66) 60.40 0.94±0.17 (0.53 - 1.65) -0.00052 0.041* 2 8.2
GRAPHIC UK Population 1,011 52.8±4.40 (40-61) 50.05 1.51±0.23 (0.50 - 2.35) -0.008** 0.052** 1 3.6
GENMETS cases Finland Metabolic syndrome cases 807 51.1±11.1 (30-75) 49.30 1.07±0.20 (0.54 - 1.71) -0.0047** 0.015 2 na
GENMETS controls Finland Metabolic syndrome controls 1,205 51.0±11.0 (30-75) 48.40 1.07±0.20 (0.51 - 1.77) -0.0037** 0.033* 2 na
HBCS Finland Population 1,699 61.5±2.9 (56-69) 42.70 1.39±0.30 (0.32 - 2.59) -0.013** 0.044* 2 24.8
KORA F3 Germany Population 3,047 57.1±12.9 (34-85) 48.80 1.72±0.29 (0.92-3.23) -0.008** 0.053** 1 3.6
KORA F4 Germany Population 2,907 56.2±13.3 (31-82) 48.30 1.85±0.33 (0.53-3.29) -0.010** 0.096** 1 3.1
LLS Netherlands Population 2,320 59.19± 6.8 (30-80) 45.20 1.46±0.27 (0.74-2.43) -0.008** 0.046** 1 2.7
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Extra rows are shown on the next page 
 
  
Cohort Nationality Cohort Type N
Age distribution 














NESDA Netherlands Psychiatric 
(depression/anxiety)  cohort
2,190 42.5±12.9 (18-65) 33.80 1.10±0.29 (0.38-2.33) -0.006** 0.062** 5 4.6
NFBC1966 Finland Population, Birth cohort 5,146 31±0 48.20 1.22±0.48 (0.28-4.88) N/A 0.059** 3 6.2
NTR Netherlands Population, Twin 4,977 42.3±15.6 (12-90) 37.60 2.67±0.49 (0.96 - 4.61) -0.014** 0.088** 1 3.7
QIMR Australia Population, Twin 2,438 24.3±14.9 (6-73) 48.77 3.49±0.61 (1.47-5.72) -0.017** 0.086* 1 3.9
RSI Netherlands Population 1800 73.4±8.3 (55-106) 42.00 0.95±0.19 (0.31-1.79) -0.006** 0.046** 4 4.5
RSIII Netherlands Population 372 62.2±8.9 (48-87) 42.30 0.99±0.14 (0.66-1.60) -0.004** 0.014 4 4.5
TWINGENE Sweden Population, Twin 295 71.8±5.9 (55-91) 0.00 1.43±0.25 (0.96–2.26) -0.011** N/A 1 2.9
TWINSUK UK Population, Twin 4,899 51.0±13.4 (16-99) 9.00 3.71±0.68 (0.68 – 
11.40)
-0.016** -0.008† 1 3.3
UKBS UK Population 1,422 43.4±12.4  (17-69) 48.40 1.80±0.50 (0.80 - 3.01) -0.009** 0.035* 1 3.5
 205 
Supplementary Table 2: Details of genotyping platforms and analysis methods used by each study. 
 
 
Human CoreExome, 550,601 13,200,213
Illumina-660W-Quad 652,061 12,133,512
Human CoreExome, 535,701 10,965,134
HumanOmniExpress 816,729 9,350,108
BHF-FHS Affymetrix 500K CHIAMO 470,454 IMPUTE2 13,620,894 SNPtest -
EGCUT_370 Illumina HumanCNV370 
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GenomeStudio 306,817 IMPUTE2 30,071,938 SNPtest -
EGCUT_OMNI Illumina HumanCNV370 
HumanOmniExpress
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FTC/NAG-FIN Illumina HumanHap670K Illuminus 549,060 IMPUTE2 13,142,398 SNPtest -
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Genmets Control Illumina 610 Quad Illuminus 555,388 IMPUTE2 13,399,633 SNPtest -
GRAPHIC HumanOmniExpress-12v1 Illumina 648,651 IMPUTE2 13,293,341 SNPtest -
HBCS Illumina HumanHap670K Illuminus 546,814 IMPUTE2 13,806,578 SNPtest -
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KORA F4 Affymetrix Axiom Affymetrix software 523,260 IMPUTE v2.3.0 20,283,581 SNPtest -
LLS Illumina 660w-quad / 
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Affymetrix 6.0 
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softwares 
733,592 Mach/Minimac 8,957,775 SNPtest chip, top 3 PCs
NFBC1966 Illumina HumanCNV370DUO Beadstudio 339,629 IMPUTE2 12,253,310 SNPtest Sex, Age, Plate, Top 3 PCs
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Study-specific covariates
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NTR
Family Structure
KORA F3 GenomeStudio 600,641 IMPUTE v2.3.0 19,805,480 SNPtest -
Analysis 
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Supplementary Table 3: LD between sentinel variants for previously reported loci. LD (R2 and D') were calculated using LDLink 
(https://ldlink.nci.nih.gov) between sentinel variants identified in this study and those previously reported. These are broken down by ancestry 




Population Chr Gene New Lead Previous lead R2/D’ to new R2/D’ to new lead R2/D’ to new 
3 TERC rs10936600 rs10936599 1.0/1.0
4 NAF1 rs4691895 rs7675998 0.97/1.0
5 TERT rs7705526 rs2736100 0.46/1.0
European 5 TERT rs2853677 rs2736100 0.41/0.80
10 STN1 (OBFC1) rs9419958 rs9420907 1.0/1.0
14 DCAF4 rs2302588 rs2535913 0.05/1.0
19 ZNF208 rs8105767 rs8105767 -
20 RTEL1 rs75691080 rs755017 0.01/1.0
20 RTEL1 rs34978822 rs755017 0.004/0.22
20 RTEL1 rs73624724 rs755017 0.89/1.0
Singaporean Chinese 1 PARP1 rs3219104 rs3219104 - -
7 POT1 rs59294613 rs7776744 0.23/0.87 0.43/1.0
11 ATM rs228595 rs227080 0.42/0.91 0.83/0.92
16 MPHOSPH6 rs7194734 rs2967374 0.95/0.97 1.0/1.0
18 TYMS rs2124616 rs1001761 0.27/1.0 0.002/1.0
20 RTEL1 rs75691080 rs41309367 0.03/0.80 0.002/1.0
20 RTEL1 rs34978822 rs41309367 0.03/1.0 NA
20 RTEL1 rs73624724 rs41309367 0.25/0.85 0.01/0.21
South Asian 20 RTEL1 rs75691080 rs2297439 0.50/0.80 0.04/0.39
20 RTEL1 rs34978822 rs2297439 0.001/1.0 NA
20 RTEL1 rs73624724 rs2297439 0.002/0.44 0.06/0.87
 208 
Supplementary Table 4: Independent variants associated with LTL at FDR<0.05. Columns indicate (Chr) chromosome ; SNP; (bp) physical position 
(hg19); (freq) frequency of the effect allele in the original GWAS data; (refA) the effect allele; (b) effect size, (se) standard error and (p) p-value 
from single variant based GWAS meta-analysis; (n) estimated effective sample size; (freq_geno) frequency of the effect allele in the reference 
sample; (bJ),(bJ_se), (pJ) effect size, standard error and p-value from joint models; and (LD_r) between the variant and the locus sentinel variant. 
 
 
Chr SNP bp refA freq b se p n freq_geno bJ bJ_se pJ LD_r
3 rs10936600 169514585 T 0.243 -0.0858 0.0057 6.42E-51 80402 0.243 -0.0858 0.0057 8.79E-51 0
5 rs7705526 1285974 A 0.328 0.0820 0.0058 4.82E-45 64656.3 0.324 0.0662 0.0063 3.55E-26 -0.36568
5 rs2853677 1287194 A 0.592 -0.0638 0.0055 3.12E-31 66348.1 0.576 -0.0413 0.0059 2.41E-12 0
4 rs4691895 164048199 C 0.783 0.0577 0.0061 1.47E-21 77751.1 0.775 0.0577 0.0061 1.55E-21 0
10 rs9419958 105675946 C 0.862 -0.0636 0.0071 4.77E-19 79673.7 0.869 -0.0636 0.0071 4.96E-19 0
20 rs75691080 62269750 T 0.091 -0.0671 0.0089 5.75E-14 73299.7 0.085 -0.0636 0.0090 1.44E-12 -0.04694
7 rs59294613 124554267 A 0.293 -0.0407 0.0055 1.12E-13 77807.4 0.290 -0.0407 0.0055 1.14E-13 0
19 rs8105767 22215441 G 0.289 0.0392 0.0054 5.21E-13 80103 0.289 0.0392 0.0054 5.30E-13 0
20 rs73624724 62436398 C 0.129 0.0507 0.0074 6.08E-12 79451.3 0.137 0.0390 0.0075 2.07E-07 0
1 rs3219104 226562621 C 0.830 0.0417 0.0064 9.31E-11 82701.8 0.847 0.0417 0.0064 9.41E-11 0
20 rs932827 62380527 T 0.238 -0.0374 0.0060 3.28E-10 75271.4 0.229 -0.0308 0.0061 4.31E-07 -0.18363
6 rs2736176 31587561 C 0.313 0.0345 0.0055 3.41E-10 74733.4 0.284 0.0322 0.0055 5.18E-09 0
16 rs3785074 69406986 G 0.263 0.0351 0.0056 4.50E-10 78946.7 0.284 0.0350 0.0056 5.01E-10 -0.00293
16 rs7194734 82199980 T 0.782 -0.0369 0.0060 6.72E-10 79221.3 0.770 -0.0372 0.0060 5.39E-10 0
20 rs34978822 62291599 G 0.015 -0.1397 0.0227 7.04E-10 64578.6 0.021 -0.1486 0.0228 7.04E-11 -0.07009
6 rs34991172 25480328 G 0.068 -0.0608 0.0105 6.03E-09 69563.3 0.082 -0.0560 0.0105 9.24E-08 -0.08086
11 rs228595 108105593 A 0.417 -0.0285 0.0050 1.39E-08 79131.2 0.411 -0.0285 0.0050 1.40E-08 0
14 rs2302588 73404752 C 0.100 0.0476 0.0084 1.64E-08 75515 0.103 0.0482 0.0084 1.07E-08 -0.02093
4 rs13137667 71774347 C 0.959 0.0765 0.0137 2.37E-08 65743.6 0.974 0.0765 0.0137 2.39E-08 0
3 rs55749605 101232093 A 0.579 -0.0373 0.0067 2.38E-08 44477.5 0.622 -0.0373 0.0067 2.41E-08 0
16 rs62053580 74680074 G 0.169 -0.0389 0.0071 3.96E-08 68784.9 0.169 -0.0390 0.0071 3.48E-08 -0.00711
2 rs754017156 54482703 D 0.165 0.0471 0.0088 7.52E-08 45835 0.146 0.0471 0.0088 7.59E-08 0
15 rs12909131 50387678 T 0.231 -0.0308 0.0058 1.15E-07 80706.5 0.239 -0.0310 0.0058 9.60E-08 -0.01047
20 rs1744757 35734863 T 0.851 0.0359 0.0068 1.38E-07 82222.6 0.852 0.0359 0.0068 1.38E-07 0
18 rs2124616 661917 A 0.140 -0.0374 0.0072 1.72E-07 78571.2 0.153 -0.0374 0.0072 1.73E-07 0
3 rs2613954 112847045 T 0.886 -0.0381 0.0078 1.10E-06 78132.7 0.878 -0.0381 0.0078 1.11E-06 0
1 rs12065882 114078755 G 0.208 0.0298 0.0062 1.36E-06 77170.9 0.207 0.0298 0.0062 1.37E-06 0
10 rs2386642 5702259 A 0.673 -0.0256 0.0053 1.44E-06 78324.5 0.665 -0.0256 0.0053 1.44E-06 0
2 rs56810761 210663697 T 0.270 0.0275 0.0057 1.45E-06 75729.8 0.268 0.0275 0.0057 1.45E-06 0
5 rs62365174 78925743 G 0.088 -0.0544 0.0113 1.50E-06 47138.2 0.093 -0.0544 0.0113 1.51E-06 0
12 rs112655343 14430807 T 0.102 0.0425 0.0090 2.22E-06 65703.2 0.110 0.0425 0.0090 2.23E-06 0
15 rs55710439 65229816 T 0.014 0.1050 0.0223 2.65E-06 69379.6 0.012 0.1050 0.0224 2.66E-06 0
16 rs11640926 1249877 G 0.139 0.0557 0.0119 2.93E-06 28512.8 0.140 0.0557 0.0119 2.95E-06 0
4 rs60160057 151000830 A 0.211 -0.0287 0.0062 3.15E-06 76458.6 0.219 -0.0287 0.0062 3.16E-06 0
14 rs117536281 105494403 G 0.034 0.0850 0.0183 3.31E-06 43901.3 0.035 0.0850 0.0183 3.33E-06 0
22 rs7510583 44698803 G 0.290 0.0347 0.0075 3.38E-06 42136.9 0.280 0.0347 0.0075 3.40E-06 0
14 rs59192843 74514120 G 0.059 0.0655 0.0141 3.52E-06 43632 0.043 0.0668 0.0141 2.28E-06 0
8 rs57415150 2882469 A 0.042 -0.0584 0.0126 3.68E-06 76209.6 0.040 -0.0584 0.0126 3.69E-06 0
20 rs6038821 7402809 T 0.038 0.0596 0.0129 3.98E-06 78795.1 0.025 0.0593 0.0129 4.49E-06 0
17 rs144204502 76183233 T 0.014 -0.0896 0.0196 4.92E-06 90239 0.012 -0.0896 0.0196 4.94E-06 0
20 rs6107615 5310273 C 0.422 -0.0228 0.0050 5.30E-06 79235.8 0.422 -0.0227 0.0050 5.98E-06 -0.00545
15 rs9972513 38930961 T 0.281 0.0247 0.0055 5.75E-06 80585.1 0.278 0.0247 0.0055 5.76E-06 0
11 rs117037102 93404608 T 0.018 0.0979 0.0218 6.81E-06 58251 0.021 0.0979 0.0218 6.83E-06 0
21 rs7276273 45994841 C 0.007 -0.1502 0.0334 6.90E-06 58815.8 0.010 -0.1502 0.0334 6.92E-06 0
19 rs11665818 39768216 A 0.195 0.0278 0.0062 7.04E-06 80994.7 0.188 0.0278 0.0062 7.06E-06 0
14 rs3213718 90869913 T 0.583 0.0224 0.0050 7.22E-06 79728.4 0.602 0.0224 0.0050 7.24E-06 0
5 rs112347796 138964816 D 0.049 0.0691 0.0154 7.29E-06 43935.8 0.054 0.0691 0.0154 7.32E-06 0
19 rs143276018 3939249 C 0.018 -0.1015 0.0229 9.02E-06 51875.2 0.015 -0.1015 0.0229 9.06E-06 0
8 rs201375979 100917632 D 0.317 0.0332 0.0075 9.11E-06 39878.3 0.358 0.0332 0.0075 9.15E-06 0
12 rs7311314 54592103 A 0.317 0.0240 0.0054 9.50E-06 75916 0.309 0.0240 0.0054 9.52E-06 0
1 rs35675808 167399643 G 0.028 0.0736 0.0166 9.54E-06 64171.8 0.022 0.0736 0.0166 9.57E-06 0
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4 rs13137667 71774347 C 0.959 0.0765 0.0137 2.37E-08 65743.6 0.974 0.0765 0.0137 2.39E-08 0
3 rs55749605 101232093 A 0.579 -0.0373 0.0067 2.38E-08 44477.5 0.622 -0.0373 0.0067 2.41E-08 0
16 rs62053580 74680074 G 0.169 -0.0389 0.0071 3.96E-08 68784.9 0.169 -0.0390 0.0071 3.48E-08 -0.00711
2 rs754017156 54482703 D 0.165 0.0471 0.0088 7.52E-08 45835 0.146 0.0471 0.0088 7.59E-08 0
15 rs12909131 50387678 T 0.231 -0.0308 0.0058 1.15E-07 80706.5 0.239 -0.0310 0.0058 9.60E-08 -0.01047
20 rs1744757 35734863 T 0.851 0.0359 0.0068 1.38E-07 82222.6 0.852 0.0359 0.0068 1.38E-07 0
18 rs2124616 661917 A 0.140 -0.0374 0.0072 1.72E-07 78571.2 0.153 -0.0374 0.0072 1.73E-07 0
3 rs2613954 112847045 T 0.886 -0.0381 0.0078 1.10E-06 78132.7 0.878 -0.0381 0.0078 1.11E-06 0
1 rs12065882 114078755 G 0.208 0.0298 0.0062 1.36E-06 77170.9 0.207 0.0298 0.0062 1.37E-06 0
10 rs2386642 5702259 A 0.673 -0.0256 0.0053 1.44E-06 78324.5 0.665 -0.0256 0.0053 1.44E-06 0
2 rs56810761 210663697 T 0.270 0.0275 0.0057 1.45E-06 75729.8 0.268 0.0275 0.0057 1.45E-06 0
5 rs62365174 78925743 G 0.088 -0.0544 0.0113 1.50E-06 47138.2 0.093 -0.0544 0.0113 1.51E-06 0
12 rs112655343 14430807 T 0.102 0.0425 0.0090 2.22E-06 65703.2 0.110 0.0425 0.0090 2.23E-06 0
15 rs55710439 65229816 T 0.014 0.1050 0.0223 2.65E-06 69379.6 0.012 0.1050 0.0224 2.66E-06 0
16 rs11640926 1249877 G 0.139 0.0557 0.0119 2.93E-06 28512.8 0.140 0.0557 0.0119 2.95E-06 0
4 rs60160057 151000830 A 0.211 -0.0287 0.0062 3.15E-06 76458.6 0.219 -0.0287 0.0062 3.16E-06 0
14 rs117536281 105494403 G 0.034 0.0850 0.0183 3.31E-06 43901.3 0.035 0.0850 0.0183 3.33E-06 0
22 rs7510583 44698803 G 0.290 0.0347 0.0075 3.38E-06 42136.9 0.280 0.0347 0.0075 3.40E-06 0
14 rs59192843 74514120 G 0.059 0.0655 0.0141 3.52E-06 43632 0.043 0.0668 0.0141 2.28E-06 0
8 rs57415150 2882469 A 0.042 -0.0584 0.0126 3.68E-06 76209.6 0.040 -0.0584 0.0126 3.69E-06 0
20 rs6038821 7402809 T 0.038 0.0596 0.0129 3.98E-06 78795.1 0.025 0.0593 0.0129 4.49E-06 0
17 rs144204502 76183233 T 0.014 -0.0896 0.0196 4.92E-06 90239 0.012 -0.0896 0.0196 4.94E-06 0
20 rs6107615 5310273 C 0.422 -0.0228 0.0050 5.30E-06 79235.8 0.422 -0.0227 0.0050 5.98E-06 -0.00545
15 rs9972513 38930961 T 0.281 0.0247 0.0055 5.75E-06 80585.1 0.278 0.0247 0.0055 5.76E-06 0
11 rs117037102 93404608 T 0.018 0.0979 0.0218 6.81E-06 58251 0.021 0.0979 0.0218 6.83E-06 0
21 rs7276273 45994841 C 0.007 -0.1502 0.0334 6.90E-06 58815.8 0.010 -0.1502 0.0334 6.92E-06 0
19 rs11665818 39768216 A 0.195 0.0278 0.0062 7.04E-06 80994.7 0.188 0.0278 0.0062 7.06E-06 0
14 rs3213718 90869913 T 0.583 0.0224 0.0050 7.22E-06 79728.4 0.602 0.0224 0.0050 7.24E-06 0
5 rs112347796 138964816 D 0.049 0.0691 0.0154 7.29E-06 43935.8 0.054 0.0691 0.0154 7.32E-06 0
19 rs143276018 3939249 C 0.018 -0.1015 0.0229 9.02E-06 51875.2 0.015 -0.1015 0.0229 9.06E-06 0
8 rs201375979 100917632 D 0.317 0.0332 0.0075 9.11E-06 39878.3 0.358 0.0332 0.0075 9.15E-06 0
12 rs7311314 54592103 A 0.317 0.0240 0.0054 9.50E-06 75916 0.309 0.0240 0.0054 9.52E-06 0
1 rs35675808 167399643 G 0.028 0.0736 0.0166 9.54E-06 64171.8 0.022 0.0736 0.0166 9.57E-06 0
15 rs117610974 55105443 G 0.009 -0.1540 0.0350 1.05E-05 42498.8 0.010 -0.1555 0.0350 8.74E-06 0
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Supplementary Table 5: Comparison of all loci at FDR<0.05 to that reported in the Singaporean Chinese Health Study (SCHS). Data is sorted by 
original p-value, pJ indicates p-value from conditional (GCTA) analyses. Minor allele frequencies (MAF) are given from 1000 genomes populations 
for information. Variants with MAF<0.01 were excluded in the SCHS study so not available. Many of our variants were monoallelic in the SCHS 









Allele Closest gene (prioritised) beta se p pJ rsid_SCHS
reporte
d allele p beta se p_het MAF CEU MAF CSH
R2 CEU R2 CSH
3 rs10936600 169514585 T LRRC34 -0.09 0.01 6.42E-51 8.79E-51 rs10936600 T 1.85E-38 -0.12 0.01 0.57 0.26 0.47
5 rs7705526 1285974 A TERT 0.08 0.01 4.82E-45 3.55E-26 rs7705526 A 2.61E-38 0.12 0.01 0.06 0.32 0.34
5 rs2853677 1287194 A TERT -0.06 0.01 3.12E-31 2.41E-12 rs2853677 A 2.73E-29 -0.10 0.01 0.60 0.40 0.33
4 rs4691895 164048199 C NAF1 0.06 0.01 1.47E-21 1.55E-21 rs4691895 C 1.36E-08 0.06 0.01 0.70 0.22 0.22
10 rs9419958 105675946 C STN1 (OBFC1) -0.06 0.01 4.77E-19 4.96E-19 rs9419958 C 0.247663 -0.04 0.04 0.66 0.14 0.02
20 rs75691080 62269750 T STMN3 -0.07 0.01 5.75E-14 1.44E-12 - 0.07 0.005
7 rs59294613 124554267 A POT1 -0.04 0.01 1.12E-13 1.14E-13 rs59294613 A 0.000391 -0.03 0.01 0.97 0.26 0.36
19 rs8105767 22215441 G ZNF257 0.04 0.01 5.21E-13 5.30E-13 rs8105767 G 0.000221 0.04 0.01 0.20 0.29 0.3
20 rs73624724 62436398 C ZBTB46 0.05 0.01 6.08E-12 2.07E-07 rs73624724 C 0.840162 0.00 0.01 0.03 0.16 0.48
1 rs3219104 226562621 C PARP1 0.04 0.01 9.31E-11 9.41E-11 rs3219104 C 2.43E-16 0.07 0.01 0.32 0.14 0.44
20 rs932827 62380527 T ZBTB46 -0.04 0.01 3.28E-10 4.31E-07 rs932827 T 0.001667 -0.05 0.02 0.30 0.24 0.07
6 rs2736176 31587561 C PRRC2A (CSNK2B, BAG6) 0.03 0.01 3.41E-10 5.18E-09 rs2736176 C 0.034688 0.02 0.01 0.85 0.30 0.38
16 rs3785074 69406986 G TERF2 0.04 0.01 4.50E-10 5.01E-10 rs3785074 G 5.78E-05 0.06 0.02 0.20 0.30 0.12
16 rs7194734 82199980 T MPHOSPH6 -0.04 0.01 6.72E-10 5.39E-10 rs7194734 T 5.84E-06 -0.06 0.01 0.62 0.24 0.19
20 rs34978822 62291599 G RTEL1 -0.14 0.02 7.04E-10 7.04E-11 - 0.02 -
6 rs34991172 25480328 G CARMIL1 -0.06 0.01 6.03E-09 9.24E-08 - 0.09 -
11 rs228595 108105593 A ATM -0.03 0.01 1.39E-08 1.40E-08 rs228595 A 1.11E-07 -0.05 0.01 0.54 0.37 0.44
14 rs2302588 73404752 C DCAF4 0.05 0.01 1.64E-08 1.07E-08 rs2302588 C 0.000127 0.04 0.01 0.38 0.11 0.22
4 rs13137667 71774347 C MOB1B (DCK) 0.08 0.01 2.37E-08 2.39E-08 rs13137667 C 0.027597 0.05 0.02 0.35 0.05 0.04
3 rs55749605 101232093 A SENP7 -0.04 0.01 2.38E-08 2.41E-08 rs55749605 A 0.134509 -0.01 0.01 0.14 0.37 0.34
16 rs62053580 74680074 G RFWD3 -0.04 0.01 3.96E-08 3.48E-08 rs62053580 G 0.0224 -0.02 0.01 0.19 0.14 0.29
If proxy used
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Chr SNP bp ref 
Allele
Closest gene (prioritised) beta se p pJ rsid_SCHS reporte
d allele
p beta se p_het MAF CEU MAF CSH
R2 CEU R2 CSH
2 rs754017156 54482703 D ACYP2 0.05 0.01 7.52E-08 7.59E-08 rs1872329 1 0.91 A 0.001684 0.04 0.01 0.74 0.16 0.19
15 rs12909131 50387678 T ATP8B4 -0.03 0.01 1.15E-07 9.60E-08 rs12909131 T 0.028708 -0.02 0.01 0.47 0.21 0.24
20 rs1744757 35734863 T MROH8 (SAMHD1) 0.04 0.01 1.38E-07 1.38E-07 rs1744757 T 0.002198 0.03 0.01 0.06 0.17 0.49
18 rs2124616 661917 A TYMS -0.04 0.01 1.72E-07 1.73E-07 - 0.16 0.005
3 rs2613954 112847045 T RP11-572M11.4 -0.04 0.01 1.10E-06 1.11E-06 0.12 0.0095
1 rs12065882 114078755 G MAGI3 0.03 0.01 1.36E-06 1.37E-06 rs12065882 G 0.691999 0.01 0.03 0.25 0.17 0.02
10 rs2386642 5702259 A ASB13 -0.03 0.01 1.44E-06 1.44E-06 rs2386642 A 0.768391 0.00 0.01 0.15 0.32 0.28
2 rs56810761 210663697 T UNC80 0.03 0.01 1.45E-06 1.45E-06 rs56810761 T 0.003973 0.04 0.01 0.27 0.25 0.16
5 rs62365174 78925743 G PAPD4 -0.05 0.01 1.50E-06 1.51E-06 rs62365174 G 0.047553 -0.02 0.01 0.56 0.10 0.14
12 rs112655343 14430807 T ATF7IP 0.04 0.01 2.22E-06 2.23E-06 - 0.11 -
15 rs55710439 65229816 T ANKDD1A 0.10 0.02 2.65E-06 2.66E-06 - 0.01 -










Chr SNP bp ref 
Allele
Closest gene (prioritised) beta se p pJ rsid_SCHS reporte
d allele
p beta se p_het MAF CEU MAF CSH
R2 CEU R2 CSH
4 rs60160057 151000830 A DCLK2 -0.03 0.01 3.15E-06 3.16E-06 rs60160057 A 0.554438 -0.01 0.02 0.91 0.27 0.11
14 rs117536281 105494403 G CDCA4 0.08 0.02 3.31E-06 3.33E-06 - 0.04 -
22 rs7510583 44698803 G KIAA1644 0.03 0.01 3.38E-06 3.40E-06 - NA NA
14 rs59192843 74514120 G CCDC176 0.07 0.01 3.52E-06 2.28E-06 rs59192843 G 0.423169 -0.01 0.02 0.69 0.06 0.18
8 rs57415150 2882469 A CSMD1 -0.06 0.01 3.68E-06 3.69E-06 rs57415150 A 0.040218 -0.04 0.02 0.30 0.06 0.09
20 rs6038821 7402809 T LINC01706 0.06 0.01 3.98E-06 4.49E-06 rs6038821 T 0.878709 0.00 0.01 0.07 0.04 0.30
17 rs144204502 76183233 T TK1 -0.09 0.02 4.92E-06 4.94E-06 - 0.01 -
20 rs6107615 5310273 C PROKR2 -0.02 0.01 5.30E-06 5.98E-06 rs6107615 C 0.712051 0.00 0.01 0.80 0.45 0.26
15 rs9972513 38930961 T RP11-275I4.2 0.02 0.01 5.75E-06 5.76E-06 - NA NA
11 rs117037102 93404608 T CEP295 0.10 0.02 6.81E-06 6.83E-06 - 0.005 -
21 rs7276273 45994841 C KRTAP10-4 -0.15 0.03 6.90E-06 6.92E-06 - 0.03 -
19 rs11665818 39768216 A IFNL2 0.03 0.01 7.04E-06 7.06E-06 rs11665818 A 0.392 -0.02 0.03 0.62 0.19 0.04
14 rs3213718 90869913 T CALM1 0.02 0.00 7.22E-06 7.24E-06 rs3213718 T 0.166871 -0.02 0.01 0.81 0.39 0.2
5 rs112347796 138964816 D UBE2D2 0.07 0.02 7.29E-06 7.32E-06 - NA NA
19 rs143276018 3939249 C NMRK2 -0.10 0.02 9.02E-06 9.06E-06 - 0.03 -
8 rs201375979 100917632 D COX6C 0.03 0.01 9.11E-06 9.15E-06 rs10098852 1 1 G 0.709197 0.00 0.01 0.52 0.39 0.46
12 rs7311314 54592103 A SMUG1 0.02 0.01 9.50E-06 9.52E-06 rs7311314 A 0.331608 -0.01 0.01 0.65 0.23 0.4
1 rs35675808 167399643 G CD247 0.07 0.02 9.54E-06 9.57E-06 - 0.02 -
15 rs117610974 55105443 G UNC13C -0.15 0.03 1.05E-05 8.74E-06 - 0.03 -
SCHS data Allele frequencies
If proxy used
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Supplementary Table 6: Functional prediction of nonsynonymous variants. Coding variants were identified within each locus with r2≥0.8 to the 
locus lead SNP. Functional prediction of the amino acid changes was carried out using PolyPhen, SIFT and CADD prediction tools. CADD scores 





Chr Lead SNP SNP r2 Variant Gene Transcript CADD
Score Prediction Score Prediction Confidence
1 rs3219104 rs1136410 1 A|G PARP1 ENST00000366794 762 V A 0.827 PD 0.24 T HIGH 28.1
rs1805415 1 T|G ENST00000366794 352 K N 0.059 B 0.47 T HIGH 10.25
3 rs55749605 rs2433031 1 T|A SENP7 ENST00000394095 612 Q H 0.678 PD 0.55 T HIGH 23.3
ENST00000394091 448 Q H 0.413 PD 0.54 T HIGH 23.3
ENST00000394094 547 Q H 0.948 PD 0.54 T HIGH 23.3
ENST00000314261 546 Q H 0.678 PD 0.55 T HIGH 23.3
ENST00000348610 579 Q H 0.678 PD 0.58 T HIGH 23.3
ENST00000366089 14 Q H 0.433 PD 0.25 T HIGH 23.3
ENST00000358203 448 Q H 0.413 PD 0.54 T HIGH 23.3
3 rs10936600 rs10936600 - A|T LRRC34 ENST00000446859 286 L I 0.863 PD 0.69 T HIGH 14.74
ENST00000522830 225 L I 0.93 PD 0.53 T HIGH 14.74
ENST00000522526 254 L I 0.863 PD 0.42 T HIGH 14.74
ENST00000528597 35 L I 0.958 PD 0.06 T HIGH 14.74
ENST00000316515 241 L I 0.93 PD 0.44 T HIGH 14.74
rs6793295 0.93 T|C LRRC34 ENST00000446859 249 S G 0 B 0.51 T HIGH 11.05
ENST00000522830 188 S G 0 B 0.52 T HIGH 11.05
4 rs4691895 rs4691895 - G|C NAF1 ENST00000422287 368 L V 0 B 0.66 T HIGH 0.505
rs4691896 1 T|C ENST00000422287 162 I V 0 B 0.33 T HIGH 3.449
ENST00000274054 162 I V 0 B 0.3 T HIGH
11 rs117037102 rs117405490 1 C|G CEP295 ENST00000325212 783 P A 0.907 PD 0.24 T HIGH 11.9
ENST00000411936 783 P A 0.907 PD 0.27 T HIGH 11.9
14 rs2302588 rs2302588 - G|C DCAF4 ENST00000358377 22 W C 0.993 PD 0.01 D LOW 14.81
ENST00000353777 22 W C 0 U 0 D LOW 14.81
ENST00000509320 22 W C 0 U 0.04 D LOW 14.81
ENST00000509153 22 W C 0.993 PD 0.01 D LOW 14.81
rs3815460 1 C|G ENST00000358377 345 S C 0.995 PD 0.03 D HIGH 28.5
ENST00000353777 175 S C 0.994 PD 0.05 D HIGH 28.5
ENST00000394234 245 S C 0.995 PD 0 D HIGH 28.5
ENST00000509153 285 S C 0.998 PD 0.01 D HIGH 28.5
rs2286838 0.9 G|C ZFYVE1 ENST00000318876 408 S R 0.788 PD 0 D HIGH 3.451
16 rs7194734 rs2303262 0.95 C|T MPHOSPH6 ENST00000258169 8 R K 0 B 1 T HIGH 19.52
20 rs34978822 rs35640778 1 G|A RTEL1 ENST00000370018 684 R Q 0.008 B 0.69 T HIGH 19.92
ENST00000508582 708 R Q 0.008 B 0.71 T HIGH 19.92
ENST00000360203 684 R Q 0.008 B 0.76 T HIGH 19.92
ENST00000425905 77 R Q 0.008 B 19.92
ENST00000318100 684 R Q 0.02 B 0.63 T HIGH 19.92
ENST00000492259 712 R Q 0.08 B 19.92
ENST00000482936 684 R Q 0.02 B 19.92
20 rs73624724 rs2281929 0.89 T|C ZBTB46 ENST00000245663 11 T A 0 B 0.36 T HIGH 11.68
ENST00000302995 11 T A 0 B 0.36 T HIGH 11.68











Chr Lead SNP SNP r2 Variant Gene Transcript CADD
Score Prediction Score Prediction Confidence
1 rs3219104 rs1136410 1 A|G PARP1 ENST00000366794 762 V A 0.827 PD 0.24 T HIGH 28.1
rs1805415 1 T|G ENST00000366794 352 K N 0.059 B 0.47 T HIGH 10.25
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ENST00000522830 225 L I 0.93 PD 0.53 T HIGH 14.74
ENST00000522526 254 L I 0.863 PD 0.42 T HIGH 14.74
ENST00000528597 35 L I 0.958 PD 0.06 T HIGH 14.74
ENST00000316515 241 L I 0.93 PD 0.44 T HIGH 14.74
rs6793295 0.93 T|C LRRC34 ENST00000446859 249 S G 0 B 0.51 T HIGH 11.05
ENST00000522830 188 S G 0 B 0.52 T HIGH 11.05
4 rs4691895 rs4691895 - G|C NAF1 ENST00000422287 368 L V 0 B 0.66 T HIGH 0.505
rs4691896 1 T|C ENST00000422287 162 I V 0 B 0.33 T HIGH 3.449
ENST00000274054 162 I V 0 B 0.3 T HIGH
11 rs117037102 rs117405490 1 C|G CEP295 ENST00000325212 783 P A 0.907 PD 0.24 T HIGH 11.9
ENST00000411936 783 P A 0.907 PD 0.27 T HIGH 11.9
14 rs2302588 rs2302588 - G|C DCAF4 ENST00000358377 22 W C 0.993 PD 0.01 D LOW 14.81
ENST00000353777 22 W C 0 U 0 D LOW 14.81
ENST00000509320 22 W C 0 U 0.04 D LOW 14.81
ENST00000509153 22 W C 0.993 PD 0.01 D LOW 14.81
rs3815460 1 C|G ENST00000358377 345 S C 0.995 PD 0.03 D HIGH 28.5
ENST00000353777 175 S C 0.994 PD 0.05 D HIGH 28.5
ENST00000394234 245 S C 0.995 PD 0 D HIGH 28.5
ENST00000509153 285 S C 0.998 PD 0.01 D HIGH 28.5
rs2286838 0.9 G|C ZFYVE1 ENST00000318876 408 S R 0.788 PD 0 D HIGH 3.451
16 rs7194734 rs2303262 0.95 C|T MPHOSPH6 ENST00000258169 8 R K 0 B 1 T HIGH 19.52
20 rs34978822 rs35640778 1 G|A RTEL1 ENST00000370018 684 R Q 0.008 B 0.69 T HIGH 19.92
ENST00000508582 708 R Q 0.008 B 0.71 T HIGH 19.92
ENST00000360203 684 R Q 0.008 B 0.76 T HIGH 19.92
ENST00000425905 77 R Q 0.008 B 19.92
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ENST00000492259 712 R Q 0.08 B 19.92
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Supplementary Table 7: Integration of eQTLs using S-PrediXcan and co-localisation analyses. 
Genes are identified by Ensembl IDs and gene names are derived from the UCSC Human 
Genome database. Genes were allocated to overlapping LTL loci where possible, with sentinel 
SNPs of the corresponding loci shown. Detailed column specifications were given in software 
websites (section 2.2.6.2). 
 
Extra columns are shown on the next page  
rs12065882 1 114437370 114447762 AP4B1 5041 Whole_Blood 0.00 0.00 0.01 0.03 0.97
rs12065882 1 114437370 114447762 AP4B1 4998 Uterus 0.00 0.02 0.01 0.05 0.91
rs12065882 1 114437370 114447762 AP4B1 5041 Heart_Left_Ventricle 0.00 0.00 0.03 0.15 0.82
rs12065882 1 114437370 114447762 AP4B1 5041 Muscle_Skeletal 0.00 0.00 0.03 0.15 0.81
rs12065882 1 114399257 114443857 AP4B1-AS1 5024 Nerve_Tibial 0.01 0.03 0.01 0.06 0.88
rs12065882 1 114399257 114443857 AP4B1-AS1 5024 Skin_Not_Sun_Exposed_Suprapubic 0.01 0.02 0.03 0.11 0.83
rs12065882 1 114399257 114443857 AP4B1-AS1 5024 Thyroid 0.00 0.01 0.03 0.13 0.82
rs12065882 1 114399257 114443857 AP4B1-AS1 5024 Whole_Blood 0.00 0.00 0.02 0.08 0.89
rs12065882 1 114239453 114302111 PHTF1 5069 Muscle_Skeletal 0.00 0.02 0.02 0.08 0.88
rs12065882 1 114356433 114414381 PTPN22 5033 Brain_Cerebellum 0.00 0.00 0.02 0.08 0.90
rs12065882 1 114356433 114414381 PTPN22 5038 Colon_Transverse 0.00 0.00 0.01 0.05 0.94
rs12065882 1 114356433 114414381 PTPN22 5038 Pancreas 0.00 0.00 0.01 0.07 0.92
rs3219104 1 226736501 226796915 C1orf95 6156 Brain_Anterior_cingulate_cortex_BA24 0.00 0.01 0.00 0.04 0.95
rs3219104 1 226548392 226595780 PARP1 6127 Pancreas 0.00 0.00 0.00 0.03 0.97
rs754017156 2 54480315 54483409 TSPYL6 7075 Testis 0.00 0.00 0.00 0.04 0.96
rs56810761 2 210673528 210674304 SNAI1P1 5605 Testis 0.00 0.00 0.03 0.13 0.84
rs55749605 3 101043049 101232085 SENP7 5676 Small_Intestine_Terminal_Ileum 0.00 0.01 0.01 0.15 0.83
rs10936600 3 169490619 169507504 MYNN 5774 Artery_Aorta 0.00 0.22 0.00 0.30 0.48
rs10936600 3 169490619 169507504 MYNN 5774 Testis 0.00 0.00 0.00 0.02 0.98
rs10936600 3 169511216 169530774 LRRC34 5802 Adipose_Subcutaneous 0.00 0.00 0.00 1.00 0.00
rs10936600 3 169511216 169530774 LRRC34 5802 Adipose_Visceral_Omentum 0.00 0.00 0.00 1.00 0.00
rs10936600 3 169511216 169530774 LRRC34 5800 Adrenal_Gland 0.00 0.00 0.00 1.00 0.00
rs10936600 3 169511216 169530774 LRRC34 5802 Artery_Aorta 0.00 0.00 0.00 1.00 0.00
rs10936600 3 169511216 169530774 LRRC34 5802 Artery_Tibial 0.00 0.00 0.00 1.00 0.00
rs10936600 3 169511216 169530774 LRRC34 5801 Cells_Transformed_fibroblasts 0.00 0.00 0.00 0.97 0.03
rs10936600 3 169511216 169530774 LRRC34 5801 Colon_Sigmoid 0.00 0.00 0.00 1.00 0.00
rs10936600 3 169511216 169530774 LRRC34 5801 Esophagus_Gastroesophageal_Junction 0.00 0.00 0.00 1.00 0.00
rs10936600 3 169511216 169530774 LRRC34 5802 Esophagus_Mucosa 0.00 0.38 0.00 0.59 0.04
rs10936600 3 169511216 169530774 LRRC34 5802 Heart_Atrial_Appendage 0.00 0.50 0.00 0.32 0.18
rs10936600 3 169511216 169530774 LRRC34 5801 Heart_Left_Ventricle 0.00 0.00 0.00 0.96 0.04
rs10936600 3 169511216 169530774 LRRC34 5802 Muscle_Skeletal 0.00 0.00 0.00 1.00 0.00
rs10936600 3 169511216 169530774 LRRC34 5802 Nerve_Tibial 0.00 0.00 0.00 1.00 0.00
rs10936600 3 169511216 169530774 LRRC34 5802 Thyroid 0.00 0.00 0.00 1.00 0.00
rs10936600 3 169539710 169555563 LRRIQ4 5821 Cells_Transformed_fibroblasts 0.00 0.04 0.00 0.95 0.01
rs10936600 3 169539710 169555563 LRRIQ4 5820 Testis 0.00 0.00 0.00 1.00 0.00
rs60160057 4 150999426 151178609 DCLK2 4857 Spleen 0.00 0.00 0.02 0.09 0.90
rs4691895 4 164031225 164088073 NAF1 7177 Muscle_Skeletal 0.00 0.00 0.00 0.93 0.07
rs4691895 4 164031225 164088073 NAF1 7177 Skin_Sun_Exposed_Lower_leg 0.00 0.27 0.00 0.23 0.50
rs4691895 4 164031225 164088073 NAF1 7177 Thyroid 0.00 0.02 0.00 0.06 0.92
rs4691895 4 164031225 164088073 NAF1 7177 Cells_Transformed_fibroblasts 0.00 0.03 0.00 0.08 0.89
rs4691895 4 164029937 164041117 RP11-563E2.2 7235 Adipose_Subcutaneous 0.00 0.02 0.00 0.06 0.92
rs4691895 4 164029937 164041117 RP11-563E2.2 7235 Nerve_Tibial 0.00 0.00 0.00 0.04 0.96
rs4691895 4 164029937 164041117 RP11-563E2.2 7235 Skin_Not_Sun_Exposed_Suprapubic 0.00 0.04 0.00 0.07 0.89
rs4691895 4 164029937 164041117 RP11-563E2.2 7235 Skin_Sun_Exposed_Lower_leg 0.00 0.01 0.00 0.04 0.95
rs62365174 5 78908243 78982471 PAPD4 6194 Skin_Not_Sun_Exposed_Suprapubic 0.00 0.00 0.02 0.11 0.86
rs62365174 5 78908243 78982471 PAPD4 6194 Breast_Mammary_Tissue 0.00 0.00 0.02 0.11 0.86
rs62365174 5 78908243 78982471 PAPD4 6194 Colon_Transverse 0.00 0.00 0.03 0.15 0.82
rs62365174 5 78908243 78982471 PAPD4 6194 Esophagus_Muscularis 0.00 0.00 0.03 0.13 0.85
rs62365174 5 78908243 78982471 PAPD4 6194 Lung 0.00 0.00 0.02 0.12 0.86
rs62365174 5 78908243 78982471 PAPD4 6194 Nerve_Tibial 0.00 0.00 0.02 0.11 0.86
rs62365174 5 78908243 78982471 PAPD4 6194 Skin_Sun_Exposed_Lower_leg 0.00 0.00 0.03 0.12 0.86
rs62365174 5 78908243 78982471 PAPD4 6181 Small_Intestine_Terminal_Ileum 0.00 0.00 0.02 0.12 0.86
rs62365174 5 78908243 78982471 PAPD4 6194 Thyroid 0.00 0.00 0.02 0.12 0.86
rs2736176 6 31082527 31107869 PSORS1C1 17178 Heart_Left_Ventricle 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31110216 31126015 CCHCR1 16891 Colon_Sigmoid 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31110216 31126015 CCHCR1 16891 Nerve_Tibial 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31132119 31148508 POU5F1 16841 Adipose_Visceral_Omentum 0.00 0.00 0.00 0.96 0.04
rs2736176 6 31236526 31239882 HLA-C 17050 Adrenal_Gland 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31236526 31239882 HLA-C 17059 Artery_Aorta 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31236526 31239882 HLA-C 17053 Artery_Coronary 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31236526 31239882 HLA-C 17059 Artery_Tibial 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31236526 31239882 HLA-C 17059 Breast_Mammary_Tissue 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31236526 31239882 HLA-C 17059 Colon_Transverse 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31236526 31239882 HLA-C 17059 Heart_Atrial_Appendage 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31236526 31239882 HLA-C 17059 Heart_Left_Ventricle 0.00 0.00 0.00 1.00 0.00
H4_abf
Sentinel SNP and tissue-specific gene expression Co-localisation



















PARP1 Pancreas 0.12 6.10 1.08E-09 0.03 0.06 2.63E-03 3.12E-03 rs2255403 -6.39 4 4 4
TSPYL6 Testis -0.03 -5.32 1.02E-07 0.47 0.56 1.43E-29 6.56E-28 rs12615793 5.22 30 30 30
SNAI1P1 Testis
SENP7 Small_Intestine_Terminal_Ileum
MYNN Artery_Aorta -0.09 -6.62 3.69E-11 0.08 0.07 2.58E-04 2.66E-04 rs7621631 -14.97 31 31 31
MYNN Testis -0.24 -13.35 1.23E-40 0.04 0.06 1.75E-03 1.46E-03 rs7621631 -14.97 10 10 10
LRRC34 Adipose_Subcutaneous 0.20 13.09 3.58E-39 0.05 0.09 1.28E-07 1.49E-07 rs3821383 -14.15 21 22 22
LRRC34 Adipose_Visceral_Omentum 0.37 12.29 1.09E-34 0.01 0.05 1.32E-03 1.82E-03 rs3821383 -14.15 16 18 18
LRRC34 Adrenal_Gland 0.43 12.31 7.59E-35 0.01 0.08 1.21E-03 2.11E-03 rs9833035 -13.05 7 8 8
LRRC34 Artery_Aorta 0.08 7.30 2.89E-13 0.10 0.12 1.02E-06 1.64E-06 rs6793160 -11.54 32 34 34
LRRC34 Artery_Tibial 0.09 8.85 8.66E-19 0.10 0.08 1.00E-06 1.03E-06 rs6793160 -11.54 43 48 48
LRRC34 Cells_Transformed_fibroblasts 0.14 12.54 4.40E-36 0.10 0.13 4.93E-10 5.88E-10 rs1997392 -14.17 26 30 30
LRRC34 Colon_Sigmoid 0.18 10.98 4.69E-28 0.05 0.19 4.49E-07 2.35E-06 rs10936596 -11.97 16 17 17
LRRC34 Esophagus_Gastroesophageal_Junction 0.15 8.46 2.58E-17 0.04 0.13 3.43E-05 1.25E-04 rs9878797 -10.62 10 11 11
LRRC34 Esophagus_Mucosa 0.16 5.97 2.30E-09 0.02 0.04 2.73E-03 1.49E-03 rs9878797 -10.62 26 27 27
LRRC34 Heart_Atrial_Appendage 0.11 9.67 4.16E-22 0.10 0.06 1.42E-03 1.89E-03 rs1997392 -14.17 48 49 49
LRRC34 Heart_Left_Ventricle 0.24 12.46 1.24E-35 0.04 0.11 1.92E-06 4.41E-06 rs1997392 -14.17 13 14 14
LRRC34 Muscle_Skeletal 0.17 8.09 5.99E-16 0.03 0.06 1.07E-06 1.21E-06 rs6793160 -11.54 16 18 18
LRRC34 Nerve_Tibial 0.25 14.31 1.92E-46 0.04 0.10 2.21E-07 2.06E-07 rs3821383 -14.15 11 12 12
LRRC34 Thyroid 0.44 11.91 1.06E-32 0.01 0.04 1.40E-03 8.07E-04 rs6793160 -11.54 7 9 9
LRRIQ4 Cells_Transformed_fibroblasts -0.41 -10.95 6.89E-28 0.01 0.01 1.32E-01 4.22E-02 rs6793160 -11.54 13 13 13
LRRIQ4 Testis -0.21 -12.45 1.45E-35 0.05 0.09 1.74E-04 1.83E-04 rs1997392 -14.17 22 23 23
DCLK2 Spleen
NAF1 Muscle_Skeletal -0.20 -7.75 9.15E-15 0.02 0.06 5.47E-06 5.53E-06 rs1055263 7.79 3 3 3
NAF1 Skin_Sun_Exposed_Lower_leg -0.22 -8.87 7.50E-19 0.02 0.02 3.01E-02 1.24E-02 rs1351222 9.44 28 28 28















PSORS1C1 Heart_Left_Ventricle 0.03 5.40 6.52E-08 0.41 0.48 8.24E-29 3.56E-27 rs3020644 5.56 35 35 35
CCHCR1 Colon_Sigmoid -0.04 -5.66 1.56E-08 0.21 0.13 2.87E-05 9.86E-05 rs707939 6.22 34 34 34
CCHCR1 Nerve_Tibial -0.04 -5.20 1.98E-07 0.30 0.39 4.49E-29 3.03E-28 rs3094005 -5.08 26 27 27
POU5F1 Adipose_Visceral_Omentum -0.05 -5.27 1.36E-07 0.17 0.18 2.10E-09 9.67E-09 rs3130484 -4.71 42 42 42
HLA-C Adrenal_Gland -0.04 -5.48 4.37E-08 0.31 0.56 9.29E-24 9.31E-22 rs2736428 5.79 38 39 39
HLA-C Artery_Aorta -0.03 -5.32 1.06E-07 0.52 0.72 1.07E-55 1.44E-52 rs2075800 6.04 99 100 100
HLA-C Artery_Coronary -0.04 -5.49 3.98E-08 0.31 0.49 7.31E-19 5.47E-17 rs3094005 -5.08 60 61 61
HLA-C Artery_Tibial -0.03 -5.45 5.06E-08 0.36 0.71 1.79E-78 6.72E-76 rs2844458 5.36 33 34 34
HLA-C Breast_Mammary_Tissue -0.03 -5.24 1.64E-07 0.37 0.61 6.04E-39 1.42E-36 rs3020644 5.56 33 34 34
HLA-C Colon_Transverse -0.03 -5.49 4.03E-08 0.46 0.63 2.57E-38 6.71E-36 rs3094005 -5.08 64 65 65
HLA-C Heart_Atrial_Appendage -0.03 -5.32 1.06E-07 0.37 0.52 3.78E-27 2.93E-25 rs3094005 -5.08 45 47 47
HLA-C Heart_Left_Ventricle -0.04 -5.24 1.60E-07 0.30 0.58 3.52E-37 4.97E-35 rs3094005 -5.08 36 37 37









rs2736176 6 31236526 31239882 HLA-C 17059 Pancreas 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31236526 31239882 HLA-C 17047 Spleen 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31236526 31239882 HLA-C 17058 Stomach 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31321649 31324219 HLA-B 17420 Liver 0.00 0.07 0.00 0.92 0.01
rs2736176 6 31588497 31605548 PRRC2A 18856 Whole_Blood 0.00 0.00 0.00 0.55 0.45
rs2736176 6 31606805 31620482 BAG6 19732 Artery_Tibial 0.00 0.00 0.00 1.00 0.00
rs2736176 6 31606805 31620482 BAG6 19698 Brain_Anterior_cingulate_cortex_BA24 0.00 0.00 0.00 0.02 0.98
rs2736176 6 31606805 31620482 BAG6 19577 Brain_Frontal_Cortex_BA9 0.00 0.00 0.00 0.01 0.99
rs2736176 6 31606805 31620482 BAG6 19701 Brain_Hypothalamus 0.00 0.00 0.00 0.01 0.99
rs2736176 6 31606805 31620482 BAG6 19732 Breast_Mammary_Tissue 0.00 0.30 0.00 0.45 0.24
rs2736176 6 31606805 31620482 BAG6 19732 Heart_Left_Ventricle 0.00 0.04 0.00 0.30 0.67
rs2736176 6 31606805 31620482 BAG6 19694 Ovary 0.00 0.03 0.00 0.09 0.88
rs2736176 6 31606805 31620482 BAG6 19730 Stomach 0.00 0.00 0.00 0.10 0.90
rs2736176 6 31629006 31634060 GPANK1 20119 Adipose_Subcutaneous 0.00 0.09 0.00 0.87 0.04
rs2736176 6 31633168 31637847 CSNK2B 20121 Adipose_Visceral_Omentum 0.00 0.04 0.00 0.11 0.86
rs2736176 6 31633168 31637847 CSNK2B 20121 Colon_Sigmoid 0.00 0.00 0.00 0.02 0.98
rs2736176 6 31633168 31637847 CSNK2B 20121 Esophagus_Muscularis 0.00 0.00 0.00 0.10 0.90
rs2736176 6 31633168 31637847 CSNK2B 20121 Heart_Atrial_Appendage 0.00 0.00 0.00 0.01 0.99
rs2736176 6 31633168 31637847 CSNK2B 20121 Heart_Left_Ventricle 0.00 0.00 0.00 0.05 0.95
rs2736176 6 31633168 31637847 CSNK2B 20121 Lung 0.00 0.00 0.00 0.03 0.97
rs2736176 6 31633168 31637847 CSNK2B 20121 Muscle_Skeletal 0.00 0.00 0.00 0.06 0.94
rs2736176 6 31847536 31865461 EHMT2 22103 Skin_Sun_Exposed_Lower_leg 0.00 0.00 0.00 0.30 0.70
rs2736176 6 31847536 31865461 EHMT2 22103 Testis 0.00 0.08 0.00 0.50 0.42
rs2736176 6 31865562 31913426 C2 22102 Whole_Blood 0.00 0.00 0.00 0.98 0.01
rs2736176 6 31865562 31913426 C2 22102 Testis 0.00 0.00 0.00 0.16 0.84
rs2736176 6 32083112 32096030 ATF6B 22268 Small_Intestine_Terminal_Ileum 0.00 0.03 0.00 0.12 0.85
rs2736176 6 31588497 31605548 PRRC2A 18856 Adipose_Subcutaneous 0.00 0.00 0.00 0.04 0.96
rs2736176 6 31588497 31605548 PRRC2A 18856 Muscle_Skeletal 0.00 0.00 0.00 0.15 0.85
rs2736176 6 31588497 31605548 PRRC2A 18856 Thyroid 0.00 0.00 0.00 0.10 0.90
rs2736176 6 31830969 31846823 SLC44A4 22041 Thyroid 0.00 0.00 0.00 0.11 0.89
rs59294613 7 124386051 124405681 GPR37 6504 Artery_Coronary 0.00 0.25 0.00 0.46 0.30
rs59294613 7 124570038 124819369 RP11-3B12.1 6950 Thyroid 0.00 0.00 0.00 0.05 0.95
rs59294613 7 124570038 124819369 RP11-3B12.1 6950 Pancreas 0.00 0.01 0.00 0.11 0.88
rs9419958 10 105642300 105677963 OBFC1 4964 Cells_Transformed_fibroblasts 0.00 0.00 0.00 0.07 0.93
rs9419958 10 105642300 105677963 OBFC1 4964 Colon_Transverse 0.00 0.00 0.00 0.03 0.97
rs9419958 10 105642300 105677963 OBFC1 4964 Esophagus_Gastroesophageal_Junction 0.00 0.11 0.00 0.08 0.82
rs9419958 10 105642300 105677963 OBFC1 4964 Esophagus_Mucosa 0.00 0.00 0.00 0.01 0.99
rs9419958 10 105642300 105677963 OBFC1 4964 Esophagus_Muscularis 0.00 0.01 0.00 0.02 0.97
rs9419958 10 105642300 105677963 OBFC1 4964 Heart_Atrial_Appendage 0.00 0.00 0.00 0.03 0.97
rs9419958 10 105642300 105677963 OBFC1 4964 Lung 0.00 0.03 0.00 0.04 0.94
rs9419958 10 105642300 105677963 OBFC1 4964 Skin_Sun_Exposed_Lower_leg 0.00 0.01 0.00 0.12 0.88
rs9419958 10 105642300 105677963 OBFC1 4964 Thyroid 0.00 0.11 0.00 0.06 0.83
rs9419958 10 105637132 105639519 RP11-541N10.3 4957 Adipose_Subcutaneous 0.00 0.03 0.00 0.02 0.95
rs9419958 10 105637132 105639519 RP11-541N10.3 4957 Thyroid 0.00 0.05 0.00 0.04 0.91
rs9419958 10 105726959 105788991 SLK 5037 Artery_Tibial 0.00 0.01 0.00 0.08 0.91
rs228595 11 108093211 108239829 ATM 6082 Cells_Transformed_fibroblasts 0.00 0.00 0.00 0.36 0.64
rs228595 11 107992478 108018503 ACAT1 6123 Artery_Aorta 0.00 0.00 0.00 0.15 0.84
rs2302588 14 73436159 73493920 ZFYVE1 6890 Colon_Sigmoid 0.00 0.05 0.00 0.09 0.86
rs3213718 14 90862846 90874605 CALM1 6373 Testis 0.00 0.00 0.04 0.02 0.93
rs12909131 15 50150435 50411654 ATP8B4 6190 Brain_Cortex 0.00 0.06 0.00 0.10 0.83
rs12909131 15 50171801 50175722 CTD-2647E9.3 6219 Lung 0.00 0.10 0.00 0.07 0.83
rs55710439 15 65204101 65251042 ANKDD1A 4785 Thyroid 0.00 0.00 0.01 0.02 0.97
rs11640926 16 1408901 1411406 LA16c-316G12.2 8048 Artery_Coronary 0.02 0.02 0.07 0.04 0.85
rs11640926 16 1256560 1257124 RP11-616M22.3 8297 Skin_Not_Sun_Exposed_Suprapubic 0.00 0.00 0.09 0.06 0.85
rs3785074 16 69354043 69373332 COG8 4584 Brain_Cerebellum 0.00 0.63 0.00 0.30 0.08
rs3785074 16 69354043 69373332 COG8 4577 Brain_Cortex 0.00 0.00 0.00 0.66 0.34
rs3785074 16 69354043 69373332 COG8 4533 Brain_Frontal_Cortex_BA9 0.00 0.02 0.00 0.16 0.82
rs3785074 16 69354043 69373332 COG8 4586 Esophagus_Muscularis 0.00 0.02 0.00 0.08 0.90
rs3785074 16 69363900 69364498 PDF 4599 Adipose_Subcutaneous 0.00 0.00 0.00 0.04 0.96
rs3785074 16 69363900 69364498 PDF 4599 Adipose_Visceral_Omentum 0.00 0.00 0.00 0.89 0.11
rs3785074 16 69363900 69364498 PDF 4599 Skin_Not_Sun_Exposed_Suprapubic 0.00 0.00 0.00 0.84 0.16
rs3785074 16 69363900 69364498 PDF 4599 Skin_Sun_Exposed_Lower_leg 0.00 0.00 0.00 0.73 0.27
rs3785074 16 69363900 69364498 PDF 4599 Artery_Tibial 0.00 0.00 0.00 0.18 0.82
rs3785074 16 69363900 69364498 PDF 4599 Breast_Mammary_Tissue 0.00 0.03 0.00 0.06 0.91
rs3785074 16 69363900 69364498 PDF 4599 Colon_Transverse 0.00 0.00 0.00 0.03 0.97
rs3785074 16 69363900 69364498 PDF 4599 Esophagus_Gastroesophageal_Junction 0.00 0.03 0.00 0.13 0.84
rs3785074 16 69363900 69364498 PDF 4599 Lung 0.00 0.00 0.00 0.15 0.85
rs3785074 16 69363900 69364498 PDF 4599 Nerve_Tibial 0.00 0.00 0.00 0.02 0.98
rs3785074 16 69363900 69364498 PDF 4599 Thyroid 0.00 0.00 0.00 0.16 0.84
rs3785074 16 69377151 69385712 TMED6 4549 Cells_EBV-transformed_lymphocytes 0.00 0.47 0.00 0.29 0.24
Sentinel SNP and tissue-specific gene expression Co-localisation
SNP CHR Gene_start Gene_end Gene name Gene nsnps Tissue H0_abf H1_abf H2_abf H3_abf H4_abf
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r2 pval qval ID Z
HLA-C Pancreas -0.04 -5.37 7.87E-08 0.23 0.50 9.57E-24 4.39E-22 rs2075800 6.04 21 22 22
HLA-C Spleen -0.04 -5.78 7.27E-09 0.36 0.52 1.37E-15 8.47E-14 rs707939 6.22 49 50 50
HLA-C Stomach -0.04 -5.16 2.46E-07 0.23 0.59 4.26E-34 9.26E-32 rs2075800 6.04 20 21 21
HLA-B Liver -0.06 -5.77 8.00E-09 0.12 0.08 5.82E-03 1.24E-02 rs2736428 5.79 22 22 22
PRRC2A Whole_Blood 0.13 5.31 1.10E-07 0.02 0.03 7.70E-04 5.10E-04 rs707939 6.22 13 13 13
BAG6 Artery_Tibial 0.05 5.77 8.15E-09 0.21 0.30 2.47E-23 1.19E-22 rs707939 6.22 31 31 31
BAG6 Brain_Anterior_cingulate_cortex_BA24 0.10 6.49 8.73E-11 0.05 0.09 9.04E-03 1.93E-02 rs707939 6.22 11 11 11
BAG6 Brain_Frontal_Cortex_BA9 0.06 7.01 2.42E-12 0.15 0.18 2.97E-05 1.42E-04 rs707939 6.22 21 21 21
BAG6 Brain_Hypothalamus 0.06 5.49 4.12E-08 0.12 0.10 3.55E-03 1.08E-02 rs707939 6.22 17 17 17
BAG6 Breast_Mammary_Tissue 0.20 5.89 3.95E-09 0.01 0.02 4.89E-02 4.06E-02 rs707939 6.22 2 2 2
BAG6 Heart_Left_Ventricle 0.11 5.43 5.61E-08 0.03 0.03 1.74E-02 1.49E-02 rs2736428 5.79 11 11 11
BAG6 Ovary 0.07 6.49 8.35E-11 0.11 0.10 3.77E-03 8.70E-03 rs2734325 5.37 19 19 19
BAG6 Stomach








EHMT2 Skin_Sun_Exposed_Lower_leg -0.14 -5.57 2.59E-08 0.02 0.03 1.58E-03 8.82E-04 rs2075800 6.04 9 9 9
EHMT2 Testis -0.15 -5.63 1.78E-08 0.02 0.04 1.39E-02 8.82E-03 rs2736428 5.79 6 6 6































COG8 Brain_Cerebellum 0.12 5.69 1.28E-08 0.03 0.04 3.90E-02 2.61E-02 rs3785073 6.19 7 7 7
COG8 Brain_Cortex 0.05 5.24 1.60E-07 0.11 0.10 1.68E-03 3.62E-03 rs877534 5.03 16 16 16
COG8 Brain_Frontal_Cortex_BA9 0.05 5.48 4.33E-08 0.15 0.12 5.64E-04 1.62E-03 rs877534 5.03 25 25 25
COG8 Esophagus_Muscularis
PDF Adipose_Subcutaneous -0.18 -5.76 8.34E-09 0.01 0.04 1.06E-03 6.64E-04 rs12922774 5.91 3 3 3
PDF Adipose_Visceral_Omentum -0.11 -5.40 6.51E-08 0.03 0.05 1.63E-03 2.18E-03 rs7191614 6.15 9 9 9
PDF Skin_Not_Sun_Exposed_Suprapubic -0.09 -5.19 2.06E-07 0.04 0.05 1.39E-03 1.54E-03 rs12922774 5.91 16 16 16








TMED6 Cells_EBV-transformed_lymphocytes 0.07 5.45 5.09E-08 0.08 0.11 2.68E-04 6.17E-04 rs3743669 6.08 14 14 14











rs3785074 16 69377151 69385712 TMED6 4560 Adipose_Subcutaneous 0.00 0.00 0.00 0.10 0.90
rs3785074 16 69389464 69442474 TERF2 4423 Brain_Cerebellar_Hemisphere 0.00 0.00 0.00 0.04 0.96
rs3785074 16 69389464 69442474 TERF2 4479 Brain_Cerebellum 0.00 0.01 0.00 0.02 0.97
rs3785074 16 69389464 69442474 TERF2 4482 Colon_Sigmoid 0.00 0.00 0.00 0.03 0.96
rs3785074 16 69389464 69442474 TERF2 4453 Ovary 0.00 0.01 0.00 0.02 0.98
rs3785074 16 69389464 69442474 TERF2 4482 Thyroid 0.00 0.00 0.00 0.01 0.99
rs3785074 16 69373571 69377014 NIP7 4585 Skin_Not_Sun_Exposed_Suprapubic 0.00 0.07 0.00 0.12 0.81
rs3785074 16 69345259 69358945 VPS4A 4635 Muscle_Skeletal 0.00 0.07 0.00 0.11 0.82
rs62053580 16 74655292 74700779 RFWD3 6797 Adrenal_Gland 0.00 0.00 0.00 0.05 0.95
rs62053580 16 74655292 74700779 RFWD3 6771 Cells_EBV-transformed_lymphocytes 0.00 0.00 0.00 0.09 0.91
rs62053580 16 74655292 74700779 RFWD3 6801 Esophagus_Mucosa 0.00 0.00 0.00 0.07 0.93
rs62053580 16 74655292 74700779 RFWD3 6801 Muscle_Skeletal 0.00 0.00 0.00 0.19 0.81
rs62053580 16 74655292 74700779 RFWD3 6801 Skin_Not_Sun_Exposed_Suprapubic 0.00 0.00 0.00 0.05 0.95
rs62053580 16 74655292 74700779 RFWD3 6801 Skin_Sun_Exposed_Lower_leg 0.00 0.00 0.00 0.07 0.93
rs62053580 16 74456018 74469152 RP11-252A24.5 6741 Brain_Cerebellum 0.00 0.02 0.00 0.06 0.92
rs62053580 16 74481325 74483790 RP11-252A24.7 6759 Artery_Tibial 0.00 0.03 0.00 0.13 0.83
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Adipose_Subcutaneous 0.00 0.00 0.00 0.04 0.96
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Adipose_Visceral_Omentum 0.00 0.00 0.00 0.60 0.40
rs7194734 16 82181403 82203831 MPHOSPH6 10987 Adrenal_Gland 0.00 0.00 0.00 0.19 0.81
rs7194734 16 82181403 82203831 MPHOSPH6 10986 Artery_Aorta 0.00 0.00 0.00 0.02 0.98
rs7194734 16 82181403 82203831 MPHOSPH6 10936 Artery_Coronary 0.00 0.08 0.00 0.14 0.78
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Artery_Tibial 0.00 0.00 0.00 0.02 0.98
rs7194734 16 82181403 82203831 MPHOSPH6 10949 Brain_Cerebellar_Hemisphere 0.00 0.00 0.00 0.09 0.91
rs7194734 16 82181403 82203831 MPHOSPH6 10976 Brain_Cerebellum 0.00 0.00 0.00 0.60 0.40
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Breast_Mammary_Tissue 0.00 0.00 0.00 0.06 0.94
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Colon_Transverse 0.00 0.00 0.00 0.13 0.87
rs7194734 16 82181403 82203831 MPHOSPH6 10986 Esophagus_Gastroesophageal_Junction 0.00 0.00 0.00 0.16 0.84
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Esophagus_Mucosa 0.00 0.01 0.00 0.99 0.00
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Esophagus_Muscularis 0.00 0.00 0.00 0.02 0.98
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Heart_Atrial_Appendage 0.00 0.00 0.00 0.05 0.95
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Heart_Left_Ventricle 0.00 0.00 0.00 0.02 0.98
rs7194734 16 82181403 82203831 MPHOSPH6 10976 Liver 0.00 0.00 0.00 0.02 0.98
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Lung 0.00 0.00 0.00 0.11 0.89
rs7194734 16 82181403 82203831 MPHOSPH6 10870 Minor_Salivary_Gland 0.00 0.01 0.00 0.04 0.94
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Muscle_Skeletal 0.00 0.00 0.00 0.02 0.98
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Nerve_Tibial 0.00 0.00 0.00 0.02 0.98
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Pancreas 0.00 0.00 0.00 0.04 0.96
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Skin_Not_Sun_Exposed_Suprapubic 0.00 0.00 0.00 0.04 0.96
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Skin_Sun_Exposed_Lower_leg 0.00 0.00 0.00 0.04 0.96
rs7194734 16 82181403 82203831 MPHOSPH6 10948 Small_Intestine_Terminal_Ileum 0.00 0.00 0.00 0.05 0.95
rs7194734 16 82181403 82203831 MPHOSPH6 10982 Spleen 0.00 0.00 0.00 0.60 0.40
rs7194734 16 82181403 82203831 MPHOSPH6 10991 Stomach 0.00 0.00 0.00 0.03 0.97
rs7194734 16 82181403 82203831 MPHOSPH6 10991 Testis 0.00 0.00 0.00 0.02 0.98
rs7194734 16 82181403 82203831 MPHOSPH6 10992 Thyroid 0.00 0.00 0.00 0.03 0.97
rs144204502 17 76170160 76183314 TK1 8131 Brain_Nucleus_accumbens_basal_ganglia 0.00 0.00 0.01 0.01 0.99
rs144204502 17 76170160 76183314 TK1 8142 Esophagus_Mucosa 0.02 0.01 0.01 0.01 0.95
rs144204502 17 76170160 76183314 TK1 8126 Brain_Putamen_basal_ganglia 0.01 0.00 0.03 0.02 0.94
rs2124616 18 657604 673578 TYMS 6126 Cells_EBV-transformed_lymphocytes 0.00 0.00 0.00 0.03 0.96
rs8105767 19 22235254 22274282 ZNF257 8158 Artery_Coronary 0.00 0.00 0.00 0.08 0.92
rs8105767 19 22235254 22274282 ZNF257 8160 Brain_Cerebellum 0.00 0.00 0.00 0.03 0.97
rs8105767 19 22235254 22274282 ZNF257 8110 Brain_Hypothalamus 0.00 0.00 0.00 0.06 0.94
rs8105767 19 22235254 22274282 ZNF257 8105 Brain_Spinal_cord_cervical_c-1 0.00 0.00 0.00 0.15 0.84
rs8105767 19 22235254 22274282 ZNF257 8163 Colon_Transverse 0.00 0.00 0.00 0.00 1.00
rs8105767 19 22235254 22274282 ZNF257 8164 Esophagus_Mucosa 0.00 0.00 0.00 0.00 1.00
rs8105767 19 22235254 22274282 ZNF257 8164 Nerve_Tibial 0.00 0.00 0.00 0.55 0.45
rs8105767 19 22235254 22274282 ZNF257 8157 Prostate 0.00 0.00 0.00 0.02 0.98
rs8105767 19 22235254 22274282 ZNF257 8164 Skin_Sun_Exposed_Lower_leg 0.00 0.00 0.00 0.19 0.81
rs8105767 19 22235254 22274282 ZNF257 8158 Small_Intestine_Terminal_Ileum 0.00 0.00 0.00 0.16 0.84
rs8105767 19 22235254 22274282 ZNF257 8164 Stomach 0.00 0.00 0.00 0.05 0.95
rs8105767 19 22235254 22274282 ZNF257 8164 Whole_Blood 0.00 0.00 0.00 0.04 0.96
rs8105767 19 22361893 22379753 ZNF676 8116 Lung 0.00 0.01 0.00 0.04 0.95
rs1744757 20 35624752 35724187 RBL1 3897 Muscle_Skeletal 0.00 0.00 0.00 0.09 0.91
rs1744757 20 35624752 35724187 RBL1 3897 Cells_Transformed_fibroblasts 0.00 0.03 0.00 0.12 0.85
rs1744757 20 35518632 35580246 SAMHD1 3834 Whole_Blood 0.00 0.00 0.00 0.05 0.95
rs1744757 20 35518632 35580246 SAMHD1 3819 Ovary 0.00 0.07 0.00 0.09 0.84
rs75691080 20 62585007 62585495 AL118506.1 5283 Artery_Tibial 0.00 0.32 0.00 0.64 0.04
rs75691080 20 62704534 62711323 RGS19 4672 Brain_Hypothalamus 0.00 0.69 0.00 0.27 0.04
H3_abf H4_abfGene nsnps Tissue H0_abf H1_abf H2_abfSNP CHR Gene_start Gene_end Gene name









TERF2 Ovary -0.08 -5.25 1.50E-07 0.06 0.09 4.66E-03 1.03E-02 rs3785074 6.24 9 9 9












MPHOSPH6 Adipose_Visceral_Omentum 0.06 5.43 5.61E-08 0.12 0.18 1.79E-09 8.27E-09 rs2967355 -6.11 33 33 33
MPHOSPH6 Adrenal_Gland
MPHOSPH6 Artery_Aorta
MPHOSPH6 Artery_Coronary 0.09 5.39 7.19E-08 0.06 0.10 6.36E-04 1.67E-03 rs2967355 -6.11 22 22 22
MPHOSPH6 Artery_Tibial 0.05 5.78 7.62E-09 0.18 0.30 2.68E-23 1.28E-22 rs2967374 -6.13 21 21 21
MPHOSPH6 Brain_Cerebellar_Hemisphere
MPHOSPH6 Brain_Cerebellum 0.04 5.36 8.20E-08 0.21 0.35 6.72E-11 4.69E-10 rs2967355 -6.11 17 17 17
MPHOSPH6 Breast_Mammary_Tissue 0.20 5.95 2.64E-09 0.01 0.05 3.74E-03 5.08E-03 rs2967374 -6.13 10 11 11
MPHOSPH6 Colon_Transverse
MPHOSPH6 Esophagus_Gastroesophageal_Junction
MPHOSPH6 Esophagus_Mucosa 0.08 5.34 9.49E-08 0.06 0.11 8.51E-08 1.01E-07 rs12102917 -5.16 16 16 16
MPHOSPH6 Esophagus_Muscularis 0.05 5.32 1.02E-07 0.17 0.27 2.39E-16 1.02E-15 rs2967374 -6.13 34 34 34
MPHOSPH6 Heart_Atrial_Appendage
MPHOSPH6 Heart_Left_Ventricle 0.05 5.98 2.28E-09 0.19 0.34 1.33E-18 1.75E-17 rs2967374 -6.13 11 11 11
MPHOSPH6 Liver 0.06 5.89 3.79E-09 0.13 0.31 4.14E-09 6.79E-08 rs7202258 -6.09 13 13 13
MPHOSPH6 Lung 0.09 5.76 8.23E-09 0.06 0.14 1.11E-10 2.76E-10 rs2911423 -5.43 21 21 21
MPHOSPH6 Minor_Salivary_Gland
MPHOSPH6 Muscle_Skeletal 0.04 5.51 3.64E-08 0.21 0.32 3.48E-32 3.13E-31 rs2967355 -6.11 22 22 22
MPHOSPH6 Nerve_Tibial 0.04 5.16 2.46E-07 0.22 0.28 5.96E-20 1.94E-19 rs2967355 -6.11 51 51 51





MPHOSPH6 Stomach 0.04 5.84 5.36E-09 0.28 0.35 1.17E-17 2.62E-16 rs2967374 -6.13 35 35 35
MPHOSPH6 Testis 0.04 5.28 1.29E-07 0.23 0.34 1.44E-15 8.48E-15 rs2967374 -6.13 39 39 39









ZNF257 Colon_Transverse 0.06 6.84 7.73E-12 0.14 0.22 1.44E-10 7.83E-10 rs8105767 7.22 19 19 19
ZNF257 Esophagus_Mucosa
ZNF257 Nerve_Tibial 0.04 5.39 6.93E-08 0.23 0.30 1.77E-21 6.58E-21 rs8105767 7.22 33 33 33
ZNF257 Prostate
ZNF257 Skin_Sun_Exposed_Lower_leg 0.04 5.47 4.63E-08 0.21 0.25 2.50E-20 9.39E-20 rs8105767 7.22 40 41 41
ZNF257 Small_Intestine_Terminal_Ileum
ZNF257 Stomach
ZNF257 Whole_Blood 0.10 6.14 8.48E-10 0.05 0.07 1.17E-06 1.21E-06 rs1912576 6.63 13 15 15





AL118506.1 Artery_Tibial -0.45 -6.32 2.61E-10 0.00 0.01 8.30E-02 3.29E-02 rs2281929 6.32 2 2 2
RGS19 Brain_Hypothalamus 0.53 5.92 3.20E-09 0.00 0.12 1.47E-03 5.59E-03 rs6089956 5.58 3 3 3
Gene name Tissue














rs75691080 20 62289163 62327606 RTEL1 6542 Breast_Mammary_Tissue 0.00 0.00 0.00 0.11 0.89
rs75691080 20 62289163 62327606 RTEL1 6542 Muscle_Skeletal 0.00 0.00 0.00 0.10 0.90
rs75691080 20 62289163 62327606 RTEL1 6542 Heart_Atrial_Appendage 0.00 0.06 0.00 0.05 0.89
rs75691080 20 62289163 62327606 RTEL1 6542 Adipose_Visceral_Omentum 0.00 0.00 0.00 0.04 0.96
rs75691080 20 62271061 62284780 STMN3 6556 Artery_Aorta 0.00 0.00 0.00 0.02 0.98
rs75691080 20 62271061 62284780 STMN3 6555 Colon_Sigmoid 0.00 0.07 0.00 0.05 0.88
rs75691080 20 62271061 62284780 STMN3 6556 Cells_Transformed_fibroblasts 0.00 0.00 0.00 0.01 0.99
rs75691080 20 62271061 62284780 STMN3 6556 Artery_Tibial 0.00 0.00 0.00 0.01 0.99
rs75691080 20 62328021 62329995 TNFRSF6B 6353 Adipose_Visceral_Omentum 0.00 0.03 0.00 0.05 0.92
rs75691080 20 62328021 62329995 TNFRSF6B 6353 Cells_Transformed_fibroblasts 0.00 0.03 0.00 0.04 0.93
Sentinel SNP and tissue-specific gene expression Co-localisation
SNP CHR Gene_start Gene_end Gene name Gene nsnps Tissue H0_abf H1_abf H2_abf H3_abf H4_abf
r























rs144204502 rs144204502 10.52 8.95 1.92 8.51 0.23 0.05 2.72 0.46 0.4 0.96 0.91 5.82 4.40E-03 6.10 2.68E-03
rs3213718 rs2300496 12.82 9.60 1.89 5.99 0.83 0.21 2.10 0.38 0.24 0.84 0.93 5.75 4.86E-03 5.82 3.98E-03
rs59192843 rs73301475 18.64 6.98 1.60 0.41 0.91 0.10 1.57 0.75 0.73 0.98 0.98 5.65 5.51E-03 5.81 4.04E-03
rs59294613 rs2239532 8.359 9.19 1.50 3.44 0.38 0.11 2.53 0.4 0.62 0.93 0.99 4.93 1.33E-02 5.10 1.00E-02
rs2736176 rs805299 8.595 6.72 1.68 1.43 0.93 0.14 2.28 0.57 0.42 0.87 0.96 4.77 1.60E-02 4.88 1.30E-02
rs3213718 rs12885713 9.24 6.15 0.63 2.77 0.99 0.03 1.48 0.77 0.79 0.97 0.81 4.51 2.13E-02 4.75 1.53E-02
rs3219104 rs907187 9.385 5.67 0.77 NA 0.67 0.09 3.20 0.63 0.46 0.99 0.88 4.62 1.88E-02 4.73 1.55E-02
rs10936600 rs10936599 11.71 9.08 1.79 0.76 0.95 0.66 NA 0.4 0.34 0.79 0.96 4.91 1.37E-02 4.60 1.81E-02
rs3785074 rs9939705 14.76 9.12 1.20 2.99 0.03 0.12 2.46 0.55 0.58 0.56 0.21 3.70 4.85E-02 3.85 3.99E-02
rs59192843 rs17094157 6.374 7.09 0.97 1.59 0.79 0.05 1.65 0.53 0.46 0.96 0.83 3.62 5.21E-02 3.80 4.18E-02
rs34991172 rs913455 18.28 8.30 1.26 0.05 0.85 0.71 NA 0.49 0.55 0.68 0.31 4.24 2.85E-02 3.68 4.70E-02































Supplementary Table 9: Identification of meQTLs. Independent SNPs associated with LTL at FDR<0.05 and their proxies (r2<0.8) were searched 
in meQTL databases using PhenoScanner (section 2.2.6.3). Best proxy SNPs were those that exhibited the highest LD r2 with locus sentinel SNPs; 
the corresponding lines indicate their associations with DNA methylation markers. Most significant meQTLs indicate SNPs that were most 
significantly associated with DNA methylation markers within each independent LTL signal, and their blocks show their associations with the 
DNA methylation markers and LD r2 with the independent LTL signal SNPs. 
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Chr Region_Start Region_End lead_snp nearest_gene top_gene_candidate rsID hg19_coordinates A1 A2 distance r2 correlated_alleles beta se p direction
1 113578755 114578755 rs12065882 MAGI3 AP4B1 rs12065882 chr1:114078755 A G 0 1.00 A=A,G=G NA NA 3.92E-12 -
1 226062621 227062621 rs3219104 PARP1 PARP1 rs2377312 chr1:226561761 G C -860 1.00 A=G,C=C NA NA 2.57E-237 +
1 226062621 227062621 rs3219104 PARP1 PARP1 rs2377312 chr1:226561761 G C -860 1.00 A=G,C=C NA NA 7.85E-37 -
1 226062621 227062621 rs3219104 PARP1 PARP1 rs2377312 chr1:226561761 G C -860 1.00 A=G,C=C NA NA 2.57E-190 +
3 169014585 170014585 rs10936600 LRRC34 TERC,LRRC34 rs10936600 chr3:169514585 A T 0 1.00 A=A,T=T NA NA 2.15E-88 -
4 78425743 79425743 rs62365174 PAPD4 PAPD4 rs62365174 chr5:78925743 A G 0 1.00 A=A,G=G NA NA 5.64E-12 -
4 78425743 79425743 rs62365174 PAPD4 PAPD4 rs59421001 chr5:78925953 A G 210 1.00 A=G,G=A 1.06 0.16 1.06E-10 +
11 107605593 108605593 rs228595 ATM ATM rs228595 chr11:108105593 A G 0 1.00 G=G,A=A -0.23 0.04 8.37E-10 -
12 13930807 14930807 rs112655343 ATF7IP ATF7IP rs112655343 chr12:14430807 C T 0 1.00 C=C,T=T NA NA 5.71E-26 -
14 72904752 73904752 rs2302588 DCAF4 DCAF4 rs78044039 chr14:73454645 A G 49893 0.90 G=G,C=A NA NA 1.45E-12 +
14 72904752 73904752 rs2302588 DCAF4 DCAF4 rs76891117 chr14:73399837 A G -4915 1.00 G=A,C=G NA NA 3.04E-124 -
14 74014120 75014120 rs59192843 BBOF1 ENTPD5 rs140682464 chr14:74520830 C T 6710 0.82 T=C,G=T NA NA 5.35E-66 -
15 49887678 50887678 rs12909131 ATP8B4 ATP8B4 rs12909131 chr15:50387678 C T 0 1.00 C=C,T=T NA NA 7.29E-254 -
15 49887678 50887678 rs12909131 ATP8B4 ATP8B4 rs12909131 chr15:50387678 C T 0 1.00 C=C,T=T NA NA 1.76E-65 -
15 49887678 50887678 rs12909131 ATP8B4 ATP8B4 rs12909131 chr15:50387678 C T 0 1.00 C=C,T=T -0.73 0.04 4.48E-54 -
16 68906986 69906986 rs3785074 TERF2 TERF2 rs3785074 chr16:69406986 A G 0 1.00 A=A,G=G NA NA 1.54E-267 -
16 81699980 82699980 rs7194734 MPHOSPH6 MPHOSPH6 rs7194734 chr16:82199980 C T 0 1.00 C=C,T=T NA NA 2.60E-40 +
16 81699980 82699980 rs7194734 MPHOSPH6 MPHOSPH6 rs7194734 chr16:82199980 C T 0 1.00 C=C,T=T NA NA 4.83E-256 +
19 21715441 22715441 rs8105767 ZNF208 ZNF257 rs8105767 chr19:22215441 A G 0 1.00 A=A,G=G NA NA 4.61E-22 -
20 61769750 62769750 rs73624724 ZBTB46 ZBTB46 rs73624724 chr20:62436398 C T 0 1.00 T=T,C=C NA NA 6.71E-235 +
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Chr Region_Start Region_End rsID hg19_coordinates P_value r2 marker RefGene_Name RefGene_Group marker_position DMR Enhancer DHS
1 113578755 114578755 rs11588901 chr1:114091058 3.88E-13 0.86 cg16515600 RSBN1 Body NA NA TRUE NA
1 226062621 227062621 rs76887998 chr1:226539353 2.34E-251 0.92 cg04208928 LIN9 TSS1500 S_Shore NA NA NA
1 226062621 227062621 rs4653729 chr1:226537535 6.80E-40 0.92 cg13952899 C1orf95 Body S_Shore RDMR NA NA
1 226062621 227062621 rs76887998 chr1:226539353 1.65E-193 0.92 cg23712594 PARP1 Body N_Shelf NA TRUE NA
3 169014585 170014585 rs9822885 chr3:169486144 6.49E-101 0.93 cg14222479 ARPM1 1stExon;5'UTR S_Shore NA NA TRUE
4 78425743 79425743 rs62365229 chr5:78958549 1.24E-17 0.94 cg02754494 HOMER1 TSS1500 Island NA NA NA
4 78425743 79425743 rs62364124 chr5:78910132 2.75E-13 0.94 Percent-splice-in PAPD4 protein_coding NA NA NA NA
11 107605593 108605593 rs11212620 chr11:108290959 2.36E-10 1.00 cg05081395 KDELC2 3'UTR NA NA NA NA
12 13930807 14930807 rs73056729 chr12:14432076 2.70E-26 0.95 cg19789919 ATF7IP TSS200 Island NA NA NA
14 72904752 73904752 rs362408 chr14:73698548 4.42E-16 0.90 cg19585100 PAPLN TSS1500 N_Shore RDMR NA NA
14 72904752 73904752 rs77694099 chr14:73398446 2.01E-124 1.00 cg23196123 DCAF4 TSS200 Island NA NA NA
14 74014120 75014120 rs140682464 chr14:74520830 5.35E-66 0.82 cg18638434 C14orf45;ENTPD5 Body;TSS1500 S_Shore NA NA NA
15 49887678 50887678 rs12903325 chr15:50353277 1.35E-263 0.94 cg00868652 ATP8B4 TSS200 NA NA TRUE NA
15 49887678 50887678 rs41362650 chr15:50369375 4.69E-66 1.00 cg02726943 SLC27A2 1stExon Island NA TRUE TRUE
15 49887678 50887678 rs7172615 chr15:50357743 3.07E-57 0.97 cg23504246 C15orf33;FGF7 Body;TSS200 NA NA TRUE NA
16 68906986 69906986 rs9939870 chr16:69396585 2.98E-268 1.00 cg02192472 PDF;COG8 TSS1500;Body S_Shore NA NA NA
16 81699980 82699980 rs2967352 chr16:82196676 8.91E-42 0.97 cg00540449 MPHOSPH6 TSS1500 S_Shore NA NA NA
16 81699980 82699980 rs7203990 chr16:82185320 1.42E-259 0.97 cg19807685 HSD17B2 5'UTR;1stExon NA NA NA NA
19 21715441 22715441 rs7248898 chr19:22245354 3.58E-23 0.98 cg06852575 ZNF257 Body NA DMR NA TRUE
20 61769750 62769750 rs6011173 chr20:62460780 6.77E-237 1.00 cg01209296 ZBTB46 5'UTR S_Shore NA NA NA




Chr Region_Start Region_End dataset pmid ancestry year tissue n
1 113578755 114578755 BIOSQTL 27918535 European 2017 Whole blood 3841
1 226062621 227062621 BIOSQTL 27918535 European 2017 Whole blood 3841
1 226062621 227062621 BIOSQTL 27918535 European 2017 Whole blood 3841
1 226062621 227062621 BIOSQTL 27918535 European 2017 Whole blood 3841
3 169014585 170014585 BIOSQTL 27918535 European 2017 Whole blood 3841
4 78425743 79425743 BIOSQTL 27918535 European 2017 Whole blood 3841
4 78425743 79425743 BLUEPRINT 27863251 European 2016 Monocytes 194
11 107605593 108605593 Gaunt T 27036880 European 2016 Whole blood 837
12 13930807 14930807 BIOSQTL 27918535 European 2017 Whole blood 3841
14 72904752 73904752 BIOSQTL 27918535 European 2017 Whole blood 3841
14 72904752 73904752 BIOSQTL 27918535 European 2017 Whole blood 3841
14 74014120 75014120 BIOSQTL 27918535 European 2017 Whole blood 3841
15 49887678 50887678 BIOSQTL 27918535 European 2017 Whole blood 3841
15 49887678 50887678 BIOSQTL 27918535 European 2017 Whole blood 3841
15 49887678 50887678 Gaunt T 27036880 European 2016 Whole blood 837
16 68906986 69906986 BIOSQTL 27918535 European 2017 Whole blood 3841
16 81699980 82699980 BIOSQTL 27918535 European 2017 Whole blood 3841
16 81699980 82699980 BIOSQTL 27918535 European 2017 Whole blood 3841
19 21715441 22715441 BIOSQTL 27918535 European 2017 Whole blood 3841
20 61769750 62769750 BIOSQTL 27918535 European 2017 Whole blood 3841
methQTL source and sample sizeTelomere GWAS Locus
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Supplementary Table 10: Gene prioritisation. Evidence to support likely-causal genes, including nonsynonymous variants, eQTLs, known roles 
in telomere regulation and having other supportive information from literature. Genes were prioritised based on the most lines of evidence or 
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Chr1p13.2 1 114078755 rs12065882 MAGI3 3 AP4B1 PTPN22, AP4B1-AS1 AP4B1
Chr1q24.2 1 167399643 rs35675808 CD247 0
Chr1q42.12 1 226562621 rs3219104 PARP1 43 PARP1* PARP1 C1orf95 PARP1 PARP1
Chr2p16.2 2 54482703 rs754017156 ACYP2 0 TSPYL6 TSPYL6
Chr2q34 2 210663697 rs56810761 UNC80 0 SNA1P1 SNA1P1
Chr3q12.3 3 101232093 rs55749605 SENP7 76 SENP7 SENP7 SENP7
Chr3q13.2 3 112847045 rs2613954 RP11-572M11.4 21
Chr3q26.2 3 169514585 rs10936600 LRRC34 47 LRRC34 MYNN TERC TERC, LRRC34
Chr4q13.3 4 71774347 rs13137667 MOB1B 49
Chr4q31.23 4 151000830 rs60160057 DCLK2 64
Chr4q32.2 4 164048199 rs4691895 NAF1 69 NAF1 NAF1 NAF1 NAF1
Chr5p15.33 5 1285974 rs7705526 TERT 0 TERT TERT
Chr5p15.33 5 1287194 rs2853677 TERT 0 TERT TERT
Chr5q14.1 5 78925743 rs62365174 PAPD4 137 PAPD4 PAPD4
Chr5q31.2 5 138964816 rs112347796 UBE2D2 0
Chr6p22.2 6 25480328 rs34991172 CARMIL1 10
Chr6p21.33 6 31587561 rs2736176 PRRC2A 11 BAG6 CSNK2B, PRRC2A CSNK2B, BAG6 CSNK2B, BAG6
Chr7q31.33 7 124554267 rs59294613 POT1 118 RP11-3B12.1 POT1 POT1
Chr8p23.2 8 2882469 rs57415150 CSMD1 51
Chr8q22.2 8 100917632 rs201375979 COX6C 3
Chr10p15.1 10 5702259 rs2386642 ASB13 5




















Chr11q21 11 93404608 rs117037102 CEP295 10 CEP295 CEP295
Chr11q22.3 11 108105593 rs228595 ATM 57 ATM ATM
Chr12p13.1 12 14430807 rs112655343 ATF7IP 2 ATF7IP ATF7IP
Chr12q13.13 12 54592103 rs7311314 SMUG1 6 SMUG1 SMUG1
Chr14q24.2 14 73404752 rs2302588 DCAF4 71 DCAF4, ZFYVE1 DCAF4 DCAF4
Chr14q24.3 14 74514120 rs59192843 CCDC176 155
Chr14q32.11 14 90869913 rs3213718 CALM1 7 CALM1 CALM1
Chr14q32.33 14 105494403 rs117536281 CDCA4 1
Chr15q14 15 38930961 rs9972513 RP11-275I4.2 1
Chr15q21.2 15 50387678 rs12909131 ATP8B4 16
Chr15q21.3 15 55105443 rs117610974 UNC13C 0
Chr15q22.31 15 65229816 rs55710439 ANKDD1A 47 ANKDD1A ANKDD1A
Chr16p13.3 16 1249877 rs11640926 CACNA1H 0
Chr16q22.1 16 69406986 rs3785074 TERF2 21 TERF2, PDF, COG8 TMED6, TERF2 TERF2
Chr16q23.1 16 74680074 rs62053580 RFWD3 1 RFWD3, RP11-252A24.5 RFWD3 RFWD3
Chr16q23.3 16 82199980 rs7194734 MPHOSPH6 67 MPHOSPH6 MPHOSPH6 MPHOSPH6
Chr17q25.3 17 76183233 rs144204502 TK1 1 TK1 TK1
Chr18p11.32 18 661917 rs2124616 TYMS 8 TYMS TYMS
Chr19p13.3 19 3939249 rs143276018 NMRK2 7
Chr19p12 19 22215441 rs8105767 ZNF257 9 ZNF257, ZNF676 ZNF257
Chr19q13.2 19 39768216 rs11665818 IFNL2 0
Chr20p12.3 20 5310273 rs6107615 PROKR2 1
Chr20p12.3 20 7402809 rs6038821 LINC01706 19
Chr20q11.23 20 35734863 rs1744757 MROH8 80 SAMHD1, RBL1 SAMHD1, RBL1
Chr20q13.33 20 62269750 rs75691080 STMN3 3 RTEL1, STMN3, TNFRSF6B RTEL1 RTEL1,STMN3
Chr20q13.33 20 62291599 rs34978822 RTEL1 6 RTEL1 RTEL1 RTEL1
Chr20q13.33 20 62380527 rs932827 ZBTB46 1 RTEL1 RTEL1
Chr20q13.33 20 62436398 rs73624724 ZBTB46 112 ZBTB46 RTEL1 ZBTB46
Chr21q22.3 21 45994841 rs7276273 KRTAP10-4 1 KRTAP10-4** KRTAP10-4














strong in COLOC only Known biologyLocus Chr bp lead Closest gene
 228 
Supplementary Table 11: Pathway analysis. Prioritized genes or the closest genes to locus sentinel variants where no prioritization was possible 
were used as input to PANTHER (section 2.2.8.1). A statistical over-representation analysis was performed. Pathways over-represented at 
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regulation of telomeric loop disassembly (GO:1904533) 3 2 0.01  > 100 5.29E-05 2.39E-02
regulation of single strand break repair (GO:1903516) 3 2 0.01  > 100 5.29E-05 2.32E-02
negative regulation of t-circle formation (GO:1904430) 4 2 0.01  > 100 7.92E-05 2.91E-02
establishment of protein localization to telomere (GO:0070200) 7 3 0.02  > 100 1.41E-06 1.85E-03
telomeric loop disassembly (GO:0090657) 11 3 0.03  > 100 4.24E-06 4.18E-03
protein localization to chromosome, telomeric region (GO:0070198) 15 4 0.04  > 100 9.80E-08 2.21E-04
establishment of protein localization to chromosome (GO:0070199) 15 3 0.04 85.7 9.44E-06 7.10E-03
negative regulation of cellular senescence (GO:2000773) 19 3 0.04 67.66 1.77E-05 1.22E-02
negative regulation of telomere maintenance (GO:0032205) 38 6 0.09 67.66 7.66E-10 6.05E-06
telomere capping (GO:0016233) 19 3 0.04 67.66 1.77E-05 1.16E-02
negative regulation of telomere maintenance via telomerase (GO:0032211) 21 3 0.05 61.21 2.32E-05 1.36E-02
negative regulation of telomere maintenance via telomere lengthening (GO:1904357) 28 4 0.07 61.21 8.89E-07 1.56E-03
positive regulation of nitric-oxide synthase activity (GO:0051000) 23 3 0.05 55.89 2.97E-05 1.67E-02
negative regulation of cell aging (GO:0090344) 25 3 0.06 51.42 3.73E-05 1.96E-02
regulation of telomere capping (GO:1904353) 26 3 0.06 49.44 4.15E-05 2.05E-02
regulation of telomere maintenance via telomere lengthening (GO:1904356) 63 7 0.15 47.61 2.55E-10 4.02E-06
positive regulation of telomere maintenance via telomere lengthening (GO:1904358) 37 4 0.09 46.32 2.46E-06 2.59E-03
positive regulation of monooxygenase activity (GO:0032770) 29 3 0.07 44.33 5.61E-05 2.39E-02
telomere maintenance via telomere lengthening (GO:0010833) 30 3 0.07 42.85 6.16E-05 2.49E-02
replication fork processing (GO:0031297) 31 3 0.07 41.47 6.75E-05 2.66E-02
2'-deoxyribonucleotide metabolic process (GO:0009394) 32 3 0.07 40.17 7.37E-05 2.77E-02
regulation of telomere maintenance via telomerase (GO:0032210) 55 5 0.13 38.95 2.75E-07 5.43E-04
FDRTotal gene 
counts










Extra rows are shown on the next page 
  
positive regulation of telomere maintenance via telomerase (GO:0032212) 34 3 0.08 37.81 8.72E-05 3.13E-02
deoxyribose phosphate metabolic process (GO:0019692) 34 3 0.08 37.81 8.72E-05 3.06E-02
regulation of telomere maintenance (GO:0032204) 82 7 0.19 36.58 1.41E-09 7.45E-06
RNA-dependent DNA biosynthetic process (GO:0006278) 37 3 0.09 34.74 1.10E-04 3.71E-02
deoxyribonucleotide metabolic process (GO:0009262) 37 3 0.09 34.74 1.10E-04 3.63E-02
positive regulation of telomere maintenance (GO:0032206) 50 4 0.12 34.28 7.53E-06 5.94E-03
negative regulation of DNA biosynthetic process (GO:2000279) 39 3 0.09 32.96 1.28E-04 4.12E-02
regulation of cellular senescence (GO:2000772) 40 3 0.09 32.14 1.37E-04 4.33E-02
DNA-dependent DNA replication maintenance of fidelity (GO:0045005) 41 3 0.1 31.35 1.47E-04 4.46E-02
telomere maintenance (GO:0000723) 99 7 0.23 30.3 4.86E-09 1.92E-05
telomere organization (GO:0032200) 102 7 0.24 29.41 5.91E-09 1.87E-05
protein localization to chromosome (GO:0034502) 64 4 0.15 26.78 1.89E-05 1.20E-02
DNA biosynthetic process (GO:0071897) 109 5 0.25 19.66 6.73E-06 5.91E-03
regulation of DNA biosynthetic process (GO:2000278) 109 5 0.25 19.66 6.73E-06 5.59E-03
negative regulation of chromosome organization (GO:2001251) 137 6 0.32 18.77 9.74E-07 1.54E-03
negative regulation of DNA metabolic process (GO:0051053) 154 6 0.36 16.69 1.88E-06 2.12E-03
positive regulation of DNA metabolic process (GO:0051054) 233 7 0.54 12.87 1.31E-06 1.88E-03
positive regulation of chromosome organization (GO:2001252) 172 5 0.4 12.46 5.62E-05 2.34E-02
regulation of response to DNA damage stimulus (GO:2001020) 214 5 0.5 10.01 1.53E-04 4.56E-02
DNA recombination (GO:0006310) 215 5 0.5 9.96 1.56E-04 4.57E-02
regulation of chromosome organization (GO:0033044) 345 8 0.81 9.94 1.43E-06 1.74E-03
anatomical structure homeostasis (GO:0060249) 337 7 0.79 8.9 1.40E-05 1.00E-02
regulation of DNA metabolic process (GO:0051052) 424 8 0.99 8.08 6.37E-06 5.92E-03













DNA metabolic process (GO:0006259) 801 13 1.87 6.95 2.85E-08 7.50E-05
chromosome organization (GO:0051276) 1036 11 2.42 4.55 2.24E-05 1.36E-02
organophosphate metabolic process (GO:0019637) 1068 10 2.49 4.01 1.58E-04 4.53E-02
regulation of organelle organization (GO:0033043) 1272 11 2.97 3.71 1.41E-04 4.36E-02
nucleic acid metabolic process (GO:0090304) 2309 16 5.39 2.97 4.41E-05 2.11E-02
nucleobase-containing compound metabolic process (GO:0006139) 2960 18 6.91 2.61 6.99E-05 2.69E-02
heterocycle metabolic process (GO:0046483) 3128 19 7.3 2.6 4.01E-05 2.04E-02
cellular aromatic compound metabolic process (GO:0006725) 3172 19 7.4 2.57 4.88E-05 2.27E-02
organic cyclic compound metabolic process (GO:1901360) 3391 20 7.91 2.53 3.46E-05 1.88E-02
organelle organization (GO:0006996) 3342 19 7.8 2.44 1.01E-04 3.46E-02










Supplementary Table 12: LD score regression (p-value<0.05). Genome-wide genetic 





Trait PMID Study n Year r se z p
Maternal smoking around birth 0 UKBB_Ben_Neale 289727 2017 -0.18 0.06 -3.17 1.50E-03
LDL cholesterol 20686565 GLGC 95454 2010 -0.24 0.08 -2.96 3.10E-03
Diagnoses - main ICD10: E04 Other non-
toxic goitre 0 UKBB_Ben_Neale 337199 2017 0.34 0.12 2.89 3.90E-03
Age of first birth 27798627 SSGAC 222037 2016 0.16 0.06 2.83 4.60E-03
Ulcerative colitis 26192919 IIBDGC 27432 2015 0.20 0.07 2.75 0.01
Overweight 23563607 GIANT 158855 2013 -0.14 0.05 -2.71 0.01
Anorexia Nervosa 24514567 GCAN 17767 2014 0.16 0.06 2.68 0.01
HDL cholesterol 20686565 GLGC 100184 2010 0.18 0.07 2.67 0.01
Waist-to-hip ratio 25673412 GIANT 212244 2015 -0.13 0.05 -2.62 0.01
PGC cross-disorder analysis 23453885 PGC 61220 2013 0.16 0.06 2.60 0.01
Infant head circumference 22504419 EGG 10768 2012 0.32 0.13 2.50 0.01
Coronary artery disease 26343387 Cardiogram 184035 2015 -0.14 0.06 -2.49 0.01
Illnesses of father: Heart disease 0 UKBB_Ben_Neale 298237 2017 -0.15 0.06 -2.49 0.01
Urate 23263486 GUGC 110347 2013 -0.11 0.04 -2.44 0.01
Platelet count 22139419 HaemGen 48666 2011 0.16 0.07 2.39 0.02
Smoking status: Previous 0 UKBB_Ben_Neale 336024 2017 -0.12 0.05 -2.34 0.02
Ever smoked 0 UKBB_Ben_Neale 336067 2017 -0.11 0.05 -2.33 0.02
Mothers age at death 0 UKBB_Ben_Neale 199690 2017 0.21 0.09 2.32 0.02
College completion 23722424 SSGAC 95427 2013 0.15 0.07 2.26 0.02
Body mass index 20935630 GIANT 123912 2010 -0.11 0.05 -2.22 0.03
Years of schooling 2016 27225129 SSGAC 293723 2016 0.09 0.04 2.22 0.03
Diagnoses - main ICD10: L03 Cellulitis 0 UKBB_Ben_Neale 337199 2017 -0.35 0.16 -2.18 0.03
Waist circumference 25673412 GIANT 232101 2015 -0.10 0.05 -2.18 0.03
Age at last live birth 0 UKBB_Ben_Neale 123676 2017 0.13 0.06 2.17 0.03
Total Cholesterol 20686565 GLGC 99900 2010 -0.14 0.07 -2.16 0.03
Celiac disease 20190752 NA 15283 2010 -0.22 0.10 -2.15 0.03
Schizophrenia 25056061 PGC 77096 2014 0.09 0.04 2.12 0.03
Cancer code_ self-reported: malignant 
melanoma 0 UKBB_Ben_Neale 337159 2017 0.31 0.15 2.09 0.04
Smoking status: Current 0 UKBB_Ben_Neale 336024 2017 -0.11 0.05 -2.03 0.04
Diagnoses - main ICD10: J22 Unspecified 
acute lower respiratory infection 0 UKBB_Ben_Neale 337199 2017 -0.38 0.19 -2.01 0.04
Illnesses of father: None of the above (group 
1 - Heart disease, high blood pressure, 
Chronic bronchitis/emphysema, Alzheimers 
disease/dementia, Diabetes) 0 UKBB_Ben_Neale 294791 2017 0.19 0.10 1.99 0.05
Weight 0 UKBB_Ben_Neale 336227 2017 -0.07 0.03 -1.99 0.05
Age at Menarche 25231870 ReproGen 182416 2014 0.10 0.05 1.99 0.05
Qualifications: CSEs or equivalent 0 UKBB_Ben_Neale 334070 2017 -0.16 0.08 -1.97 0.05
Whole body fat mass 0 UKBB_Ben_Neale 330762 2017 -0.07 0.03 -1.97 0.05
Hand grip strength (right) 0 UKBB_Ben_Neale 335842 2017 -0.09 0.04 -1.96 0.05
Alanine 27005778 MAGNETIC 24796 2016 0.22 0.11 1.95 0.05
Trunk fat mass 0 UKBB_Ben_Neale 331093 2017 -0.07 0.03 -1.94 0.05
Diagnoses - main ICD10: N20 Calculus of 
kidney and ureter 0 UKBB_Ben_Neale 337199 2017 0.21 0.11 1.93 0.05
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Disease group Phenotype Definition
Coronary artery diseases (CAD)
Self-reported history of heart attack/myocardial infarction, coronary 
angioplasty (PTCA) stent, coronary artery bypass grafts (CABG) or triple 
heart bypass; or hospitalization for ICD9 410-412, 414, ICD10 I21-I25, 
OPCS-4 K40-K46, K49, K50.1, K75, or cause of death ICD10 I21-I25
Atrial fibrillation (AF)
Self-reported history of atrial fibrillation or atrial flutter, or 
hospitalization or death due to ICD9 427.3, ICD10 I48
Heart failure (HF)
Self-reported history of heart failure/pulmonary odema, or 
hospitalization or death due to ICD9 428, ICD10 I50
Peripheral vascular disease (PVD)
Self-reported history of peripheral vascular disease (PVD) or leg 
claudication/ intermittent claudication, or hospitalization or death due 
to ICD9 443.9, 444, ICD10 I73.9,I74
Venous thromboembolism
Self-reported history of venous thromboembolic disease, pulmonary 
embolism or deep venous thrombosis (DVT), or hospitalization or death 
due to ICD9 415.1, 451-453, ICD10 I26,I80-I82
Aortic valve stenosis
Self-reported history of aortic stenosis, or hospitalization or death due to 
ICD9 424.1, ICD10 I35.0
Hypertensive diseases
Self-reported use of blood pressure medications, or systolic blood 
pressure >140 mmHg or diastolic blood pressure >90 mmHg, or 
hospitalization or death due to ICD9 401-405, ICD10 I10-I13,I15
Stroke
Self-reported history of  stroke, subarachnoid haemorrhage or ischaemic 
stroke, or hospitalization or death due to ICD9 430-432, ICD10 I60-I64
Varicose veins
Self-reported history of varicose veins or varicose ulcer, hospitalization or 
deat due to ICD-10: I83, I84, ICD-9-CM: 454, OPER code 1479 varicose 
vein surgery
Raynaud's phenomenon/disease
Self-reported history of raynaud's phenomenon/disease, ICD-10: I73.0 
ICD-9-CM: 443.0
Diabetes
Self-reported diabetes, type 1 or type 2 diabetes or hospitalization or 
death due to ICD9 250, ICD10 E10-E11,E13-E14
Diabetes type I
Self-reported type 1 diabetes or hospitalization or death due to ICD9 250 
(juvenile type - 250.01, 250.03, 250.11, 250.13, 250.21, 250.23, 
250.31, 250.33, 250.41, 250.43, 250.51, 250.53, 250.61, 250.63, 
250.71, 250.73, 250.81, 250.83, 250.91, 250.93), ICD10 E10
Diabetes type II
Self-reported generic or type 2 diabetes and age of onset 35+ years old, or 
hospitalization or death due to ICD9 250 (non juvenile type), ICD10 
E11,E13-E14
Hyperthyroid
Self-reported history of  hyperthyroidism/thyrotoxicosis or 
hospitalization or death due to ICD9 242.9, ICD10 E05
Hypothyroid
Self-reported history of hypothyroidism/myxoedema or hospitalization 







Anxiety Self-reported history of anxiety/panic attacks or hospitalization or death 
due to ICD9 300.0, ICD10 F41
Depression Self-reported history of depression or hospitalization or death due to 
ICD9 296.2-296.3, ICD10 F32-F33
Multiple sclerosis Self-reported history of multiple sclerosis or hospitalization or death due 
to ICD9 340, ICD10 G35
Epilepsy Self-reported history of epilepsy or hospitalization or death due to ICD9 
345, ICD10 G40-G41
Dementia
Self-reported history of dementia/alzheimers/cognitive impairment, or 
hospitalization or death due to ICD9 290,330-331, ICD10 F00-F03,G30-
G31 
Parkinsons' disease Self-reported history of  Parkinson's disease, or hospitalization or death 
due to ICD9 332, ICD10 G20-G21
Migraine Self-reported history of migraine, or hospitalization due to ICD9 346, 
ICD10 G43
Mania/bipolar disorder/manic depression Self-reported history of mania/bipolar disorder/manic depression, ICD10 
F30-F31, ICD9 296.0-296.1, 296.4-296.8 
Anorexia nervosa Self-reported history of anorexia, ICD-10: F500,F502,F508,R630, ICD-9-
CM: 3071,7830,30751
Schizophrenia Self-reported history of schizophrenia, ICD-10: F20, ICD-9-CM: 295
Chronic fatigue syndrome Self-reported history of chronic fatigue syndrome, ICD10 R5382, ICD9 
78071
Gastro-oesophageal reflux disease (GORD) Self-reported history of gastro-oesophageal reflux or gastric reflux, or 
hospitalization or death due to ICD9 530.11, 530.81, ICD10 K21
Irritable bowel syndrome (IBS) Self-reported history of irritable bowel syndrome, or hospitalization or 
death due to ICD9 564.1, ICD10 K58
Inflammatory bowel disease (IBD)
Self-reported history of inflammatory bowel disease, Crohn's disease, or 
ulcerative colitis, or hospitalization or death due to ICD9 555-556, ICD10 
K50-K51
Gallstone
Self-reported history of cholelithiasis/gall stones, or hospitalization or 
death due to ICD9 574, ICD10 K80, or OPER4 code 1455 
cholecystectomy/gall bladder removal, 1528 gallstones removed
Peptic ulcer
Self-reported history of peptic ulcer, duodenal ulcer or gastric/stomach 
ulcers, or hospitalization or death due to ICD9 531-533, ICD10 K25-K27, 
OPER code 1566 peptic ulcer surgery, 1567 gastric ulcer surgery
Liver cirrhosis
Self-reported history of liver failure/cirrhosis, primary biliary cirrhosis, 
alcoholic liver disease or alcoholic cirrhosis, or hospitalization or death 
due to ICD9 571, ICD10 K70, K74
Appendicitis Self-reported history of appendicitis, or hospitalization or death due to 
ICD9 540-543, ICD10 K35-K37
Oesophagitis/barretts oesophagus
Self-reported history of oesophagitis/barretts oesophagus, ICD10 K20 
and ICD9 530.10 (oesophagitis), ICD-10: K22.7 and ICD-9-CM: 530.85 
(barretts oesophagus)
Hiatus hernia Self-reported history of hiatus hernia,  ICD-10: K44.0,K44.1,K44.9, ICD-9-
CM: 552.3, 553.3, 551.3
Abdominal hernia Self-reported history of abdominal hernia,  ICD-10: K45-K46
Umbilical hernia Self-reported history of umbilical hernia,  ICD-10: K42, ICD-9-CM: 5511, 
5521, 5531
Inguinal hernia Self-reported history of inguinal hernia,  ICD-10: K40, ICD-9-CM: 
5500,5501,5509
Malabsorption/coeliac disease Self-reported history of coeliac disease,  ICD-10: K90.0 ICD-9-CM: 579.0
Diverticular disease/diverticulitis Self-reported history of diverticular disease/diverticulitis, ICD-10: K57 
ICD-9-CM: 562
Rectal or colon adenoma/polyps
Self-reported history of rectal or colon adenoma/polyps or benign 
neoplasms, ICD10 K63.5,K62.1,D12, ICD9 5690,211.3,211.4,2095, 
OPCS4 H481 - Excision of polyp of anus
Haemorrhoids / piles
Self-reported history of haemorroids, OPER code 1483 
haemorroidectomy / piles surgery/ banding of piles,  ICD-10: K64 ICD-9-
CM: 455
Pancreatitis Self-reported history of pancreatitis, ICD-10: K85, K86.0–K86.1, 
B25.2,B26.3,K87.1, ICD-9-CM: 577.0–577.1, 0723
Peritonitis














Self-reported history of renal/kidney failure requiring or not requiring 
dialysis, or hospitalization or death due to ICD9 585, ICD10 N18
Benign prostatic hyperplasia (BPH)
(Male only) Self-reported history of enlarged prostate or benign prostatic 
hypertrophy (BPH), or hospitalization or death due to ICD9 600, ICD10 
N40
Uterine fibroid
(Female only) Self-reported history of uterine fibroids, or hospitalization 
or death due to ICD9 218, ICD10 D25, 1509 myomectomy/fibroids 
removed
Kidney stone/ureter stone/bladder stone
Self-reported history of kidney stone/ureter stone/bladder stone, OPER 
code 1197 percutaneous/open kidney stone surgery/lithotripsy, ICD-10: 
N20.0 – N20.9,N21,N22,N13.2, ICD-9-CM: 592.0, 592.1,592.9,594 
Female infertility
Female-only. Self-reported history of female infertility, ICD-10 N97.0, ICD-
9-CM 628
Ovarian cyst
Female-only. Self-reported history of 1349 ovarian cyst or cysts, 1350 
polycystic ovaries/polycystic ovarian syndrome, OPER code 1506 ovarian 
cyst removal/surgery, OPCS Q474 (open drainage of cyst of ovary) and 
Q493 (endoscopic drainage of cyst of ovary), ICD-10: N83.0-
N83.2,E282,D27, ICD-9-CM: 620.0-620.2,2564,
Uterine polyps
Female-only. Self-reported history of uterine polyps, ICD10 
N84.0,N84.1,D26, ICD9 6210,2190,2191, OPER code 1539 uterine 
polypectomy/uterine polyps removed
Vaginal prolapse/uterine prolapse
Female-only. Self-reported history of vaginal prolapse/uterine prolapse, 
ICD10 N81, ICD9 618.0-618.4,618.6-618.9
Endometriosis
Female-only. Self-reported history of endometriosis, ICD-10: N80 ICD-9-
CM: 617
Breast cyst
Female only. Self-reported history of breast cysts, ICD10 N60.0-N60.4, 
ICD9 610.0-610.4, OPER code 1513 breast cyst/abscess removal
Benign breast lump
Female only. Self-reported history of breast lump, ICD10 
D24,N608,N609, ICD9 217,6108,6109
Gout
Self-reported history of gout, or hospitalization or death due to ICD9 
274, ICD10 M10
Rheumatoid arthritis
Self-reported history of rheumatoid arthritis, or hospitalization or death 
due to ICD9 714, ICD10 M05-M06
Osteoarthritis
Self-reported history of osteoarthritis, or hospitalization or death due to 
ICD9 715, ICD10 M15-M19
Osteoporosis
Self-reported history of osteoporosis, or hospitalization or death due to 
ICD9 733.0, ICD10 M80-M82
Sciatica
Self-reported history of sciatica, or hospitalization or death due to ICD9 
724.3, ICD10 M54.3-M54.4
Intervertebral disc disorder - prolased disc / 
degenerative disc
Self-reported history of prolapsed disc/slipped disc or disc degeneration, 
or hospitalization or death due to ICD9 722, ICD10 M50-M51
Spine arthritis/spondylitis
Self-reported history of spine arthritis/spondylitis (ICD-10 
M46.0,M46.1,M46.5-M46.9, ICD-9-CM 721.90,721.91) or ankylosing 
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Chronic obstructive pulmonary disease (COPD)
Self-reported history of COPD,emphysema/chronic bronchitis, or 
hospitalization or death due to ICD9 490-492,495-496, ICD10 J40-J44
Asthma
Self-reported history of asthma, or hospitalization or death due to ICD9 
493, ICD10 J45-J46
Lower respiratory infection / pneumonia
Self-reported history of pneumonia, or hospitalization or death due to 
ICD9 466,480-487, ICD10 J10-J18,J20-J22
Otitis media
Self-reported history of otitis media, or hospitalization or death due to 
ICD9 381-382, ICD10 H65-H66
Hayfever_eczema
Self-reported history of hayfever, allergic rhinitis, eczema or contact 
dermatitis
Bronchiectasis
Self-reported history of bronchiectasis, ICD-10: J47, Q33.4; ICD-9-CM: 
494, 748.61
Sleep apnoea
Self-reported history of sleep apnoea,  ICD-10: G47.3, ICD-9-CM: 327.2, 
780.57
Pleurisy
Self-reported history of pleurisy, hospitalisation or death due to ICD-10: 
R09.1, ICD-9-CM: 511.0,511.1
Pneumothorax
Self-reported history of spontaneous pneumothorax/recurrent 
pneumothorax, hospitalisation or death due to ICD-10: 
J93.0,J93.1,J9381 , ICD-9-CM: 512.0,512.81,512.82
Chronic sinusitis
Self-reported history of chronic sinusitis, ICD-10: J01, J32, ICD-9-CM: 
461, 473
Nasal polyps
Self-reported history of nasal polyps, hospitalisation due to ICD10 J33, or 
ICD9  471, OPER codes 1559 nasal polyp surgery / nasal polypectomy
Tonsillitis
Self-reported history of tonsillitis, hospitalisation due to ICD-10: J03, 
J35.0 ICD-9-CM: 463, 474.0, OPER code 1478 tonsillectomy +/- adenoids
Meniere's disease Self-reported history of meniere's disease, ICD-10: H81.0 ICD-9-CM: 386.0
Tinnitus Self-reported history of tinnitus, ICD-10: H93.1 ICD-9-CM: 388.3
Rheumatic fever
Self-reported rheumatic fever, ICD10 I00-I02, ICD9 390 (rheum fever) and 
391 (with heart involvement), rheumatic chorea ICD9 392
Meningitis Self-reported history of meningitis, ICD-10: G00–G03 ICD-9-CM: 320–321
Measles / morbillivirus
Self-reported history of measles / morbillivirus,  ICD-10: B05 ICD-9-CM: 
055
Rubella / german measles
Self-reported history of rubella / german measles, ICD-10: B06 ICD-9-CM: 
056
Chickenpox Self-reported history of chickenpox,  ICD-10: B01 ICD-9-CM: 052
Shingles Self-reported history of shingles,  ICD-10: B02 ICD-9-CM: 053
Infectious mononucleosis / glandular fever / 
epstein barr virus (ebv)
Self-reported history of infectious mononucleosis / glandular fever / 
epstein barr virus (ebv),  CD-10: B27 ICD-9-CM: 075
Mumps / epidemic parotitis
Self-reported history of mumps / epidemic parotitis,  ICD-10: B26 ICD-9-
CM: 072
Helicobacter pylori
Self-reported history of helicobacter pylori, ICD-10: B9681, ICD-9-CM: 
041.86
Tuberculosis (tb)
Self-reported history of tuberculosis (tb), ICD-10: A15–A19 ICD-9-CM: 
010–018
Whooping cough / pertussis
Self-reported history of whooping cough / pertussis, ICD-10: A37 ICD-9-
CM: 033
Scarlet fever / scarlatina
Self-reported history of scarlet fever / scarlatina, ICD-10: A38 ICD-9-CM: 
034.1
Malaria Self-reported history of malaria, ICD-10: B50-B54 ICD-9-CM: 084
Retinal detachment
Self-reported history of retinal detachment, ICD-10: H330,H332,H334, 
ICD-9-CM: 3610,3612,3618
Diabetic eye disease
Self-reported history of diabetic eye disease, ICD-10 H36 (E10.3 E11.3 
E12.3 E13.3 E14.3), ICD-9-CM 250.5, 3620,36641
Glaucoma
Self-reported history of glaucoma, ICD-10: H40-H42 ICD-9-CM: 365, OPER 
code 1436 glaucoma surgery/trabeculectomy
Cataract
Self-reported history of cataract, ICD-10: H25-H26, H28, Q12.0 ICD-9-
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Sarcoidosis Self-reported history of sarcoidosis, ICD-10: D86 ICD-9-CM: 135
Psoriasis Self-reported history of psoriasis, ICD-10: L40 ICD-9-CM: 696
Allergy/hypersensitivity/anaphylaxis
Self-reported history of allergy/hypersensitivity/anaphylaxis (combines 
all allergies and anahylaxis)
General: ICD-10: T78.2, T78.4, ICD-9-CM: 995.0, V1381 (anaphylaxis)
To food: ICD10 T780-T781, Z9101, Z9102, ICD9 9956, 997 (please see ICD 
codes description in following phenotype)
To drugs: ICD10 T886, Z88, ICD9 99527 (please see ICD codes description 
in following phenotype)
Additional: ICD10 Z91103-Z9109, K0855, ICD9 52566, 9953, V150
Allergy or anaphylactic reaction to food
Self-reported history of allergy or anaphylactic reaction to food, ICD10 
T780-T781, Z9101, Z9102, ICD9 9956, 997
Allergy or anaphylactic reaction to drug
Self-reported history of allergy or anaphylactic reaction to drug, ICD10 
T886, T887, Z88, ICD9 99527
Polymyalgia rheumatica
Self-reported history of polymyalgia rheumatica, ICD-10 M35.3, ICD-9-
CM 725
Systemic lupus erythematosis/sle
Self-reported history of systemic lupus erythematosis/sle, ICD-10: 
M32,H0112, L93, ICD-9-CM: 710.0,37334,6954
Sjogren's syndrome/sicca syndrome








Self-reported history of lung cancer, small cell or non-small cell lung 
cancer or trachea cancer, or cancer registration or death due to ICD9 
162, ICD10 C33-C34
Colorectal cancer
Self-reported history of large bowel/colorectal cancer, colon 
cancer/sigmoid cancer, rectal cancer or anal cancer, or cancer 
registration or death due to ICD9 153, 154.0-154.1, ICD10 C18-C20
Breast cancer
(Female only) Self-reported history of breast cancer, or cancer 
registration or death due to ICD9 174, ICD10 C50
Prostate cancer
(Male only) Self-reported history of prostate cancer, or cancer 
registration or death due to ICD9 185, ICD10 C61
Thyroid cancer
Self-reported history of thyroid cancer, or cancer registration or death 
due to ICD9 193, ICD10 C73
Oesophageal cancer
Self-reported history of oesophageal cancer, or cancer registration or 
death due to ICD9 150, ICD10 C15
Stomach cancer
Self-reported history of stomach cancer, or cancer registration or death 
due to ICD9 151, ICD10 C16
Pancreas cancer
Self-reported history of  pancreas cancer, or cancer registration or death 
due to ICD9 157, ICD10 C25
Melanoma
Self-reported history of malignant melanoma, or cancer registration or 
death due to ICD9 172, ICD10 C43, OPER code 1593 removal of 
malignant melanoma
Skin cancer (including melanoma)
Self-reported history of skin cancer, malignant melanoma, non-
melanoma skin cancer, basal cell carcinoma or squamous cell carcinoma, 
or cancer registration or death due to ICD9 172-173, ICD10 C43-C44, 
OPER codes 1595 removal of squamous cell carcinoma (scc), 1593 
removal of malignant melanoma, 1596 removal of rodent ulcer / basal 
cell carcinoma (bcc)
Cervical cancer
Self-reported history of cervical cancer, or cancer registration or death 
due to ICD9 180, ICD10 C53
Uterus cancer
Self-reported history of uterine/endometrial cancer, or cancer 
registration or death due to ICD9 179,182, ICD10 C54-C55
Ovary cancer
Self-reported history of ovarian cancer or fallopian tube cancer, or cancer 
registration or death due to ICD9 183, ICD10 C56-C57.4
Kidney cancer
Self-reported history of kidney/renal cell cancer, or cancer registration or 
death due to ICD9 189, ICD10 C64-C66,C68
Bladder cancer
Self-reported history of  bladder cancer, or cancer registration or death 
due to ICD9 188, ICD10 C67
Non-Hodgkin lymphoma
Self-reported history of non-Hodgkins lymphoma, or cancer registration 
or death due to ICD9 200,202, ICD10 C82-C86
Lymphomas and multiple myeloma
Self-reported history of lymphoma, Hodgkins or non-Hodgkins 
lymphoma,  multiple myeloma, or cancer registration or death due to 
ICD9 200-203, ICD10 C81-C88,C90,C96
Leukaemia
Self-reported history of leukaemia, acute myeloid leukaemia, chronic 
lymphocytic or chronic myeloid, or cancer registration or death due to 
ICD9 204-208, ICD10 C91-C95
Brain cancer / primary malignant brain tumour
Self-reported history of brain cancer / primary malignant brain tumour, 
or cancer registration or death due to ICD-10: C71, ICD-9-CM: 191
Head and neck cancer
Self-reported history of larynx/throat cancer, parotid gland cancer, other 
salivary gland cancer, lip cancer, tongue cancer, gum cancer, mouth 
cancer, tonsil cancer, oropharynx / oropharyngeal cancer, nasal cavity 
cancer, sinus cancer, or cancer registration or death due to ICD-10 C32, 
ICD-9-CM 161 (laryngeal cancer), C30 (nasal cavity), and 
C00–C14/D10–D11, 140–149/210 (head and neck cancers)
Testicular cancer
Self-reported history of testicular cancer, or cancer registration or death 
due to ICD-10 C62, ICD-9-CM 186
Cancer
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Supplementary Table 14: Estimated power to detect an odds ratio (OR) in the range of 0.9 to 




0.9 0.95 0.975 0.99 1.01 1.025 1.05 1.1
abdominal hernia 753            82% 29% 10% 5% 5% 10% 27% 74%
allergy hypersensitivity 32,232     100% 100% 99% 41% 41% 99% 100% 100%
allergy to drug 31,852     100% 100% 99% 41% 40% 99% 100% 100%
allergy to food 2,333        100% 70% 23% 7% 7% 22% 65% 100%
anorexia 1,264        96% 44% 14% 5% 5% 14% 41% 92%
anxiety 12,253     100% 100% 79% 19% 19% 77% 100% 100%
aortic valve stenosis 1,894        100% 61% 19% 6% 6% 19% 56% 99%
appendicitis 7,840        100% 99% 60% 14% 14% 58% 99% 100%
asthma 59,305     100% 100% 100% 63% 62% 100% 100% 100%
atrial fibrillation 16,439     100% 100% 89% 24% 24% 87% 100% 100%
benign breast lump 3,786        100% 88% 34% 9% 9% 33% 85% 100%
benign prostatic hyperplasia 16,562     100% 100% 89% 25% 24% 88% 100% 100%
bladder cancer 2,529        100% 73% 25% 7% 7% 24% 69% 100%
brain cancer 688            79% 27% 10% 4% 4% 9% 25% 70%
breast cancer 15,018     100% 100% 86% 23% 22% 85% 100% 100%
breast cyst 6,906        100% 99% 55% 13% 13% 53% 98% 100%
bronchiectasis 2,564        100% 74% 25% 7% 7% 24% 69% 100%
cad 31,486     100% 100% 99% 41% 40% 99% 100% 100%
cataract 27,998     100% 100% 98% 37% 36% 98% 100% 100%
cervical cancer 4,570        100% 93% 40% 10% 10% 38% 91% 100%
chickenpox 3,196        100% 82% 30% 8% 8% 28% 78% 100%
chronic fatigue syndrome 2,012        100% 63% 20% 7% 6% 20% 59% 99%
chronic kidney disease 5,536        100% 97% 47% 11% 11% 45% 95% 100%
coeliac disease 2,713        100% 76% 26% 8% 7% 25% 72% 100%
colorectal cancer 5,558        100% 97% 47% 11% 11% 45% 95% 100%
colorectal polyp 25,760     100% 100% 98% 35% 34% 97% 100% 100%
copd 15,032     100% 100% 86% 23% 22% 85% 100% 100%
dementia 1,681        99% 56% 18% 6% 6% 17% 51% 97%
depression 34,400     100% 100% 99% 43% 43% 99% 100% 100%
diabetes 30,804     100% 100% 99% 40% 39% 99% 100% 100%
diabetes1 3,469        100% 85% 32% 9% 8% 30% 82% 100%
diabetes2 20,576     100% 100% 94% 29% 29% 93% 100% 100%
diabetic eye disease 2,643        100% 75% 25% 7% 7% 24% 71% 100%
diverticulitis 31,164     100% 100% 99% 40% 40% 99% 100% 100%
endometriosis 7,312        100% 99% 57% 13% 13% 55% 99% 100%
epilepsy 5,560        100% 97% 47% 11% 11% 45% 95% 100%
female infertility 1,003        92% 37% 12% 5% 5% 12% 34% 85%
gallstone 26,233     100% 100% 98% 35% 35% 97% 100% 100%
gastro gord 40,496     100% 100% 100% 49% 48% 100% 100% 100%
glaucoma 8,143        100% 100% 62% 14% 14% 60% 99% 100%
gout 8,373        100% 100% 63% 15% 15% 61% 99% 100%
Phenotype N(Cases) Detectable OR
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0.9 0.95 0.975 0.99 1.01 1.025 1.05 1.1
haemorrhoids 9,132        100% 100% 67% 16% 15% 65% 100% 100%
hayfever eczema 113,143  100% 100% 100% 83% 83% 100% 100% 100%
head and neck cancer 2,636        100% 75% 25% 7% 7% 24% 70% 100%
heart failure 6,113        100% 98% 50% 12% 12% 48% 97% 100%
helicobacter pylori 1,334        97% 46% 15% 6% 6% 14% 43% 94%
hiatus hernia 33,483     100% 100% 99% 42% 42% 99% 100% 100%
hypertension 232,147  100% 100% 100% 92% 92% 100% 100% 100%
hyperthyroid 5,023        100% 95% 43% 11% 10% 41% 93% 100%
hypothyroid 26,729     100% 100% 98% 36% 35% 97% 100% 100%
inflamatory bowel disease 6,163        100% 98% 51% 12% 12% 49% 97% 100%
inguinal hernia 18,516     100% 100% 92% 27% 26% 91% 100% 100%
intervertebral disc disorder 16,648     100% 100% 89% 25% 24% 88% 100% 100%
irritable bowel syndrome 15,175     100% 100% 87% 23% 23% 85% 100% 100%
kidney cancer 1,412        98% 49% 16% 6% 6% 15% 45% 95%
kidney stone 9,168        100% 100% 67% 16% 15% 65% 100% 100%
leukemia 1,306        97% 46% 15% 6% 5% 14% 42% 93%
liver cirrhosis 2,614        100% 74% 25% 7% 7% 24% 70% 100%
lung cancer 2,485        100% 72% 24% 7% 7% 23% 68% 100%
lupus 812            85% 31% 11% 5% 5% 10% 28% 77%
lymphomas 3,300        100% 84% 30% 8% 8% 29% 80% 100%
malaria 779            84% 30% 10% 5% 5% 10% 27% 76%
mania 1,882        100% 60% 19% 6% 6% 19% 56% 98%
measles 2,659        100% 75% 26% 7% 7% 24% 71% 100%
melanoma 4,766        100% 94% 41% 10% 10% 40% 92% 100%
meniere disease 1,554        99% 52% 17% 6% 6% 16% 48% 96%
meningitis 2,050        100% 64% 21% 7% 7% 20% 60% 99%
migraine 16,022     100% 100% 88% 24% 23% 87% 100% 100%
mononucleosis 757            83% 29% 10% 5% 5% 10% 27% 75%
multiple sclerosis 1,951        100% 62% 20% 6% 6% 19% 58% 99%
mumps 1,567        99% 53% 17% 6% 6% 16% 49% 96%
nasal polyp 5,526        100% 97% 46% 11% 11% 45% 95% 100%
non.hodgkin lymphoma 2,200        100% 67% 22% 7% 7% 21% 63% 99%
oesophageal cancer 795            84% 30% 11% 5% 5% 10% 28% 77%
oesophagitis 3,623        100% 87% 33% 9% 9% 32% 83% 100%
osteoarthritis 71,185     100% 100% 100% 69% 68% 100% 100% 100%
osteoporosis 12,562     100% 100% 80% 20% 19% 78% 100% 100%
otitis media 1,963        100% 62% 20% 6% 6% 19% 58% 99%
ovarian cyst 13,177     100% 100% 82% 21% 20% 80% 100% 100%
ovary cancer 1,462        98% 50% 16% 6% 6% 15% 46% 95%
pancreatitis 2,816        100% 77% 27% 8% 8% 26% 73% 100%
parkinsons 1,489        98% 51% 16% 6% 6% 16% 47% 96%
peptic ulcer 12,671     100% 100% 80% 20% 20% 78% 100% 100%
periph vascular disease 4,287        100% 92% 38% 10% 9% 36% 89% 100%
peritonitis 2,446        100% 72% 24% 7% 7% 23% 67% 100%
pertussis 757            83% 29% 10% 5% 5% 10% 27% 75%





0.9 0.95 0.975 0.99 1.01 1.025 1.05 1.1
pleurisy 2,131        100% 66% 21% 7% 7% 21% 61% 99%
pneumonia 23,222     100% 100% 96% 32% 31% 96% 100% 100%
pneumothorax 1,209        96% 43% 14% 5% 5% 14% 40% 91%
polymyalgia rheumatica 1,826        99% 59% 19% 6% 6% 18% 55% 98%
prostate cancer 7,173        100% 99% 57% 13% 13% 55% 98% 100%
psoriasis 6,695        100% 99% 54% 13% 12% 52% 98% 100%
raynauds 4,096        100% 90% 36% 9% 9% 35% 87% 100%
retinal detachment 3,405        100% 85% 31% 8% 8% 30% 81% 100%
rheumatic fever 1,359        97% 47% 15% 6% 6% 15% 43% 94%
rheumatoid arthritis 7,714        100% 99% 60% 14% 14% 58% 99% 100%
rubella 807            85% 31% 11% 5% 5% 10% 28% 77%
sarcoidosis 1,226        96% 43% 14% 5% 5% 14% 40% 92%
scarlatina 684            79% 27% 10% 4% 4% 9% 25% 70%
schizophrenia 957            90% 35% 12% 5% 5% 12% 33% 84%
sciatica 7,018        100% 99% 56% 13% 13% 54% 98% 100%
shingles 1,042        92% 38% 13% 5% 5% 12% 35% 87%
sinusitis 6,201        100% 98% 51% 12% 12% 49% 97% 100%
sjogren 794            84% 30% 11% 5% 5% 10% 28% 77%
skin cancer 19,457     100% 100% 93% 28% 27% 92% 100% 100%
sleep apnoea 5,729        100% 97% 48% 11% 11% 46% 96% 100%
spondilitis 6,449        100% 98% 52% 12% 12% 50% 97% 100%
stomach cancer 710            80% 28% 10% 5% 5% 10% 25% 72%
stroke 11,650     100% 100% 77% 19% 18% 75% 100% 100%
testicular cancer 854            87% 32% 11% 5% 5% 11% 30% 79%
thyroid cancer 671            78% 26% 10% 4% 4% 9% 24% 69%
tinnitus 1,884        100% 60% 19% 6% 6% 19% 56% 98%
tonsilitis 71,654     100% 100% 100% 70% 69% 100% 100% 100%
tuberculosis 2,535        100% 73% 25% 7% 7% 24% 69% 100%
umbilical hernia 4,521        100% 93% 40% 10% 10% 38% 90% 100%
uterine fibroid 19,278     100% 100% 93% 28% 27% 92% 100% 100%
uterine polyps 13,014     100% 100% 81% 20% 20% 79% 100% 100%
uterine prolapse 13,789     100% 100% 83% 21% 21% 81% 100% 100%
uterus cancer 1,993        100% 63% 20% 7% 6% 19% 58% 99%
varicose 48,825     100% 100% 100% 56% 55% 100% 100% 100%
venous thromboembolism 16,244     100% 100% 89% 24% 24% 87% 100% 100%
vertigo 7,873        100% 99% 61% 14% 14% 58% 99% 100%
Phenotype N(Cases) Detectable OR
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Supplementary Table 15: Significant associations (p-value < 0.05) between genetically predicted LTL and diseases among 122 diseases manually 
curated in UK Biobank. Nominally significant associations were highlighted in yellow, among which those passed the Bonferroni corrected 
significance threshold were in red. 
  
Disease group Phenotype N cases IVW Eggers Median-
MR






Coronary artery diseases (CAD) 31,486 0.01 0.27 0.03 0.02 1.11 1.12 1.14 1.10 0.95
Hypertensive diseases 232,147 0.02 0.06 1.00E-06 0.01 0.92 0.84 0.85 0.91 0.27
Aortic valve stenosis 1,894 0.03 0.32 0.13 0.03 1.37 1.39 1.38 1.37 0.96
Venous thromboembolism 16,244 0.04 0.85 0.04 0.03 0.90 0.98 0.87 0.89 0.45
Heart failure (HF) 6,113 0.12 0.56 0.02 0.08 1.13 1.12 1.31 1.16 0.93
Hypothyroid 26,729 2.91E-05 0.03 1.20E-05 0.00 1.37 1.49 1.35 1.24 0.60
Hyperthyroid 5,023 0.01 0.14 0.00 0.03 1.44 1.68 1.55 1.34 0.62
Multiple sclerosis 1,951 0.03 0.08 0.04 0.04 0.67 0.46 0.64 0.70 0.36
Anxiety 12,253 0.04 0.95 0.82 0.07 0.88 0.99 0.98 0.88 0.39
Chronic fatigue syndrome 2,012 0.12 0.02 0.12 0.11 0.79 0.42 0.71 0.77 0.05
Diverticular disease/Diverticulitis 31,164 0.03 0.05 0.02 0.06 0.91 0.81 0.88 0.92 0.22
Rectal or colon adenoma/polyps 25,760 0.05 0.07 0.01 0.00 0.88 0.76 0.84 0.87 0.27
Haemorrhoids / piles 9,132 0.08 0.02 0.06 0.05 0.89 0.69 0.83 0.88 0.07
Malabsorption/Coeliac disease 2,713 0.25 0.08 0.00 0.09 1.86 9.63 1.74 1.55 0.16
Oesophagitis/barretts oesophagus 3,623 0.31 0.58 0.01 0.04 0.88 1.17 0.65 0.80 0.28
Musculoskeletal 
diseases
Rheumatoid arthritis 7,714 0.00 0.23 0.03 0.03 1.33 1.34 1.27 1.23 0.98
Bronchiectasis 2,564 0.01 0.13 0.07 0.03 1.35 1.55 1.38 1.31 0.59
Chronic obstructive pulmonary disease 
(COPD)
15,032 0.03 0.13 0.19 0.05 1.14 1.25 1.12 1.13 0.49
Hayfever_eczema 113,143 0.21 0.30 0.02 0.41 1.04 1.09 1.10 1.03 0.56
Tuberculosis (tb) 2,535 0.01 0.62 0.01 0.03 1.35 1.16 1.70 1.35 0.55
Meningitis 2,050 0.06 0.74 0.48 0.03 0.76 0.89 0.86 0.73 0.61
Eye Problems Retinal detachment 3,405 0.17 0.00 0.01 0.13 0.84 0.40 0.65 0.81 0.01
Immune / 
inflammatory














Disease group Phenotype N cases IVW Eggers Median-
MR






Lung cancer 2,485 1.03E-05 0.02 2.66E-04 1.99E-05 0.55 0.47 0.49 0.54 0.60
Skin cancer (including melanoma) 19,457 1.77E-05 0.00 4.20E-05 5.12E-11 0.69 0.51 0.70 0.72 0.09
Thyroid cancer 671 4.76E-05 0.04 0.00 3.09E-06 0.35 0.27 0.28 0.31 0.66
Lymphomas and multiple myeloma 3,300 1.52E-04 0.02 1.92E-05 4.76E-07 0.60 0.45 0.49 0.56 0.32
Leukaemia 1,306 1.74E-04 0.00 7.92E-05 2.77E-04 0.50 0.23 0.35 0.49 0.05
Kidney cancer 1,412 0.01 0.00 0.02 0.00 0.57 0.20 0.52 0.51 0.02
Melanoma 4,766 0.01 0.07 0.00 3.50E-04 0.70 0.54 0.63 0.71 0.39
Brain cancer / primary malignant brain 
tumour
688 0.01 0.19 0.18 0.30 0.43 0.34 0.58 0.70 0.76
Non-Hodgkin lymphoma 2,200 0.01 0.13 0.03 0.00 0.68 0.56 0.63 0.66 0.58
Bladder cancer 2,529 0.05 0.07 0.00 0.22 0.76 0.54 0.57 0.83 0.27
Pancreas cancer 676 0.50 0.02 0.37 0.35 1.21 4.58 1.39 1.32 0.02
Uterine fibroid 19,273 6.26E-07 1.81E-04 5.70E-05 9.37E-05 0.60 0.39 0.67 0.70 0.04
Uterine polyps 13,007 8.76E-05 0.02 3.72E-07 5.73E-11 0.73 0.62 0.63 0.68 0.37
Ovarian cyst 13,161 0.02 0.03 0.13 0.14 0.84 0.68 0.86 0.90 0.17
Breast cyst 6,747 0.02 0.17 0.06 0.01 0.82 0.75 0.80 0.82 0.64
Endometriosis 7,312 0.07 0.01 0.01 0.08 0.87 0.63 0.75 0.86 0.05
Female infertility 1,003 0.13 0.75 0.50 0.15 1.39 1.18 1.24 1.43 0.74
Cervical cancer 3,250 0.14 0.14 0.04 0.11 1.14 1.38 1.34 1.18 0.34
Benign breast lump 3,740 0.19 0.37 0.04 0.08 0.87 0.80 0.74 0.83 0.70
Benign prostatic hyperplasia (BPH) 16,557 2.09E-04 1.15E-03 2.43E-04 0.01 0.69 0.44 0.68 0.77 0.05
Prostate cancer 7,168 1.93E-03 0.24 2.96E-04 4.99E-04 0.65 0.68 0.60 0.63 0.90





Supplementary Table 16: Definition of 27 cancers based on self-reported disease histories and ICD-10 codes in UK Biobank. 
Disease_ID N_total N_case Disease_name Disease_definition
CAN-0001 352070 3222 Lung/bronchus/trachea cancer
Self-reported history of lung cancer, small cell lung cancer, non-small cell lung 
cancer, or trachea cancer, or cancer registration or death due to ICD10 C33-C34, 
C78.0, D02.2, D38.1
CAN-0002 352070 11542 Breast cancer
Self-reported history of breast cancer, or cancer registration or death due to ICD10 
C50, D48.6
CAN-0003 352070 15901 Skin cancer, including melanoma
Self-reported history of skin cancer, malignant melanoma, non-melanoma skin 
cancer, basal cell carcinoma, or squamous cell carcinoma, or cancer registration or 
death due to ICD10 C43-44, C79.2, D48.5
CAN-0004 352070 1966 Cancer of lip/mouth/pharynx/larynx/oral cavity
Self-reported history of cancer of lip/mouth/pharynx/oral cavity, salivary gland 
cancer, larynx/throat cancer, lip cancer, tongue cancer, gum cancer, parotid gland 
cancer, other salivary gland cancer, rodent ulcer, mouth cancer, tonsil cancer or 
oropharynx / oropharyngeal cancer, or cancer registration or death due to ICD10 
C00-C14, C32, D00.0, D02.0, D38.0, D37.0
CAN-0005 352070 653 Oesophageal cancer
Self-reported history of oesophageal cancer, or cancer registration or death due to 
ICD10 C15, D00.1
CAN-0006 352070 619 Stomach cancer
Self-reported history of stomach cancer, or cancer registration or death due to ICD10 
C16, D00.2, D37.1
CAN-0008 352070 14263 Intestinal tract cancer
Self-reported history of small intestine/small bowel cancer, large bowel 
cancer/colorectal cancer, anal cancer, colon cancer/sigmoid cancer, rectal cancer or 
appendix cancer, or cancer registration or death due to ICD10 C17-C21, C26.0, 
C78.4-C78.5, D37.2-D37.5, D01.0-D01.4, D12
CAN-0009 352070 51514 All cancer
Self-reported history of all types of cancers, or cancer registration or death due to 
ICD10 C*
CAN-0010 352070 2254 Liver cancer
Self-reported history of liver/hepatocellular cancer, or cancer registration or death 
due to ICD10 C78.7, D01.5, D37.6
CAN-0012 352070 570 Pancreas cancer
Self-reported history of pancreas cancer, or malignant insulinoma, or cancer 
registration or death due to ICD10 C25, D13.6
CAN-0013 352070 1098 Mesothelial, connective and soft tissue cancer
Self-reported history of peripheral nerve/autonomic nerve cancer, mesothelioma, 
sarcoma/fibrosarcoma, or kaposis sarcoma, or cancer registration or death due to 
ICD10 C21, C45-C49, D48.1-D48.4, D78.6
CAN-0015 352070 1591 Brain/central nervous cancer
Self-reported history of meningeal cancer / malignant meningioma, brain cancer / 
primary malignant brain tumour, or spinal cord or cranial nerve cancer, or cancer 
registration or death due to ICD10 C70-C72, C79.3, D33, D43
CAN-0016 352070 3362 Urinary cancer
Self-reported history of kidney/renal cell cancer, bladder cancer, or other cancer of 
urinary tract, or cancer registration or death due to ICD10 C64-C68, C79.0, D41.0-
D41.4, D41.9, D09.0-D09.1, D30.3
CAN-0017 189755 1233 Ovary cancer
Self-reported history of ovarian cancer, or cancer registration or death due to ICD10 
C56, D39.1
CAN-0018 352070 1603 Uterine/endometrical cancer
Self-reported history of uterine/endometrial cancer, or cancer registration or death 
due to ICD10 C54-C55, D39.0, D07.0
CAN-0019 189755 3251 Cervical cancer
Self-reported history of cervical cancer, or cin/pre-cancer cells cervix, or cancer 
registration or death due to ICD10 C53, D06
CAN-0023 189755 6088 Female genital cancer
Self-reported history of  ovarian cancer, uterine/endometrial cancer, cervical cancer, 
or cin/pre-cancer cells cervix, vaginal cancer, vulval cancer, or female genital tract 
cancer, or cancer registration or death due to ICD10 C51-C57, D39.0-D39.2, D39.7, 
D06, D07.0-D07.3
CAN-0024 162291 5737 Prostate cancer
Self-reported history of prostate cancer, or cancer registration or death due to ICD10 
C61, D07.5, D40.0
CAN-0025 162291 708 Testicular cancer
Self-reported history of testicular cancer, or cancer registration or death due to 
ICD10 C62, D40.1
CAN-0027 162291 6518 Male genital cancer
Self-reported history of prostate cancer,  testicular cancer, penis cancer, or male 
genital tract cancer, or cancer registration or death due to ICD10 C60-C63, D07.4-
D07.6, D40.0-D40.1, D40.7
CAN-0028 352070 2093 Lymphoma
Self-reported history of lymphoma, hodgkins lymphoma / hodgkins disease, or non-
hodgkins lymphoma, or cancer registration or death due to ICD10 C81-C85, C88
CAN-0029 352070 1472 Leukaemia
Self-reported history of leukaemia, multiple myeloma, myelofibrosis or 
myelodysplasia, chronic lymphocytic, chronic myeloid, or acute myeloid leukaemia, 
or cancer registration or death due to ICD10 C90-C95
CAN-0030 352070 5405 Haematological malignancy
Self-reported history of lymphoma, hodgkins lymphoma / hodgkins disease, non-
hodgkins lymphoma, leukaemia, multiple myeloma, myelofibrosis or 
myelodysplasia, chronic lymphocytic, chronic myeloid, acute myeloid leukaemia, or 
other haematological malignancy, or cancer registration or death due to ICD10 C81-
C85, C88, C90-C96, C42.0-C42.1, C42.4, D18, D45-D47
CAN-0032 352070 680 Thyroid cancer
Self-reported history of thyroid cancer, or cancer registration or death due to ICD10 
C73, D34, D44.0
CAN-0034 352070 1611 Endocrine gland cancer
Self-reported history of thyroid cancer,  adrenal cancer, or parathyroid cancer, or 
cancer registration or death due to ICD10 C73-C75, D09.3, D34, D35, D44, D79.7
CAN-0036 352070 5655 Metastatic(secondary) cancer
Self-reported history of metastatic cancer (unknown primary), or cancer registration 
or death due to ICD10 C76, C78-C80
CAN-0038 352070 634 Heart/mediastinum/pleura cancer
Self-reported history of heart/mediastinum cancer, or cancer registration or death 




Disease_ID N_total N_case Disease_name Disease_definition
CAN-0001 352070 3222 Lung/bronchus/trachea cancer
Self-reported history of lung cancer, small cell lung cancer, non-small cell lung 
cancer, or trachea cancer, or cancer registration or death due to ICD10 C33-C34, 
C78.0, D02.2, D38.1
CAN-0002 352070 11542 Breast cancer
Self-reported history of breast cancer, or cancer registration or death due to ICD10 
C50, D48.6
CAN-0003 352070 15901 Skin cancer, including melanoma
Self-reported history of skin cancer, malignant melanoma, non-melanoma skin 
cancer, basal cell carcinoma, or squamous cell carcinoma, or cancer registration or 
death due to ICD10 C43-44, C79.2, D48.5
CAN-0004 352070 1966 Cancer of lip/mouth/pharynx/larynx/oral cavity
Self-reported history of cancer of lip/mouth/pharynx/oral cavity, salivary gland 
cancer, larynx/throat cancer, lip cancer, tongue cancer, gum cancer, parotid gland 
cancer, other salivary gland cancer, rodent ulcer, mouth cancer, tonsil cancer or 
oropharynx / oropharyngeal cancer, or cancer registration or death due to ICD10 
C00-C14, C32, D00.0, D02.0, D38.0, D37.0
CAN-0005 352070 653 Oesophageal cancer
Self-reported history of oesophageal cancer, or cancer registration or death due to 
ICD10 C15, D00.1
CAN-0006 352070 619 Stomach cancer
Self-reported history of stomach cancer, or cancer registration or death due to ICD10 
C16, D00.2, D37.1
CAN-0008 352070 14263 Intestinal tract cancer
Self-reported history of small intestine/small bowel cancer, large bowel 
cancer/colorectal cancer, anal cancer, colon cancer/sigmoid cancer, rectal cancer or 
appendix cancer, or cancer registration or death due to ICD10 C17-C21, C26.0, 
C78.4-C78.5, D37.2-D37.5, D01.0-D01.4, D12
CAN-0009 352070 51514 All cancer
Self-reported history of all types of cancers, or cancer registration or death due to 
ICD10 C*
CAN-0010 352070 2254 Liver cancer
Self-reported history of liver/hepatocellular cancer, or cancer registration or death 
due to ICD10 C78.7, D01.5, D37.6
CAN-0012 352070 570 Pancreas cancer
Self-reported history of pancreas cancer, or malignant insulinoma, or cancer 
registration or death due to ICD10 C25, D13.6
CAN-0013 352070 1098 Mesothelial, connective and soft tissue cancer
Self-reported history of peripheral nerve/autonomic nerve cancer, mesothelioma, 
sarcoma/fibrosarcoma, or kaposis sarcoma, or cancer registration or death due to 
ICD10 C21, C45-C49, D48.1-D48.4, D78.6
CAN-0015 352070 1591 Brain/central nervous cancer
Self-reported history of meningeal cancer / malignant meningioma, brain cancer / 
primary malignant brain tumour, or spinal cord or cranial nerve cancer, or cancer 
registration or death due to ICD10 C70-C72, C79.3, D33, D43
CAN-0016 352070 3362 Urinary cancer
Self-reported history of kidney/renal cell cancer, bladder cancer, or other cancer of 
urinary tract, or cancer registration or death due to ICD10 C64-C68, C79.0, D41.0-
D41.4, D41.9, D09.0-D09.1, D30.3
CAN-0017 189755 1233 Ovary cancer
Self-reported history of ovarian cancer, or cancer registration or death due to ICD10 
C56, D39.1
CAN-0018 352070 1603 Uterine/endometrical cancer
Self-reported history of uterine/endometrial cancer, or cancer registration or death 
due to ICD10 C54-C55, D39.0, D07.0
CAN-0019 189755 3251 Cervical cancer
Self-reported history of cervical cancer, or cin/pre-cancer cells cervix, or cancer 
registration or death due to ICD10 C53, D06
CAN-0023 189755 6088 Female genital cancer
Self-reported history of  ovarian cancer, uterine/endometrial cancer, cervical cancer, 
or cin/pre-cancer cells cervix, vaginal cancer, vulval cancer, or female genital tract 
cancer, or cancer registration or death due to ICD10 C51-C57, D39.0-D39.2, D39.7, 
D06, D07.0-D07.3
CAN-0024 162291 5737 Prostate cancer
Self-reported history of prostate cancer, or cancer registration or death due to ICD10 
C61, D07.5, D40.0
CAN-0025 162291 708 Testicular cancer
Self-reported history of testicular cancer, or cancer registration or death due to 
ICD10 C62, D40.1
CAN-0027 162291 6518 Male genital cancer
Self-reported history of prostate cancer,  testicular cancer, penis cancer, or male 
genital tract cancer, or cancer registration or death due to ICD10 C60-C63, D07.4-
D07.6, D40.0-D40.1, D40.7
CAN-0028 352070 2093 Lymphoma
Self-reported history of lymphoma, hodgkins lymphoma / hodgkins disease, or non-
hodgkins lymphoma, or cancer registration or death due to ICD10 C81-C85, C88
CAN-0029 352070 1472 Leukaemia
Self-reported history of leukaemia, multiple myeloma, myelofibrosis or 
myelodysplasia, chronic lymphocytic, chronic myeloid, or acute myeloid leukaemia, 
or cancer registration or death due to ICD10 C90-C95
CAN-0030 352070 5405 Haematological malignancy
Self-reported history of lymphoma, hodgkins lymphoma / hodgkins disease, non-
hodgkins lymphoma, leukaemia, multiple myeloma, myelofibrosis or 
myelodysplasia, chronic lymphocytic, chronic myeloid, acute myeloid leukaemia, or 
other haematological malignancy, or cancer registration or death due to ICD10 C81-
C85, C88, C90-C96, C42.0-C42.1, C42.4, D18, D45-D47
CAN-0032 352070 680 Thyroid cancer
Self-reported history of thyroid cancer, or cancer registration or death due to ICD10 
C73, D34, D44.0
CAN-0034 352070 1611 Endocrine gland cancer
Self-reported history of thyroid cancer,  adrenal cancer, or parathyroid cancer, or 
cancer registration or death due to ICD10 C73-C75, D09.3, D34, D35, D44, D79.7
CAN-0036 352070 5655 Metastatic(secondary) cancer
Self-reported history of metastatic cancer (unknown primary), or cancer registration 
or death due to ICD10 C76, C78-C80
CAN-0038 352070 634 Heart/mediastinum/pleura cancer
Self-reported history of heart/mediastinum cancer, or cancer registration or death 





Disease_ID N_total N_case Disease_name Disease_definition
CAN-0001 352070 3222 Lung/bronchus/trachea cancer
Self-reported history of lung cancer, small cell lung cancer, non-small cell lung 
cancer, or trachea cancer, or cancer registration or death due to ICD10 C33-C34, 
C78.0, D02.2, D38.1
CAN-0002 352070 11542 Breast cancer
Self-reported history of breast cancer, or cancer registration or death due to ICD10 
C50, D48.6
CAN-0003 352070 15901 Skin cancer, including melanoma
Self-reported history of skin cancer, malignant melanoma, non-melanoma skin 
cancer, basal cell carcinoma, or squamous cell carcinoma, or cancer registration or 
death due to ICD10 C43-44, C79.2, D48.5
CAN-0004 352070 1966 Cancer of lip/mouth/pharynx/larynx/oral cavity
Self-reported history of cancer of lip/mouth/pharynx/oral cavity, salivary gland 
cancer, larynx/throat cancer, lip cancer, tongue cancer, gum cancer, parotid gland 
cancer, other salivary gland cancer, rodent ulcer, mouth cancer, tonsil cancer or 
oropharynx / oropharyngeal cancer, or cancer registration or death due to ICD10 
C00-C14, C32, D00.0, D02.0, D38.0, D37.0
CAN-0005 352070 653 Oesophageal cancer
Self-reported history of oesophageal cancer, or cancer registration or death due to 
ICD10 C15, D00.1
CAN-0006 352070 619 Stomach cancer
Self-reported history of stomach cancer, or cancer registration or death due to ICD10 
C16, D00.2, D37.1
CAN-0008 352070 14263 Intestinal tract cancer
Self-reported history of small intestine/small bowel cancer, large bowel 
cancer/colorectal cancer, anal cancer, colon cancer/sigmoid cancer, rectal cancer or 
appendix cancer, or cancer registration or death due to ICD10 C17-C21, C26.0, 
C78.4-C78.5, D37.2-D37.5, D01.0-D01.4, D12
CAN-0009 352070 51514 All cancer
Self-reported history of all types of cancers, or cancer registration or death due to 
ICD10 C*
CAN-0010 352070 2254 Liver cancer
Self-reported history of liver/hepatocellular cancer, or cancer registration or death 
due to ICD10 C78.7, D01.5, D37.6
CAN-0012 352070 570 Pancreas cancer
Self-reported history of pancreas cancer, or malignant insulinoma, or cancer 
registration or death due to ICD10 C25, D13.6
CAN-0013 352070 1098 Mesothelial, connective and soft tissue cancer
Self-reported history of peripheral nerve/autonomic nerve cancer, mesothelioma, 
sarcoma/fibrosarcoma, or kaposis sarcoma, or cancer registration or death due to 
ICD10 C21, C45-C49, D48.1-D48.4, D78.6
CAN-0015 352070 1591 Brain/central nervous cancer
Self-reported history of meningeal cancer / malignant meningioma, brain cancer / 
primary malignant brain tumour, or spinal cord or cranial nerve cancer, or cancer 
registration or death due to ICD10 C70-C72, C79.3, D33, D43
CAN-0016 352070 3362 Urinary cancer
Self-reported history of kidney/renal cell cancer, bladder cancer, or other cancer of 
urinary tract, or cancer registration or death due to ICD10 C64-C68, C79.0, D41.0-
D41.4, D41.9, D09.0-D09.1, D30.3
CAN-0017 189755 1233 Ovary cancer
Self-reported history of ovarian cancer, or cancer registration or death due to ICD10 
C56, D39.1
CAN-0018 352070 1603 Uterine/endometrical cancer
Self-reported history of uterine/endometrial cancer, or cancer registration or death 
due to ICD10 C54-C55, D39.0, D07.0
CAN-0019 189755 3251 Cervical cancer
Self-reported history of cervical cancer, or cin/pre-cancer cells cervix, or cancer 
registration or death due to ICD10 C53, D06
CAN-0023 189755 6088 Female genital cancer
Self-reported history of  ovarian cancer, uterine/endometrial cancer, cervical cancer, 
or cin/pre-cancer cells cervix, vaginal cancer, vulval cancer, or female genital tract 
cancer, or cancer registration or death due to ICD10 C51-C57, D39.0-D39.2, D39.7, 
D06, D07.0-D07.3
CAN-0024 162291 5737 Prostate cancer
Self-reported history of prostate cancer, or cancer registration or death due to ICD10 
C61, D07.5, D40.0
CAN-0025 162291 708 Testicular cancer
Self-reported history of testicular cancer, or cancer registration or death due to 
ICD10 C62, D40.1
CAN-0027 162291 6518 Male genital cancer
Self-reported history of prostate cancer,  testicular cancer, penis cancer, or male 
genital tract cancer, or cancer registration or death due to ICD10 C60-C63, D07.4-
D07.6, D40.0-D40.1, D40.7
CAN-0028 352070 2093 Lymphoma
Self-reported history of lymphoma, hodgkins lymphoma / hodgkins disease, or non-
hodgkins lymphoma, or cancer registration or death due to ICD10 C81-C85, C88
CAN-0029 352070 1472 Leukaemia
Self-reported history of leukaemia, multiple myeloma, myelofibrosis or 
myelodysplasia, chronic lymphocytic, chronic myeloid, or acute myeloid leukaemia, 
or cancer registration or death due to ICD10 C90-C95
CAN-0030 352070 5405 Haematological malignancy
Self-reported history of lymphoma, hodgkins lymphoma / hodgkins disease, non-
hodgkins lymphoma, leukaemia, multiple myeloma, myelofibrosis or 
myelodysplasia, chronic lymphocytic, chronic myeloid, acute myeloid leukaemia, or 
other haematological malignancy, or cancer registration or death due to ICD10 C81-
C85, C88, C90-C96, C42.0-C42.1, C42.4, D18, D45-D47
CAN-0032 352070 680 Thyroid cancer
Self-reported history of thyroid cancer, or cancer registration or death due to ICD10 
C73, D34, D44.0
CAN-0034 352070 1611 Endocrine gland cancer
Self-reported history of thyroid cancer,  adrenal cancer, or parathyroid cancer, or 
cancer registration or death due to ICD10 C73-C75, D09.3, D34, D35, D44, D79.7
CAN-0036 352070 5655 Metastatic(secondary) cancer
Self-reported history of metastatic cancer (unknown primary), or cancer registration 
or death due to ICD10 C76, C78-C80
CAN-0038 352070 634 Heart/mediastinum/pleura cancer
Self-reported history of heart/mediastinum cancer, or cancer registration or death 
due to ICD10 C38, C45.0, C78.2
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Extra columns are shown on the next page 
  
Disease_super_category Disease_ID Disease_Name N_case Beta SE p-value Cochran
's Q
p-value Beta SE p-value intercept 
p- value
ICD10-D25 Leiomyoma of uterus 5333 1.01 0.12 4.07E-18 33.38 0.01 1.73 0.34 3.11E-07 0.21
ICD10-D17 Benign lipomatous neoplasm 3818 0.83 0.14 1.23E-09 23.89 0.12 1.81 0.40 6.27E-06 0.07
ICD10-D22 Melanocytic naevi 2850 0.65 0.16 4.09E-05 18.75 0.34 1.75 0.47 2.02E-04 0.02
CAN-0009 all cancer 51514 0.48 0.04 7.92E-33 13.76 0.68 0.82 0.12 3.63E-12 0.12
CAN-0030 haematological malignancy 5405 0.88 0.12 2.35E-14 41.65 0.00 2.11 0.34 3.98E-10 0.04
CAN-0029 leukaemia 1472 1.26 0.22 1.05E-08 20.31 0.26 2.47 0.65 1.34E-04 0.03
CAN-1061 basal cell carcinoma 3399 0.68 0.14 2.56E-06 22.17 0.18 1.58 0.43 2.06E-04 0.08
CAN-0024 prostate cancer 5737 0.79 0.11 5.77E-12 37.12 0.00 0.62 0.34 6.82E-02 0.81
CAN-0027 male genital cancer 6518 0.61 0.11 1.08E-08 34.30 0.01 0.49 0.32 1.17E-01 0.85
CAN-0034 endocrine gland cancer 1611 0.98 0.21 2.80E-06 5.11 1.00 1.36 0.62 2.82E-02 0.26
CAN-0032 thyroid cancer 680 1.39 0.33 1.86E-05 17.88 0.40 2.55 0.98 9.50E-03 0.15
CAN-0016 urinary cancer 3362 0.72 0.15 8.24E-07 32.43 0.01 1.81 0.42 1.81E-05 0.07
CAN-0003 skin cancer, including 
melanoma
15901 0.60 0.07 9.75E-19 23.41 0.14 0.96 0.20 1.34E-06 0.34
CAN-1059 malignant melanoma 2869 0.96 0.16 8.34E-10 24.95 0.10 1.28 0.46 5.44E-03 0.62
ICD10-C44 Other malignant neoplasms 
of skin
4934 0.54 0.12 7.85E-06 30.47 0.02 0.55 0.35 1.10E-01 0.97
Neoplasms




Extra rows are shown on the next page 
  
Disease_super_category Disease_ID Disease_Name Beta SE P value Beta SE p-value
ICD10-D25 Leiomyoma of uterus 1.29 0.19 9.69E-12 1.30 0.18 1.68E-12
ICD10-D17 Benign lipomatous neoplasm 0.93 0.23 3.83E-05 0.78 0.22 4.24E-04
ICD10-D22 Melanocytic naevi 0.83 0.24 5.48E-04 0.84 0.24 4.88E-04
CAN-0009 all cancer 0.45 0.06 5.65E-12 0.43 0.06 2.46E-11
CAN-0030 haematological malignancy 0.95 0.21 4.96E-06 0.74 0.20 2.67E-04
CAN-0029 leukaemia 1.41 0.30 2.27E-06 1.41 0.31 5.22E-06
CAN-1061 basal cell carcinoma 0.72 0.22 1.10E-03 0.71 0.22 1.20E-03
CAN-0024 prostate cancer 0.71 0.21 5.57E-04 0.72 0.20 3.47E-04
CAN-0027 male genital cancer 0.58 0.18 1.39E-03 0.66 0.18 3.03E-04
CAN-0034 endocrine gland cancer 1.14 0.28 5.32E-05 1.14 0.30 1.35E-04
CAN-0032 thyroid cancer 1.58 0.50 1.54E-03 1.58 0.48 8.74E-04
CAN-0016 urinary cancer 1.04 0.23 8.71E-06 1.02 0.22 4.05E-06
CAN-0003 skin cancer, including 
melanoma
0.45 0.11 5.17E-05 0.42 0.12 2.27E-04
CAN-1059 malignant melanoma 0.70 0.23 2.05E-03 0.67 0.23 3.06E-03
ICD10-C44 Other malignant neoplasms 
of skin
0.34 0.18 6.83E-02 0.30 0.19 1.24E-01
Neoplasms





Disease_super_category Disease_ID Disease_Name N_case Beta SE p-value Cochran
's Q
p-value Beta SE p-value intercept 
p- value
ICD10-Z46
Fitting and adjustment of 
other devices
2314 0.70 0.17 6.34E-05 18.39 0.36 0.49 0.51 3.28E-01 0.71
ICD10-Z85
Personal history of 
malignant neoplasm
8296 0.42 0.09 5.88E-06 14.52 0.63 0.97 0.27 3.84E-04 0.09
ICD10-N40 Hyperplasia of prostate 4727 0.81 0.12 5.90E-11 38.18 0.00 1.01 0.36 4.68E-03 0.78
ICD10-N42 Other disorders of prostate 557 1.45 0.36 4.98E-05 29.24 0.03 2.08 1.04 4.61E-02 0.54
ICD10-N84 Polyp of female genital tract 5905 0.56 0.11 4.89E-07 6.58 0.99 0.86 0.32 7.96E-03 0.22
Diseases of the digestive 
system
ICD10-K90 Intestinal malabsorption 987 -1.19 0.26 5.53E-06 23.33 0.14 -1.68 0.73 2.21E-02 0.49





29330 0.20 0.05 7.97E-05 7.34 0.98 0.53 0.15 3.67E-04 0.04
Disease description IVW-MR Cochran's Q test MR Egger
Diseases of the genitourinary 
system
Factors influencing health 
status and contact with 
health services
Beta SE P value Beta SE p-value
0.77 0.26 2.46E-03 0.78 0.26 2.40E-03
0.45 0.14 1.04E-03 0.45 0.14 1.08E-03
0.86 0.21 5.11E-05 0.87 0.21 5.31E-05
1.50 0.50 2.79E-03 1.49 0.49 2.56E-03
0.56 0.15 1.59E-04 0.57 0.15 2.00E-04
-1.12 0.35 1.46E-03 -1.14 0.35 1.11E-03
0.16 0.08 3.48E-02 0.17 0.08 3.19E-02
Median-MR Penalised median-MR
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Supplementary Table 18: Distribution of the mLRRY values in each EPIC-InterAct country, separately, and overall. Distributions before (upper) 
and after (bottom) data transformation are shown. 
 
 
Country N Mean (SD) Skewness Kurtosis Minimum Maximum
UK Biobank
Overall 221,597 0 (0.05) -1.22 7.31 -0.31 0.29
InterAct
 Overall 6,099 0.01 (0.08) -23.11 935.34 -3.77 0.33
country
Italy 492 0.02 (0.04) -2.17 25.62 -0.35 0.20
Spain 882 0.03 (0.04) -2.58 40.99 -0.49 0.28
UK 453 0.01 (0.10) -9.46 130.47 -1.57 0.24
Netherlands 227 0.02 (0.05) -5.06 51.32 -0.52 0.16
Germany 887 0.02 (0.05) -4.10 46.46 -0.61 0.25
Sweden 1,093 0 (0.14) -19.80 491.89 -3.77 0.33
Denmark 2,065 0.01 (0.05) -10.40 172.36 -1.15 0.15
UK Biobank
Overall 221,597 0 (1.00) 0.00 3.00 -4.41 4.41
InterAct
Overall 6,073 0 (1.00) 0.00 2.95 -3.42 3.42
Italy 491 0.13 (0.94) 0.07 2.71 -2.65 2.81
Spain 881 0.40 (0.94) -0.15 3.34 -3.40 3.09
UK 450 0.08 (1.12) -0.34 2.99 -3.21 3.23
Netherlands 226 0.35 (1.02) -0.24 3.02 -2.85 3.42
Germany 884 0.16 (1.01) -0.05 2.87 -3.00 2.93
Sweden 1,085 -0.30 (0.97) 0.25 3.19 -3.02 3.40
Denmark 2,056 -0.17 (0.93) 0.02 3.04 -3.42 3.11
Raw measurements of mLOY
After winsorisation and rank-based inverse normal transformation
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Supplementary Table 19: Observational associations between mLOY (binary, mLRRY<0) and T2D risk in UK Biobank. Associations were analysed 




Additional adjustment HR Beta SE P-value total N case N OR Beta SE P-value n_total n_case
centre, array 1.09 0.09 0.03 7.58E-04 196,171 6,831 0.97 -0.03 0.02 8.95E-02 218,665 12,490
age, centre, array 1.08 0.08 0.03 2.26E-03 196,171 6,831 1.12 0.12 0.02 5.46E-10 218,665 12,490
age, smoking, centre, array 1.10 0.09 0.03 4.80E-04 195,992 6,822 1.13 0.12 0.02 1.34E-10 218,428 12,462
age, smoking, alchol consumption, education, 
BMI and wasit circumference, centre, array 1.07 0.06 0.03 1.59E-02 195,172 6,757 1.10 0.09 0.02 1.69E-06 217,239 12,357
Incident T2D (Cox regression models) Prevalent T2D (logistic regression models)
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Supplementary Table 20: Age or smoking stratification analyses in UK Biobank. Associations were analysed using logistic or Cox regression 
models for prevalent and incident T2D cases, respectively. Models were adjusted for centre and array in the age-band stratified analyses, and 




Incident T2D Age band (years) HR Beta SE P-value n_total n_case
<50 1.08 0.07 0.04 8.84E-02 47,313 755
50-59 0.99 -0.01 0.02 8.05E-01 63,040 1,818
60-69 1.08 0.07 0.02 2.93E-06 84,812 4,194
70-73 1.12 0.11 0.13 3.91E-01 1,006 64
Pinteraction = 0.4286
Never smoker 1.09 0.09 0.02 1.29E-04 97,300 2,455
Ever smoker 1.05 0.05 0.02 1.73E-03 97,913 4,324
Pinteraction = 0.1106
Prevalent T2D Age band (years) OR Beta SE P-value n_total n_case
<50 1.11 0.11 0.03 0.001 51,623 1,124
50-59 1.04 0.03 0.02 0.058 70,960 3,543
60-69 1.06 0.06 0.01 5.14E-07 97,841 7,700
70-73 1.32 0.28 0.09 0.002 1,167 123
Pinteraction = 0.0208
Never smoker 1.10 0.09 0.02 9.43E-10 107,105 4,666
Ever smoker 1.08 0.08 0.01 7.42E-11 110,401 7,697
Pinteraction = 0.1286
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Supplementary Table 21: Meta-regression analyses to identify sources of heterogeneity for associations between mLRRY and T2D risk. Smoking 
status and age band were analysed separately, i.e. individuals were stratified by country and smoking status (ever vs. never) or by country and 
age band (<50, 50-65 and >65), resulting in 14 and 18 strata, respectively. In each stratified analysis, beta coefficients were combined across 
strata using random-effects meta-regression models. variances between strata (tau2) were estimated by the residual (restricted) maximum 
likelihood (REML) algorithm with Knapp and Hartung modification to control type I error. In addition, permutation-based p-values were 





Study-level covariate Beta Se T stat KH-adjusted p Tau2_total Tau2_res R2(%) I2_res (%) T stat (observed) p p-joint p-adjusted N_studies
Country 0.04 0.01 4.30 1.00E-03 0.02 0.00 100.00 13.95 3.97 4.00E-03 0.01 18
Age (50-65 vs.  <50 ys) -0.11 0.07 -1.54 0.15 -1.52 0.18 0.40
Age (>65 vs.  <50 ys) 4.47E-03 0.08 0.06 0.96 0.11 0.92 1.00
Country 0.04 0.01 5.09 3.58E-07 0.01 0.00 100.00 0.00 5.09 2.00E-04 2.00E-04 14
Smoking -0.01 0.05 -0.11 0.91 -0.11 0.91 0.99
REML method Moment-based method with permutation (5,000)
0.36
Study-level covariate Beta Se T stat KH-adjusted p Tau2_total Tau2_res R2(%) I2_res (%) T stat (observed) p p-joint p-adjusted N_studies
Country 0.04 0.01 4.30 1.00E-03 0.02 0.00 100.00 13.95 3.97 4.00E-03 0.01 18
Age (50-65 vs.  <50 ys) -0.11 0.07 -1.54 0.15 -1.52 0.18 0.40
Age (>65 vs.  <50 ys) 4.47E-03 0.08 0.06 0.96 0.11 0.92 1.00
Country 0.04 0.01 5.09 3.58E-07 0.01 0.00 100.00 0.00 5.09 2.00E-04 2.00E-04 14
Smoking -0.01 0.05 -0.11 0.91 -0.11 0.91 0.99
REML method Moment-based method with permutation (5,000)
0.36
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Supplementary Table 22: Missingness of mLRRY in EPIC-InterAct study. A. Proportion of mLRRY missingness in each country. B. Proportion of 
mLRRY missingness in T2D incident cases and controls. C. Age distribution among individuals with or without mLOY measurements. D. Factors 












D. Missingness of mLRRY was coded as a binary variable: non-missing 
= 0, missing = 1. Logistic regression testing conditional effects of age, 








Italy 492 752 1244 (60.45)
Spain 882 1,813 2695 (67.27)
UK 453 625 1078 (57.98)
Netherlands 227 220 447 (49.22)
Germany 887 979 1866 (52.47)
Sweden 1,093 1,541 2634 (58.5)
Denmark 2,065 209 2274 (9.19)
Total 6,099 6,139 12238 (50.16)
mLRRY country Total (missing %)
non-missing missing
control 3,035 2,692 5,727 (47.01)
case 2,805 3,360 6,165 (54.50)
T2D status mLRRY Total (missing %)
Mean SD
non-missing 54.49 8.11 6,095
missing 53.75 8.56 6,108
total 54.12 8.35 12,203
Age
mLRRY Total
Non-random missingness of mLRRY
Missingness of mLRRY was dummy-coded as 0 (non-missing) and 1 (missing)
Logistic regression model testing conditional effects of age, T2D status and country on the missingness of mLRRY
chi-sqaure df P-value
Age 4.67 1 0.0306
T2D 81.26 1 1.9789E-19
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